PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07H 21/00, C12N 1/15, 1/21, 5/10, 15/11, 15/63 — A1

(11) International Publication Number: WO 99/31117

(43) International Publication Date: 24 June 1999 (24.06.99)

(21) International Application Number: PCT/US98/27059

(22) International Filing Date: 17 December 1998 (17.12.98)

(30) Priority Data:

60/070,923	18 December 1997 (18.12.97)	US
60/068,007	18 December 1997 (18.12.97)	US
60/068,057	18 December 1997 (18.12.97)	US
60/068,006	18 December 1997 (18.12.97)	US
60/068,008	18 December 1997 (18.12.97)	US
60/068,054	18 December 1997 (18.12.97)	US
60/068,064	18 December 1997 (18.12.97)	US
60/068,053	18 December 1997 (18.12.97)	US
60/068,169	19 December 1997 (19.12.97)	US
60/068,368	19 December 1997 (19.12.97)	US
60/068,367	19 December 1997 (19.12.97)	US
60/068,369	19 December 1997 (19.12.97)	US
60/068,365	19 December 1997 (19.12.97)	US

(71) Applicant *(for all designated States except US)*: HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: MOORE, Paul, A. [US/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). CARTER, Kenneth, C. [US/US]; 11601 Brandy Hall Lane, North Potomac, MD 20878 (US). SHI, Yang-gu [CN/US]; 437 West Side Drive, Gaithersburg, MD 20878 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). KYAW, Hla [MM/US]; 520 Sugarbush Circle, Frederick, MD 21703 (US). WEI, Ying-Fei [CN/US]; 1714-C Marina Court, San Mateo, CA 94403 (US). FLORENCE, Kimberly [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). DUAN, Roxanne, D. [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). FLORENCE, Charles [US/US]; 12805 Altantic Avenue, Rockville, MD 20851 (US). GREENE, John, M. [US/US]; 872 Diamond Drive, Gaithersburg, MD 20878 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). FERRIE, Ann, M. [US/US]; 120 Fox Run Drive, Tewksbury, MA 01876 (US). YU, Guo-Liang [CN/US]; 1714-C Marina Court, San Mateo, CA 94403 (US). JANAT, Fouad [SY/US]; 140 High Street, No. 202, Westerly, RI 02891 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US).

(74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: 110 HUMAN SECRETED PROTEINS

(57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

110 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoeitin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein , a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH_2PO_4; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched , for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The translation product of this gene shares sequence homology with a neurogenic secreted signaling protein, in addition to the human UDP-galactose:2-acetamido-2-deoxy-D-glucose3beta-galactosyltransferase (See Genbank Accession No. gnl|PID|e1237254) which is thought to be vital in glycoprotein biosynthesis. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GLGPAQVALSLQGPA (SEQ ID NO:239), SSWMAGTQPRTSWWEMSS AKPCPTGTLRSNTSSHPQCTGPPTTHPMLVGEDMSCPEPQCGASRLSWKMNS

SPLMMSLWVCA (SEQ ID NO:240), QPRTSWWEMSSAKPCPTGTLRSN (SEQ ID NO:241), MSCPEPQCGASRLSWKMLNSSPL (SEQ ID NO:242), WVALYIEG GMKYLTLVFLLGRAWRMTSPTRRSWAGSQPSRNSNTLGTWTKTSSSPFSMK WAWGQAATTQRCRCSSLSVRLKKSSVKSHWRMSSNSLLS (SEQ ID NO:243), GGMKYLTLVFLLGRAWRMTS (SEQ ID NO:244), SQPSRNSNTLGTWTKTS SSPFSMKW (SEQ ID NO:245), and/or TTQRCRCSSLSVRLKKSSVKSHWRMS (SEQ ID NO:246). Polynucleotides encoding these polypeptides are also encompassed by the invention.The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

This gene is expressed primarily in human fetal brain, epileptic frontal cortex and 12 week old early stage human.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or immune disorders, particularly neurodegenerative conditions such as epilepsy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:125 as residues: Ala-27 to Ser-38, Pro-43 to Asn-54, Thr-115 to Asp-121, Leu-225 to Val-232, Pro-247 to Gly-252, Arg-306 to Leu-311.

The tissue distribution in fetal brain tissue, combined with the homology to a neurogenic secreted signaling protein, in addition to the conserved UDP-galactose:2-acetamido-2-deoxy-D-glucose3beta-galactosyltransferase protein indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, detection, and/or prevention of a variety of neural disorders, particularly epilepsy and other disorders of the CNS. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are

not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. In addition, the protein may show utility in the creation of novel therapeutics which depend upon the localizing benefits (cell and tissue specificity) of glycoproteins. This protein may also be used to produce physiologically active saccharide chains and varients, and for improvement of saccharide chains bound to physiologically active proteins. Expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1257 of SEQ ID NO:11, b is an integer of 15 to 1271, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ASTLAQ TTGTCKXXXSSRRARSRTQRXFQLRPDKRSAPSLLQFIQAQEELSKENTGRQLA AREAVLALEGSTQLTGPVTQVAASKTHCSGMALTASPVPVLGAAPAKXPTQ NXPGQXGRAXXKVXTSWXXVATKVLHGLEVSTHLGKRKLSGRSWLPGP ALHATPSQSHTQTGSQIVHPPQGEVREVGRGRGQPPAQPVHAHPSQQHPSPAH LAGLSLWTGTA (SEQ ID NO:247), AMLETWRPGPSXGELATNSGQRASQDSQ HSPPHVRAHLLISPLPAFPSMGGPAGRSAPXXLTETKSELQRLRRRQARASXS XPAGEPGAGHSDSFNCVPTNGQPLRSCSLSKLRRSFLKRTQGDSWLPEKQSW LWKAPPS (SEQ ID NO:248), SHQSHLINPASSAKGSWAQLKAQPPAHVLGGT GQEGPPPTADQPESPGWDPSSFTNGSSGPRALPTSVHPTLQQGAPCRRNWA PCRGLVETRMLRRQLPHGTSKRDLGWASLQRGSPQETPQ (SEQ ID NO:249), RPDKRSAPSLLQFIQAQEELSKENTGRQLAAREAV (SEQ ID NO:250), ATPSQ SHTQTGSQIVHPPQGEVREVGRGRGQPP (SEQ ID NO:251), QDSQHSPPHVR AHLLISPLPAFPSMGGPA (SEQ ID NO:252), DSFNCVPTNGQPLRSCSLS KLRRSFLKR (SEQ ID NO:253), KGSWAQLKAQPPAHVLGGTGQEGPP (SEQ ID NO 254:), KPSHQP (SEQ ID NO:256), and/or APSLLQFIQAQEELSKENTGRQLA AR (SEQ ID NO:255). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed exclusively in adult human testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly abnormalities of the testis, in addition to impotence and infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, testicular, adrogen regulated, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:126 as residues: His-45 to Gly-56, Trp-62 to Tyr-68, His-94 to Trp-100.

The tissue distribution in testis indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention for abnormalities of the reproductive system. In addition, expression of this gene product in the testis may implicate this gene product in normal testicular function. This gene product may be useful in the treatment of male infertility, and/or could be used as a male contraceptive. Moreover, the protein product of this gene may be useful in the treatment, detection, and/or prevention of a variety of disorders related to androgen-regulated tissues, particularly the prostate gland. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1437 of SEQ ID NO:12, b is an integer of 15 to 1451, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

The translation product of this gene shares sequence homology with the human VAKTI precursor (See Genbank Accession No. gnl|PID|e1311078 (AJ228139)), in addition to the ovoinhibitor and thrombin inhibitors, which are thought to be important in inhibition of protease activities. Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of monocytes to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both immunce cells , in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to

receptors of a particular cell. Moreover, when tested against NIH3T3 and U937 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response) and GAS (gamma activating sequence) promoter elements. Thus, it is likely that this gene activates fibroblasts or hematopoietic cells through the EGR1 and/or JAK-STAT signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. GAS is also a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: CSYRPQFPVDPRVRATCIVFN (SEQ ID NO:257), GTENLLA PERTILSRAQMGKCMATPAPCVRSSSKQKKKKRKRRKVXQETKDNLRVQLPL XSCVVNXANPGKTDGFFAPERMTPSRAQMEKCMATPAPCVRPSFNKKKEQE QRLKEKLQRKSAVNFGTK (SEQ ID NO:258), LLAPERTILSRAQMGKCMAT PAPCVR (SEQ ID NO:259), PGKTDGFFAPERMTPSRAQMEKCM (SEQ ID NO:260), EQRLKEKLQRKSAVNFG (SEQ ID NO:261), KTLLENFSTQGTFVAMH PAVRATDWITLPCTKKPSISHLFFXFLAKILFSISSNSSFTLSLGIFSFFXXQLST HCTLIAMRLPIRTKNRIIFPCASKSSISNKGPKSTAYILLWITALTFPFTFYTNL GPGFRILSTQCTSVVICFPICATNSFIIIRTDKIPISFSFFKIITIQLC WGSSLGSSC (SEQ ID NO:262), MHPAVRATDWITLPCTKKPSIS (SEQ ID NO:263), LIAMRLP IRTKNRIIFP (SEQ ID NO:264), SSISNKGPKSTAYILL WITALTFPFT (SEQ ID NO:265), IIIRTDKIPISFSFFKIITIQLC (SEQ ID NO:266), NDGQCLAYNTTHY RERAMTSHARVSLGPSRDPLERPPFFFFFFFFFFKFEHTGTHGTLVSMHFAI WATDRIMLPGAYKCSIPHLVPKFTADFLCSFSFSLCSCSFFLLKEGLTHGAGVA MHFSIWALDGVILSGAKKPSVFPGFAXFTTQLXKGSCTL RLSFVS (SEQ ID NO:267), CLAYNTTHYRERAMTSHARVSL (SEQ ID NO:268), GTLVSMHFAI WATDRIMLPGAYKCSIPHLVP (SEQ ID NO:269), GVILSGAKK PSVFPGFAX FTTQLX (SEQ ID NO:270), KKASHMEQVLPCIFPSGPWMGSFSLXQKSRPF FLDLRXSLHNSXKEAVLLDCLLFLXXPSFFFFSSSSAWKKTSHMEQVLPCT FPSGPWIGLFSLVQASFPFLTSFRYSLQSSAYEVAFPDSLLFLARASAFFFSSFSA WK (SEQ ID NO:271), CIFPSGPWMGSFSLXQKSRPFFLDLRXS (SEQ ID NO:272), WIGLFSLVQASFPFLTSFRYSLQSSAYE (SEQ ID NO:273), NSAVN IKIRQRMEYFSVPEKMTLFVVQMGKCMATCVPCVKPTSKQKMKKRKRLKHE LETKENLEKQPHMQSFAVNIESL (SEQ ID NO:274), IKIRQRMEYFSVPEKMTL

FVVQM (SEQ ID NO:275), and/or VKPTSKQKMKKRKRLKHELETKENL (SEQ ID NO:276). Polynucleotides encoding these polypeptides are also encompassed by the invention.The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in heart, tonsils, Hodgkin's lymphoma, neuroblastoma, leukocyte and lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular, immune, or hemodynamic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cardiovascular, muscle, immune, hematopoietic, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, pulmonary surfactant or sputum, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:127 as residues: Ala-20 to Gln-27.

The tissue distribution in heart and immune cells and tissues, the homology to protease inhibitors, in addition to the detected calcium flux, EGR1, and GAS biological activities indicates polynucleotides and polypeptides corresponding to this gene are useful for disgnosis and treatment of hemodynamic or vascular disorders, including hemorrhage, heart failure, and embolism, because proteases and their inhibitors are often involved in the cascades controlling hemadynamic controls. Protein may also show utility in the treatment, detection, and/or prevention of a variety of metabolic (i.e. cellular or physiological) and/or proliferative disorders in which aberrant regulation of a protease is thought to be involved, particularly in the premature activation of zymogens, for example. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines;

immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2303 of SEQ ID NO:13, b is an integer of 15 to 2317, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The translation product of this gene shares sequence homology with the ecotropic retrovirus receptor and the human cationic amino acid transporter-3 (See Genbank Accession No. gnl|PID|e1198517) which are thought to be important in viral infections and amino acid and polyamine transport. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PRVRGTVVRLRQHRPSAYILVSTVLTLMVPWHSLDPDSALADAFYQRGYRWAG FIVAAGSICA (SEQ ID NO:277), TVVRLRQHRPSAYILVSTVLTLMVP (SEQ ID NO:278), WHSLDPDSALADAFYQRGYRWAGFIV (SEQ ID NO:279), TPSCSASS SPCHALSMPWPPMGSSSRCLPMCTPGHRCLWRAPWRSGSSRPSWHCCWTWS

RWFSSCPLAHSWPTHSWPPVSLCCASRSLPRPAPQAQPALAP (SEQ ID NO:280), LSMPWPPMGSSSRCLPMCTPGHRC (SEQ ID NO:281), APWRSGSS RPSWHCCWTWSRWFSSCPL (SEQ ID NO:282), THSWPPVSLCCASRSL PRPAPQ (SEQ ID NO:283), AYILVSTVLTLMVPWHSLDPDSALADAFYQRGYRW AGFIVAAGSICAMNTVLLSLLFSLP (SEQ ID NO:284), PWHSLDPDSALADAF YQRGYRWAGFIVAAGS (SEQ ID NO:285), RIVYAMAADGLFFQVFAHVHPRTQ VPV (SEQ ID NO:286), DLESLVQFLSLGTLLA (SEQ ID NO:287), YTFVATSII VLRFQK (SEQ ID NO:288), LTKQQSSFSDHLQLVGTVHASVPEPGELKPA (SEQ ID NO:289), LRPYLGFLDGYSPGAVVTWALGVMLASAITIGCVLVFGNSTL HLPHWGYI (SEQ ID NO:290), PGAVVTWALGVMLASAITIGCVLVFGN (SEQ ID NO:291), GAHQQQYREDLFQIPMVPLIPALSIVLNICLMLKLSYLTWVRFSIW LLMGLAV (SEQ ID NO:292), MVPLIPALSIVLNICLMLKLSYLTWV (SEQ ID NO:293), and/or YFGYGIRHSKENQRELPGLNSTHYVVFPR (SEQ ID NO:294). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in placenta and brain tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, neural, or metabolic disorders, in addition to viral infections. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and placenta, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, neural, hepatic, metabolic,and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, bile, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:128 as residues: Gln-87 to Ser-99, Pro-102 to Phe-110, Gln-204 to Leu-211, Ser-262 to Glu-268, Pro-294 to His-305.

The tissue distribution in placenta, combined with the homology to a retroviral receptor and cationic amino acid transporters, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of viral infections, or diseases and malfunctions related to amino acid transport. Specifically, soluble forms of this protein or, polynucleotides of the present invention,

can be used to bind to retroviruses so as to prevent their entry and infection of susceptible cells. They can be used for therapy/prevention of HIV infection and certain forms of leukaemia. Polynucleotide or polypeptides of the present invention can be used to identify susceptibility to retroviral infection. Based upon the tissue distribution in the brain, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1458 of SEQ ID NO:14, b is an integer of 15 to 1472, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: FPPSPAPPHSLPLRSWLWSRQMG (SEQ ID NO:295), GTSF RGMISTQPGSTPLASFKILALESADGHGGCSAGNDIGPYGERDDQQVFIQKVVP SASQLFVRLSSTGQRVCSVRSVDGSPTTAFTVLECEGSPAARLSAPALPAHWP

GQRQLGHVGPNHRHGRPRPGPCRWPDGAR ADGTAGTL (SEQ ID NO:296), PGSTPLASFKILALESADGHGGCSAGNDI (SEQ ID NO:297), GERDDQQVF IQKVVPSASQLFVRL (SEQ ID NO:298), RSVDGSPTTAFTVLECEGSPAARLS (SEQ ID NO:299), PALPAHWPGQRQLGHVGPNHRHGRPR (SEQ ID NO:300), PFIPRRPWPEPGVPTGIREAPESPRTRASQGIMAAALFKKEVSLSFILGGVRG VPRPLEGHGAGVGGRRRSGPLRTSSWQRSTKLPPPRRRASACGGLGLPRWP DKEVLLEAEWRLVREMRGEGLGRQPHEGAERSRRGQLTVFQLFHQLLLRQATC RGLA EAVHGGG (SEQ ID NO:301), PGVPTGIREAPESPRTRASQGIMAAALF KKEV (SEQ ID NO:302), FILGGVRGVPRPLEGHGAGVGGRRRSGP (SEQ ID NO:303), GLPRWPDKEVLLEAEWRLVREMRG (SEQ ID NO:304), and/or GAER SRRGQLTVFQLFHQLLLRQ (SEQ ID NO:305). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human fetal kidney, and to a lesser extent, in thymus and bone marrow cell line (RS4;11).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, metabolic, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, metabolic, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:129 as residues: Thr-17 to Trp-26, Pro-54 to Trp-61, Ala-65 to Arg-74, Pro-142 to Leu-147, Pro-158 to Ala-165.

The tissue distribution in thymus and bone marrow cell lines indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders involving stem cells. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are

important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the expression within fetal kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Moreover, the expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1002 of SEQ ID NO:15, b is an integer of 15 to 1016, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HASAHASAHASGCGA (SEQ ID NO:306), QGVGVADEGG

LERQRVDAGARLGHMGQPVAFSTRQLHLALPAPGTAGVTVPHPHAREGVV GDLPLVPDAEDPTVGVPAEGLLVLGHVVERAELILVRGLHQAEALARESEEMH GSRHG (SEQ ID NO:307), EGGLERQRVDAGARLGHMGQPVAFS (SEQ ID NO:308), LALPAPGTAGVTVPHPHAREGVVGDLPLV (SEQ ID NO:309), PAEG LLVLGHVVERAELILVRGLHQAEA (SEQ ID NO:310), HLFKFFYTIAFMQWF TEFMELFLSVWELIKTXNLCFVCFSEHKPGQLVPAGPTSQLLCRALGRVH LCSPTTRSQTPTQSWVTPQLLWRLGSGRLVAQVLQVGSFCGPRVGDAVLGEQT FQP FDLL (SEQ ID NO:311), AFMQWFTEFMELFLSVWELIKTXNLCFVC (SEQ ID NO:312), and/or RSQTPTQSWVTPQLLWRLGSGRLVAQ (SEQ ID NO:313). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

This gene is expressed primarily in human infant brain, and to a lesser extent, in adult brain and lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, developmental, or pulmonary disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system (CNS), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, developmental, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:130 as residues: Ser-47 to Pro-57, Ser-77 to Glu-82, Thr-90 to Trp-98, Arg-124 to Lys-137, Ala-183 to Glu-192, Lys-220 to Gln-229, Asn-244 to Arg-258, Thr-271 to Asn-278, Glu-285 to Gly-297.

The tissue distribution in infant and adult brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of diseases of the CNS, such as mental retardation, schizophrenia, Alzheimer's disease, paranoia, depression, and mania. Moreover, polynucleotides and

polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, dementia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The protein product of this gene may also show utility in the detection, treatment, and/or prevention of a variety of pulmonary disorders, particularly those related to disorders of the mucosal or endothelial tissues. The expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1225 of SEQ ID NO:16, b is an integer of 15 to 1239, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GAWGVEVVAVGSKAGCLVYQLCDLKQITFFFRASVCLSV (SEQ ID NO:314), PASLGSSWGQKLRGGTRKSFQELSPSSAPPACLPQPPASTWLSSWPRPPCW PPMCSWALGXCFCPATGQWLPTSCCLWWCPDAGGRQKHFRSRWXTSWETW QPYLTGLISSVLRAXRPDSYLQRFRSLXQXXLCCAFVIALGGGCFLLTALYLER DETRAWQXVTGTPDSNDVDSNDLERQGLLSGXGASTEEP (SEQ ID NO:315), L RGGTRKSFQELSPSSAPPACLPQPP (SEQ ID NO:316), ATGQWLPTSCCLW WCPDAGGRQKHFRSR (SEQ ID NO:317), GGCFLLTALYLERDETRAWQXV (SEQ ID NO:318), APHLRLQPACHSPLPLPGSRPGPDHPAGLLCVPGPWGX ASVLQLGSGCRHPAVCGGAQMPGDGRSTSDHGGXHPGXPGSPISQDLSLVSC GPXALTPICSASAAXXXXXCAAPLSSPWGAAASC (SEQ ID NO:319), PACHSPLPLPGSRPGPDH PAGLLCV (SEQ ID NO:320), and/or SGCRHPAVCGGAQMPGDGRSTSDHGG (SEQ ID NO:321). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in pineal gland and thymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, endocrine, emotional or behavior disorders, in addition to autoimmune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, endocrine, hematopoietic, neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:131 as residues: Asp-18 to Gln-27, Arg-44 to Asn-49.

The tissue distribution in thymus indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of

immune and autoimmune diseases, such as lupus, neutropenia, transplant rejection, and inflammatory diseases. Moreover, the expression within pineal gland indicates the protein product of this gene may be useful in disorders associated with biological clock aberrations, emotional distress, lethargy, or metabolic conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1391 of SEQ ID NO:17, b is an integer of 15 to 1405, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element) promoter element. Thus, it is likely that this gene activates leukemia cells, or more generally, immune or hematopoietic cells, through the JAK-STAT signal transduction pathway. ISRE is a a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GLKVMEICSLTFLEATNLQSRCQQAMLPLKALRKNPFLLLPSFDGCCQSLA FPGLWLQHSNLCLNHHMTFLVYLLCVSVFKYFFPFSCTYTSHWI (SEQ ID NO:322), ICSLTFLEATNLQSRCQQAMLP (SEQ ID NO:323), and/or GLWLQHS NLCLNHHMTFLVYLLCVSV (SEQ ID NO:324). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in IL-1 and LPS induced neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:132 as residues: Ser-45 to His-50, His-52 to Ile-57, Lys-67 to His-81.

The tissue distribution in neutrophils, combined with the detected ISRE biological activity indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of inflammatory disorders, such as psoriasis, inflammatory bowel disease, rheumatoid arthritis, and sepsis. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1520 of SEQ ID NO:18, b is an integer of 15 to 1534, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PFPLLPPKRRGLLYHLIQKSTLGLVVWFREHLDSRSQ (SEQ ID NO:325), RGXPSWPMHTLVYAQHSTTHTPLIQPQWTQVIDQPPGITHQFCVR XCXCPTLESCVQECVTRSRXKPTTGVPGPQRLA (SEQ ID NO:326), TPLIQPQW TQVIDQPPGITHQFCV (SEQ ID NO:327), ALGPSQTCDLDVWLVAKPSFFRGPQ GIHYFSLWRRKPLSHWVSIWQLQGQETMPAMLRSRPAGQATVATGPPRGSPS PQDLPSYHRKQVESSHRHSWEPASQSQ (SEQ ID NO:328), CDLDVWLVAKPSF FRGPQGIHYFSLWRR (SEQ ID NO:329), and/or AGQATVATGPPRGSPSPQDLP SYHRKQV (SEQ ID NO:330). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in synovial fibroblasts, and to a lesser extent, in endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal or vascular disorders, particularly arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.,skeletal, vascular, endothelial, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in synovial fibroblasts indicates polynucleotides and polypeptides corresponding to this gene are useful for treatment of arthritis. Moreover, polynucleotides and polypeptides corresponding to this gene are useful in the detection

and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). The protein product of this gene may also be useful for the detection, treatment, and/or prevention of a variety of vascular disorders which include, but are not limited to, atherosclerosis, embolism, stroke, microvascular disease, or aneurysm. The protein may also be useful in the treatment of integumentary disorders, particularly those related to aberrations in the extracellular matrix or lamina. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1219 of SEQ ID NO:19, b is an integer of 15 to 1233, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:
XGDTXTQNSRHDTPXLIDYYRESCTLQYRPEFPGRPTRPRGSCPQYPGPAIPRT SWALGEGDAAPRGAHH PRRADVPLG (SEQ ID NO:331), YRESCTLQYRPEFPG RPTRPRGSCPQYPGP (SEQ ID NO:332), GKLYAAVPSGIPGSTHASARLMPPVS RSSYSEDIVGSRRRRRSSSGSPPSPQSRCSSWDGCSRSHSRGREGXRPPWSEL DVGALYPFSRSGSRGRLPRFRNYAFASSWSTSYSGYRYHRALLCRRTAVSGR LREGREPSAEEAEGEREDWGIGSA (SEQ ID NO:333), SGIPGSTHASARLMPP

VSRSSYS (SEQ ID NO:334), GCSRSHSRGREGXRPPWSELDVGALYPFS (SEQ ID NO:335), TAVSGRLREGREPSAEEAEGEREDW (SEQ ID NO:336), RIRKAA VQIPTRKNIGXRRPVVQETRKKERISRLKESIGNILIVTVTQSLTQILTLMMI KRELKPRRKRRKRNTKQXKRRIRKPKKNPVTQAVKTQKRTCQKLPGMEQ PNVADTMDLIGPEAPINTYLFKMKNL (SEQ ID NO:337), TRKKERISRLKESI GNILIVTVTQSLTQ (SEQ ID NO:338), and/or VKTQKRTCQKLPGMEQPNVA DTMDLIGP (SEQ ID NO:339). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in retina.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, visual disorders, particularly retinopathy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the ocular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, vitreous humor, aqueous humor, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in retina indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of diseases of the retina, for example, diabetic retinopathy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1076 of SEQ ID NO:20, b is an integer of 15

to 1090, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

When tested against NIH3T3 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates fibroblast cells, or more generally, other cells of the integumentary system, through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT. Genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:
LPFTLKPKMVKIPFSSRLINNNLQYIDCILSLKRCEEILLMWHGLLLCLASVFLE LRGDRPPLLASLLEPHKMPLHSSSL (SEQ ID NO:340), LKPKMVKIPFSSRLIN NNLQYIDC (SEQ ID NO:341), SLKRCEEILLMWHGLLLCLASVF (SEQ ID NO:342), LRGDRPPLLASLLEPHKMPLH (SEQ ID NO:343), LQMHTGSGFKGK SCEVAFYVAQAEKPGEGAYLHGAQETQKQGIEADHATLRGSPHSVSKTKYNLY IANYYLLAWRKMES (SEQ ID NO:344), CEVAFYVAQAEKPGEGAYLH (SEQ ID NO:345), and/or ATLRGSPHSVSKTKYNLYIANYY (SEQ ID NO:346). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human ovarian cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly cancers, such as ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human ovarian cancer tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 668 of SEQ ID NO:21, b is an integer of 15 to 682, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

Contact of cells with supernatant expressing the product of this gene increases the permeability of the plasma membrane of myeloid leukemia cells to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of immune or hematopoietic cells, in addition to other cells or cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating myeloid cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

LSASLLDRYPASESNNYIFNFVLYMLHFLAGTLFSLFPDFELSPRSATLFPDLR TVQLLSSRPHL (SEQ ID NO:347), LLDRYPASESNNYIFNFVLYMLH (SEQ ID NO:348), FPDFELSPRSATLFPDLRTV (SEQ ID NO:349), NGGFYDVSFKQAG LIEFLCIIYFYPMAHVICGSRFTIVRTIPVHYVGEYFIKSSIWILYRINERTATKK AASDFQKNFRCFLDAF (SEQ ID NO:350), KQAGLIEFLCIIYFYPMAH (SEQ ID NO:351), and/or YFIKSSIWILYRINERTATKKAA (SEQ ID NO:352). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly immunodeficiencies and inflammatory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in anergic T-cells, combined with the detected calcium flux biological activity, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders, particularly those involving anergic T-cells. Moreover, the secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological acitivities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac

infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:22, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SPRXGRXFXTSRKQISGFLEFD (SEQ ID NO:353). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly leukemia or multiple myeloma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in bone marrow tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of some types of leukemia, and other disorders involving bone marrow tissues or cells. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 551 of SEQ ID NO:23, b is an integer of 15 to 565, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MKHAAFGLIPLVKEIYRYLKIKSKLLIGSGKCQLQPEWL QTSLINSSLLMDWLTPY (SEQ ID NO:354), IYRYLKIKSKLLIGSGKCQLQPE WLQTSL (SEQ ID NO:355), QLGLPWDQSKGPRKNGLSMCGSVYSTIWSLIA SRREETIRVIVLYIQSPNINTRHISKRGLNKALTNP (SEQ ID NO:356), SKGPR

KNGLSMCGSVYSTIWS (SEQ ID NO:357), and/or QSPNINTRHISKRGLNK (SEQ ID NO:358). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in adult retina, and to a lesser extent, in 12 week old early stage human.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, visual or developmental disorders, particularly retinopathy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the ocular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., visual, developmental cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, aqueous humor, vitreous humor, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human retina indicates polynucleotides and polypeptides corresponding to this gene are useful for treatment of retinopathy, and other disorders involving the visual system. Moreover, the expression within embryonic tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1342 of SEQ ID NO:24, b is an integer of 15

to 1356, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The translation product of this gene has homology to the conserved human non-differentiated blood cell tyrosine kinase receptor fragment (See Genbank Accession No. R76466) which is thought to be important in signalling essential cellular pathways. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HPQTSAGGFPLHQGLPTVS (SEQ ID NO:359), PSWFPELSPWPLKTL KKRRQMRLRRRGRLCRLSPATTTTADTCRCPARSYRGSGRRPACAQDSPAPPS RPTRRAWEKCALRPKRAAQWSTGVPPSPRSSTTGCCFGTAAXCAEGARR (SEQ ID NO:360), TTTADTCRCPARSYRGSGRRPA (SEQ ID NO:361), and/or PSRPTRRAWEKCALRPKRAAQWST (SEQ ID NO:362). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human fetal epithelium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, integumentary, immune, or hematopoietic disorders, particularly skin cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the integumental system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, integumentary, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:139 as residues: Gln-26 to Ala-39, Cys-48 to His-55.

The tissue distribution in human fetal epithelium, combined with the homology to a conserved tyrosine kinase receptor, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of skin cancer, or other disorders related to the integument, particularly proliferative

conditions. Similarly, polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chrondomalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 603 of SEQ ID NO:25, b is an integer of 15 to 617, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

When tested against PC12 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) pathway. Thus, it is likely that this gene activates sensory neuron cells, or generally other cells or cell types, particularly immune cells, through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARGVLNLRNRFECFSIIETV (SEQ ID NO:363), IGQLVMKSICHFQRLLSVAI DFASQFLKNYIFSSTHSSKAGFSVVCSLPKWLYTDGMEMVLKITHKLSF (SEQ ID NO:364), and/or QRLLSVAIDFASQFLKNYIFSSTH (SEQ ID NO:365). Polynucleotides encoding these polypeptides are also encompassed by the invention.The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in fetal liver, and to a lesser extent, in resting T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, hepatic, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal liver and resting T-cells, combined with the detected EGR1 biological activity indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders involving T-cells, and more generally, hematopoietic conditions. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia,

pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 634 of SEQ ID NO:26, b is an integer of 15 to 648, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LMKTASRMLLLE (SEQ ID NO:366). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in CD34-positive T cells from cord blood, and to a lesser extent, in anergic T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly in immune system maturation and hematopoeitic development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:141 as residues: Ile-46 to Tyr-56.

The tissue distribution in CD34-positive T cells and anergic T cells. indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of diseases involving hematopoeitc development and stem cell maturation, including protection of stem cells from chemotherapy, immunosuppression during transplant rejection, and neutropenia. Moreover, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1374 of SEQ ID NO:27, b is an integer of 15 to 1388, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

When tested against U937 and Jurket cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) pathway. Thus, it is likely that this gene activates myeloid and T-cells, or more generally cells of immune or hematopoietic origin, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ATXWDXPGCRNSARGERLHVGDAPW (SEQ ID NO:367), ARDER REVLKTLMRLSTQRPQAFLPSQSWFVRLQKAGEGALKQENSLTIQNCLLCL PRVHRQRPTPPQPQRGNTEASVLQTSTEHLPRAAVLLVPNSCSPGXPTXLLSS (SEQ ID NO:368), ERREVLKTLMRLSTQRPQAFLP (SEQ ID NO:369), GALKQEN SLTIQNCLLCLPRVHRQR (SEQ ID NO:370), and/or SVLQTSTEHLPRAAVLLVP NS (SEQ ID NO:371). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in activated human neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:142 as residues: Val-25 to Gly-33.

The tissue distribution in activated neutrophils, combined with the detected GAS biological activity, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders involving neutrophils. Moreover, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 602 of SEQ ID NO:28, b is an integer of 15 to 616, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ALVISNPLL (SEQ ID NO:372), PYINTQMCVSSRNKFCISG HQKYDSHGRETRFEMHKARASSWKNILKIRSLKIISRGFEITNA (SEQ ID NO:373), KFCISGHQKYDSHGRETRFEMHKARAS (SEQ ID NO:374), HTLLEI ANPLQAAVLGASSIHPSIHTSTHLMFMGLKWTELHHSPDSVQGAGAAEAAQTR HSLRPGRGRERHDCTLKNLTLFIIC (SEQ ID NO:375), NPLQAAVLGASSIHP SIHTSTH (SEQ ID NO:376), and/or SLRPGRGRERHDCTLKN (SEQ ID NO:377). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as neutropenia, inflammatory, or allergic conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders involving neutrophils, or more generally, immune or hematopoietic disorders. Moreover, the expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other

processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 814 of SEQ ID NO:29, b is an integer of 15 to 828, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

This gene is expressed primarily in 7 week old early stage human.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fetal or developmental abnormalities, particularly congenital defects, including metabolic conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,

particularly of the developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in 7 week old early stage human tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of fetal abnormalities. Expression within embryonic tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Futhermore, the protein is useful in the diagnosis, prevention, and/or treatment of various metabolic disorders such as Tay-Sachs disease, phenylkenonuria, galactosemia, hyperlipidemias, porphyrias, leukemias, or Hurler's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 567 of SEQ ID NO:30, b is an integer of 15 to 581, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

AENVHCTPAWETGRDSEDGKGREGMGRDRKGWDGTGLDGTGWEGKRERNV

PA (SEQ ID NO:378), GRDSEDGKGREGMGRDRKGWDGTGLD (SEQ ID NO:379), TSLGDLWDYNNSSH (SEQ ID NO:380), DRRIIRTREAAVAVSRERP LHSSLGNRERLRRWEGTGRDGKGQEGMGRDGTGWDGMGREERKKCPS (SEQ ID NO:381), RPLHSSLGNRERLRRWEGTGRDGKG (SEQ ID NO:382), NQSWGPMGL (SEQ ID NO:383), GGGGCSEPRTSIALQPGKQGETPKMGRD GKGWEGTGRDGTGRDWMGRDGKGREKEMSQQ (SEQ ID NO:384), KQGE TPKMGRDGKGWEGTGRDGTG (SEQ ID NO:385), and/or PVLGTYGTITTPV TELTKGQEKEGGVETVLYE (SEQ ID NO:386). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in frontal cortex from a patient suffering from schizophrenia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, such as Schizophrenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in frontal cortex tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of some central nervous system disorders, for example, schizophrenia. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural

function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 775 of SEQ ID NO:31, b is an integer of 15 to 789, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: KIVFIDQKWSK (SEQ ID NO:387), CSLFWGILFLSRLRIH LFLSLKPCMCLRPIDILSHFLDIFVTSVLSELEKSSLKTTETFSFAVFLLLMMN (SEQ ID NO:388), LSRLRIHLFLSLKPCMCLRPIDILSH (SEQ ID NO:389), and/or VLSELEKSSLKTTETFSFAVFL (SEQ ID NO:390). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in thymus and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammation, or disorders related to immune cell maturation and/or activation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain

tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:146 as residues: Lys-38 to Leu-46.

The tissue distribution in thymus and neutrophils indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of inflammatory disorders, such as psoriasis, inflammatory bowel disease, rheumatoid arthritis, and sepsis. Moreover, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 870 of SEQ ID NO:32, b is an integer of 15 to

884, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: TLFRYILH (SEQ ID NO:391). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and disorders afflicting blood cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoeitic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:147 as residues: Pro-30 to Asn-36.

The tissue distribution in bone marrow indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of diseases afflicting the blood, including leukemia, neutropenia, anemia, and stem cell protection during chemotherapy. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the

expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 852 of SEQ ID NO:33, b is an integer of 15 to 866, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

This gene is expressed primarily in Merkel cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary disorders, particularly aberrations in mechanic sensory function. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly in tissues involved in sensory function, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., integumentary, sensory, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in Merkel cells indicates polynucleotides and polypeptides corresponding to this gene are useful for Merkel cell dysfunctions, which may include aberrations in sensory function. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or

prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chrondomalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1680 of SEQ ID NO:34, b is an integer of 15 to 1694, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

The translation product of this gene shares sequence homology with dihydropyridine receptor or nitrate transporter which are thought to be important in transport of small molecules across the cell membrane. In specific embodiments,

polypeptides of the invention comprise the following amino acid sequence: GTSFSVLSLIHDTG (SEQ ID NO:392). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

This gene is expressed primarily in kidney cortex and muscle tissue from a patient with multiple sclerosis, and to a lesser extent, in fetal liver/spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscle, urogenital, or renal disorders, particularly musculodegenrative conditions such as multiple sclerosis, in addition to kidney or metabolic disorders and diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the multiple sclerosis and renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., muscle, urogenital, renal, hepatic, metabolic, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, bile, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:149 as residues: Ala-66 to Leu-73.

The tissue distribution in kidney cortex and muscle tissue, combined with the homology to small molecule transporters indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of disorders of renal functions and muscular diseases, including multiple sclerosis, muscular dystrophy, cardiomyopathy, fibroids, myomas, and rhabdomyosarcomas. The tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor

marker and/or immunotherapy targets for the above listed tissues. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. .

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1201 of SEQ ID NO:35, b is an integer of 15 to 1215, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

VLISASTIGSRTSGAQGMEKMTIPTLAVGEPKTPEKSKCSLKQCFSSCNVHIDH LGLLLKCKF (SEQ ID NO:393), ASTIGSRTSGAQGMEKMTIPTLA (SEQ ID

NO:394), and/or GEPKTPEKSKCSLKQCFSSCNVHIDHL (SEQ ID NO:395). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in kidney medulla.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal, urogenital, or more generally, disorders afflicting endothelial tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, urogentital, endothelial, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in kidney medulla indicates polynucleotides and polypeptides corresponding to this gene are useful for the disgnosis, treatment, and/or prevention of renal disorders, including lesions, vascular diseases, hydronephrosis, and renal diseases associated with systemic disorders. Moreover, the gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. The protein product can also be used for the treatment, detection, and/or prevention of various endothelial disorders, which include microvascular disease, embolism, aneurysm, stroke, or atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1780 of SEQ ID NO:36, b is an integer of 15 to 1794, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RIRSQDLAIMTTCFKKYEFSFFVLGFLRRWGATLCLGFTSFAIKFHPSSLCSEKE GKDFSGFALSIHGPERKKEEGWARWLTPVVPVLWEAEVGGSPEVSS (SEQ ID NO:396), TTCFKKYEFSFFVLGFLRRWGA (SEQ ID NO:397), SEKEGKDFSGF ALSIHGPERKKEEGW (SEQ ID NO:398), MNECIAKPCMAAFCSCPSCCLPSR PGCSREQRCAFSCEPCHTVEHWVEPMGQGQRQEHTQGSVLPSSHPSRGKATT VHSCCQEPWG (SEQ ID NO:399), FCSCPSCCLPSRPGCSREQRCAFSCEP (SEQ ID NO:400), GQRQEHTQGSVLPSSHPSRGKAT (SEQ ID NO:401), GVVNSCLL PLPPRLLATGMDCGGFASRRMGGRQHAALSVFLPLPLAHGLYPMFNCVAGLT GKGTSLLSGAARPAGEAAARAGTKGSHARFGNAFIHSF HSFIECLLNTYCVP SSALTAVGIGDILKNKNDKSSCLCSC (SEQ ID NO:402), GMDCGGFASRRMG GRQHAALSVFLP (SEQ ID NO:403), LTGKGTSLLSGAARPAGEAAARAGT (SEQ ID NO:404), and/or LNTYCVPSSALTAVGIGDILKN (SEQ ID NO:405). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary or developmental disorders and/or diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., pulmonary, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, pulmonary surfactant or sputum, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal lung indicates polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of diseases related to pulmonary functions and infections. Moreover, the expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1160 of SEQ ID NO:37, b is an integer of 15 to 1174, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

This gene is expressed primarily in hepatocellular tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic or hepatic disorders or diseases, particularly hepatocellular tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., metabolic, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, bile, plasma, urine, synovial fluid and

spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in hepatocellular tumors indicates polynucleotides and polypeptides corresponding to this gene are useful for disgnosis and treatment of hepatic disorders, particularly proliferative conditions such as hepatocellular tumors. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition, the protein may play a role in the treatment, detection, and/or prevention of developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1073 of SEQ ID NO:38, b is an integer of 15 to 1087, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The translation product of this gene has homology to a contains a helix-loop-helix motif from a Caenorhabditis elegans protein (See Genbank Accession No. gil1326280) which is thought to function as a modulator of gene expression. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: TSLSQLWHFCHFWPVKFCCGGCPVHCRMFSSISGLYLLNASAPSLQLNDPKCL QT (SEQ ID NO:406), and/or WPVKFCCGGCPVHCRMFSSISGLYLLNA (SEQ ID NO:407). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in normal breast.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, or endocrine disorders, particularly of the breast, such as breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancer and metabolic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, breast milk, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in breast indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of some types of breast cancer. The protein can also be used for the treatment, detection, and/or prevention of disorders related to ductile tissues or cell types, particularly secretory dysfunctions. The protein can also be used for the treatment of vascular disorders such as atherosclerosis, microvascular disease, embolism, stroke, or aneurysm. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 424 of SEQ ID NO:39, b is an integer of 15 to 438, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element) promoter element. Thus, it is likely that this gene activates leukemia cells, or potentially other cells or cell-types, through the JAK-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SCRCWALGAGGGQRQWVGRS (SEQ ID NO:408), TGAQAPKMGARQRKRPL QTRIKNSSKSTLWPPQWVRCGRWWTWPSRKKTSRPRRQLFTSTLSTSASALV WPVSWFSQEGH (SEQ ID NO:409), MGARQRKRPLQTRIKNSSKSTLWPP (SEQ ID NO:410), and/or PRRQLFTSTLSTSASALVWPVSW (SEQ ID NO:411). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly abnormalities of the testes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:154 as residues: Leu-26 to Glu-52, Gln-71 to Lys-79.

The tissue distribution in testes, combined with the detected ISRE biological activity, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of abnormalities of the testes, such as male infertility and proliferative conditions, and/or could be used as a male

contraceptive. The protein can also be used for the maintainance normal testicular function. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 720 of SEQ ID NO:40, b is an integer of 15 to 734, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

This gene is expressed primarily in colon, and to a lesser extent, in thymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal, immune, or hematopoietic disorders, particularly abnormalities of the colon, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., gastrointestinal, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in colon and thymus tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of abnormalities of the colon. The protein can also be used for treating inflammatory conditions, or potentially in modulating immune system activation in the treatment of gastrointestinal disorders. Protein, as well as, antibodies directed against

the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1332 of SEQ ID NO:41, b is an integer of 15 to 1346, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DGGGKEEGVSCLKISLLCGPWLWLP (SEQ ID NO:412), HE MGELAICHTRVPFSLPSSAQGVPQNLQGPIGHLAVCTPSSLTSWHFPQKREKW STVNKRQRFLQFPAPLRNWIPQTPLSLSVSSGPLGSFTVFTLLSLCAWPWCCRD CYKSCCPIPIFNLTAPLCVHTPEPSS (SEQ ID NO:413), SSAQGVPQNLQGPIGH LAVCTPS (SEQ ID NO:414), VNKRQRFLQFPAPLRNWIPQTPLSLSVS (SEQ ID NO:415), CCRDCYKSCCPIPI FNLTAPLCV (SEQ ID NO:416), DLNVTNEGEGKE VLGQGSTNNEKKCQKATSNTEPRAREAKARHANMGTSDRESPTWSLTAE GLKAKSKMQGKATKGAASTMGSHNQGPHKREIFKHETPSSFPPPSQCQPE LLPYKYWATLASGYVPSWLPSVDSYRINTAIKDKNGQDT (SEQ ID NO:417), VLGQGSTNNEKKCQKA TSNTEPRA (SEQ ID NO:418), RESPTWSLTAE GLKAKSKMQGKATKGAAS (SEQ ID NO:419), and/or GYVPSWLPSVDSYRI NTAIKDK (SEQ ID NO:420). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in rhabdomyosarcoma, and to a lesser extent in heart and thymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscle disorders, particularly rhabdomyosarcoma and other proliferative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are

useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., muscle, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:156 as residues: Gly-28 to Asp-33.

The tissue distribution in rhabdomyosarcoma tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of rhabdomyosarcoma. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various muscle disorders, such as muscular dystrophy, cardiomyopathy, fibroids, or myomas. The protein can also be used for the amelioration of proliferative conditions in other tissues, including modulation of the immune respone to such tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 984 of SEQ ID NO:42, b is an integer of 15 to 998, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NSAEQSMLILVT (SEQ ID NO:421), RXDRXPVPELPGYEPT RTDISSFKNIYRYAFDFARDKDQRSLDIDTAKSMLALLLGRTWPLFSVFYQYLE QSKYRVMNKDQWYNVLEFSRTVHADLSNYDEDGAWPVLLDEFVEWQKVRQT

S (SEQ ID NO:422), PTRTDISSFKNIYRYAFDFARDKDQRSL (SEQ ID NO:423), SMLALLLGRTWPLFSVFYQYLE QSKYRVM (SEQ ID NO:424), FSRTVHADLSN YDEDGAWPVLLDEFVE (SEQ ID NO:425), IYRYAFDFAR (SEQ ID NO:426), KD QRSLDI (SEQ ID NO:427), NVLEFSRT (SEQ ID NO:428), and/or DLSNYDEDGA WPVLLDEFVEW (SEQ ID NO:429). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

This gene is expressed primarily in aortic endothelium, and to a lesser extent, in cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endothelial disorders, particularly abnormalities of the vascular system and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endothelial, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:157 as residues: Arg-22 to Lys-31.

The tissue distribution in aortic endothelium indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, detection, and/or prevention of abnormalities of the vascular system (i.e. embolism, atherosclerosis, aneurysm, stroke, microvascular disease, etc.) and cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 644 of SEQ ID NO:43, b is an integer of 15 to 658, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

Polypeptides of the invention do not comprise the polypeptide sequence shown as Genbank Accession W59652, which is hereby incorporated herein by reference. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LFRCPIGKAGTPAGXGPEFPGRPTRPVREKELTETFE (SEQ ID NO:430), FFVFPYPYPFRPLPPIPFPRFPWFRRNFPIPIPESAPTTPLPSEK (SEQ ID NO:432), PWFRRNFPIPIPESAPTTPLP (SEQ ID NO:433), and/or GKAGTPAGXG PEFPGRPTRPV (SEQ ID NO:431). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly Hodgkin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:158 as residues: Ser-21 to Asp-35, Pro-47 to Pro-52, Pro-62 to Asn-67.

The tissue distribution in Hodgkin's lymphoma tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of Hodgkin's lymphoma. Moreover, polynucleotides and

polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic-related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 552 of SEQ ID NO:44, b is an integer of 15 to 566, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

When tested against U937 and K562 cell lines, supernatants removed from cells containing this gene activated both the GAS (gamma activating sequence), and the ISRE (interferon-sensitive responsive element) promoter elements. Thus, it is likely that this gene activates pro-myeloid, leukemic, or more generally, other cells or cell-types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. ISRE is a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a

large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The translation product of this gene was shown to have homology to a conserved trypsin inhibitor which is thought to play an essential role in protein metabolism and regulation (See Genbank Accession No. pirlS35098lS35098). In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: FYPPMTQGKESLPLLALQIFNTTFRPSFAFFSGHRTLFFGVRSPNPPKPRIFLIW LIAVAL (SEQ ID NO:434), LLALQIFNTTFRPSFAFFSGHRTLFFGVRSP (SEQ ID NO:435), HLAQTVMMHPQKSFYQVKNTNHSDRGAIEETQILEDRLGQIPLCLES QIWEA (SEQ ID NO:436), KNTNHSDRGAIEET QILEDRLGQIPLCL (SEQ ID NO:437), QGCYRRDS NIGRQVRPDSIMLRKPDLGSITHYGSVLGNLNYCDLP QLYRNPSLGNSGMREMFSPFYNPVECHP (SEQ ID NO:438), PDSIMLRKPD LGSITHYGSVLGN (SEQ ID NO:439), and/or YRNPSLGNSGMREMFSPFYNPV (SEQ ID NO:440). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in brain frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly disorders of the central nervous system or endocrine system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system or endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain frontal cortex, combined with the detected GAS and ISRE biological activities indicates polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of disoders of the central nervous system, caused by trauma, inflammation, demyelination, neoplasia, and degenerative diseases. Additionally, the molecule may function as a neuropeptide or hormone.

Moreover, considering the homology to a trypsin inhibitor and its localization in the brain, indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1263 of SEQ ID NO:45, b is an integer of 15 to 1277, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

The translation product of this gene was found to have homology to a zinc finger protein from Mus musculus (See Genbank Accession No. gnllPIDle225687) which is thought to be involved in the modulation of gene regulation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NSARGLSGGHPFPWLSEGHPF (SEQ ID NO:441), TDSDLTLGILLLGI YTNHIWEMFLAASRINSPKLEPEKSVKRQINFPSSKDVGCSLEVPKDGPPL SHGKEWIPLSHRKGWIPLSHMKGWPSLSHGKGWPP LSPRAEF (SEQ ID

NO:442), LGILLLGIYTNHIWEMFLAA (SEQ ID NO:443), KSVKRQINFPSSKDV GCSLEVPKDGPP (SEQ ID NO:444), GKEWIPLSHRKGWIPLSHMKGWPSLSH (SEQ ID NO:445), GWASTQPRERMDPAQPQERMDPSQPHERMALTQPWKRMAP TQPSCRI (SEQ ID NO:446), and/or PAQPQERMDPSQPHERMALTQPWK (SEQ ID NO:447). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:160 as residues: Ser-30 to Asp-39.

The tissue distribution in neutrophils indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders involving neutrophils, including neutropenia. The expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue

injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The protein product of this gene can be used in the preparation of therapeutic compositions, for treating, preventing or delaying the recurrence of a tumour or neuronal disorders, e.g. genetic diseases or acquired degenerative encephalopathies such as Alzheimer's disease. Moreover, the protein is also useful in the induction or inhibition of cellular apoptosis resulting in inhibition of tumour cell growth, to suppress tumour formation, to induce G1 arrest of the cell cycle and to act as nuclear transcription factor. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 428 of SEQ ID NO:46, b is an integer of 15 to 442, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

When tested against U937 and K562 cell lines, supernatants removed from cells containing this gene activated both the GAS (gamma activating sequence), and the ISRE (interferon-sensitive responsive element) promoter elements. Thus, it is likely that this gene activates pro-myeloid, leukemic, or more generally, other cells or cell-types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. ISRE is a promoter element found upstream in

many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The protein product of this gene was found to have homology to the G-protein coupled receptor TM1 long consensus polypeptide (See Genbank Accession No. R50790) which indicates the protein is useful in the modulation of signalling events, cell-cycle regulation and/or transcriptional regulation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IANGGGRPIKLNALYK IQNECKIVFTCIDF (SEQ ID NO:448), and/or MPCIK SKMNAKLFSLVLTLCCMIPISVLFGTCI (SEQ ID NO:449). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in duodenum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal diorders, particularly abnormalities of the duodenum. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in duodenum, the homology to the TM1 g-protein coupled receptor consensus sequence, in addition to the detected GAS and ISRE biological activities, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of the abnormalities of the duodenum, particularly proliferative conditions such as cancers. Moreover, the protein can be used in G-protein coupled receptor ligand binding assays. The assay can be used to identify fragments from GPR proteins (see Genseq Accession Nos. R48686-R48758 for examples) which retain biological activity such as binding a GPR ligand or

modulating GPR ligand binding to a GPR (see Genseq Accession Nos. R48759-R48758, R50569-R50807 and R89189-R89195 for examples of polypeptide fragments). The polypeptide fragments can be used in compositions for treating subjects suffering from a pathology related to a GPR abnormality e.g. a psychotic disorder such as schizophrenia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 876 of SEQ ID NO:47, b is an integer of 15 to 890, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

The translation product of this gene shares sequence homology with a growth and transformation dependent protein (>gil207250), which is thought to be important in the regulation of cellular growth and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: QVAMGSLSGLRLAAGSCFRLCERDVSSSLRLTRSSDLKRINGFCTKPQESPG APSRTYNRVPLHKPTDWQKKILIWSGRFKKEDEIPETVSLEMLDAAKNK (SEQ ID NO:450), GLRLAAGSCFRLCERDVSSSLRLTR (SEQ ID NO:451), APSRTYNR VPLHKPTDWQKK (SEQ ID NO:452), IWSGRFKKEDEIPETVSLEMLDA (SEQ ID NO:453), MDFAQNHRKVPELHPALTTECLYTNLRIGRKRSSYGQVASKRKM KSQRLSRWRCLMLQRTRCE (SEQ ID NO:454), KVPELHPALTTECLYTNLR (SEQ ID NO:455), KRSSYGQVASKRKMKSQRLSRWRCLM (SEQ ID NO:456), INGFCTKPQESP (SEQ ID NO:457), RVPLHKPTD (SEQ ID NO:458), WSGRFK KE (SEQ ID NO:459), EMLDAAKNK (SEQ ID NO:460), SYLMIALTV (SEQ ID NO:461), and/or MVIEGKKAA (SEQ ID NO:462). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, or endocrine disorders, particularly abnormalities of the ovary. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:162 as residues: Lys-25 to Thr-33, Leu-39 to Glu-47.

The tissue distribution in ovary, combined with the homology to the growth and transformation dependent protein, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of the abnormalities of the ovary such as ovarian cancer. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 723 of SEQ ID NO:48, b is an integer of 15 to 737, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RPGMRALGSCLSLLALCSPQARPGPRTLDASTATLTPHF SPCARFSPVGPSAVPFAATPLPLAGPHQP (SEQ ID NO:463), GSCLSLLALCS PQARPGPRT (SEQ ID NO:464), HFSPCARFSPVGPSAVPFAATPL (SEQ ID NO:465), AIEERNKSRLTQQASEPTGSPRYLHEQHPGSRSQMDCGSLTMXCPPP RVRDDRTSARGVPRQAAPDIVGGRPSSRACVSXPACAPSAAVFPY (SEQ ID NO:466), LTQQASEPTGSPRYLHEQHPGSRS (SEQ ID NO:467), and/or SARG VPRQAAPDIVGGRPSSRACVS (SEQ ID NO:468). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in ovarian tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive or endocrine disorders, particularly ovarian tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, endocrine cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:163 as residues: Met-1 to Gly-6, Trp-23 to Arg-29, Ala-38 to Ser-45.

The tissue distribution in ovarian tumor tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of reproductive disorders, particularly ovarian conditions, such as tumors. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 557 of SEQ ID NO:49, b is an integer of 15 to 571, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PRVRKTPHLSASGK (SEQ ID NO:469), YYYSMLKICHITI LETLSDRTPRKFAK KCYILYIKLSDSSVEKVAYTLLLLIPAAIEKK (SEQ ID NO:470), and/or TILETLSDRTPRKFAK KCYILYIKLSDSSVEK (SEQ ID NO:471). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in endometrial stromal cells treated with estradiol.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly cancer of the endometrium. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, endometrial, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:164 as residues: Met-1 to Ser-7.

The tissue distribution in endometrial stromal cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of diseases of the endometrium, particularly cancer or diseases caused by hormonal imbalances. Protein, as well as, antibodies directed against the protein may

show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 342 of SEQ ID NO:50, b is an integer of 15 to 356, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

The translation product of this gene shares sequence homology with the smaller hepatocellular oncoprotein which is thought to be important in protein synthesis leading to cellular transformation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: VHTKEIFRERSAGFPVK (SEQ ID NO:472), LEMGFQPTKEINARGSEPCQAQSTSLPKLPRWGSRPEAPQTPQGG LESRCCTPVSKQSLNLKADRFKALTLGRAQWLT PVIQALSELRWVDHLRSGV (SEQ ID NO:473), FQPT KEINARGSEPCQAQSTSLPK (SEQ ID NO:474), PKLPR WGSRPEAPQTPQGGLESRCCTP (SEQ ID NO:475), and/or RFKALTLGRAQWLT PVIQALSELRWVD (SEQ ID NO:476). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human bladder.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, urogenital disorders, particularly proliferative conditions, such as bladder tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bladder, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., urogenital, bladder, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal

fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:165 as residues: Pro-30 to Lys-38, Pro-45 to Ile-60, Leu-79 to Ser-96, His-98 to Gly-118.

The tissue distribution in bladder tumors indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of carcinomas and preneoplastic or pathological conditions of bladder, or of the urogenital/renal system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 899 of SEQ ID NO:51, b is an integer of 15 to 913, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RIPLQSDGSFLHEKSSQQRSNRNFPCPTLQCNPEVSFWFV VTDPSKNHTLPAVEVQSAIRMNKNRINNAFFLNDQTLEFLKIPSTLAPPMDPS VPIWIIIFGVIFCIIIVAIALLILSGIWQRRRKNKEPSEVDDAEDKCENMITIENGIP SDPLDMKG GHINDAFMTEDERLTPL (SEQ ID NO:477), PCPTLQCNPEVSF WFVVTDPSKNHT (SEQ ID NO:478), AIRMNKNRINNAFFLNDQTLEFL (SEQ ID NO:479), IWQRRRKNKEPSEVDDAEDKCENM (SEQ ID NO:480), PLDMKG GHINDAFMTEDER (SEQ ID NO:481), GSRTTALQRGVSLSSSVMKASLICPP FMSRGSEGMPFSIVIMFSHLSSASSTSDGSLFFLLRCQIPDKISSAIATMM MQNITPNIIIQMGTDGSMGGASVEGIFKNSRVWSFRKKALLIRFLFILMADCTST A GRV (SEQ ID NO:482), VSLSSSVMKASLICPPFMSRGSEGMPFS (SEQ ID

NO:483), and/or SMGGASVEGIFKNSRVWSFRKKAL (SEQ ID NO:484). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in kidney, and to a lesser extent, in gall bladder and testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the renal, urogenital, or reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, urogenital, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:166 as residues: Lys-60 to Ala-66, Thr-78 to Ser-83.

The tissue distribution in kidney indicates the protein product of this gene could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Moreover, the tissue distribution in gall bladder indicates that the protein is useful for the treatment, detection, and/or prevention of various metabolic disorders. Alternatively, the expression within testes indicates that the protein is useful in normal testicular function. Therefore, this gene product may be useful in the treatment of male infertility, and/or could be used as a male contraceptive. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1342 of SEQ ID NO:52, b is an integer of 15 to 1356, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GARGSQQDAPALQEAEVRGPERAQPARGR (SEQ ID NO:485), SERPGEGPARPGQDDQGPAVPAVAGAGVGVHDPADHRVLGQRSAA HFYLHTSFSRPHTGPPLPTPGPDRTGSSRPTPMSTSFWTISHAGVKQSDLPRKE TEQPPAPGEHGGERERLRLVPARRPAQPRPGPAAGGAEERAAGLLRQLQP GLPHQGARIRRHPQLGAEPPDRGRPARGHLLLRAQGGLHQLEARDDRAER KPAAPRCALPRPAAHPARARAQRQRAPDLQQVLAPLREALPPPHEGQAQEVHQ VPLRARPLRAPDLRLPQQVRAGERGVLPQVRRAHAAGVRQPHQPARLGAR GLPRWPQGVLRQLHPVPAGPAHGEAGALQRALAAGVPPLPPVPDRLRFLG KLETLDEDAAQLLQLLQVDRQSASPRATGTGPPAAGRRTGSPRSPWPGG SSCINSTRPTLFSSATPSPKTSSETESFRVAFSRVPGT (SEQ ID NO:486), RPGQ DDQGPAVPAVAGAGVGVHDPA (SEQ ID NO:487), SRPHTGPPLPTPGPDRT GSSR (SEQ ID NO:488), SHAGVKQSDLPRKETEQPPAPGE (SEQ ID NO:489), RRPAQPRPGPAAGGAEERAAGLL (SEQ ID NO:490), RRHPQLGAEPPDRGR PARGHLLL (SEQ ID NO:491), RDDRAERKPAAPRCALPRPAAHPAR (SEQ ID NO:492), RAPDLQQVLAPLREALPPPHEGQAQEV (SEQ ID NO:493), DLRLPQQ VRAGERGVLPQVRRAHAAG (SEQ ID NO:494), QPARLGARGLPRWPQGVLR QLHPVPAG (SEQ ID NO:495), AGVPPLPPVPDRLRFLGKLETLDE (SEQ ID NO:496), QLLQLLQVDRQSASPRATGTGPPAA (SEQ ID NO:497), NSTRPTLFSS ATPSPKTSSETESFR (SEQ ID NO:498), LGGKRTAGPPGVAAAAARRPRPE SPASPGIVVDLARVAEAVHLPPVLVEGRQLLRVRVQQVLDEVGEGHLEASA EGLARRGGQAGVVGVHPQHGHGELAVELLVLQLELAAEGGDQAHEGVAHEE ELGVLLELDLHEVAGELPVAAPELVEGQVRAGVVHVLARDAQRVAVGRTA VQQASAQHDHHALPVGAGHLGHVAVDGPVPVVHDQVAQLRVGDVVECALLG GEGQAGVGAEAPQHVPPLRLLPALVWAAPGVARGPVVASHALLHAPPA QAAAPSPFWEGHSASRQHEKLSRNSSTSESAVSS LSCPARAWAAAAPCAA (SEQ ID NO:499), EAVHLPPVLVEGRQLLRVRVQQV (SEQ ID NO:500), GHLEA SAEGLARRGGQAGVVGVHP (SEQ ID NO:501), QLELAAEGGDQAHEGVAHE

EELGVLLEL (SEQ ID NO:502), GELPVAAPELVEGQVRAGVVHVLARDA (SEQ ID NO:503), AVQQASAQHDHHALPVGAGHLGHVA (SEQ ID NO:504), ALVW AAPGVARGPVVASHALLHA (SEQ ID NO:506), HDQVAQLRVGDVVECALLG GEGQAG (SEQ ID NO:505), PPAQAAAPSPFWEGHSASRQHEKLSRNS (SEQ ID NO:507), SRVTFPERRRSSRLRRGSMEESVRGYDWSPRDARRSPDQGRQQAE RRNVLRGFCANSSLAFPTKERAFDDIPNSELSHLIVDDRHGAIYCYVPKV ACTNWKRVMIVLSGSLLHRGAPYRDPLRIPREHVHNASAHLTFNKFWRRYGK LSRHLMKVKLKKYTKFLFVRDPFVRLISAFRSKFELENEEFYRKFAVPMLRVY ANHTSLPASAREAFRAGLKVSFANFIQYLLDPHTEKLAPFNEHWRQVYRLC HPCQIDYDSWGSWRLWTRTPRSCCSYSRWTGSPLPPELPEQDRQQLGGGLVR QD PPGLEAAAV (SEQ ID NO:508), RSPDQGRQQAERRNVLRGFCANSSLA (SEQ ID NO:509), TKERAFDDIPNSELSHLIVDDRHGAIYC (SEQ ID NO:510), FNKFWRRYGKLSRHLMKVKLKKY (SEQ ID NO:511), FVRLISAFRSKFELE NEEFYRKFA (SEQ ID NO:512), TSLPASAREAFRAGLKVSFANFIQYL (SEQ ID NO:513), and/or SYSRWTGSPLPPELPEQDRQQLGGG (SEQ ID NO:514). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

It has been discovered that this gene is expressed primarily in PMA activated monocytic HL60 cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: blood related disease such as leukemia. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:167 as residues: Ala-29 to Thr-37, Pro-39 to Leu-63.

The tissue distribution in HL60 cells suggests the protein product of this clone is useful for the diagnosis, treatment, and/or prevention of blood related diseases such

as leukemia. Moreover, the protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1533 of SEQ ID NO:53, b is an integer of 15 to 1547, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates fibroblasts, or more generally, other cells or cell types, through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: STGCSE (SEQ ID NO:515),

CLCLGCGLPELHSYLDPGPYLLVYPTLFWLCPSAVSPWAYTCYQLGLGPQWGA AALSFTVDAAIRVWDVSTETCVPLPWFRGGGVTNCSGPQTAAKSWLPLLQLSF ESGRPRCGLVRGGLLYQGAVRLAA GAQMAADCCSLYWESH (SEQ ID NO:516), YPTLFWLCPSAVSPWAYTCYQLGLGP (SEQ ID NO:517), DVSTETCVP LPWFRGGGVTNCSGPQ (SEQ ID NO:518), LLYQGAVRLAA GAQMAADCCSL (SEQ ID NO:519), NKRKTYLFLEVGMWGVGQNRWWPWERVPRGRGWGCL SKEGQVMNRASTPSRGFLGPPKHWAKTWKLGIDKVQRDVGNSACGPAH TEQGPFVEGRWKVMSWGWAPGSPWIMPQGRSSNTGLFRVRKRRMTGLPS CTLGFPFISTARRSPLGSQTME (SEQ ID NO:520), GVGQNRWWPWERVPRG RGWGCLSKEG (SEQ ID NO:521), AKTWKLGIDKVQRDVGNSACGPAHTE (SEQ ID NO:522), and/or WAPGSPWIMPQGRSSNTGLFRVRKRRMTGLPSC TLGFPFIST (SEQ ID NO:523). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal tissues such as fetal brain, fetal liver, fetal kidney, and to a lesser extent, in T cells and macrophages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, blood-related, immuno-related, neural-related, or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoesis and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, hematopoietic, urogenital, renal, hepatic, metabolic, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, bile, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:168 as residues: Cys-126 to Thr-138, Glu-165 to Gly-172, Thr-189 to Leu-200, Gly-222 to Gly-229, Pro-346 to Lys-354.

The tissue distribution in fetal liver indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of blood related diseases, particularly immune or hematopoietic disorders. Alternatively, the expression within fetal brain indicates polynucleotides and polypeptides

corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Alternatively, the expression within fetal kidney indicates the protein product of this gene could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Moreover, the expression within various fetal tissues, combined with the detected EGR1 biological activity, indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1324 of SEQ ID NO:54, b is an integer of 15 to 1338, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SSYQCPKVTFFKSSVDT (SEQ ID NO:524). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 15. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 15.

This gene is expressed primarily in glioblastoma, liver, fetal lung, and amygdala.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, metabolic, or developmental disorders, particularly mental or neurodegenerative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, metabolic, developmental, pulmonary, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, pulmonart surfactant or sputum, bile, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:169 as residues: Pro-31 to Ala-37, Lys-62 to Asn-72.

The tissue distribution in glioblastoma and amygdala indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of central nervous system disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,

learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The protein may also be useful in the treatment, detection, and/or prevention of liver disorders, which include, but are not limited to hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2057 of SEQ ID NO:55, b is an integer of 15 to 2071, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 46

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: YIYSYLGFFNQINK (SEQ ID NO:525). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed in only T-cell helper II cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly infectious diseases, inflammatory, or immunodefiency conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:170 as residues: Pro-44 to Tyr-49.

The tissue distribution in T-helper cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment of infectious diseases. Moreover, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1885 of SEQ ID NO:56, b is an integer of 15 to 1899, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The translation product of this gene has been shown to have homology to the human nuclear factor IV (See Genbank Accession No. gil35038), which is thought to play a role as a type 2 DNA helicase in DNA metabolism either during transcription, DNA repair, and/or during the cell-cycle. Moreover, the protein may play a role in chromosomal translocations. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARDLIL (SEQ ID NO:526), LTFYL QFLAPKDKPSGDTAAVFEEGGDVDDLVSTFNMHLVFCD (SEQ ID NO:527), and/or FLAPKDKPSGDTAAVFEEGGDVDDL (SEQ ID NO:528). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

This gene is expressed primarily in activate T-cells, and to a lesser extent, in B-cells and monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly leukemia, Grave's disease, rheumatoid arthritis and other autoimmune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:171 as residues: Gly-27 to Cys-35.

The tissue distribution in T-cells, B-cells, and monocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment or diagnosis of immune system diseases. Moreover, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1529 of SEQ ID NO:57, b is an integer of 15 to 1543, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARAGAKILFEGEF (SEQ ID NO:529), NFEIHSAFPFMLFVA CLLHSSCPRTARFLASPLSESNVIFYQNQYQFPCILCFIEFARLTSFKHLIHSQSH LVRLQYEDFSVSSE AWDTELT (SEQ ID NO:530), FPFMLFVACLLHSSCPRTA RFLASPL (SEQ ID NO:531), NVIFYQNQYQFPCILCFIEFARLTSF (SEQ ID NO:532), and/or SQSHLVRLQYEDFSVSSE AWDTE (SEQ ID NO:533). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

This gene is expressed primarily in fetal tissues such as fetal liver, fetal brain, fetal lung and fetal spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, hepatic, immune, hemaopoietic, neural, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:172 as residues: Gly-37 to Asp-46, Ser-48 to Val-54.

The tissue distribution in fetal tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of developmental disorders and cancers. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. The protein is also useful in the treatment, detection, and/or prevention of immune, hematopoietic,

pulmonary, or metabolic diseases, disorders, and/or conditions. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1119 of SEQ ID NO:58, b is an integer of 15 to 1133, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 49

The translation product of this gene was found to have homology to a 35kd pulmonary surfactant protein, as well as, a GABA-like receptor (See Genbank Accession Nos. P70663, and gil540271, respectively), the latter of which is thought to be important in neuronal function. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: QKFLCASDGD (SEQ ID NO:534), AEVPLRVRRRHGRPHGPGGRQLALGIPALRSLPGCVPRHHGC SPGYGCLHRRILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGF EASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFF PSLDPVPDSPNFEVIXPXWGTVGCCGWVWGRCI (SEQ ID NO:535), GPGG RQLALGIPALRSLPGCVPRHHGC (SEQ ID NO:536), FEASPPAQGIPEAK VRHPLSYVAQR (SEQ ID NO:537), DMSLGMWQHQWDKMDTGPPSQAPD TGHGGETSPPWHALGSPVLPEAALLSDFLFVPQWLWGQACLPTGHRHLPQLPP TSSF SEDLSTG (SEQ ID NO:538), PPSQAPDTGHGGETSPPWHALGS (SEQ ID NO:544), PVDRSSEKLLVGGSWGRWRWPVGRQAWPQSHCGTKRKSDRR AASGKTGEPSACHGGEVSPPCPVSGAWEG GPVSILSH (SEQ ID NO:539), PVDRSSEKLLVGGSWGRWRWPV (SEQ ID NO:540), TKRKSDRRAASG KTGEPSACHGGEV (SEQ ID NO:541). MTSKFGESGTGSRDGKKTSPGPG

GDRGVLGSESRCRPDSEGCRWAT (SEQ ID NO:542), and/or SPGPGGDRGV LGSESRCRPD (SEQ ID NO:543). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in hematopoiesis cells such as neutrophils, eosinophils and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, blood diseases and/or immune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoeitic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:173 as residues: Ser-44 to Ala-63, Pro-89 to Gly-98, Pro-129 to Trp-137.

The tissue distribution in neutrophils, eosinophils, and T cells indicates polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosis blood related diseases. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The homology to a pulmonary surfactant protein indicates that the protein is useful in enhancing or inhibiting the efficacy of the immune response across mucosal barriers, such as within the gastrointestinal tract, the sinuses, and the lungs. Protein, as well as, antibodies directed against the protein may

show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1476 of SEQ ID NO:59, b is an integer of 15 to 1490, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyeloid cells, or more generally, other cells of the immune or central neurvous system, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HEVQPSYLPSNSGLI (SEQ ID NO:545). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the central nervous system, adult liver, adult heart, and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, cardiovascular, or metabolic conditions or disorders. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cardiovascular, developmental, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tissues of the CNS and infant brain, combined with the detected GAS biological activity indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of CNS disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1322 of SEQ ID NO:60, b is an integer of 15 to 1336, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LRISVLCRETACNWSHHPLDSN (SEQ ID NO:546). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 18. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 18.

This gene is expressed in whole brain, embryos, fetal liver and fetal spleen, and melanocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, immune, hematopoietic, or developmental disorders, particularly mental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, hematopoietic, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:175 as residues: Pro-27 to Lys-42.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of mental or neurodegenerative disorders. Alternatively, the expression within fetal

liver/spleen indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The protein may also be useful for the treatment and/or detection of metabolic disorders, which include Tay-Sachs disease, phenylkenonuria, galactosemia, hyperlipidemias, porphyrias, and Hurler's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1691 of SEQ ID NO:61, b is an integer of 15 to 1705, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

When tested against U937 and fibroblast cell lines, supernatants removed from cells containing this gene activated both the GAS (gamma activating sequence) and EGR1 (early growth response gene 1) promoter elements. Thus, it is likely that this gene activates promyeloid cells, fibroblasts, or more generally, immune or integumentary cells or cell-types, through the JAK-STAT and/or EGR1 signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LTVTVRNPGSTHASGRPRRRSGVWARRGLVWQ (SEQ ID NO:547). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in endometrial stromal cells and fetal brain tissue, and to a lesser extent, in microvascular endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, neural, developmental, or vascular disorders, particularly vascular leak syndrome and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endothelium, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, neural, developmental, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:176 as residues: Pro-63 to Cys-72, Gly-88 to Cys-93.

The tissue distribution in endometrial stromal cells, infant brain, and microvascular endothelial cells, combined with the detected GAS and EGR1 biological activities, indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment of various vascular disorders, which include, but are not limited to vascular leak syndrome, microvascular disease, atherosclerosis, aneurysm, stroke, embolism and inflammation. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could

again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1017 of SEQ ID NO:62, b is an integer of 15 to 1031, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of HUVEC cells to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both vascular endothelial cells, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating endothelial cells, or more generally, neural or immune cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell. This protein is homologous to members of the butyrophilin gene family which are thought to play a role in myelin sheath development, in addition to serving as a membrane-specific receptor for cytoplasmic vesicles to the apical plasma membrane. In specific embodiments, polypeptides of the invention comprise the sequence SAQFSVLGPSGPILAMVGEDADLPCHLFPTMSAETMELKW (SEQ ID NO:574). Polynucleotides encoding these polypeptides are also encompassed by the invention. In specific embodiments, polypeptides of the invention comprise the sequence TPCSAQFSVLGPSGPILAMVGEDADLPCHLFPTMSAET (SEQ ID NO:548), MELKWVSSSLRQVVNVYADGKEVEDRQSAPYRGRTSILRDGITAGKAALRIHN

VTASDSG (SEQ ID NO:549), LEVKGYEDGGIHLECRSTGWYPQPQI (SEQ ID NO:550), MASSLAFLLLNFHVSLLLVQLLTPCSAQFSVLGPSGPILAMVGE DADLPCHLFPTMSAETMELKWVSSSLRQVVNVYADG (SEQ ID NO:551), RHELSHNRKNGELLIDRLYSVGSDSPMGIPRDIIFTDGFPYWNPKVKTLKDRHF WQSIDENGKFPGFPSA QLSCLPPLGPAAHSLLSSVFCAWTLWAHPGHGG (SEQ ID NO:552), LLIDRLYSVGSDSPMGIPRDIIFT (SEQ ID NO:553), NPKVKT LKDRHFWQSIDENGKFPGF (SEQ ID NO:554), LGPAAHSLLSSVFCAWTLWA HPGH (SEQ ID NO:555). RLQHWVLIFTLEVKGYEDGGIHLECRSTGWYPQP QIQWSNAKGENIPAVEAPVVADGVGLYEVAASVIMRGGSGEGVSCIIRNSLL GLEKTASISIADPSSGAPSPGSQPWQGPCLSCCCFSPEPVTSCGDNRRK (SEQ ID NO:556), GGIHLECRSTGWYPQPQIQWSNAKG (SEQ ID NO:557), PQIQWS NAKGENIPAVEAPVVADGVGL (SEQ ID NO:558), NIPAVEAPVVADGVGL YEVAASVIMRG (SEQ ID NO:559), SGAPSPGSQPWQGPCLSCCCFSPEPVT (SEQ ID NO:560), SSSICDHERRLRGGCILHHQKFPPRPGKDSQHFHRRP FFRSAQPWIAALAGTLPILLLLLAGASYFLWRQQKEITALSSEIESEQEMKE MGYAATEREISLRESLQEELKRKKIQYLTRGEESSSDTNKSA (SEQ ID NO:561), KDSQHFHRRPFFRSAQPWIAALAGTLPI (SEQ ID NO:562), EIESEQEMKE MGYAATEREISLRESLQE (SEQ ID NO:563), VNNMIAFYSARDSYVYPHFSG EEMLQMRLHLVK (SEQ ID NO:564), TPCSAQFSVLGPSGPILAMVGEDADLP CHLFPTMSAET (SEQ ID NO:565), KWVSSSLRQVVNVYADGKEVEDR (SEQ ID NO:566), RTSILRDGITAGKAALRIHNVTASD (SEQ ID NO:567), CYFQDGDFY EKALVELKVAALGS (SEQ ID NO:568), GYEDGGIHLECRSTGWYPQPQIQ (SEQ ID NO:569), NIPAVEAPVVADGVGLYEVAASV (SEQ ID NO:570), QQKEITALSS EIESEQEMKEM (SEQ ID NO:571), LRESLQEELKRKKIQYLTRGEESS (SEQ ID NO:572), and/or GEEMLQMRLHLVK (SEQ ID NO:573). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in rhabdomyosarcoma, and to a lesser extent, in T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscle, immune, or neural disorders, particularly rhabdomyosarcoma, infectious diseases, or neurodegenerative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders

of the above tissues or cells, particularly of the immune system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., muscle, immune, neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:177 as residues: Ala-78 to Arg-94.

The tissue distribution in rhabdomyosarcoma, the detected calcium flux biological activity, combined with the homology to the butyrophilin gene family indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or treatment of muscle disorders, which include, but are not limited to, muscular dystrophy, cardiomyopathy, fibroids, myomas, and/or rhabdomyosarcomas. Moreover, the homology to the butyrophilin protein indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The protein may also show utility in the correction or amelioration of myelin sheath deficiencies in developing and mature neurons and neural-cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1575 of SEQ ID NO:63, b is an integer of 15 to 1589, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 54

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PQGGLTLPSVWG (SEQ ID NO:575), GGPCHLWLLGPRRT QLPGRRASLPFRSQGELTQAFLLGLWKHQMPALTQEQQVRAERRREAVRMEI PGLFFASLANWGLLYRTSQDFISPYLCAAPSTPHPPLGGP (SEQ ID NO:576), GPRRTQLPGRRASLPFRSQGELT (SEQ ID NO:577), QMPALTQEQQVRAER RREAVRMEI (SEQ ID NO:578), and/or ANWGLLYRTSQDFISPYLCAAPSTP (SEQ ID NO:579). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in brain, and to a lesser extent, in testes tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, endocrine, or reproductive disorders, particularly depression and infertility disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, endocrine, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:178 as residues: Thr-26 to Glu-33.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of depression and

other endocrine-related disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The protein product may also be useful in the treatment, detection, and/or prevention of a variety of reproductive disorders which include, but are not limited to, the treatment of male infertility, and/or could be used as a male contraceptive. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1074 of SEQ ID NO:64, b is an integer of 15 to 1088, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 55

The translation product of this gene was found to have homology to the conserved R166.2 protein from Caenorhabditis elegans (See Genbank Accession No.gil949849), which is thought to play an important role in the regulation of cellular function and processes. In specific embodiments, polypeptides of the invention comprise the sequence: LSFKDKSTYIESSTKVYDDMAFRYLSWILFPLLG (SEQ ID

NO:580), CYAVYSLLYLEHKGWYSWVLSM (SEQ ID NO:590), LLTFGFITMTPQ LFINYKLKSVAHLPWRMLT (SEQ ID NO:581), TYKALNTFIDDLFAFVIKMP VMYRIGCLRD (SEQ ID NO:582), DVVFFIYLYQRWIYRVDPTRVNEFGMSGED (SEQ ID NO:583), VAGIFPRLSFKDKSTYIESSTKVYDDMAFRYLSWILFPLLG CYA (SEQ ID NO:584), PWVAGIFPRLSFKDKSTYIESSTKVYDD (SEQ ID NO:586), AGEDSCHPVLSVQPDVHDLGWQESSPAYPSRTSPRISSPRPKC MMIWHSGTCPGSSSR SWAAMPSTVFCTWSTRAGTPGCSACSTASC (SEQ ID NO:587), LSVQPDVHDLGWQESSPAYPSRTSPRISSP (SEQ ID NO:588), GSSSR SWAAMPSTVFCTWSTRAGTP (SEQ ID NO:589), and/or WAAMPSTVFCTWS TRAGTP (SEQ ID NO:585). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in colon, smooth muscle and fetal bone.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal or vascular disorders, and abnormal muscular-skeletal development, including proliferative conditions such as cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and musclar-skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., gastrointestinal, muscle, skeletal, vascular, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:179 as residues: Ser-128 to Thr-133, Thr-158 to Thr-166, Leu-168 to Gly-175, Ala-179 to Asp-196.

The tissue distribution in colon and fetal bone indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of abnormal bone formation, and/or various proliferative conditions (e.g. tumors), particularly of the gastrointestinal system. Moreover, the expression within smooth muscle tissue indicates polynucleotides and polypeptides corresponding to this gene are

useful for the detection, treatment, and/or prevention of a variety of vascular disorders, which include, but are not limited to the following: embolism, atherosclerosis, microvacular disease, aneurysm, stroke, and vascular leak syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1242 of SEQ ID NO:65, b is an integer of 15 to 1256, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LGEFLSSQCFLP (SEQ ID NO:591). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in brain frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly neurological or neurodegenerative disorders and diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:180 as residues: Ala-122 to Gly-128.

The tissue distribution in brain frontal cortex indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of some neurological diseases such as depression. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:66 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1588 of SEQ ID NO:66, b is an integer of 15 to 1602, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates pro-myeloid cells, or more generally, immune or hematopoietic cells, through the JAK-STAT signal transduction pathway. GAS is a

promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RSRRNRVAMGMWASLDALWE (SEQ ID NO:592), PRVRCQQRAEGGMGAG IGVGPSERTDIAVTPRGRSEGASVGVAPVHAEGAGGTGWPWGCGHRWTLCG RCR PRSVSSGPCCSFPGQCIFGRPS (SEQ ID NO:593), GGMGAGIGVGPSER TDIAVTPRGR (SEQ ID NO:594), GCGHRWTLCGRCR PRSVSSGPCCSFP (SEQ ID NO:595), and/or KKHGF NQQTLGFFTWKYNKNKNLV (SEQ ID NO:596). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in synovial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal afflictions, particularly rheumatoid arthritis or autoimmune conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:181 as residues: Gln-27 to Val-39, Glu-50 to Arg-56.

The restricted tissue distribution in synovium, combined with the detected GAS biological activity, indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of rheumatoid arthritis since synovial fibroblasts are associated with the synovium and cartilage. Moreover, polynucleotides and polypeptides corresponding to this gene are useful in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis, bone

cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). The protein may also be useful in the modulation of the immune response to regions of inflammation, or in inhibiting or ameliorating autoimmune responses. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 924 of SEQ ID NO:67, b is an integer of 15 to 938, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates pro-myeloid cells, or more generally immune or hematopoietic cells, in addition to other cells or cell-types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PKLLPCSPAEGHTSLGPLLPF (SEQ ID NO:597), ASLELXPS KSQLSTEWGFTWIVGLGMSPSTALWTECTCTPFLVLLSHASGHFFWLSPLAS

LVIPPVTDRK (SEQ ID NO:598), WGFTWIVGLGMSPSTALWTECTCTPFLVL LSH (SEQ ID NO:599), VAVGVCREDVMGITDRSKMSPDVGIWAIYWSAAGY WPLIGFPGTPTQQEPALHRVGVYLDRGTGNVSFYSAVDGVHLHTFSCS SVSRLRPFFLVESISIFSHSTSD (SEQ ID NO:600), ITDRSKMSPDVGIWAIYW SAAGYWPLI (SEQ ID NO:601), and/or RGTGNVSFYSAVDGVHLHTFSCSSV SRLRP (SEQ ID NO:602). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in fetal tissues, and to a lesser extent, in liver cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental or liver diseases, such as hepatocellular carcinoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hepatic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, hepatic, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, bile, breast milk, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:182 as residues: Pro-30 to Gln-37, Arg-39 to Ser-45, Arg-74 to Arg-85.

The tissue distribution in liver, combined with the detected GAS biological activity indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment or diagnosis of hepatic conditions such as hepatocellular carcinoma. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer

therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1571 of SEQ ID NO:68, b is an integer of 15 to 1585, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GTRGLQNHRTE (SEQ ID NO:603). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in prostate, and to a lesser extent, in tonsil and fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, immune, developmental, or pulmonary disorders and/or diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, developmental, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, pulmonary surfactant or sputum, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:183 as residues: Lys-32 to Lys-38.

The tissue distribution in prostate indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cancers, particularly of the prostate. The expression within tonsils indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. The expression also indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Moreover, the expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1662 of SEQ ID NO:69, b is an integer of 15 to 1676, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 60

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ELSGLG (SEQ ID NO:604). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, central nervous system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:184 as residues: Tyr-15 to Lys-21, Pro-62 to Phe-68.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of CNS disorders (such as Parkinson's disease). Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1330 of SEQ ID NO:70, b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 61

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, CNS diseases, such as Alzheimers and Parkinson's disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:185 as residues: Asp-44 to Cys-53, Asp-56 to Lys-66, Ser-78 to Lys-84.

The tissue distribution in brain tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of CNS diseases such as Alzheimers and Parkinson's disease. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition,

homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1460 of SEQ ID NO:71, b is an integer of 15 to 1474, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MDDIKI (SEQ ID NO:605), NFCVSKNTFNRVKRPIKWVKIF ANDISCKRLISRIHKEILPFNNKKQPDFKVKKSRK (SEQ ID NO:606), FNRVKR PIKWVKIFANDISCKRLISRIHKE (SEQ ID NO:607), ETQMANKYMKRCSTL (SEQ ID NO:608), VIRELQVKATRRCHYTPIKWSKSKTLISSNADEYVEPTRTLI HCWWKCKIVQPLCKTAW (SEQ ID NO:609), and/or ATRRCHYTPIKWSKSKT LISSN (SEQ ID NO:610). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in duodenum, and to a lesser extent, in brain frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal, neural, or endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., gastrointestinal, neural, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal

fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in colon indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of some gastrointestinal disorders, particularly cancers. Moreover , polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1998 of SEQ ID NO:72, b is an integer of 15 to 2012, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 63

This gene is expressed primarily in bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, leukemia, immune deficiency syndromes, and other immune related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of diseases of bone marrow, such as leukemia, bone cancer and immune deficiency syndrome. Furthermore, the polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e.g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1253 of SEQ ID NO:73, b is an integer of 15 to 1267, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

When tested against sensory neuron cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates sensory neuronal cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in the testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive system-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., testes, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in testes indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of reproductive system-related diseases. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1734 of SEQ ID NO:74, b is an integer of 15 to 1748, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 65

This gene is expressed primarily in synovial fibroblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, rheumatoid arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The restricted tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of rheumatoid arthritis, since synovial fibroblasts are associated with the synovium and cartilage. In addition, the expression of this gene product in synovium indicates a role in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and

specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1556 of SEQ ID NO:75, b is an integer of 15 to 1570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 66

This gene is expressed primarily in ovarian cancer, and to a lesser extent in fetal tissues such as fetal liver and fetal brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, particularly of the ovary. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., ovary, fetal, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:190 as residues: Pro-28 to Gln-33.

The tissue distribution in ovarian cancer tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cancers; e.g., ovarian cancer, as well as other tissues where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 510 of SEQ ID NO:76, b is an integer of 15 to 524, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

This gene is expressed primarily in testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, male reproductive or hormonal related disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., testes, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:191 as residues: Pro-68 to Asp-73, Gln-92 to Glu-107, Gln-120 to Lys-126.

The tissue distribution in testes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of male

reproductive or hormonal disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1292 of SEQ ID NO:77, b is an integer of 15 to 1306, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 68

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in human tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., tonsils, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders. Expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1465 of SEQ ID NO:78, b is an integer of 15 to 1479, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 69

This gene is expressed primarily in human thymus and six week old human embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine diseases and leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endocrine, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in thymus and developing embryonic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of leukemia or other immune diseases, especially those which are involved in fetal development. Furthermore, the tissue distribution in thymus and developing embryonic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,hypoparathyroidism) , hypothallamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1780 of SEQ ID NO:79, b is an integer of 15 to 1794, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 70

This gene is expressed primarily in adult pulmonary tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the cardiopulmonary system including asthma, bronchitis, apnea, enlarged heart, arythmia, strokes and heart attacks. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiopulmonary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:194 as residues: Pro-27 to Leu-41.

The tissue distribution in pulmonary tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment or diagnosis of diseases such as arythmia, apnea, asthma and possibly for the early detection and prevention of patients likely to have strokes or heart attacks. Furthermore, the tissue distribution in pulmonary tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. Additionally, the tissue distribution indicates polynucleotides

and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1266 of SEQ ID NO:80, b is an integer of 15 to 1280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 71

When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Furthermore, contact of cells with supernatant expressing the product of this gene increases the permeability of THP-1 monocyte cells to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the monocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocyte cells.

This gene is expressed primarily in adult human spleen and adult human testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to

these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., spleen, testes, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:195 as residues: Pro-32 to Gly-39.

The tissue distribution in spleen, in addition to the biological activity data, indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune disorders. Furthermore, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in the augmentation of the numbers of stem cells and committed progenitors. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:81 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 960 of SEQ ID NO:81, b is an integer of 15 to 974, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 72

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

ELSGLVIITAWIILCHSSSKNPVGGRIQLAIAIVITLFPFISWVYIYINKEMRSSWP THCKTVI (SEQ ID NO:611), QCPQGTETEAGVSVPPRKEGGGPYVAGLTAPHVA GLTAPRRVLRAMAPALWRACNGL (SEQ ID NO:612), HSSSKNPVGGRIQLA

IAIVITLFPFISWVYIY (SEQ ID NO:613), and/or RKEGGGPYVAGLTAPHVA GLTAPRRVLRAMAP (SEQ ID NO:614). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in liver tissues, and to a lesser extent in t-cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatitis, sclerosis of the liver and cancer of the liver. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in liver indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and possible treatment of diseases of the liver. Since it is primarily found in the liver, and with the additional expression seen in T-cells, it most likely deals with the immune response in the liver, for example to diseases like hepatitis, sclerosis and hepatocellular carcinoma. More generally, the tissue distribution in liver indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1941 of SEQ ID NO:82, b is an integer of 15

to 1955, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 73

The gene encoding the disclosed cDNA is thought to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

This gene is expressed primarily in myeloid progenitor cells, and to a lesser extent in leukemic cells and eosinophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, leukimia and other blood diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoesis and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of leukemia. Furthermore, the polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e.g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 624 of SEQ ID NO:83, b is an integer of 15 to 638, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 74

The translation product of this gene shares sequence homology with "neurogenic secreted signaling protein (brn)" (see gil1150971) from Drosophila melanogaster which is thought to be important in the normal development of brain tissue. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PGRPTRPAXAGLSSGGAAQEAPQADPRPWLAR (SEQ ID NO:615). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the placenta and early embryonic tissue. Northern data has demonstrated that this gene is expressed in brain, stomach and colorectal adenocarcinoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, several types of disorders of the brain including epilepsy, mood disorders, any of a variety of types of mental retardation, and addictive disorders including alcohlism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, stomach, colon, placental, embryonic, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:198 as residues: Gln-37 to Ala-42, Thr-51 to Ala-57, Pro-71 to His-79, Glu-124 to Arg-137, Ser-151 to Val-159.

The tissue distribution and homology to Drosophila melanogaster putative neurogenic secreted signaling protein (brn) indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment of various brain disorders as well as pre-natal testing for neuropathological conditions, such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Furthermore, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 845 of SEQ ID NO:84, b is an integer of 15 to 859, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

The translation product of this gene shares sequence homology with a fat-specific secreted protein.

This gene is expressed primarily in the epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic disorders and male infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., epididymus, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:199 as residues: Tyr-21 to Asp-40, Ser-58 to Arg-64, Thr-71 to Ser-76, Ser-106 to Thr-112.

Homology to a fat-specific gene indicates that this gene may also play a role in the treatment and/or detection of metabolic disorders such as obesity, diabetes, anorexia nervosa and bulemia. In addition, its expression primarily in the epididymus indicates a role in the treatment/detection of male fertility disorders such as infertility, low sperm count, spermatorrhea and spermiation. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1115 of SEQ ID NO:85, b is an integer of 15 to 1129, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 76

The translation product of this gene shares sequence homology with Slit, a secreted Drosophila protein which plays a role in the development of axon pathway development in the central nervous system. The Slit protein is necessary for the normal development of the midline of the CNS, particularly the midline glial cells, and for the concommitant formation of the commisural axon pathways. The process is dependent on the level of SLIT protein expression. It appears that the SLIT protein is excreted by the midline glial cells, where it is synthesised and is eventually associated with the surfaces of axons that traverse them. Contact of cells with supernatant expressing the product of this gene increases the permeability of THP-1 monocyte cells to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the monocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocyte cells. Furthermore, when tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in infant brain, and to a lesser extent in adult cerebellum and frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:200 as residues: Glu-25 to Lys-33, Glu-115 to Lys-120.

The tissue distribution primarily in brain and homology to Slit, a gene involved in axon pathway development, indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment/detection of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, spinal cord injury, brain injuries, crushed (optic) nerve, amytrophic lateral sclerosis, diabetes caused nerve damage, strokes, epilepsy, multiple sclerosis, paraplegia retinal degeneration, Huntingtons Disease, facial nerve damage, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:86 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2660 of SEQ ID NO:86, b is an integer of 15 to 2674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 77

The translation product of this gene shares sequence homology with human endothelial cell multimerin, which is a secreted protein that binds to the extracellular matrix and is thought to be involved in hemostasis. Multimerin is a factor V/Va-binding protein and may function as a carrier protein for platelet factor V (J. Biol Chem 1995 Aug 4;270(31):18246-51). Contact of cells with supernatant expressing the product of this gene increases the permeability of THP-1 Monocyte cells to calcium. Thus, it is

likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the monocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocyte cells.

This gene is expressed primarily in a variety of hematopoetic cells including T-cells, dendritic cells and B-cells as well as cells and tissues of epithelial and endothelial origin including healing wounds and keratinocytes, as well as placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, acute internal injury, blood clotting disorders and other disorders of hemostasis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hemostasis, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endothelial, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:201 as residues: Ala-43 to Trp-57, Ser-81 to Gly-88, Tyr-125 to Asp-134, Pro-141 to Gly-154, Val-172 to Glu-178, Lys-296 to Gly-305, Leu-307 to Arg-314, Thr-335 to His-341.

The tissue distribution in endothelial tissues, and the homology to human endothelial cell multimerin, indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders involving the vasculature. Elevated expression of this gene product by endothelial cells indicates that it may play vital roles in the regulation of endothelial cell function; secretion; proliferation; or angiogenesis. Furthermore, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene

product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells, as supported by the biological activity data mentioned previously. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:87 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1622 of SEQ ID NO:87, b is an integer of 15 to 1636, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 78

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HYXSTPGRVPVRQFAAASTSGGPWVPGGXLEAPFQVAPSLSHSTPVFPGLI (SEQ ID NO:616). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, degenerative conditions of the bone including arthritis and osteoporosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, cancerous and wounded

tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:202 as residues: Thr-45 to Cys-50, Met-55 to Pro-60.

The tissue distribution in osteoblasts indicates polynucleotides and polypeptides corresponding to this gene are useful for treating degenerative conditions of the bone mediated by alterations in the activity ratio of osteoblasts and osteoclasts. Furthermore, elevated levels of expression of this gene product in osteoblastoma indicates that it may play a role in the survival, proliferation, and/or growth of osteoblasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1625 of SEQ ID NO:88, b is an integer of 15 to 1639, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 79

The gene encoding the disclosed cDNA is thought to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARGKYESAQPGGTQPEPGLGAR (SEQ ID NO:617). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in pituitary, cerebellum and kidney and to a lesser extent in a range of fetal tissues including lung, heart and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic, neurological, and renal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine, renal and nervous systems expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., kidney, fetal, brain, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:203 as residues: Pro-29 to Gly-34, Gln-79 to Arg-84, Arg-146 to Arg-152, Ser-183 to Ser-193, Gly-233 to His-241, Tyr-265 to Pro-278, Thr-304 to Arg-320, Leu-328 to Gly-333, Glu-385 to Arg-399.

The high expression of a secreted gene in the pituitary indicates a role for this gene or gene product in the treatment/detection of metabolic disorders associated with the endocrine system, such as growth and developmental defects. Expression in the cerebellum indicates a role in the treatment/detection of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Expression in the kidney indicates a role in the treatment/detection of renal disorders such as kidney failure, Wilms Tumor and kidney stones, as well as nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. .

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1846 of SEQ ID NO:89, b is an integer of 15 to 1860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

The translation product of this gene shares sequence homology with ras-related proteins in rats which is thought to be involved in cellular signaling.

This gene is expressed primarily in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:204 as residues: Met-40 to Thr-46, Ala-57 to Glu-64, Ser-85 to Leu-91.

The tissue distribution in immune system tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility

in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in T cells also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 825 of SEQ ID NO:90, b is an integer of 15 to 839, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in fetal liver, osteoclastoma and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the bone, haemopoietic system and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune,

haemopoietic and bone, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, skeletal, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal liver, osteoclastoma and neutrophils indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of diseases of the bone, haemopoietic and immune systems, as well as cancer. Furthermore, elevated levels of expression of this gene product in osteoclastoma indicates that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. More generally, as evidenced by expression in fetal liver/spleen, as well as the biological activity data, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in the augmentation of the numbers of stem cells and committed progenitors. Expression of this gene product in neutrophils also indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1131 of SEQ ID NO:91, b is an integer of 15 to 1145, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 82

This gene is expressed primarily in endometrial stromal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, female infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:206 as residues: Gln-26 to Asn-51.

The tissue distribution in endometrial cells indicates polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelyhood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote heathy development of the endometrium. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:92 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2036 of SEQ ID NO:92, b is an integer of 15 to 2050, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 83

The gene encoding the disclosed cDNA is thought to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in tissues of the central nervous system (predominantly the cerebellum) and immune system (predominantly the tonsils).

Nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune system and CNS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and neurological system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neurological, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:207 as residues: Pro-43 to Leu-49, Pro-61 to Gly-66, Ser-71 to Ser-83.

The tissue distribution in the immune system indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In

addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Furthermore, the tissue distribution in the central nervous system indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:93 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1159 of SEQ ID NO:93, b is an integer of 15 to 1173, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 84

This gene is expressed primarily in testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders and testes diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the testes, expression of this gene at

significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., testes, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:208 as residues: Lys-28 to His-35, Asn-58 to Gly-64, Thr-80 to Asn-86, Pro-96 to Glu-111, Pro-124 to Phe-133.

The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of testes disorders. Furthermore, the tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 808 of SEQ ID NO:94, b is an integer of 15 to 822, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

This gene is expressed primarily in infant brain, bone marrow and activated T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, immune and hematopoetic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, hematopoetic and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, developmental, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:209 as residues: Asn-23 to Val-37.

Expression in infant brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of mental retardation and other developmental disorders in addition to neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Expression of the gene in bone marrow and in B-cells indicates a role in the treatment and/or detection of immune disorders such as arthritis, asthma, immunodeficiency diseases and leukemia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1063 of SEQ ID NO:95, b is an integer of 15 to 1077, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 86

The gene encoding the disclosed cDNA is thought to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SCGSSRRSAKRSLTLKLIDFSHRI (SEQ ID NO:618). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in infant brain, fetal liver and fetal spleen, and to a lesser extent in macrophages, T-cells, erythroid cells and myeloid progenitor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, developmental and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, immune and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neurological, developing, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:210 as residues: Val-34 to Leu-48, Val-51 to Gly-67, Lys-74 to Asp-81, Thr-93 to Glu-98, Ser-138 to His-149, Ala-186 to Gln-201, Pro-257 to Arg-271.

Expression in infant brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of mental retardation and other developmental disorders in addition to neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons

Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Its distribution in fetal liver and fetal spleen indicates that this gene may play a role in the development of the hematopoetic and immune systems and that it may play a role in the treatment/detection of immune system disorders such as leukemia, arthritis and asthma. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2078 of SEQ ID NO:96, b is an integer of 15 to 2092, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 87

This gene is expressed primarily in hippocampus, and to a lesser extent in fetal heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, any of a variety of brain disorders including epilepsy, stroke, palsy, and mood disorders including unipolar and bipolar depression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, heart, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in hippocampus indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, epilepsy, stroke, palsy, and mood disorders including unipolar and bipolar depression, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1338 of SEQ ID NO:97, b is an integer of 15 to 1352, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 88

The translation product of this gene shares sequence homology with a C. elegans protein (coded for by C. elegans cDNA yk112f3.5). The gene encoding the disclosed cDNA is thought to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:
HYFLRTVSGLSVVPVSLRCCMCPPPCTGPAPATAHSPFDPPALPIQFEYQQA (SEQ ID NO:619), QLEAEIENLSWKVERADSYDRGDLENQMHIAEQRRRT LLKDFHDT (SEQ ID NO:620), VPVSLRCCMCPPPCTGPAPATAHS (SEQ ID NO:621), and/or SWKVERADSYDRGDLENQMHIAEQR (SEQ ID NO:622). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal liver and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, congenital disorders of the liver and spleen. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hepatic, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal liver and spleen indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). More generally, as evidenced by expression in fetal liver/spleen, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the numbers of stem cells and committed progenitors. Expression of this gene product in primary dendritic cells also indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:98 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 899 of SEQ ID NO:98, b is an integer of 15 to 913, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 89

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, acute immunological disorders such as inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates polynucleotides and polypeptides corresponding to this gene are useful for treating an acute inflammatory response. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 707 of SEQ ID NO:99, b is an integer of 15 to 721, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in fetal liver and fetal spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and/or immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., liver, spleen, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:214 as residues: His-23 to Leu-31, His-33 to Pro-41.

The distribution of this gene in fetal liver and fetal spleen and the biological activity data indicates it may play a role in the development of the immune and hematopoetic systems. It may, therefore, play a role in the treatment and/or detection of immune and/or hematopoetic disorders including leukemia, arthritis and asthma. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:100 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 631 of SEQ ID NO:100, b is an integer of 15 to 645, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:100, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 91

This gene is expressed primarily in brain and osteoclastoma to a lesser extent in placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, bone and reproductive disorders. Similarly, polypeptides

and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, bone and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, brain, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:215 as residues: Phe-47 to Cys-54.

Expression of this gene in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Furthermore, expression in osteoclastoma indicates a role in the treatment and/or detection of bone damage such as fractures and dislocations. Elevated levels of expression of this gene product in osteoclastoma indicates that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. Expression in the placenta indicates a role in the treatment and/or detection of pregnancy disorders such as miscarriage, birth defects, premature birth, in addition to disorders such as placenta previa and placentitis. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 549 of SEQ ID NO:101, b is an integer of 15 to 563, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 92

This gene is expressed primarily in T-cells, bone marrow, fetal liver/spleen and and to a lesser extent in adipocytes, kidney, melanocytes and stimulated fibroblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoeitic disease characterized by alterations in T cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for treating autoimmune diseases or proliferative disorders of the developing immune system. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoieitic lineages. This is particularly supported by the expression of this gene product in fetal liver and bone marrow, the two primary sites of definitive hematopoiesis. Expression of this gene product in T cells also strongly indicates a role for this protein in immune function and

immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1310 of SEQ ID NO:102, b is an integer of 15 to 1324, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 93

The gene encoding the disclosed cDNA is thought to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

This gene is expressed primarily in fetal tissues including fetal liver/spleen and to a lesser extent in lung, bone marrow, adrenal gland tumor and in the Ntera2 cell line.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers . Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adrenal gland or lungs, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developing tissues, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal and developing tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for treating tumors formed by

poorly differentiated cells, as well as tumors of other tissues where expression has been observed. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:103 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1717 of SEQ ID NO:103, b is an integer of 15 to 1731, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 94

This gene is expressed primarily in the prostate derived cell line PC3 and fetal liver/spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, prostatic hypertrophy or prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the glandular tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., prostate, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:218 as residues: Leu-26 to Ser-33.

The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the prostate including prostatic tumors or benign prostatic hypertrophy. Protein, as well as, antibodies

directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:104 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1452 of SEQ ID NO:104, b is an integer of 15 to 1466, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 95

This gene is expressed primarily in small intestine, and to a lesser extent in breast tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the small intestine. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the small intestine, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., small intestine, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:219 as residues: Glu-37 to Gly-45.

The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of diseases involving the small intestine, such as cancer of the small intestine or other tissues where expression has been indicated. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1289 of SEQ ID NO:105, b is an integer of 15 to 1303, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:105, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 96

This gene is expressed primarily in fast-growing tissues such as tumor and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, growth disorders such as tumorigenesis and growth retardation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fast-growing tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., rapidly proliferating cells, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:220 as residues: Phe-32 to Cys-37.

The tissue distribution in rapidly-proliferating tissues and cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of growth disorders. Furthermore, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are

useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:106 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1502 of SEQ ID NO:106, b is an integer of 15 to 1516, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:106, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 97

When tested against Jurkat T-cells and U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates both T-cells and myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in placenta, and to a lesser extent in the endometrium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pregnancy disorders. Similarly, polypeptides and antibodies directed to

these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., placental, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Expression of this gene in the placenta and endometrium indicates a role in the treatment and/or detection of pregnancy disorders such as miscarriage, birth defects, premature birth, in addition to disorders such as endometriosis, placenta previa and placentitis. Furthermore, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Alternatively, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelyhood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote heathy development of the endometrium. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:107 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1675 of SEQ ID NO:107, b is an integer of 15 to 1689, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:107, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 98

The gene encoding the disclosed cDNA is thought to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5. Recently another group gened and sequenced this gene, calling it MDC-3.13 isoform 1 (Genbank Accession Number: g3860095), which is believed to be a cellular factor involved in the differentiation of dendritic cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

HEAWLRSAGTREPPREQRTRRRQTAQLALQVPAPSRTPPMATDVFNSKNLAVX AQKKILGKMVSKSIATTLIDDTSSEVLDELYRVTREYTQNKKEAEKIIKNLIKTVI KLAILYRNNQFNQDELALMEKFKKKVHQLAMTVVSFHQVDYTFDRNVLSRLL NECREMLHQIIQRHLTAKSHGRVNNVFDHFSDCEFLAALYNPFGNFKPHLQKL CDGINKMLDEENI (SEQ ID NO:623), HEAWLRSAGTREPPREQRTRRRQTAQLA LQVPAPSRTPPMATDVFNSKNLAV (SEQ ID NO:624), XAQKKILGKMVSKSIAT TLIDDTSSEVLDELYRVTREYTQNKKEAEKII (SEQ ID NO:625), KNLIKTVIKLA ILYRNNQFNQDELALMEKFKKKVHQLAMTVVSFHQVDYTF (SEQ ID NO:626), DRNVLSRLLNECREMLHQIIQRHLTAKSHGRVNNVFDHFSDCEFLAALYNPF (SEQ ID NO:627), and/or GNFKPHLQKLCDGINKMLDEENI (SEQ ID NO:628). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in placenta, spleen from CLL patients and various T cell libraries, and to a lesser extent in lung, bone marrow, neutrophil, osteoclastoma, and lymphoma tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the blood particularly diseases afflicting T cells and tumors of blood cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoeitic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., placental, immune, vascular, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the blood including leukemias, lymphomas and diseases that alter T-cell function or proliferation. Furthermore, the tissue distribution in placenta indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1929 of SEQ ID NO:108, b is an integer of 15 to 1943, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:108, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 99

This gene is expressed primarily in rejected kidney, placenta, and melanocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, acute or chronic renal failure. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, placental, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:223 as residues: Thr-41 to Pro-47.

The tissue distribution in kidney indicates polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the kidney, including renal failure of either an acute or chronic nature, as well as nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:109 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1580 of SEQ ID NO:109, b is an integer of 15 to 1594, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:109, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 100

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in spinal cord, and to a lesser extent in melanocytes and fetal spleen/liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, central nervous system diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., central nervous system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spinal cord tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of central nervous system disorders, such as Alzheimers Disease, Parkinsons Disease,

Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:110 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1728 of SEQ ID NO:110, b is an integer of 15 to 1742, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:110, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 101

This gene is expressed primarily in breast and dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast related disorders and inflammatory diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast tissue and dendritic cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., breast, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in breast indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of breast related diseases and inflammatory disorders. Furthermore, the tissue distribution in breast indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of breast tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:111 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1487 of SEQ ID NO:111, b is an integer of 15 to 1501, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:111, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 102

When tested against sensory neuron cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates neuronal cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. Furthermore, when tested against both Jurkat T-cells and U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates both T-cells and myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, synovial sarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the synovial sarcoma, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., synovium, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in synovial sarcoma, and the biological activity data, suggest that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of synovial sarcoma. In general, the expression of this gene product in synovium indicates a role in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:112 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 777 of SEQ ID NO:112, b is an integer of 15 to 791, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:112, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 103

This gene is expressed primarily in human tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, relating to inflammatory diseases such as tonsilitis, and immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tonsils indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of lymphoid tissue disorders such as tonsilitis. Furthermore, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:113 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1623 of SEQ ID NO:113, b is an integer of 15 to 1637, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:113, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 104

This gene is expressed primarily in activated T-cells and prostate tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T lymphocytes related diseases and inflammation of the prostate. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:228 as residues: Arg-24 to Trp-36.

The tissue distribution in immune system tissues and prostate tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune and reproductive disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin,

the gene or protein, as well as; antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in T cells also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:114 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1574 of SEQ ID NO:114, b is an integer of 15 to 1588, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:114, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 105

This gene is expressed primarily in human adult pulmonary tissue and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, relating to the lung, neurological and immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the respiratory, nervous, and immune systems expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., pulmonary, immune, nervous, cancerous and wounded tissues) or bodily fluids (e.g.,

serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pulmonary tissue and infant brain tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment for disorders relating to the pulmonary system, the central nervous system, and the immune system. Furthermore, the tissue distribution in pulmonary tissue and fetal tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors, since the gene may be involved in the regulation of cell division. Additionally, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Also, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:115 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:115, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:115, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 106

The translation product of this gene shares sequence homology with the KIAA0132 gene product, and also shares homology to Drosophila melanogaster ring canel protein. The gene encoding the disclosed cDNA is thought to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in infant brain and B-cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, relating to the central nervous system and B cell disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., central nervous system, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:230 as residues: Thr-31 to Trp-42, Gly-49 to His-54, Gly-68 to Glu-75, Ser-77 to Trp-89, Met-142 to Gly-148.

The tissue distribution in infant brain and B-cell lymphomas indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention for central nervous system and immune

disorders. Furthermore, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Additionally, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:116 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1049 of SEQ ID NO:116, b is an integer of 15 to 1063, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:116, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 107

When tested against sensory neuron cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates neuronal cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. The gene encoding the disclosed cDNA is thought to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in human gall bladder.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, relating to gastrointestinal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., gall bladder, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:231 as residues: Pro-45 to Pro-51.

The tissue distribution in gall bladder indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of gastrointestinal disorders. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:117 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 1601 of SEQ ID NO:117, b is an integer of 15 to 1615, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:117, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 108

This gene is expressed primarily in human whole brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:232 as residues: Gln-58 to Asp-64, His-69 to Pro-76, Leu-101 to Glu-108.

The tissue distribution in brain tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of the central nervous system and endocrine system disorders. Furthermore, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:118 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1207 of SEQ ID NO:118, b is an integer of 15 to 1221, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:118, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 109

The translation product of this gene shares sequence homology with human translation initiation factor eIF3 p40 subunit.

This gene is expressed primarily in human adipose, human fetal spleen, and dentritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, adipose, immune and nerve cell disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., adipose, immune, nervous, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:233 as residues: Asn-27 to Ser-33, Gln-44 to Lys-50.

The tissue distribution fetal liver/spleen and dendritic cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune and nerve cell disorders. Furthermore, the tissue distribution in adipose tissue indicates polynucleotides and polypeptides corresponding

to this gene are useful for the treatment of obesity and other metabolic and endocrine conditions or disorders. Additionally, the protein product of this gene may show utility in ameliorating conditions which occur secondary to aberrant fatty-acid metabolism (e.g. aberrant myelin sheath development), either directly or indirectly. Also, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoieitic lineages. This is particularly supported by the expression of this gene product in fetal liver, which is a primary site of definitive hematopoiesis. Expression of this gene product in primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:119 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1135 of SEQ ID NO:119, b is an integer of 15 to 1149, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:119, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 110

The translation product of this gene shares sequence homology with Ig V-chain, which is thought to be important in immune function. When tested against Jurkat cell lines, supernatants removed from cells containing this gene activated the NF-kB transcription factor. Thus, it is likely that this gene activates Jurkat cells by activating a transcriptional factor found within these cells. Nuclear factor kB is a transcription factor activated by a wide variety of agents, leading to cell activation, differentiation, or apoptosis. Reporter constructs utilizing the NF-kB promoter element are used to screen supernatants for such activity.

This gene is expressed in human synovial sarcoma, infant brain 1NIB cells, macrophages (GM-CSF treated), human endometrial stromal cells-treated with estradiol, human pancreas tumor, hemangiopericytoma, human endometrial tumor, chronic lymphocytic leukemia and a human colon carcinoma (HCC) cell line.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers such as human synovial sarcoma, human pancreas tumor, hemangiopericytoma, human endometrial tumor, chronic lymphocytic leukemia and human colon carcinoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:234 as residues: Leu-21 to Ala-30, Ser-38 to Asp-47, Pro-87 to Asp-94, Leu-197 to Thr-204, Pro-256 to Ser-262, Thr-277 to Arg-282, Thr-293 to Trp-303.

The tissue distribution in numerous cancerous tissues, and the homology to Ig V-chain, as well as the biological activity data, indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cancers, including human synovial sarcoma, human pancreas tumor, hemangiopericytoma, human endometrial tumor, chronic lymphocytic leukemia and human colon carcinoma, as well as other tissues where expression has been demonstrated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:120 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1501 of SEQ ID NO:120, b is an integer of 15

to 1515, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:120, and where b is greater than or equal to a + 14.

5

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HFCCQ50	209463 11/14/97	Uni-ZAP XR	11	1271	1	1271	47	47	125	1	20	21	352
2	HTLAI54	209463 11/14/97	Uni-ZAP XR	12	1451	1	1451	125	125	126	1	22	23	157
3	HKABT24	209463 11/14/97	pCMVSport 2.0	13	2317	1	1809	66	66	127	1	22	23	553
4	HLWBF94	209463 11/14/97	pCMVSport 3.0	14	1472	1	1472	192	192	128	1	18	19	307
5	HFKFF78	209463 11/14/97	Uni-ZAP XR	15	1016	1	961	92	92	129	1	18	19	166
6	HSYBG37	209463 11/14/97	pCMVSport 3.0	16	1239	1	1239	48	48	130	1	24	25	305
7	HTHCA77	209463 11/14/97	Uni-ZAP XR	17	1405	1	1405	160	160	131	1	24	25	219

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HNHEZ51	209463 11/14/97	Uni-ZAP XR	18	1534	1	1534	106	106	132	1	32	33	98
9	HFIAX46	209463 11/14/97	pSport1	19	1233	1	1233	195	195	133	1	20	21	60
10	HFOXO72	209463 11/14/97	pSport1	20	1090	1	862	240	240	134	1	32	33	247
11	HODDW40	209463 11/14/97	Uni-ZAP XR	21	682	1	682	139	139	135	1	19	20	40
12	HSAWG42	209463 11/14/97	Uni-ZAP XR	22	770	1	770	31	31	136	1	27	28	74
13	HBMSK09	209463 11/14/97	Uni-ZAP XR	23	565	1	565	67	67	137	1	28	29	74
14	HDPAU16	209463 11/14/97	pCMVSport 3.0	24	1356	1	1356	486	486	138	1	24	25	57
15	HFEBE12	209463 11/14/97	Uni-ZAP XR	25	617	3	617	99	99	139	1	22	23	173

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
16	HFLNB64	209463 11/14/97	Uni-ZAP XR	26	648	1	648	62	62	140	1	39	40	45
16	HCESD11	209877 05/18/98	pBluescript	121	1025	1	1025	188	188	235	1	18	19	28
17	HSAWZ41	209463 11/14/97	Uni-ZAP XR	27	1388	1	1388	98	98	141	1	24	25	57
18	HNFJF07	209463 11/14/97	Uni-ZAP XR	28	616	1	616	86	86	142	1	21	22	66
19	HNGJO57	209463 11/14/97	Uni-ZAP XR	29	828	1	828	87	87	143	1	18	19	52
20	HE7TM22	209463 11/14/97	Uni-ZAP XR	30	581	1	581	70	70	144	1	22	23	65
21	HFRBR70	209463 11/14/97	Uni-ZAP XR	31	789	1	789	40	40	145	1	20	21	56
22	HTHBK35	209463 11/14/97	Uni-ZAP XR	32	884	1	884	108	108	146	1	26	27	66

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
23	HWABA81	209463 11/14/97	pCMVSport 3.0	33	866	1	866	57	57	147	1	21	22	48
24	HKGAA73	209463 11/14/97	pSport1	34	1694	1	1694	38	38	148	1	27	28	88
25	HKIYP40	209463 11/14/97	pBluescript	35	1215	1	1215	43	43	149	1	32	33	76
26	HKMMW74	209463 11/14/97	pBluescript	36	1794	1	1794	202	202	150	1	21	22	41
27	HLFBI27	209463 11/14/97	pBluescript SK-	37	1174	1	1174	135	135	151	1	19	20	45
28	HLQCW84	209463 11/14/97	Lambda ZAP II	38	1087	1	1087	31	31	152	1	18	19	41
29	HBNAV22	209463 11/14/97	Uni-ZAP XR	39	438	1	438	13	13	153	1	40	41	43
30	HTEAM34	209463 11/14/97	Uni-ZAP XR	40	734	1	734	63	63	154	1	28	29	122

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
31	HTHDK34	209463 11/14/97	Uni-ZAP XR	41	1346	1	1346	60	60	155	1	35	36	41
32	H6BSG32	209463 11/14/97	Uni-ZAP XR	42	998	53	998	209	209	156	1	24	25	55
33	HCFAD33	209463 11/14/97	pSport1	43	658	1	658	297	297	157	1	17	18	44
34	HDTEN81	209463 11/14/97	pCMVSport 2.0	44	566	1	566	114	114	158	1	17	18	85
35	HFXDT43	209463 11/14/97	Lambda ZAP II	45	1277	1	1277	92	92	159	1	19	20	44
36	HNGHQ09	209463 11/14/97	Uni-ZAP XR	46	442	1	442	65	65	160	1	17	18	68
37	HHGDF16	209463 11/14/97	Lambda ZAP II	47	890	215	890	253	253	161	1	26	27	52
38	HJBCG12	209463 11/14/97	pBluescript SK-	48	737	40	737	382	382	162	1	24	25	56

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
39	HOGAW62	209463 11/14/97	pCMVSport 2.0	49	571	1	571	259	259	163	1	26	27	55
40	HSWBJ74	209463 11/14/97	pCMVSport 3.0	50	356	1	356	43	43	164	1	35	36	47
41	HGBHR26	209511 12/03/97	Uni-ZAP XR	51	913	1	913	174	174	165	1	22	23	129
42	HKDBF34	209511 12/03/97	pCMVSport 1	52	1356	1	1356	18	18	166	1	19	20	104
43	H6EAB28	209511 12/03/97	Uni-ZAP XR	53	1547	1	1547	116	116	167	1	21	22	76
44	HLWAO22	209511 12/03/97	pCMVSport 3.0	54	1338	1	1311	212	212	168	1	21	22	354
45	HAGFH53	209511 12/03/97	Uni-ZAP XR	55	2071	1	2071	96	96	169	1	36	37	89
46	HHENQ22	209511 12/03/97	pCMVSport 3.0	56	1899	1	1899	115	115	170	1	36	37	58

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
47	HKMLK53	209511 12/03/97	pBluescript	57	1543	1	1543	20	20	171	1	25	26	69
48	HSKGQ58	209511 12/03/97	pBluescript	58	1133	1	1133	41	41	172	1	37	38	78
49	HNFEG93	209511 12/03/97	Uni-ZAP XR	59	1490	1	1480	33	33	173	1	33	34	173
50	HAIBZ39	209511 12/03/97	Uni-ZAP XR	60	1336	1	1336	48	48	174	1	17	18	63
51	HBXFP23	209511 12/03/97	ZAP Express	61	1705	178	1705	384	384	175	1	25	26	42
52	HEQBF32	209511 12/03/97	pCMVSport 3.0	62	1031	1	1031	97	97	176	1	25	26	113
53	HETHE81	209511 12/03/97	Uni-ZAP XR	63	1589	1	1589	182	182	177	1	23	24	155
54	HFPAC12	209511 12/03/97	Uni-ZAP XR	64	1088	1	1088	140	140	178	1	21	22	88

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
55	HDPFF39	209511 12/03/97	pCMVSport 3.0	65	1256	1	1256	175	175	179	1	18	19	196
56	HFXHD88	209511 12/03/97	Lambda ZAP II	66	1602	1	1602	130	130	180	1	41	42	128
57	HFOXV65	209511 12/03/97	pSport1	67	938	1	938	204	204	181	1	26	27	154
58	HKADX21	209511 12/03/97	pCMVSport 2.0	68	1585	122	1585	414	414	182	1	18	19	106
59	HPZAB47	209511 12/03/97	pBluescript	69	1676	1	1676	34	34	183	1	18	19	47
60	HAGFE79	209511 12/03/97	Uni-ZAP XR	70	1344	1	1344	133	133	184	1	18	19	126
61	HCE1X60	209511 12/03/97	Uni-ZAP XR	71	1474	1	1474	38	38	185	1	25	26	86
62	HFXKD36	209511 12/03/97	Lambda ZAP II	72	2012	130	2012	251	251	186	1	35	36	57

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
63	HBMCU71	209511 12/03/97	pBluescript	73	1267	1	1267	77	77	187	1	21	22	68
64	HTEIV80	209511 12/03/97	Uni-ZAP XR	74	1748	1	1748	203	203	188	1	15	16	47
65	HFIAP16	209511 12/03/97	pSport1	75	1570	38	1570	44	44	189	1	30	31	50
66	HODAV86	209511 12/03/97	Uni-ZAP XR	76	524	1	524	153	153	190	1	28	29	55
67	HTEDF80	209511 12/03/97	Uni-ZAP XR	77	1306	1	1306	696	696	191	1	21	22	126
68	HTODJ69	209511 12/03/97	Uni-ZAP XR	78	1479	1	1479	123	123	192	1	23	24	69
69	HE6GR02	209511 12/03/97	Uni-ZAP XR	79	1794	1	1794	100	100	193	1	18	19	70
70	HAPNY86	209511 12/03/97	Uni-ZAP XR	80	1280	1	1280	100	100	194	1	25	26	129

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
71	HTLDR33	209511 12/03/97	Uni-ZAP XR	81	974	1	974	368	368	195	1	19	20	54
72	HACBI61	209511 12/03/97	Uni-ZAP XR	82	1955	1	1955	174	174	196	1	16	17	79
73	HMEIK34	209511 12/03/97	Lambda ZAP II	83	638	1	638	243	243	197	1	24	25	41
74	HKAAK02	209551 12/12/97	pCMVSport 2.0	84	859	1	859	97	97	198	1	33	34	196
75	HEPAA46	209551 12/12/97	Uni-ZAP XR	85	1129	1	1129	18	18	199	1	20	21	123
76	HFPCX09	209551 12/12/97	Uni-ZAP XR	86	2674	59	2674	249	249	200	1	26	27	549
76	HFPCX09	209551 12/12/97	Uni-ZAP XR	122	2207	1	2207	185	185	236	1	26	27	66
77	HLWAA88	209551 12/12/97	pCMVSport 3.0	87	1636	1	1636	51	51	201	1	22	23	488

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
77	HLWAA88	209551 12/12/97	pCMVSport 3.0	123	1770	1	1770	35	35	237	1	22	23	113
78	HOHBV89	209551 12/12/97	pCMVSport 2.0	88	1639	1	1639	158	158	202	1	28	29	85
79	HHFBY69	209852 05/07/98	Uni-ZAP XR	89	1860	2	1860	71	71	203	1	25	26	399
79	HCEFL57	209551 12/12/97	Uni-ZAP XR	124	1034	1	1032	68	68	238	1	25	26	105
80	HMEKU83	209551 12/12/97	Lambda ZAP II	90	839	1	839	35	35	204	1	28	29	194
81	HOSBY40	209551 12/12/97	Uni-ZAP XR	91	1145	1	1145	89	89	205	1	30	31	56
82	HKFBH93	209551 12/12/97	ZAP Express	92	2050	174	2050	262	262	206	1	18	19	72
83	HMTAD67	209551 12/12/97	pCMVSport 3.0	93	1173	1	1173	306	306	207	1	19	20	84

han one secreted species. These polypeptides, and the
ich polypeptides, are contemplated by the present invention.
l sequence identified by the above analysis may not
ally occurring signal sequence. For example, the naturally
ıay be further upstream from the predicted signal sequence.
: predicted signal sequence will be capable of directing the
These polypeptides, and the polynucleotides encoding such
ted by the present invention.

ypeptide Variants

polynucleotide or polypeptide differing from the
le of the present invention, but retaining essential properties
are overall closely similar, and, in many regions, identical
/peptide of the present invention.
having a nucleotide sequence at least, for example, 95%
:leotide sequence of the present invention, it is intended that
ıe polynucleotide is identical to the reference sequence
le sequence may include up to five point mutations per each
:nce nucleotide sequence encoding the polypeptide. In other
otide having a nucleotide sequence at least 95% identical to
nce, up to 5% of the nucleotides in the reference sequence
d with another nucleotide, or a number of nucleotides up to
ı the reference sequence may be inserted into the reference
ıce may be an entire sequence shown inTable 1, the ORF
fragement specified as described herein.
. whether any particular nucleic acid molecule or
95%, 96%, 97%, 98% or 99% identical to a nucleotide
ention can be determined conventionally using known
:rred method for determing the best overall match between
e of the present invention) and a subject sequence, also
ıce alignment, can be determined using the FASTDB
the algorithm of Brutlag et al. (Comp. App. Biosci. (1990)
lignment the query and subject sequences are both DNA
ce can be compared by converting U's to T's. The result
.ment is in percent identity. Preferred parameters used in a
sequences to calculate percent identiy are:
Mismatch Penalty=1, Joining Penalty=30, Randomization

88	HLQDH79	209551 12/12/97	Lambda ZAP II	98	913	1	913	205	205	212	1	19	20	58					
89	HNGFJ67	209551 12/12/97	Uni-ZAP XR	99	721	1	721	344	344	213	1	21	22	42					
90	HEIAC52	209551 12/12/97	Uni-ZAP XR	100	645	1	645	81	81	214	1	18	19	52					
91	HFXKL58	209551 12/12/97	Lambda ZAP II	101	563	1	563	120	120	215	1	17	18	67					

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
92	HMVAM60	209551 12/12/97	pSport1	102	1324	1	1324	96	96	216	1	26	27	56
93	HMVBR22	209551 12/12/97	pSport1	103	1731	1	1731	104	104	217	1	20	21	55
94	HPJCW04	209551 12/12/97	Uni-ZAP XR	104	1466	1	1466	44	44	218	1	19	20	57
95	HSIDJ81	209551 12/12/97	Uni-ZAP XR	105	1303	1	1303	8	8	219	1	22	23	58
96	HSLFU05	209551 12/12/97	Uni-ZAP XR	106	1516	1	1516	166	166	220	1	30	31	44
97	HEQAK71	209551 12/12/97	pCMVSport 3.0	107	1689	1	1689	198	198	221	1	17	18	44
98	HOSEQ49	209551 12/12/97	Uni-ZAP XR	108	1943	280	1935	544	544	222	1	32	33	51
99	HRAAM50	209551 12/12/97	pCMVSport 3.0	109	1594	1	1594	29	29	223	1	14	15	72

iclude an additional amino acid sequence which contains
s, pro-sequences, sequences which aid in purification ,
sidues, or an additional sequence for stability during

he present invention are preferably provided in an isolated
stantially purified. A recombinantly produced version of a
creted polypeptide, can be substantially purified by the
n Smith and Johnson, Gene 67:31-40 (1988).
also can be purified from natural or recombinant sources
tion raised against the secreted protein in methods which

g whether a protein has a signal sequence, as well as the
ice, are available. For instance, the method of McGeoch,
uses the information from a short N-terminal charged
arged region of the complete (uncleaved) protein. The
ic Acids Res. 14:4683-4690 (1986) uses the information
the cleavage site, typically residues -13 to +2, where +1
of the secreted protein. The accuracy of predicting the
mmalian secretory proteins for each of these methods is in
einje, supra.) However, the two methods do not always
eavage point(s) for a given protein.
deduced amino acid sequence of the secreted polypeptide
rogram called SignalP (Henrik Nielsen et al., Protein
hich predicts the cellular location of a protein based on
art of this computational prediction of localization, the
Heinje are incorporated. The analysis of the amino acid
eins described herein by this program provided the results

ll would appreciate, however, cleavage sites sometimes
m and cannot be predicted with absolute certainty.
tion provides secreted polypeptides having a sequence
h have an N-terminus beginning within 5 residues (i.e., +
1 cleavage point. Similarly, it is also recognized that in
nal sequence from a secreted protein is not entirely

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown inTable 1, the ORF (open reading frame), or any fragement specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the presence invention can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identiy are:
Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the lenght of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is becuase the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignement of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is becuase the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-

60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the

polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat

polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying

personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the

proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect

interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes

Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox , hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue

regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit

(antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors),or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity , and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type

Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

Vector Used to Construct Library	Corresponding Deposited Plasmid
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSport 2.0	pCMVSport 2.0
pCMVSport 3.0	pCMVSport 3.0
pCR®2.1	pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain

DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 µl of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 µM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is

used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P^{32} using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on

either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 ($O.D.^{600}$) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high

affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfuidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem

columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring

signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture

and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of ^{35}S-methionine and 5 µCi ^{35}S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 is cotransfected with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAACC
CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCA
GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera

containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2 x 10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in

Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl2 (anhyd); 0.00130 mg/L $CuSO_4$-$5H_2O$; 0.050 mg/L of $Fe(NO_3)_3$-$9H_2O$; 0.417 mg/L of $FeSO_4$-$7H_2O$; 311.80 mg/L of Kcl; 28.64 mg/L of $MgCl_2$; 48.84 mg/L of $MgSO_4$; 6995.50 mg/L of NaCl; 2400.0 mg/L of $NaHCO_3$; 62.50 mg/L of NaH_2PO_4-H_2O; 71.02 mg/L of Na_2HPO4; .4320 mg/L of $ZnSO_4$-$7H_2O$; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H_2O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H_2O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H_2O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalainine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-$2H_2O$; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B_{12}; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine;

0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linolcic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proxial region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

		JAKs			STATS	GAS(elements) or ISRE
Ligand	tyk2	Jak1	Jak2	Jak3		
IFN family						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
gp130 family						
IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrohic)	?	+	?	?	1,3	
OnM(Pleiotrohic)	?	+	+	?	1,3	
LIF(Pleiotrohic)	?	+	+	?	1,3	
CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrohic)	?	+	?	?	1,3	
IL-12(Pleiotrohic)	+	-	+	+	1,3	
g-C family						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
gp140 family						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
Growth hormone family						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
Receptor Tyrosine Kinases						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:
5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG
AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:
5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATG
ATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC
CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
TGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, Il-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1 x 10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2x10e^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $Na_2HPO_4.7H_2O$, 1 mM $MgCl_2$, and 675 uM $CaCl_2$. Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1x10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5x10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1x10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon

activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as $5x10^5$ cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to $1x10^5$ cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF-κB (Nuclear Factor κB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-κB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF-κB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κB is retained in the cytoplasm with I-κB (Inhibitor κB). However, upon stimulation, I- κB is phosphorylated and degraded, causing NF- κB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-κB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-kB would be useful in treating diseases. For example, inhibitors of NF-κB could be used to treat those diseases related to the acute or chronic activation of NF-kB, such as rheumatoid arthritis.

To construct a vector containing the NF-κB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-κB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCA TCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACT AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTC CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT: 3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-κB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-κB/SV40/SEAP cassette is removed from the above NF-κB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-κB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-κB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

in Example 13. As a positive control, exogenous TNF alpha (0.1,1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 µl of 2.5x dilution buffer into Optiplates containing 35 µl of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 µl Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 µl Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25

28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO_2 incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is

incubated at 37°C in a CO_2 incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10^6 cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating

tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford,MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford,MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boeheringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and

PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg_{2+} (5mM ATP/50mM $MgCl_2$), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM $MgCl_2$, 5 mM $MnCl_2$, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavadin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR

products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Manheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10.

The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracistemally, intravaginally,

intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

Applicant's or agent's file reference number	PZ021PCT	International application No.	unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 172, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*:
10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
14 November 1997	209463

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Form PCT/RO/134 (July 1992)

Applicant's or agent's file reference number	PZ021PCT	International application No	unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 174, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*:
10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
18 May 1998	209877

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Applicant's or agent's file reference number	PZ021PCT	International application No.	unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 177, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*:
10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
3 December 1997	209511

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Applicant's or agent's file reference number	PZ021PCT	International application No.	unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 181, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*:
10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
12 December 1997	209551

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Applicant's or agent's file reference number	PZ021PCT	International application No	unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 182, line N/A

B. **IDENTIFICATION OF DEPOSIT** Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*
10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
7 May 1998	209852

C. **ADDITIONAL INDICATIONS** *(leave blank if not applicable)* This information is continued on an additional sheet ☐

D. **DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** *(if the indications are not for all designated States)*

E. **SEPARATE FURNISHING OF INDICATIONS** *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc. et al

<120> 110 Human Secreted Proteins

<130> PZ021PCT

<140> PCT/US98/27059
<141> 1998-12-17

<150> 60/068,008
<151> 1998-12-18

<150> 60/068,054
<151> 1998-12-18

<150> 60/068,064
<151> 1998-12-18

<150> 60/068,053
<151> 1998-12-18

<150> 60/068,006
<151> 1998-12-18

<150> 60/068,057
<151> 1998-12-18

<150> 60/068,007
<151> 1998-12-18

<150> 60/070,923
<151> 1998-12-18

<150> 60/068,367
<151> 1998-12-19

<150> 60/068,369
<151> 1998-12-19

<150> 60/068,169
<151> 1998-12-19

<150> 60/068,365
<151> 1998-12-19

<150> 60/068,368
<151> 1998-12-19

<160> 628

<170> PatentIn Ver. 2.0

<210> 1
<211> 733
<212> DNA

<213> Homo sapiens

<400> 1
gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60
aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga 120
tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg 180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300
ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg 360
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga 540
ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg 600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660
acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
gactctagag gat 733

<210> 2
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> Site
<222> (3)
<223> Xaa equals any of the twenty naturally ocurring L-amino acids

<400> 2
Trp Ser Xaa Trp Ser
1 5

<210> 3
<211> 86
<212> DNA
<213> Homo sapiens

<400> 3
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 4
<211> 27
<212> DNA
<213> Homo sapiens

<400> 4
gcggcaagct ttttgcaaag cctaggc 27

<210> 5
<211> 271
<212> DNA
<213> Homo sapiens

<400> 5

```
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg      60
aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc     120
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat     180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt     240
ttttggaggc ctaggctttt gcaaaaagct t                                    271
```

<210> 6
<211> 32
<212> DNA
<213> Homo sapiens

<400> 6
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7
<211> 31
<212> DNA
<213> Homo sapiens

<400> 7
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8
<211> 12
<212> DNA
<213> Homo sapiens

<400> 8
ggggactttc cc 12

<210> 9
<211> 73
<212> DNA
<213> Homo sapiens

<400> 9
gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60
ccatctcaat tag 73

<210> 10
<211> 256
<212> DNA
<213> Homo sapiens

<400> 10
ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60
caattagtca gcaaccatag tcccgccccc aactccgccc atcccgcccc taactccgcc 120
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
cttttgcaaa aagctt 256

<210> 11
<211> 1271
<212> DNA
<213> Homo sapiens

<400> 11
```
ggggctgggc cctgctcagg tggctctctc cttgcaggga ccggcgatgc tctgcaggct      60
gtgctggctg gtctcgtaca gcttggctgt gctgttgctc ggctgcctgc tcttcctgag     120
gaaggcggcc aagcccgcag agaccccacg gcccaccagc ctttctgggg ctcccccaac     180
accccgtcac agccggtgtc cacccaacca cacagtgtct agcgcctctc tgtccctgcc     240
tagccgtcac cgtctcttct tgacctatcg tcactgccga aatttctcta tcttgctgga     300
gccttcaggc tgttccaagg ataccttctt gctcctggcc atcaagtcac agcctggtca     360
cgtggagcga cgtgcggcta tccgcagcac gtgggggcagg tgggggggatg ggctagggcc     420
ggcactgaag ctggtgttcc tcctaggggt ggcaggatcc gctccccccag cccagctgct     480
ggcctatgag agtagggagt ttgatgacat cctccagtgg gacttcactg aggacttctt     540
caacctgacg ctcaaggagc tgcacctgca gcgctgggtg gtggctgcct gccccccaggc     600
ccatttcatg ctaaagggag atgacgatgt ctttgtccac gtccccaacg tgttagagtt     660
cctggatggc tgggacccag cccaggacct cctggtggga gatgtcatcc gccaagccct     720
gcccaacagg aacactaagg tcaaatactt catcccaccc tcaatgtaca gggccaccca     780
ctacccaccc tatgctggtg ggggaggata tgtcatgtcc agagccacag tgcggcgcct     840
ccaggctatc atggaagatg ctgaactctt ccccattgat gatgtctttg tgggtatgtg     900
cctgaggagg ctggggctga gccctatgca ccatgctggc ttcaagacat ttggaatccg     960
gcggcccctg gaccccttag acccctgcct gtatagggggg ctcctgctgg ttcaccgcct    1020
cagccccctc gagatgtgga ccatgtgggc actggtgaca gatgaggggc tcaagtgtgc    1080
agctggcccc ataccccagc gctgaagggt gggttgggca acagcctgag agtggactca    1140
gtgttgattc tctatcgtga tgcgaaattg atgcctgctg ctctacagaa aatgccaact    1200
tggtttttta actcctctca ccctgttagc tctgattaaa aacactgcaa cccaaaaaaa    1260
aaaaaaaaaa a                                                         1271
```

<210> 12
<211> 1451
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (937)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (965)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (975)
<223> n equals a,t,g, or c

<400> 12
```
gccagttcac tcctcggctg gagacactag gtgtcctgcc cctaatctca ccagagccac      60
ctcataaacc ctgcaagctc tgcgaagggc agctgggcac agctgaaagc ccagccacca     120
gcccatgtcc tgggtgggac tgggcaggag gggccacctc ctactgctga tcaacccgag     180
agccctggct gggatccgtc ttccttcacc aacgggagct ccggccccag ggccctgccc     240
acctctgtgc accccacact gcagcaggga gcaccctgca ggaggaactg ggcaccctgc     300
aggggtctgg tggagacgag gatgctacgg aggcagctgc cccatgggac cagtaagagg     360
```

```
gatcttgggt gggcttccct gcagagagga agccctcagg agacaccaca gtaagccatg      420
ctggagacct ggaggccagg cccgtcamct ggggagctgg ccactaacag cgggcagaga      480
gcctcccagg acagccagca cagcccccca cacgtccgag cccacctcct catttccccg      540
cttcccgcgt tcccaagcat gggaggacct gccggacgca gcgcaccaty tytcctaaca      600
gagaccaagt ctgagcttca acgcttgcgc agacgacagg cacgtgcaag cytytcytyt      660
ccagcaggag agcccggagc aggacacagc gaytctttca actgcgtccc gacaaacggt      720
cagccccttc gctcctgcag tttatccaag ctcaggagga gctttctaaa gagaacacag      780
ggagacagct ggctgccaga gaagcagtcc tggctctgga aggctccacc cagctaacag      840
ggcctgtgac acaggtggca gccagcaaga cccactgcag cggcatggcc ctcacagcct      900
cccctgtccc tgtcctggga gcagccccgg caaagantcc tacccagaac aytccaggtc      960
agganggcag ggccntgarg aargtgarga catcctggar arctgtggcc accaaggtgc     1020
tgcacggcct ggaggtctcc acacatctgg gcaaacggaa gctttctggg aggagctggc     1080
tcccaggccc tgctctccac gccaccccat cacagtcgca cacacagaca ggctcccaga     1140
ttgtccaccc tccacaggga gaagtcaggg aggtgggcag gggacggggt cagccaccgg     1200
ctcagcctgt gcacgcccat ccctcccagc agcacccctc tccggcccac ctggctggcc     1260
tgagtctgtg gactggcact gcctgataga actttcagta ccttcagtgc ccaaagggcg     1320
cgacgactag cccttaaaag aggctggagc ccctgaggaa gcgggtcttt aggcaaaacc     1380
accgcacggc agagcagcca caggacagat caatgtcttc tgcgggaaaa aaaaaaaaaa     1440
aaaaactcgt a                                                          1451
```

<210> 13
<211> 2317
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1419)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2165)
<223> n equals a,t,g, or c

<400> 13

```
cctgcagcta ccgtccgcaa ttcccggtcg acccacgcgt ccgggcgact tgcatcgtct       60
tcaacatgaa gatagccaca gtgtcagtgc ttctgccctt ggctctttgc ctcatacaag      120
atgctgccag taagaatgaa gatcaggaaa tgtgccatga atttcaggca tttatgaaaa      180
akggaaaact gttctgtccc caggataaga aatttttca aagtcttgat ggaataatgt      240
tcatcaataa atgtgccacg tgcaaaatga tactggaaaa agaagcaaaa tcacagaaga      300
gggccaggca tttagcaaga gctcccaagg ctactgcccc aacagagctg aattgtgatg      360
attttaaaaa aggagaaaga gatggggatt ttatctgtcc tgattattat gaagctgttt      420
gtggcacaga tgggaaaaca tatgacaaca gatgtgcact gtgtgctgag aatgcgaaaa      480
ccgggtccca aattggtgta aaaagtgaag gggaatgtaa gagcagtaat ccagagcagg      540
atgtatgcag tgctttttcgg ccctttgtta gagatggaag acttggatgc acaagggaaa      600
atgatcctgt tcttggtcct gatgggaaga cgcatggcaa taagtgtgca atgtgtgcts      660
agctgtyyyw aaaagaagct gaaaatgcca agcgagaggg tgaaactaga attcgacgaa      720
atgctgaaaa ggatttttgc aaggaatwtg aaaaacaagt gagaaatgga aggcttttt       780
gtacacggga gagtgatcca gtccgtggcc ctgacggcag gatgcatggc aacaaatgtg      840
ccctgtgtgc tgaaattttc aagcagcgtt tttcagagga aaacagtaaa acagatcaaa      900
atttgggaaa agctgaagaa aaaactaaag ttaaaagaga aattgtgaaa ctctgcagtc      960
aatatcaaaa tcaggcaaag aatggaatac ttttctgtac cagagaaaat gaccctattc     1020
gtggtccaga tgggaaaatg catggcaact tgtgttccat gtgtcaagcc tacttccaag     1080
cagaaaatga agaaaagaaa aaggctgaag cacgagctag aaacaaaaga gaatctggaa     1140
aagcaaccctc atatgcagag ctttgcagtg aatatcgaaa gcttgtgagg aacggaaaac     1200
```



```
ttgcttgcac cagagagaac aatcctatcc agggcccaga tgggaaagtg catggcaaca     1260
cctgctccat gtgtgaggtc ttcttccaag cagaagaaga agaaaagaaa aagaaggaag     1320
gtwmmtcaag aaacaaaaga caatctaaga gtacagcttc ctttgwkgag ttgtgtagtg     1380
aatmccgcaa atccaggaaa aacggacggc ttttttgcnc cagagagaat gaccccatcc     1440
agggcccaga tggaaaaatg catggcaaca cctgctccat gtgtgaggcc ttctttcaac     1500
aagaagaaag agcaagagca aaggctaaaa gagaagctgc aaaggaaatc tgcagtgaat     1560
ttcgggacca agtgaggaat ggaacactta tatgcaccag ggagcataat cctgtccgtg     1620
gcccagatgg caaaatgcat ggaaacaagt gtgccatgtg tgccagtgtg ttcaaacttg     1680
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aagggcggcc gctctagagg atccctcgag     1740
gggcccaagc ttacgcgtgc atgcgacgtc atagctctct ccctatagtg agtcgtatta     1800
taagctaggc actggccgtc gttttacaac gtcgtgactg ggagatctgc tagcttggga     1860
tctttgtgaa ggaaccttac ttctgtggtg tgacataatt ggacaaacta cctacagaga     1920
tttaaagctc taaggtaaat ataaaatttt taagtgtata atgtgttaaa ctagctgcat     1980
atgcttgctg cttgagagtt ttgcttactg agtatgattt atgaaaatat tatacacagg     2040
agctagtgat tctaattgtt tgtgtatttt agattcacag tcccaaggct catttcaggc     2100
ccctcagtcc tcacagtctg ttcatgatca taatcagcca taccacattt gtagaggktt     2160
tactngcytt aaaaaacctc ccacacctcc ccctgaacck gaaacataaa atggaakgca     2220
atggtggtgg taactggtta atgcagcctt aataaatggg ttaccaaatt aaaggccaat     2280
aggccatcca ccmaaaattt tccacccaaa ttaaaag                              2317
```

<210> 14
<211> 1472
<212> DNA
<213> Homo sapiens

<400> 14

```
ggccacgcgt ccgcggtacg gtggtgcggc tgcggcagca cagacccagt gcctacatcc       60
ttgtctccac cgtgctaacc ctcatggtgc cctggcacag cctggacccc gactcagcgc      120
ttgcagatgc cttctaccag cggggctaca ggtgggctgg cttcatcgtg gcagctggct      180
ccatctgcgc catgaacacc gtcctgctca gcctcctctt ctccctgcca cgcattgtct      240
atgccatggc cgccgatggg ctcttcttcc aggtgtttgc ccatgtgcac ccccggacac      300
aggtgcctgt ggcgggcacc ctggcgttcg ggctcctcac ggccttcctg gcactgctgc      360
tggacctgga gtcgctggtt cagttcctgt cccttggcac actcctggcc tacacattcg      420
tggccaccag tatcattgtg ctgcgcttcc agaagtcttc cccgcccagc tccccaggcc      480
cagccagccc tggccccctg accaagcagc agagctcctt ctcagaccac ctacagctgg      540
tgggcactgt acacgcctcc gtccctgagc caggggagct gaagccagcc ctgaggccct      600
acctgggctt cttggatggg tacagccctg gagcagtggt gacttgggcg cttggcgtta      660
tgttggcctc agccatcacc ataggctgcg tgcttgtctt tgggaactcg accctgcacc      720
tcccacactg gggttacatc ctgctgctcc tgctcaccag tgtcatgttt ctgctcagcc      780
tccttgtcct gggggctcac cagcaacagt atcgggaaga cttatttcag atcccatgg       840
ttcccctgat tccagccctg agcatcgtcc tcaacatctg cctcatgctg aaacttagct      900
atctgacctg ggtgcgcttc tccatctggc tgctgatggg acttgcagtg tatttcggct      960
atggcatccg gcatagcaag gagaaccagc gggagctgcc agggctgaac tccacacact     1020
acgtggtatt ccccaggggc agcctggagg agacagtgca ggctatgcag ccccccagcc     1080
aggcaccagc acaggaccct ggccatatgg agtagctgat cagcccacac ttgccccgcc     1140
ctcccacacc tgcttgggag gccagagagg ccagacaagc cgagagcccc ttctgttgtg     1200
ggcagcctgg gtttgcaggc ctgcacaggc tggggagtcc tcaggacctt aggaccttca     1260
tccaggggct gggcttcggg tcttcaggag tgggccttgg ctggtgctgg tgccatggac     1320
tctgcccaga gccttcttgt ttatgatcag ctccagctac ctgggcagtt gtggtggggt     1380
ggatgggaag gcccacagcc caagggatcc ataataataa ttgcttggcc agccatgtgg     1440
cctgctggcg taaaaaaaaa aaaaaaaaaa aa                                   1472
```

<210> 15
<211> 1016
<212> DNA

<213> Homo sapiens

<400> 15
ggcacgagct tccgcggcat gatttccacc cagcccggct ccaccccact cgcttccttt 60
aagatcctgg ctctggagtc ggcagatggg catggcggct gcagtgctgg caatgacatt 120
ggcccctacg gtgagcggga cgaccagcaa gtgttcatcc agaaggtggt gcccagtgcc 180
agccagctct tcgtgcgtct ctcatctact gggcagcggg tgtgctccgt gcgctccgtg 240
gacggctcac ccacgacagc cttcacagtg ctggagtgcg agggctcccc ggcggctcgg 300
ctctcggccc cggcgctacc tgctcactgg ccaggccaac ggcagcttgg ccatgtggga 360
cctaaccacc gccatggacg gcctcggcca ggcccctgca ggtggcctga cggagcaaga 420
gctgatggaa cagctggaac actgtgagct ggccccgccg gctcctttca gctccctcat 480
ggggctgtct ccccagcccc tcaccccgca tctccctcac cagcctccac tcagcctcca 540
gcaacacctc cttgtctggc caccgtggga gcccaagccc cccgcaggct gaggcccggc 600
gccgtggtgg gggcagcttt gtggaacgct gccaggaact ggtgcggagt gggccagacc 660
tccgacggcc acccacacca gccccgtggc cctccagcgg tctcggcact cccctcacac 720
ctcccaagat gaagctcaat gaaacttcct ttttgaacaa cgcagctgcc atgatgcctt 780
gggatgccct ggtcctgggg gactcaggtg cctccctgat tcctgtggga acccgggttt 840
caggccaggg cctccttgga ataaatggtt attgttacta ggtccccacc ttccctcttt 900
tctggaagcc aaagtcaccc tccccaataa agtcctcact gccaaaaaaa aaaaaaaaaa 960
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1016

<210> 16
<211> 1239
<212> DNA
<213> Homo sapiens

<400> 16
cccacgcgtc cgcccacgcg tccgcccacg cgtccggctg cggcgcgatg gcggcggggc 60
tggcgcggct cctgttgctc ctcgggctct cggccggcgg gcccgcgccg gcaggtgcag 120
cgaagatgaa ggtggtggag gagcccaacg cgtttggggt gaacaacccg ttcttgcctc 180
aggccagtcg cctccaggcc aagagggatc cttcacccgt gtctggaccc gtgcatctct 240
tccgactctc gggcaagtgc ttcagcctgg tggagtccac gtacaagtat gagttctgcc 300
cgttccacaa cgtgacccag cacgagcaga ccttccgctg gaacgcctac agtgggatcc 360
tcggcatctg gcacgagtgg gagatcgcca acaacacctt cacgggcatg tggatgaggg 420
acggtgacgc ctgccgttcc cggagccggc agagcaaggt ggagctggcg tgtggaaaaa 480
gcaaccggct ggcccatgtg tccgagccga gcacctgcgt ctacgcgctg acgttcgaga 540
ccccctcgt ctgccacccc cacgccttgc tagtgtaccc aaccctgcca gaggccctgc 600
agcggcagtg ggaccaggta gagcaggacc tggccgatga gctgatcacc ccccagggcc 660
atgagaagtt gctgaggaca ctttttgagg atgctggcta cttaaagacc ccagaagaaa 720
atgaacccac ccagctggag ggaggtcctg acagcttggg gtttgagacc ctggaaaact 780
gcaggaaggc tcataaagaa ctctcaaagg agatcaaaag gctgaaaggt ttgctcaccc 840
agcacggcat cccctacacg aggcccacag aaacttccaa cttggagcac ttgggccacg 900
agacgcccag agccaagtct ccagagcagc tgcggggtga cccaggactg cgtgggagtt 960
tgtgaccttg tggtgggaga gcagaggtgg acgcggccga gagccctaca gagaagctgg 1020
ctggtaggac ccgcagggac cagctgacca ggcttgtgct cagagaagca gacaaaacaa 1080
agattcsagg ttttaattaa ttcccatact gataaaaata actccatgaa ttctgtaaac 1140
cattgcataa atgctatagt gtaaaaaaat ttaaacaagt gttaacttta aacagttcgc 1200
tacaagtaaa tgattataaa tactaaaaaa aaaaaaaaa 1239

<210> 17
<211> 1405
<212> DNA
<213> Homo sapiens

<220>

<221> SITE
<222> (1403)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1404)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1405)
<223> n equals a,t,g, or c

<400> 17
gaattcggca cgaggcagct ttggacatgt cgggcctcat agggagcatg gggtgtggaa 60
gtggtggccg tgggctcaaa agctggctgc ttagtttacc agctgtgtga tctcaagcag 120
atcaccttct tcttcagagc ctcagtttgc ctgtcggtca tgccctgcct ggaggccgtg 180
gccttgatcc tgcttatcct gctggttcca gacccacccc ggggagctgc cgagacacag 240
ggggaggggg ccgtgggagg cttcaggagc agctggtgtg aggacgtcag atacctgggg 300
aaaaactgga gtttcgtgtg gtcgayyctc rgagtgaccg ccatggcctt tgtgactgga 360
gccctggggt tctgggcccc caagtttctg ctcgaggcac gcgtggttca cgggctgcag 420
cctccctgct tccaggagcc gtgcagcaac cccgacagcc tgatttttgg ggcactgacc 480
atcatgaccg gcgtcattgg ggtcatcttg ggggcagaag ctgcgaggag gtacaagaaa 540
gtcattccag gagctgagcc cctcatctgc gcctccagcc tgcttgccac agccccctgc 600
ctctacctgg ctctcgtcct ggccccgacc accctgctgg cctcctatgt gttcctgggc 660
cttggggarc tgcttctgtc ctgcaactgg gcagtggttg ccgacatcct gctgtctgtg 720
gtggtgccca gatgccgggg gacggcagaa gcacttcaga tcacggtggk ycacatcctg 780
ggaracctgg cagccctatc tcacaggact tatctctagt gtcctgcggg ccargcgccc 840
tgactcctat ctgcagcgct tccgcagcct gsarcararc tycctgtgct gcgcctttgt 900
catcgccctg gggggcggct gcttcctgct gactgcgctg tacctggaga gagacgagac 960
ccgggcctgg cagmctgtca cagggacccc agacagcaat gatgtggaca gcaatgacct 1020
ggagagacaa ggcctgcttt cgggcgytgg cgcctctaca gaggagccct gaggtccctg 1080
cctgcactcg tcctgcctgc aagcctcccg ttggtcccca cagcagcagt gcctcggttc 1140
ctctttggct gtcctcgggg actccggctg aggcacatct gccacttttg aattcccggc 1200
tggagagctg gcaggaccct gtggctgggc tgggaatgga gctgtcagca ctctgcgtgg 1260
gaggcctggg cctgtgcctg catcccgctc aaggctgccc cagcctgggg tccccagcct 1320
ggctgctgct gggccctgra taaayagagg ccagtacaaa gcccatggat tttgggcctg 1380
taaaaaaaaa aaaaaaaaaa aannn 1405

<210> 18
<211> 1534
<212> DNA
<213> Homo sapiens

<400> 18
ggcacgagtc aagcaatctg tccacctcag cctcccaaag tgctggaatt acaagcataa 60
ccactgcacc tggtaggcat caaattttga atagagaagt taaccatgat gaatcaacac 120
ttgcttgaat cgtttggttc tccctcctcc ttgttcattg tctttattct gctcatctgg 180
atgttgcaaa gatgtaaaga ttttttcctt tgttgctata gagtagtgct aactccatca 240
ttctggcaga agcaccaaca cccagatccc aaaattaagc atcatttgaa gctatactca 300
ctgaaataca gttcttctgg gcagaacaac ttcagaaagg acaaacattg gctttctggc 360
cacacggaag aggcaaattt aataaaggaa gaatggaagt aatgttcaat atcaccagga 420
tagcctacct gaaatttctt agtacaaatg agaagcaatg tggcccatgt ggctgctata 480
tgagcacgtg gaaagagtga tcttaagttc tccactgatc ctaatctaat ctgttgtatt 540
cgcgtgtacc cttaattatc catttaaaaa gctaattatt gctgttagtg gtggtggtgg 600

```
ttgcatgtat atacgtgttt caaaaccatc tgacacagcc tattcaatgc tttcctctag      660
ttcatacctc tgtactggtt tcctgtgtct gccacagaaa ttgccaccaa ggtagcttaa      720
agtaatggaa atctgctctc tcacttttct ggaggctaca aatctgcaat caaggtgtca      780
acaggccatg ctcccctctga aggctctgcg gaagaatcct ttcttgcttc ttcctagttt      840
tgatggttgc tgccaatcct tggcattccc tggcttgtgg ctgcaacact ccaatctctg      900
cctcaatcat cacatgacct tccttgtgta tctcctttgt gtctctgtgt tcaaatattt      960
cttccctttc tcctgtacat ataccagtca ttggatttag ggttctcttg atccagtatg     1020
atcttatctc aactggatta tatcttcaaa gaccttattt gaacgcctta tttccataac     1080
ggtcacattt ccaagtacaa gggttaggac ttaaaacata ccttcttggg ggccacaatt     1140
taacctatta tatcccacta cacagtatat gccatgacag aacctctttc atgagaccaa     1200
catgaaatgt agagtgatat gattctttat gtgatcaatg agtatttgca gacaatgctg     1260
atgattcccc tgagaatatc atggctccct cccttactta tttagatatc tgttcaggct     1320
gggtgctgtg gctcatgcct ataatcccag cactttggga ggggaggaag gtggttcact     1380
tgagcccagg agttcaagac cagcttgggc aacatggtga gaccttgttt ttaccaaaaa     1440
aaagaaagaa aaatacaaaa aattagctgg gtgtggtggc acatgcctgt agttcctgct     1500
acttgggtgg ctggggtggg agaatcatct gagc                                 1534
```

<210> 19
<211> 1233
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (491)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (493)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (497)
<223> n equals a,t,g, or c

<400> 19

```
gcagcgtgag ccaccgtgcc tggctggttt ggggattttc atattgcatg tgacagaaaa       60
cctatctgta actagctaaa tagccctttc ccctactgcc ccccaaaagg cggggtttat      120
tgtatcatct gattcagaaa tctacgctgg gcttggtagt ttggtttcgg gaacatctgg      180
attccaggtc tcaaatgaca tcatcgctat tcatttttct ctttctctgg ttctgccctc      240
caccacgtat cagctttgtt ctgtgttggc ctcagcccca ttctcaagtt cacattcagc      300
atgaaaaggc tgatcacctc ttccagtcac tcaagcaaaa agccccaggt ttgctgcaat      360
gggctagaat agtttgactg taatcacatg accacctcta agccaatctc tgtgggccag      420
gcaccccagt ggttggttta rgcctggatc ttgtgacaca ctcctgaaca catgactcga      480
gggtggggca nangcanatc ctcacacaga actggtgcgt gattccaggt ggctgatcaa      540
tcacctgtgt ccactgtggt tgtatcaarg gcgtgtgggt tgtgctgtgc tgggcgtaca      600
ctagtgtgtg cattggccag ctcggkktgc cacgttattg gctttgggat gctggttccc      660
aggagtggcg gtgggaagat tccacctgct ttctatggta ggaaggcagg tcctggggtg      720
agggtgagcc ccgaggggga ccagtggcca ctgtggcttg acccgcaggc cttgacctga      780
gcattgcagg catagtttcc tgcccctgta actgccagat cgagacccag tgagacagtg      840
gtttccgtcg ccagagactg aaatagtgta ttccctgagg acccctgaag aagcttggct      900
ttgctacgag ccagacgtcc aggtcacaag tctggctggg acccaaggct cagtcccttt      960
ataatagctg ttgagttcac ggagtgagta caattatgca tccccactga ggctcaagag     1020
gtgaagtcac atagccagtt agtggtagag atggggcttg aacctgggtc ttcctgactc     1080
```



```
actcagctac ctttccatag aaatagggac tggaggccgg gcgcagtggc tcatgccttt     1140
aatccccagc acgttggaag gccgaagagg gtggatcact tgagggcagg agttcaaaca     1200
aaaaaattaa aaaaaaaaaa aaaaagggcg gcc                                  1233
```

<210> 20
<211> 1090
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (17)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (47)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1033)
<223> n equals a,t,g, or c

<400> 20

```
gatntggcga tacattnaca cagaacagta gacatgatac gccaagntta atagactact       60
atagggaaag ctgtacgctg cagtaccgtc cggaattccc gggtcgaccc acgcgtccgc      120
gcggctcatg cccccagtat cccggtccag ctattccgag gacatcgtgg gctctcggag      180
aaggcgacgc agctcctcgg ggagcccacc atccccgcag agcagatgtt cctcttggga      240
tggctgttcc cgctctcact cccgcggccg tgagggccmc aggcctcctt ggagtgagtt      300
ggacgtgggc gctctttacc cctttagtcg ctctgggtcg cgagggcggc tcccaagatt      360
ccgcaactac gccttcgcgt cctcctggtc gacctcgtat agtggatatc gctaccatcg      420
tgcactgcta tgcagaagaa cggcagtcag cggaagacta cgagaaggaa gagagccatc      480
ggcagaggag gctgaaggag agagagagga ttggggaatt gggagcgcct gaagtgtggg      540
ggccgtctcc aaagttccct cagctagatt ctgacgaaca taccccagtt gaggatgaag      600
aagaggtaac gcatcagaaa agcagcagtt cagattccaa ctcggaagaa cataggaaam      660
agaagaccag tcgttcaaga aacaagaaaa aaagaaagaa taagtcgtct aaaagaaagc      720
ataggaaata ttctgatagt gacagtaact cagagtctga cacaaattct gactctgatg      780
atgataaaaa gagagttaaa gccaagaaga aaaagaagaa aaagaaacac aaaacaaara      840
aaaagaagaa taagaaaacc aaaaaagaat ccagtgactc aagctgtaaa gactcagaag      900
aggacttgtc agaagctacc tgggatggag cagccaaatg tggcagatac tatggattta      960
atagggccag aagcacctat taatacatac ctcttcaaga tgaaaaacct ttgaagtatg     1020
ggccatgctt tgnttcccgg tggaaggtgc agctatggct gagtatgtta aaagctggga     1080
agcgattccc                                                            1090
```

<210> 21
<211> 682
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (624)
<223> n equals a,t,g, or c

<400> 21
gcaaatatta attgccattt actttgaaac ctaaaatggt caagattcca ttttcctcca 60
ggctaataaa taataatttg caatatatag attgtatttt gtctttgaaa cgctgtgagg 120
agatcctctt aatgtggcat ggtctgcttc tatgccttgc ttctgtgttt cttgagctcc 180
gtggagatag gccccctctc ctggcttctc tgcttgagcc acataaaatg ccacttcaca 240
gctcttccct ttgaagcctg atccagtatg catttggagc taattactgc agttgacaca 300
actccatcta aaagcgtcat gaaagattct gtaatcactg ataagaaaat gatcttgcaa 360
attattgctg tgtcctcctt tattgcctct ttaccttaac agtacagttt acaataatgt 420
aaatttttct ctaatctttc aactttaacc ctagaaattg tagatgtttt agcagtggtt 480
atgtgatatt ggcacaacat aactatataa tttgctcaat attgtggtgc atacctgtaa 540
tcccagctgc tcaggagtct gaggcatgag aatcacatga acccaggaga tggaggttgc 600
ggtgagctga gagcgagtca ctgnactcca gccaggacga cagagtgaaa ccctgtctca 660
aaaaaaaaaa aaaaaactcg ag 682

<210> 22
<211> 770
<212> DNA
<213> Homo sapiens

<400> 22
ccaatactcc tttacttttct ttgagttaca atgttgcatc tattctgttc acagccccta 60
ggrctccttt tcctgctgat ctttctaggt cttgactctc tgcctcgttg cttgaccgct 120
acccggcttc agagtccaat aattatattt tcaactttgt cctgtatatg ctccacttct 180
tggctggaac tctgttcagt ttatttcctg actttgaact atctccacgt agtgccacct 240
tgtttcctga tctaaggact gtgcaactcc tctccagtcg gccacatctc tgaccaaggg 300
attcagtgaa aactctggtt tctcacctga actttgatct ttaaccccag ctgacactag 360
taatggcctt tgtgatcagg ctctgaaaga agactgactt catgtgaacc atgtgagcat 420
attgttcata tatccctcaa ggtggatcct tcttttctaa aaggcatcta aaaagcaacg 480
gaagttcttt tgaaaatcag aggctgcctt tttggtagca gttctttcat ttattctgta 540
gaggatccag attgagctct ttataaaata ttctcctaca taatgtactg ggatagtcct 600
aacaatagta aaccttgatc cacagatcac atgtgccatt ggataaaaat aaataatgca 660
ragraactca ataagaccag cctgtttaaa ggagacatca taaaaacctc cattaaaaaa 720
aaaaaaaaaa aactcgaggg ggggcccgta cccaatcgcc tgtgatgatc 770

<210> 23
<211> 565
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (21)
<223> n equals a,t,g, or c

<220>

<221> SITE
<222> (538)
<223> n equals a,t,g, or c

<400> 23
tccccccggn ctggcaggaa nttcgscacg agcagaaagc aaatcagtgg ttttctggag 60
tttgacatgg gggtactaac aagggaactt tttggggtgg tgggaatgct gtatattttg 120
attgtgggga tggttacatg gttggatgca tttgtcaaaa cacacttaat ggtaatgcaa 180
aatgaatata ttttatttta tgtaaattat acctcaaagt tgaatttttt taaaaagttt 240
cttttaaaaa gtaaagacat ttgtggtgct tcttgtaaat tttactgctg attatgacct 300
tgtttcttta gatttgactt tccaagtttg aaaagaccag tttaaaaatg acttttgctg 360
ggcatggtgg catgtgcacg tagtcttacc tactcaggag gctgacgcag gagggtccct 420
tgagcccagg agttggaggc tacagtgagc tatgattatg ccactgcact ccagcttggg 480
tgaaactgtg agaccctgtc tctaaaaaca aaaaaaaaaa aaaaaaactc gaggggggncc 540
cggtacccaa ttcgcccaaa atgga 565

<210> 24
<211> 1356
<212> DNA
<213> Homo sapiens

<400> 24
ggtcattaag tcctagtctc attaattgtt ttcaagcttt tcgcctacat tttagactaa 60
ccctgcttat tcctgtgaat caagtagtga tctcctgcag cttggaagaa aaaataaggg 120
atgggtaatg taaaaatctg gatcaatata ctggttctgg gcaattatcc tgcaaattct 180
gccaggtaat aaaagtgagt agggtgccca taatccggaa gtttctttgt ttaggaaaat 240
aaaaacaagg aacttcatag acccccccaa aggggaattc tatatcttga caagtaaaat 300
tttagatgga aattatctac aacaccacac ttacggaaat tgctatcctc actctattat 360
ttgcaaaagg gttatacaca gtagcacctt ctaactgaag tattaaacag agtttccatt 420
gctgtcgtat tttgcttaat tattatcctt atagcaggga taatagttac taacaaaaag 480
gaagcatgaa agtttttacta tcactgagcc tggtaggact ttttattggg tttagtgatg 540
cagtttttaaa tgaaacatgc cgcttttgga ttaatacctc tagtaaagga aatttacaga 600
tacttaaaaa tcaaatccaa attattgata ggctcaggaa aatgccagct tcagcctgag 660
tggctacaaa cctctttaat aaattccagt cttcttatgg attggttaac gccttattaa 720
gccctctctt gcttatatgt cttgtattga tatttggact ctgtatatac aatactataa 780
ctcgaattgt ttcttctcgc ctagaagcaa tcaaactcca aatggtgctg taaactgaac 840
cacacatgga caggccattc ttccgaggac ccttagattg atcccagggg agccctagct 900
gctattcccc attcacgccc ttttcagcag gaagtagcca gaaggagtcg ccgcccaaaa 960
tcccctaaca gcagttagtg tggcatctcc acaggaagta atgttgtagg agttactaag 1020
aaattatttt aggcagatag agaggaaaag gggtccttgg gaagttttca ttttttaaag 1080
catctctgga aaagtttctt gtaaagcccc ggctcttaga gccaggctgg caacctttga 1140
tatgcaaatg taagccatta gaaaccaggt ccacccaggc caggtgtggt gctcacgcct 1200
gtaatcccaa cactttggga agcctaggca ggtggatcac ctgaggtcag gagttcgaga 1260
ccagcctggc caacatggtg aaaccccgcc tctaataaaa acacaaaaaa ctaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1356

<210> 25
<211> 617
<212> DNA
<213> Homo sapiens

<400> 25
ggcacagcac agcctgagat cttggggatc cctcagccta acacccacag acgtcagctg 60
gtggattccc gctgcatcaa ggcctaccca ctgtctccat gctgggctct ccctgccttc 120
tgtggctcct ggccgtgacc ttcttggttc ccagagctca gcccttggcc cctcaagact 180

ttgaagaaga ggaggcagat gagactgaga cggcgtggcc gcctttgccg gctgtcccct 240
gcgactacga ccactgccga cacctgcagg tgccctgcaa ggagctacag agggtcgggc 300
cggcggcctg cctgtgccca ggaytctcca gccccgccca gccgcccgac ccgccgcgca 360
tgggagaagt gcgcattgcg gccgaagagg gccgcgcagt ggtccactgg tgtgcccccc 420
tctccccggt cctccactac tggctgctgc tttgggacgg cagcgagstg cgcagaaggg 480
gcccgccgct gaacgctacg gtccgcagag ccgaactgaa ggggctgaag ccaggggca 540
tttatgtcgt ttgcgtagtg gccgctaacg aggccggggc aagccgcgtg ccccaggctg 600
gaggagaggg cctcgag 617

<210> 26
<211> 648
<212> DNA
<213> Homo sapiens

<400> 26
ggcacgaggt gttttaaacc tcagaaacag atttgagtgt ttcagtatta tagaaacagt 60
gatgactatt catgctctgc tagtctatgc ctgcaactcc aaatgtttgt ggttcagtat 120
ttcccaccta catttctgtt tggtgacatt gctcatttta acaaatatga ccgagtctag 180
tttttcttta aaaggatagt ttatgagtaa tctttaaaac catttccata ccatctgtat 240
ataaccattt cggtagagaa cacactacac tgaaccctgc tttagagctg tgtgttgagc 300
taaaaatata atttttaaa aattgactag caaaatctat ggccacactg agaagccttt 360
gaaaatggca aatacttttc atcaccaatt gcccaattca tctttcttct gcttcctcag 420
ccttgtagca aaggctacac agcagcccac agtccacagt ctttttggga aaattggcct 480
gccaccttct ttaagctcag tttatttttg acttactttc tttgctgtag ttatgaacct 540
tggggcatta aaatcccatg gcaaggagca taagagatgt tctcgtagct ctgcgttgtg 600
tgaaatgtcc atcttagttt tgttaaaaaa aaaaaaaaaa aaaaaaaa 648

<210> 27
<211> 1388
<212> DNA
<213> Homo sapiens

<400> 27
ggcacgaggt aagttgcaag gtacacccac gggtgattta tcactcttac aaagatgata 60
actaatgaag accgcatcta gaatgctctt actggagatg gtttacagag cattttaat 120
catcatactt agatttatat taatatttct tttcaaacta aattattcca aactgtgccc 180
tgagatacca tttggcctca agttcttttc tttcgtctgt attaaggtgc aaataaaaaa 240
gactagtagg aaaagaaggc cttatttatg aaggttgtct atagctctga gcttggtagc 300
tacataaaat gagtaataac ctaaataagt aaaactaatg aagatctaac tagattactt 360
tgcttaatat taacatttta cccgcccccc gccgtgaaac atttggcaga tgttctgcag 420
gactcatgag gacattggtg gctacagctg cttctggcac tgccccccca acccccagt 480
gaggtgaact tctttacaca tccagcaagc tttagttatc ttcttctccc atttgagata 540
actgtggcta caagaatctc agttaaatca gatgtttaaa ttaggtgcca aaaaatctta 600
cagacactga actaatactt aaatcaagga acacttcagt tctccataaa atctggtgcc 660
attttccaaa gaaacagagg atctttgttt cacacccgtg gtactggaat tgcaacagtg 720
aggcattcta gctctcacat gccaatgcga gtggcattca ttcttgctca ctcatttctg 780
cttctcattg tcacacttgg aggctctttg ggggtatgtt tcagttgatc tgagaaactg 840
ggtgttacca atttactaga gagtttctta aaatgtatct gaaacaaact attaatgggc 900
attctgtggt ggtaaaacca ggcaacgcct ccctacacta tctgtccttt cagagctaag 960
aatctgttat tttgaattgt tcacgaagag tgattctgac tctgcttcag tgcacacttt 1020
acaaaccatc gagcctcatc aaaggagtga gttgagctga ggaattagag taaagaatac 1080
aggtatagtg ccgggcgtgg tgctcacgcc tgtaatccca acattttggg aggacaagga 1140
gggtggatca cctgaggtca ggagttcgag accagcctga ccaacatgga gaaaccctgt 1200
ctttactaaa aatacaaaat tagctggacg tggtggcaca tgcctgtgat cacagctact 1260
caggaggctg aggcaggaga atcgcttgaa cccaggaggc ggaggttgtg gtgagccgag 1320

atcacgtcac tgcactccag cctgggcaac aagagtgaaa ttccatctca aaaaaaaaaa 1380
aaaaaaaa 1388

<210> 28
<211> 616
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (580)
<223> n equals a,t,g, or c

<400> 28
cmgctrctra gcaactnagt gggatscccc gggctgcagg aattcggcac gaggagaacg 60
gctgcacgtg ggagatgctc cgtggatgtt tgtagaacgc tggcttccgt gtttcctcgt 120
tgtggctgtg gtggtgtggg tctttgcctg tggacccgtg gaagacaaag aagacagttt 180
tggatggtca agctattttc ttgcttcagg gctccctccc ctgctttttg aagcctcaca 240
aaccaggact gtgagggcag gaaggcttgg ggtctttgtg tgctgagcct cattagggtt 300
ttaagaacct ccctcctttc atctctagct tacgagaggg atgattcatt atcttccctc 360
ctcaggctgc agtagaagca gacagtctct gcctccctgc ttgccttttcc tccctcccat 420
tcactgttga ttattgccct caagaataac aggttgccca gctactcgag argcttaagt 480
gggaggattg cttgacccca ggagttcgag gctgcagtga gctatgatcg cttcactgcg 540
ctatagcctg gcagacacag agagacccta tctcaagcan acagacaaac aaaaaaaaaa 600
aaaaaaaaaa ctcgag 616

<210> 29
<211> 828
<212> DNA
<213> Homo sapiens

<400> 29
acgagaacac catgctagtg agttcattcc taacagagga gaacttgcat cttgactaag 60
cattagtgat ctcaaatcct ctgcttatga tttttaaact tctgatcttc agaatatttt 120
tccatgagct agctctggct ttgtgcatct caaaccttgt ttctctccca tggctgtcat 180
acttctggtg ccctgagatg cagaatttat ttctacttga tacacacatt tgggtattga 240
tgtagggtta gtacagcagg taggttgaga atttctggag cctcccctccc tccctttgtt 300
ctgacctttc cttagtcata tcatcctaga aagatcttcc ctggcttcgt ctaaaacatg 360
gcctctcatt tcattctctc cctgacaacc ctgatgtagt tttcatttca ggactcatca 420
ccccaacatc ctttcctgtt tacagcccat ctcccctgct agaacacaag ctctgagagg 480
tggaaggcct ctattgtggg ttttggcgaa tccccaatct ctagatggtg tctggcatgt 540
gatagagatt caacaaacac ttcaacaaat aatgaataaa gttaaatttt tcagagtgca 600
atcatgcctc tcccttcctc tgccagggcg gaggctgtgc ctggtttgcg cggcttctgc 660
agctccagct ccttgtactg agtctggaga atgatggagc tcagtccatt ttaatcccat 720
gaacattaaa tgcgtggatg tgtggatgct gggatggatg gatgacgctc ctagcacggc 780
agcttgcagg ggattggcga tttccagtaa ggtgtgctaa gactcgag 828

<210> 30
<211> 581

<212> DNA
<213> Homo sapiens

<400> 30
ggcacgagat tatgggggca gtttccccaa tgctgttctt gtgatagtag ggaattctca 60
tgagagctga tggttttaag tgtggcactt cttcacgctc tctctcacct gatgccatgt 120
aagacgtgcc ttgcttccac ttcaccttct gccatgattg taagtttcct gaggcctccc 180
cagccagcca tgtggaactg tgagtcaatt aaacctttt tgtttataca ttacccagtc 240
tcaggtagta tctttatagc agtgtgagaa tggactaatg cagtctcttt gttagattgc 300
ctatgtttct tgactgtcta ataagatatg actttcagtg atacaaatga tcagagaacc 360
ttgcaaagct gatgtggtgg agagagttca gggagaacca gagtggaaca aaccggagga 420
atgaatatgg tagagtgcaa gtgaatttgc tcctgatttc cagaagcagt tgtcagcaac 480
agagtttacc cttgtatagc attaaaatag tctaggacaa accagaaagt ccataatgtc 540
ctccagcatt aagagagcac ctcgtgccga attcggcacg a 581

<210> 31
<211> 789
<212> DNA
<213> Homo sapiens

<400> 31
ggcacgagcc tccttccaga agttccaggg ttttcttga tggttgccat tctgcttaga 60
gaacttccat tagcctttct tttggtgggg tcttctggtg acaaattctg tttcacttcc 120
tctgagaatg ttttgctttc ctttttcattc ctgaaggaca tttttgctgg atataagaat 180
tctgggttaa tggttctttt cattgtttaa aaaatatttt gtactttcag ctgggctcca 240
tggtttctga tgagaaattc gctgtcattt gacttgttaa tgcacgatag ttaaggcagt 300
ttttgtttag tggcttttga aatgttttgt cttttgtttt ttggagtttg attattgtat 360
gtcttagttt ggatttcttt gggttcatcc tgtttagggt ttgcttacct aagatctgta 420
gatttatgtc tcttgccaaa tttgggaact tttaagccat cattcgtaga gtacagtttc 480
aaccccacct tctttctcct gtcccttcgt gagttcagtg actggagttg ttatagtccc 540
ataggtcccc aagactggtt ttttttttt ttttttttt ttttgctggg acatttcttt 600
ctctcttccc ttcccatccc gtcccatcca gtcccgtccc gtcccatccc ttcctgtccc 660
ttcccatccc ttcccgtccc ttcccatctt cggagtctct ccctgtttcc caggctggag 720
tgcaatggac gttctcggct cactgcaacc gccgcctccc tagttcgaat gattcttctg 780
tctcagcct 789

<210> 32
<211> 884
<212> DNA
<213> Homo sapiens

<400> 32
ggcacgagca gaatcagggc actgagctct actgtaagtg tgtatttaat ctccatttt 60
aatttgaccc atagaaaatt gtctttatag accaaaaatg gtcaaagatg agcaatttca 120
tatctattac atgcttagtg ttcactattt tggggcatct tgtttctctc caggttgcgc 180
attcatctgt ttttgagttt aaaaccttgt atgtgcttaa gaccaataga tattctcagt 240
cacttttag acatttttgt cacctcagtt ttatcagaac tagaaaaatc ttccttaaaa 300
acaactgaaa cctttttctt tgcagtgttt cttttgctaa tgatgaacta atattaacaa 360
cttaccttct aataactttg tctttgtaac tcaggtttaa aagcattact ccaccaatct 420
cttttattct ccattaaaag atattatttc ctttataatt catttttatt ccttatttgt 480
ttagtgcctt aagtctgttt ctgtacagct tggagactgt aacttggaaa aatgtagata 540
tattcattat atactatctc acttaaatgt gaattctgaa gaagtttttc tgagaaaata 600
aattcgtctt gttttgagtgt tccttctctg tctgctgtat tctaccaggg ggacagagga 660
aagaagggca gagaaattct ttcctggatt tcatgaaatc actgaggcca gagcaacaga 720
tcatttaact tttctttatc ccgtgtatgt attactgaaa aaaatggtac ataatagaat 780

ttgagtttat ttttatctga cttcaggtac atagggacac ttcctgttta aaagaactct 840
gcattgaatt gtgcctttca caaagcaaaa aaaaaaaaaa aaaa 884

<210> 33
<211> 866
<212> DNA
<213> Homo sapiens

<400> 33
ccacgcgtcc gctccaaaca aacaaaaaat gaactttatt tagatatatt ttacatatga 60
tgaagtattt ttttgatgta gtagtttttc tcacctttctt tttagtcttc tctttatcca 120
ttttctttc tgatgaagaa ttccctgtga gtaggaccca gaacataggc ctttgtcatt 180
tcaacccttc gttctctgaa taggctgttt attggcaaca ttaactggaa acatttatg 240
tacagcattg gagtctcact ctgtcgcctc agctcactgc aacctccgcc tcctgggttc 300
aagtgatgtg cactgtatga actgtgagag caagcatatc attataacat tggacaatga 360
gccaagacag ttctgatgga cttttgaaga gggatttttc aaaagcattt aactcatcat 420
attaataaaa taaatcctat gatttatggg aaattctgtt ggatcaactt tggaaactgt 480
ttactataaa ggtagcatgc gtaggcatga atcttgataa gacaagattc tgatccgggg 540
ttctgagtgg gtccttatat tctgcagagc tgaaccaggt ggaataggag gagagtttgg 600
gtaacagtca aacacaacat ccaaaattat gttgaatgca gtggtgagag ctattccctt 660
taaaactctc tcttggttct tctgactgtg tcaagaatac tgtatttgtt tggtactggt 720
ctggtttttt ttttttttt tttgaaatgc actccagcct gggcgacaag agtgaaactc 780
tgtctgaaaa gaaagaaaga aagaaaaaga aagaaaggaa agaaggaagg aagaaaaaaa 840
agaaaagaaa gaaaaaaaaa aaaaaa 866

<210> 34
<211> 1694
<212> DNA
<213> Homo sapiens

<400> 34
ccacgcgtcc gggataaact atttatcata aatttaaatg ttgttattgt gcctttattg 60
cacatttttt ctcatgcctt ttattataaa atatacttgt tttcaccttg tttttggtca 120
aatcccagtt actgtccatg taaacatatg gcaacataag aacgtcactt tttttatcct 180
gcactgtggc atacctgctc ttacaagaga ttctgctgca cttacatatt caaatgatgg 240
cacagttata gagactttat tattcttaat tctttattta gacttaaaca ttatttgttg 300
ctaattaaaa cagttcatat gatgaacttt ataataaaat atatattttt caggccaggc 360
atagtggctc atgtctgtaa tcccagcact ccaggagtct gaggcaggcg gaccacttga 420
gcccaagagt ttgagaccag cctggacaac atagggaggt cctgtctcca caaaaaattt 480
ttaaaaaatt agctaggcat tgtggtgcat tcttgtggtc ccagctactc cggaggctga 540
ggtaggagga ccacttgagc cccagaggtc aagggcgcag taagttgtga gagtgagact 600
ctgtctcaat gataataatc ataatcataa taaagatatg taccccagag tcaagaatgc 660
aataagctgt gagagtgaga ccctgtctca atgatcttaa taatagtcac aataaagata 720
tatattttgc atcagtctgt gggtaattga atgatgattg ctggagtaaa actgagcaga 780
atggtacagt gctgtactgt acagtacata agaatcagga gaggcagctg ttttaagccc 840
cagtcttatt atgcccattt aatcaaggca tgctggctcc tgtcatgaat tattctgatg 900
ttgagtaaaa ctgtcatctt caattcatat cactttcaaa tgttacatta taagagaaat 960
gtaacctggt aagtactaag ttgtagattg ttacagagtc agaaaagttg gatgtaattg 1020
ctgatattga ttatggtaag tagtctttcc ttgctaaagg aatgccaatt tttaaacaaa 1080
ttataaagca atcatttta cacaaagatg aaaatacaca tgggtcctca tatgctaaaa 1140
tgttatatgt ataggtttaa atatctaatt tggaaaagct agacatataa ataggttttc 1200
atccttgcag ctaccaatat caaactatac agttcttgtt agtacctcct ctagggtgtt 1260
tggagagggg gcagagaaaa gagctcaaat tcaagttgtt tttatatctg acataatttt 1320
ttaaaattat aagtcaaatg tttgttaagg gaggggattt aagttattaa ttaaaataag 1380
atttttagat cttcagattt tacttatcta tcctaccttc cattgttatt gagagttggc 1440

tgtatttttct ttttttttta ctccctggcc tgatttaaag atactctgga acattccaga 1500
ggcactgaat ttatcattct aaaagggcca tgtagtactc ccaggaggca tagagctgag 1560
ccactcaatg tgtcttgagg ttccaaaatt ctgattctat gcttttatga acatgtaatt 1620
tagcagatgt tacctaatag caaaagaaaa tgctatcttt accagaatgc acttaggaaa 1680
aaaaaaaaaa aaaa 1694

<210> 35
<211> 1215
<212> DNA
<213> Homo sapiens

<400> 35
ggcacgagct tttcagtact ctcacttatt catgacacag gaatgaccct ttactcaaaa 60
ctcttgtggt tgttcaaagg tgagcttctt tttcccttag tcttagccta tgtgttgctg 120
ttgtatattg ttaccaagtt caactaccta attttgaagc tctttccaaa taagatacaa 180
attaaaaggg gaagcattgc cagtaacagg tccctagaga gcagtgccag cctgcctgca 240
agaaaagagg agaaacttct taaaaagttt taagcctggg caacataagg agattgtttc 300
tatgaaaaat aaaaattagc caggatggtg gtgtacacct gtagtcccag ctactcggga 360
agatgagatt ggaggatcac ttgggcctgg gaggttgagg ctacagtgaa ctgtgattgt 420
gccactgtac tccagtctgg gcgacagtga aatcttgtct aaacaaaaac aatttaactg 480
ggaagcacag tggtccttga ggacatttaa tatcaggaca aagagcctat gaatatatca 540
ctgatgtata taaaccctaa ggcgttaata aaagctaact gtttagtgtt atccatttaa 600
gggaacagga ggaattgcat aacttttaga ttagtcatag tggtgcctaa gggatatgct 660
gtggtatatt tgtatagcca gggcacttag ccttccaacc aatttatata ccatgttctt 720
caactgtggg tgagatttag cctcaagatt tgatttacta tatgtaagta cattacttga 780
tttctataaa gaatctttag tggaagatgt tattctgaat tatttatcaa tatgattaat 840
ccagttagaa attattaatg atcttccttt atactataca taggataact tttaaccttgt 900
cgctacagtt gttgctctga ggatcttaat tttgttactt tctaggctac atgaagctat 960
ctttttaaaa agtgtactct tcattttcac tgttattgtg tacttagcat aaaaaactca 1020
aatctaggcc aggtgcagtg gctcatgcct gtaatcccag cactttggga ggctgaagca 1080
tgcggatcac ttgagcccag gagttcaaga ccagcctggg caacatggct aatgaacact 1140
aagcatagtt ttgatgtctt tcatattaaa gactttctca aattcttaaa aaaaaaaaaa 1200
aaaaaaaaaa aaaaa 1215

<210> 36
<211> 1794
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1675)
<223> n equals a,t,g, or c

<400> 36
gctcctctag tgactgctgg ggtgctagtt ttcacggtta ccacagaact tgagagagga 60
aaatgagaac ggcaaattaa aatgccataa aattccattc ttaacaagcg ttagtttttt 120
tttcctatat atccactccc tcacctatct tatgacatat gagaaatcct aacatgggac 180
ttggtgtata attagcattg aatgaattta agttttcttt ctttctttct tttcttttat 240
cttctgtggt ctcctgcaga atcagtctat aaaaagggca tggtaaaaaa aaatctatct 300
catagcattg ttgaaaagat taaatgacat aataagatga tgcatatata gtagctagca 360
ctgtacctga tgcatattag gagcttgata atattactaa cattatcatc atcaatgcta 420
tctgagcaaa gaggctgttc cttctttcca gccagagttc ttctgttgga taatatttcc 480
agctgtgaac cccaaccaga gaccttgaag cctttatttc cttttctctc attggccttt 540
ggctgaagtc tcctttctgc agagaacaaa gtgaccagct tttgatgaac tattttcctc 600

ttttatccat ttccaagtgt tagccatagt gaagaagtgt agctgggtgc tagcccaact 660
caagaagtga taatgtwata tccaacccaa gataaactca aggataactt tcaacacggc 720
tactcaagca gttcaggggg gaggcatctt gtagagagga gaccaggaag tcacttggca 780
gctgggccag cacacagagg gccattgctc cagtaaagca gctaacctcc atctcttcat 840
caaaccatcc tagactcagc actctgcaga gaaggagcag atggagggaa tgtgtggaga 900
gattagataa gaaggatttc taatctagtg ggggagcgag taaaatgtac agaagtttga 960
gaagccaagc tcttatgtam maatccrccc ccatcactca acaatcccca ctgtatgaat 1020
aaagcctgga aagtttccaa ttaaaacagt gcttgtgaat attggcaagg ggtatctttg 1080
tgtgcagggt acatttaaag ggagaagggt gaagatacac ccttgcctty taggagtaca 1140
ctttctgaga gcttgttcac caggctgtga gtttctcagt ctatctgttt ctcagtctgt 1200
tagtaatgaa tgtatctccc acttagcaca gcagctagca catagtagat gcctaacaaa 1260
tgtgtgttaa attgaatgtt ggaagtctgt gtcctgaaag cttttcttca catattacaa 1320
ggctttttat ttgttcaaca cattttacc aagtttttt ctgtgttcca ggtcttttga 1380
ttagctgttt ttaagtcaca gaaatgggtg tcgggaacaa aaccagtcaa aagtcctcat 1440
tctacatcat ttacactttc ccttcctata tttataagtt ttaatatcag cttctacaat 1500
aggttccaga acaagtggtg ctcaaggaat ggagaaaatg actattccaa ccctagctgt 1560
aggtgaacca aaaaccccag agaaatcaaa gtgtagttta aagcagtgct tctcaagttg 1620
taatgtgcat atagatcacc tggggttgtt attaaaatgc aaattctaaa agagncagga 1680
gaatatcttg agcctgggag ccagaggttg cagtgagccg agatcattcc actgcattcc 1740
agcctgggtg acacagcgag actccatctt aaaaaaaaaa aaaaaaaact cgta 1794

<210> 37
<211> 1174
<212> DNA
<213> Homo sapiens

<400> 37
ggcacgagca aaggcaggaa cttttgtcat ttttgttctt caagatgtcc ccaatgccta 60
cagcagtaag tgcactgctg ggcacacagt aggtattcaa taaacattca atgaatgaat 120
gaatgaatga atgaatgaat gcattgccaa accttgcatg gctgcctttt gttcctgccc 180
tagctgctgc ctccccagcc ggcctggctg ctcccgagag cagagatgtg ccttttcctg 240
tgagccctgc cacacagttg aacattgggt agagcccatg ggccaggggc agaggcagga 300
acacactcag ggcagcgtgc tgccttcctc ccatccttct agaggcaaag ccaccacagt 360
ccattcctgt tgccaagagc cttgggggta ggggaagtag acaggaattc accactcctt 420
aaaaccagag aagtccagag tcctctgagg gacagggctc ttgatgttca gagggaatca 480
gcctcggcct ggggaggctg ggatttgggt ggtttattct tcagcatcca cttcttctcc 540
agggagtctg tcagtgacag gaaaagtgac tcagaacccc agagccaggc ctagtggaca 600
ctaggttctg cctgtcccat ggagggtgct gtggctttga cggattagaa gtcaggactt 660
ggccatcatg actacatgct ttaaaaaata tgagttttct ttttttgttt tgggtttttt 720
aaggcggtgg ggggctactt tgtgtttagg ttttacatcc tttgcaataa agttccaccc 780
atccagcttg tgcagtgaaa aagagggaaa ggacttcagt ggctttgcct tgtctataca 840
tgggccagag agaaaaaagg aagagggctg ggcgcggtgg ctcacgcctg tggtcccagt 900
actttgggag gccgaggtgg gaggatcacc tgaggtcagt agttgagacc agcctggcca 960
acatggcaaa atcccgtctc tactaaaaat acaaaaatta cctgggcgtg gtggtgggca 1020
tctgtaatcc cagctactcc agaggctgag gcgggagaat ggcttgaacc caggaggcat 1080
aggctgccag tgagccgaga tcatcccatg gcactctagc ctaagggata gagtgagact 1140
ctgtctcaaa aaaaaaaaaa aaaaaaaaaa aaaa 1174

<210> 38
<211> 1087
<212> DNA
<213> Homo sapiens

<220>
<221> SITE

<222> (408)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1005)
<223> n equals a,t,g, or c

<400> 38
gtccattctt accaccactc tcccaggtaa atgctccatc ttctctgtct tgggttgcat 60
ttggtcccac ctggtcttct ttcagttaac tcccttcagt ccacccaatg cagtcttttc 120
tctgcagcca aatttttttc tatagttcag gtctgatgat accactttcc attttcaaac 180
tccttaaatt ggcctcggag acctgtgatg gccaatcttc cccacccctg tgggtcaggt 240
tcctctggtg tgggcctatc tcttagtgca aggctccctg tagactgtcc tggggctgcc 300
tgtctaattg tcttctcatg aaccaggtag gcargcagga accactcatc tagtctgggg 360
gtgactgggg ggtgcgaaag ttttgttaca ggatgtattt aacacttnca ttgtctggct 420
caaaattctc tttgaagaaa ctgcctttgt ttaattctgt ttawttattt agaacttacc 480
tagaattgat ttgcacttgc aaaaatgctg ctgttttaga gtttgctttc taggctggtt 540
gcttgctctg tcaccttagc taaaaactag gtactggagt gccttttcta ttcycttctc 600
ttctttcttt cttcttcttt ttttttttkt tttttagtgg agtctggctt tgtcgcccgg 660
gcttaagtgc agtggcacga tcccggctca ctgcmtcctc cgcctcccag gakaagccct 720
tgaacctggg agggagttgc ggtgagcgga gatcgggcca ttgcactcca gcccgggcaa 780
cagatcctga ctcttatcaa aaaaaaaaaa aaaagaaaat taaccttagt ttaactttct 840
tgctttacca agtttttaat ttttaaaatt ttttactctt ttgtaatagc acttagttta 900
aaacacaaca cattgtacag ctgtactaaa tatatcttca tttatatcat tgttccatag 960
ctttttttctt ttgtgtgtgt gtgtgtgtgt gtatgtgtgg gtgancagtg agatccgtct 1020
caaaaaaaaa ccaaccaaac aaaaaaaaaa aaaaaaactc gtaggggggg atccggtacc 1080
caattcg 1087

<210> 39
<211> 438
<212> DNA
<213> Homo sapiens

<400> 39
ggcacgaggc aaatgccata tatgtttaga ccagcctttc tcaattgtgg cacttttgcc 60
atttttggcc agttaaattc tgttgtgggg gctgtcctgt gcattgcagg atgtttagca 120
gcatctctgg cctctaccta ctaaatgcca gtgcaccctc cctgcagtta aatgacccca 180
aatgtctcca gacataggca aatgttcccc ggagaacaaa gtcatctttg gttgaggaac 240
aaaatgaacc tatatttaag atggtctaaa tgtttctgag atggtctaaa catttataag 300
cttaacaatt aacttgaaac tcttcaggac tagagaagct atttgtaaat ttaaacatct 360
gacgccttga aacaccttta tcataaagat aactaaacca gtgttctttg tgaatggcca 420
aaaaaaaaaa aaaaaaaa 438

<210> 40
<211> 734
<212> DNA
<213> Homo sapiens

<400> 40
gctcgtgccg ctgctgggca ctgggagcag ggggcggcca aaggcagtgg gtgggcaggt 60
ccatgcctcc cctggccccc cagctctgca gggcagtgtt cctggttcct atcttgctgc 120
tgctgcaggt gaagcctctg aacgggagcc caggccccaa agatgggagc cagacagaga 180
aaacgccctc tgcagaccag aatcaagaac agttcgaaga gcactttgtg gcctcctcag 240
tgggtgagat gtggcaggtg gtggacatgg cccagcagga agaagaccag tcgtccaaga 300

cggcagctgt tcacaagcac tctttccacc tcagcttctg ctttagtctg gccagtgtca 360
tggttttctc aggagggcca ttgaggcgga cattcccaaa tatccaactc tgcttcatgc 420
tcactcactg accctccctc cctcctgggc tccaggtcac aactcccaaa ggagatgcag 480
gcatggctct ctgcctctga tcaccatcac tgtatctcaa ggttcagcag cagagatacc 540
agttgccatc agtgctaact gactgcctct ccaggttcgg agtttcatct cccagggcca 600
gagacagcag acccacatcc ttctctccca cacctctcct ggttttgttc aggacagcag 660
attagaggca ggaggcaatg acaataaaat aacgataaaa tcctgagaac aaaaaaaaaa 720
aaaaaaaact cgag 734

<210> 41
<211> 1346
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (707)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (998)
<223> n equals a,t,g, or c

<400> 41
gggcagmgya aacacctctt cttataaaca tggccctgct ttagcaacag gtctccatta 60
tgaagcaatt tggatttgga catcctatca agttacttaa aactaaactc tgccgtatag 120
tgttttactt ggtatttttt gtgtggccac agtctagtgt gatcagagaa gccacacaga 180
cataaattcc cagtcctgat tccattgatt attagatatg tacttaccct gaacatctgt 240
aagatgggga gtaatgatgt ttaccacaaa gagttagtgt aaggattcga tgagagaact 300
tgcatttgag ccatctggag agaatgttag ttttagcact aacgatcgtt tataatactg 360
ctgaggagga aggactgaca tcaccctgct tgagaatcta gtatatgttg ggcattccyt 420
atccattcat gagcctgaga gtacttgaga wgttttgatc ttggacactg ytgtgcagct 480
ttaaggatga tgaggggaaa atggaaagag tcytgaaggg accagtgtca gagacagata 540
gaaaagggct gcctgagccg ggcgcagtga ctcacgcctg taatcccaac actttgggag 600
gccggggcgg gtggatcacc tgaggtcggg agttcgagac ccgtctaacc aacatggaga 660
aaccctgctt ctactawaaa tacaaaatta gccaggtatg gtggcanatg cctgttaccc 720
cagctgcttg ggaggctgag gcaggagaat tgcttgagag gcagaggttg ttgtaagccg 780
agwtcgcgcc attgcacgcc agcctgggca acaagatkga aactcccatc tcaaaaaaag 840
aaaagaaaag ggctgcctgg gtccctggga agacccagct cccctctgta tcctagccaa 900
ctccttaagt gcacacaacc tcagctgacc acataggtgg cagtgatagc aaatggtgag 960
gtgggtgggg gtgggggtcc tgcagctcac tttctgtnct gcgtaataag ggagagatca 1020
gagatgcata gacttttaaa ctggtacggt tcttagagat ggtccttggc cttctgttgt 1080
tgttgttgtt tttttctttt tcttcttctc cttctccttc ttcttctctt ctccttcttt 1140
cttctttttt ttttcagagt cttgctctgt caccaagact ggagtgaagt gatgtgatct 1200
cggcttactg caacctccac ctcctgaggt caggagaatt gcttgagagg cagaggttgt 1260
tgtaagccga gatcgcgcca ttgcacgcca gcctgggcaa caagattgaa actcccatct 1320
caaaaaaaaa aaaaaaaaac tcgtag 1346

<210> 42
<211> 998
<212> DNA
<213> Homo sapiens

<400> 42

```
ggtgtcctgc ccgtttttgt ccttaatggc cgtgttgatt cgataggaat cgacagatgg      60
gagccaagag gggacgtaac cacttgccag tgtggcccag tatttatatg gtagaagctc     120
gggctggcat tgagatggag gtgggaaaga ggagggtgtc tcgtgtttaa agatttctct     180
cttgtgtggt ccttggttat ggctccccat ggtgcttgct gctcccttgg tcgcctttcc     240
ttgcattttg ctttttgcct ttagtccttc tgcagtcagg gaccatgttg gtgactctcg     300
gtcagatgtt cccatatttg catgtcttgc tttggcctct ctggctctag gttctgtatt     360
gctagttgct ttctgacatt ttttctcatt gtttgtgcta ccttggccaa gaacctcttt     420
gccttctccc tcgtttgtaa cattgagatc ctagtagcag ttacttctta gggttgttag     480
gatgacatga gatgggcgag ttggccatct gccacacaag agttcccttc tcactgccat     540
cctctgccca gggtgttccc cagaatctgc agggccccat tggtcatctt gctgtctgca     600
caccttcctc tctcacctct tggcacttcc ctcaaaaaag agagaagtgg agcacagtaa     660
ataaacgcca gcgtttttctc cagttcccag cacctctccg gaactggatc ccccaaactc     720
ctctgtcact ttctgtgtcc agcgggcccc tggggtcctt cactgtcttc actctgctca     780
gcctgtgcgc ttggccttgg tgctgtaggg actgttataa gagctgctgt ccgatcccca     840
tattcaatct cacagcccca ctttgtgtac acacaccaga gccatcttct taaaatcaga     900
tcctgtcact cctctcccta aaatctacca gtggtctaat aaaatcttga atttttagca     960
taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaactcga                             998
```

<210> 43
<211> 658
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (15)
<223> n equals a,t,g, or c

<400> 43

```
acgacnagac aggtnaccgg taccggaatt acccgggtac gaacccacgc gtaccgatat      60
ttcgtcattt aagaatatct acagatatgc ctttgatttt gcaagggata aagatcagag     120
aagccttgat attgatactg ctaaatctat gttagctctt ctgcttggga ggacatggcc     180
actgttttca gtattttacc agtacctgga gcaatcaaag tatcgtgtta tgaacaaaga     240
tcaatggtac aatgtattag aattcagcag aacagtccat gctgatctta gtaactatga     300
tgaagatggt gcttggcctg ttcttcttga tgaatttgtt gagtggcaaa aagtccgtca     360
gacatcatag caagaactat gtgaagaaaa tgcaaacctt tcaattccca cgtgtataca     420
agctaatgtg atgaggggga aaaaaatcca acgggtgcat tttcattcat atgaaagact     480
tctcatagta ctttttttc ctttttttaa aggaggtttt tcttgttaca tgtgatgggc     540
attgagccac acctcttctt agactgaata ttgaagtttt tgttttgagt tatgtttata     600
acatttattt cagaacaata aagattcaga tttgtgacaa aaaaaaaaaa aaaaaaaa      658
```

<210> 44
<211> 566
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (68)
<223> n equals a,t,g, or c

<400> 44

```
ggctatttag gtgccctata gggaaagctg gtacgcctgc aggtmccggt ccggaattcc      60
cgggtcgncc cacgcgtccg gtcagagaga aagaactgac tgaaacgttt gagatgaaga     120
aagttctcct cctgatcaca gccatcttgg cagtggctgt tggtttccca gtctctcaag     180
accaggaacg agaaaaaaga agtatcagtg acagcgatga attagcttca gggttttttg     240
tgttcccttа cccatatcca tttcgcccac ttccaccaat tccatttcca agatttccat     300
ggtttagacg taatttttcct attccaatac ctgaatctgc ccctacaact ccccttccta     360
gcgaaaagta aacaagaagg aaaagtcacg ataaacctgg tcacctgaaa ttgaaattga     420
gccacttcct tgaagaatca aaattcctgt taataaaaga aaaacaaatg taattgaaat     480
agcacacagc attctctagt caatatcttt agtgatcttc tttaataaac atgaaagcaa     540
aaaaaaaaaa aaaaaagggs ggccgc                                          566
```

<210> 45
<211> 1277
<212> DNA
<213> Homo sapiens

<400> 45

```
ggcacgagga ataatcctag ctctatctgc agggttttat cgtggtttcc ctgagtttaa      60
acatgtaaca ggggagcaga aggagggata aatgatttgt ttatgctcaa taaagatgtt     120
gctgctgttc tgtcagctaa cctttgctct cataacctgc ataaacttgc aaagtcttta     180
tttattctcc taccagcaaa ttattggaat tcatagtcat gtctaatttt agttagctta     240
gggatggcac tcaacagggt tataaaaggg ggagaacatc tctctcattc ctgaatttcc     300
aaggctggga ttacggtaaa gctgtgggag atcacagtaa ttgaggtttc ccaggacact     360
cccatagtgg gttatgcttc ccaaatctgg ctttctaagc ataatggaat ctggcctaac     420
ctgtcttcca atatttgagt ctcttctata gcacccctgt cagagtggtt tgtgttcttc     480
acttgataaa aacttttttg gggatgcatc attacagttt gagccaggtg atttcatctt     540
caggcagctg tgatagataa taatacacaa taaggaaaca acgaaacact ttttaatgga     600
ttagtaagtg ggaatagata gggcacctgt catttcattg ttgtccgcat gacctgatga     660
ggtagttaac tgttagtgtc acttccattt tcaggccaaa aactgggggc ttggaatagt     720
ggagcaactc cggcagtgcc acacagctat gaaatatcag gtcagaaccc cagggatact     780
ggatccaaaa acctgagagg aagctatata tcctttaact tcttcaccca aagctgaaat     840
ctgcttccta gttctatcct ccaatgaccc aaggaaaaga atctcttccg ctacttgctc     900
ttcagatatt taacacaact ttcaggcctt cttttgcatt cttttcaggc cacaggacac     960
tgtttttcgg tgttcgttcc cccaaccccc ccaaaccacg tatttttctc atttggctta    1020
ttgcagtagc tctctaaagg tctgcctgct ctgttcccta ttcttcaccc agcagccaag    1080
gccacgctta aaatacaagt caaatcactt cattcctctg ctcagaacac ttctgcagtt    1140
tttcctgtca cttgaggtaa aaccttaagt caacttgaag attacagaat tgaattgtct    1200
tactgaaatt acctttccaa aatcgatggt tcccaactcg tgccgaattc gatatcaagc    1260
ttatcgatac cgtcgac                                                   1277
```

<210> 46
<211> 442
<212> DNA
<213> Homo sapiens

<400> 46

```
gaattcggca cgagggctga gtgggggcca tccttttcca tggctgagtg agggccatcc      60
tttcatgtgg ctgagaggga tccatccttt cctgtggctg agcgggatcc attctttccc     120
gtggctgagt ggaggcccat ccttaggtac ctccagtgag cagcctacat ccttggagga     180
tggaaaattg atttgcctct tcacagactt ctctggttct agctttgggc tatttatgcg     240
tgaagctgct aagaacattt cccaaatgtg atttgtataa atacctagga gtaggattcc     300
tagtgtgagg tcagagtctg tctagcagca taaaaacaac caaaagattt tctgagcctc     360
agggcacatg ggtggggccc agagagcacc caggaccgaa gctgcccagg acctccctcg     420
```

aggggggccc gtaacccatt cg 442

<210> 47
<211> 890
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (818)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (819)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (829)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (859)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (887)
<223> n equals a,t,g, or c

<400> 47
cttgtaaatg tttcttttcc cttaaataca gataattcat ttgtattgct tattttatta 60
tgagctacaa caaaaggact tcaggaacaa gtaatgtatt agtatggttc aagattgttg 120
ataggaactg tctcaaaagg atggtggtta ttttaaatat aaatagctaa tgggggtggt 180
aggcctataa aattaaatgc cttgtataaa atccaaaatg aatgcaaaat tgttttcact 240
tgtattgact ttatgttgta tgattccaat ctctgttctg tttggcactt gtatttaatt 300
cttcaccttt gtaagacatt tgtatattgt ggatgtgttc attcaagcta tttaatatct 360
ggcactgtta atacacagta ctttattgta cagactgttt tactgtttta attgtagttc 420
tgtgtacttt ttttggatgg ggctggcatg ttttctttgt ttcctggcaa tacgacgtgg 480
gaatttcaat gcgttttgtt gtagatgcta acgtgtcaga atcctttaca ttcaactttt 540
ctaagaaaag cattttcagt cttgtagtgt gtgcttacag taactaattt tgttgaaaat 600
ggttttcaagt tattcaaatt tgtacaggac tgtaaagatt tgttgacagc aaaatgttga 660
agaaaaaagc ttatagaata aaagctataa agtatatatt aggatctgca aacaatgaag 720
aattatgtaa tatattgtac aaatgtaagc aaaggcctg aaataaaatg ccatagtttg 780
tgaaaaaaaa aaaaaaaaaa actcgagggg gggcccgnna cccaatcgnc caaaagtgag 840
tcgtattaca attcactgng ccgtcgttta caacgtcgtg actgggnaaa 890

<210> 48
<211> 737
<212> DNA
<213> Homo sapiens

<220>

<221> SITE
<222> (736)
<223> n equals a,t,g, or c

<400> 48
gctgcgagaa gacgacagaa gggggagctc accagcgcca ccgtccccgg cgaagttctg 60
cgctggtcgg cggagtagca agtggccatg gggagcctca gcggtctgcg cctggcagca 120
ggaagctgtt ttaggttatg tgaaagagat gtttcctcat ctctaaggct taccagaagc 180
tctgatttga agagaataaa tggattttgc acaaaaccac aggaaagtcc cggagctcca 240
tcccgcactt acaacagagt gcctttacac aaacctacgg attggcagaa aaagatcctc 300
atatggtcag gtcgcttcaa aaaggaagat gaaatcccag agactgtctc gttggagatg 360
cttgatgctg caaagaacaa gatgcgagtg aagatcagct atctaatgat tgccctgacg 420
gtggtaggat gcatcttcat ggttattgag ggcaagaagg ctgcccaaag acacgagact 480
ttaacaagct tgaacttaga aaagaaagct cgtctgaaag aggaagcagc tatgaaggcc 540
aaaacagagt agcagaggta tccgtgttgg ctggattttg aaaatccagg aattatgtta 600
taacgtgcct gtattaaaaa ggatgtggta tgaggatcca tttcataaag tatgatttgc 660
ccaaacctgt accatttccg tatttctgct gtagaagtag aaataaattt tcttaaataa 720
aaaaaaaaaa aaaaanc 737

<210> 49
<211> 571
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (249)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (548)
<223> n equals a,t,g, or c

<400> 49
tcgacccacg cgtccggggg cgtacgcggg caagatggag gcgactacgg ctggtgtggg 60
ccggctagag gaagaggcgt tgcggcgaaa ggaacggctg aaggccctac gggagaaaac 120
cgggcgcaag gtgagaagtg tggagtgagg gtcgcagttg aggcgtccag cgttcggggt 180
ccgggtcgcg cttgaggaga gcaaagggct aataaggaaa gacagctgcc gagggcgcgc 240
atgccgggnc gctaacgcat gcgcgagaag acgggcgccc tcccacgatg tctggggctg 300
cttggcgtgg gactcctctg gcgctggtgc ggtcgtcgcg cacgcgcggg ggtgggcaar 360
gcatggtcag cgacccgcag tccatctgac tcctgcttcc cgggtgttgc tcgtgtaggt 420
atctagggct gcctgtaggt tcagatgctt gttgggttag gcgtgatttg ttccgttcct 480
ctatggccta gctggtcttt aacccccgcc ttcgattctg agtcagacag actccccagt 540
tcgggcangc aattcccttg gaacaagggc a 571

<210> 50
<211> 356
<212> DNA
<213> Homo sapiens

<400> 50
ccacgcgtcc gtaaaactcc acatttgtct gcatcaggga aaatgcatgg gcacacatcc 60
tccctccctc cctctctact ctcctccctt ccttcaggcc tcttagcatt gtttgttttc 120
ccatttctga tactactact ccatgctgaa gatttgccat attactattt tggaaacatt 180

gagtgataga actcctagaa aatttgcaaa gaaatgttac atactgtata tcaaacctctc 240
agattctagt gttgaaaaag tagcctatac tttgctatta cttatacctg ctgccataga 300
aaaaaaataa gtttattcat gacacattta catttgatca taaaaaaaaa aaaaaa 356

<210> 51
<211> 913
<212> DNA
<213> Homo sapiens

<400> 51
ggcacgagtt agtgtcctga aacgcctatg acagtgcctg gcccagggtt gggcacttac 60
tcatgttatt cacttattca tatgtgggaa tgaacagttc agccagtata aaggacaggt 120
gagtacacac caaggagatc ttcagggaga gatcagctgg ttttcctgtg aagatgtcag 180
cttcatccct ccaccgtctc cctgtgctca tggctctgtt ccctttccag gctgctgctg 240
ctggttcttt gggtctgcag ccacctccca cccccatgaa gggcaaaccc agcattatgt 300
tacctcctca gtataaaagg agagagggtc tcaaaaaaaa aaaaaaaaaa atccaaaaag 360
ttgctcttgt cagctttggg agggcagact ccatagttgg agatgggctt ccaaccaacc 420
aaggagataa atgccagagg gagcgaacca tgccaggctc aaagcacatc tctccccaaa 480
ctccccaggt ggggaagcag gccagaggct ccacaaaccc ctcagggagg cctggagtcc 540
agatgctgta ctccagtatc taaacaatca ctgaatctta aagctgacag gttcaaagct 600
cttactttgg gccgagcgca gtggcttacg cctgtaaccc aggcactttc ggagctgagg 660
tgggtggatc acctgaggtc aggagtttga gaccaaccta gccaacatgg tgaaaaccca 720
tctctactaa aaatacaaaa attagctggg cgtgttgaca cgtgcctgta atcccagcta 780
ctcggtaggc tgaggcagaa gaatcgcttg aacccaggag gcagaggttg cagtgagctg 840
agatcatgcc actgcactcc agcgtgggtg acagagtgag actcccgtct tgggaaaaaa 900
aaaaaaaaaa aaa 913

<210> 52
<211> 1356
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1231)
<223> n equals a,t,g, or c

<400> 52
cccacgcgtc cgaaagaatg ttgtggctgc tctttttttct ggtgactgcc attcatgctg 60
aactctgtca accaggtgca gaaaatgctt ttaaagtgag acttagtatc agaacagctc 120
tgggagataa agcatatgcc tgggatacca atgaagaata cctcttcaaa gcgatggtag 180
ctttctccat gagaaaagtt cccaacagag aagcaacaga aatttcccat gtcctacttt 240
gcaatgtaac ccagaggtat cattctggtt tgtggttaca gacccttcaa aaaatcacac 300
ccttcctgct gttgaggtgc aatcagccat aagaatgaac aagaaccgga tcaacaatgc 360
cttctttcta aatgaccaaa ctctggaatt tttaaaaatc ccttccacac ttgcaccacc 420
catggaccca tctgtgccca tctggattat tatatttggt gtgatatttt gcatcatcat 480
agttgcaatt gcactactga ttttatcagg gatctggcaa cgtagaagaa agaacaaaga 540
accatctgaa gtggatgacg ctgaagataa gtgtgaaaac atgatcacaa ttgaaaatgg 600
catcccctct gatcccctgg acatgaaggg agggcatatt aatgatgcct tcatgacaga 660
ggatgagagg ctcacccctc tctgaagggc tgttgttctg cttcctcaag aaattaaaca 720
tttgtttctg tgtgactgct gagcatcctg aaataccaag agcagatcat atattttgtt 780
tcaccattct tcttttgtaa taaattttga atgtgcttga aagtgaaaag caatcaatta 840
tacccaccaa caccactgaa atcataagct attcacgact caaaatattc taaaatattt 900
ttctgacagt atagtgtata aatgtggtca tgtggtattt gtagttattg atttaagcat 960
ttttagaaat aagatcaggc atatgtatat attttcacac ttcaaagacc taaggaaaaa 1020

taaattttcc agtggaggat acatataata tggtgtagaa atcattgaaa atggatcctt 1080
tttgacgatc acttatatca ctctgtatat gactaagtaa acaaaagtga gaagtaatta 1140
ttgtaaatgg atggataaaa ttggaattac tcatatacag ggtgggattt tatcctgtta 1200
tcacaccaac agttgattat atatttctg natatcagcc cctaatagga caattctatt 1260
tgttgaccat ttctacaatt tgtaaaagtc caatctgtgc taacttaata aagtaataat 1320
catccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1356

<210> 53
<211> 1547
<212> DNA
<213> Homo sapiens

<400> 53
ggcacgagcg gctgcgggcg cgaggtgagg ggcgcgaggt tcccagcagg atgccccggc 60
tctgcaggaa gctgaagtga gaggcccgga gagggcccag cccgccgggg gcaggatgac 120
caaggcccgg ctgttccggc tgtggctggt gctggggtcg gtgttcatga tcctgctgat 180
catcgtgtac tgggacagcg cagcgccgcg cacttctact tgcacacgtc cttctctagg 240
ccgcacacgg ggccgccgct gcccacgccc gggccggaca ggacagggag ctcacggccg 300
actccgatgt cgacgagttt ctggacaatt tctcatgctg gcgtgaagca gagtgacctt 360
cccagaaagg agacggagca gccgcctgcg ccgggggagc atggaggaga gcgtgagagg 420
ctacgactgg tccccgcgcg acgcccggcg cagcccagac cagggccggc agcaggcgga 480
gcggaggaac gtgctgcggg gcttctgcgc caactccagc ctggccttcc ccaccaagga 540
gcgcgcattc gacgacatcc ccaactcgga gctgagccac ctgatcgtgg acgaccggca 600
cggggccatc tactgctacg tgcccaaggt ggcctgcacc aactggaagc gcgtgatgat 660
cgtgctgagc ggaagcctgc tgcaccgcgg tgcgccctac cgcgacccgc tgcgcatccc 720
gcgcgagcac gtgcacaacg ccagcgcgca cctgaccttc aacaagttct ggcgccgcta 780
cgggaagctc tcccgccacc tcatgaaggt caagctcaag aagtacacca agttcctctt 840
cgtgcgcgac cccttcgtgc gcctgatctc cgccttccgc agcaagttcg agctggagaa 900
cgaggagttc taccgcaagt tcgccgtgcc catgctgcgg gtgtacgcca accacaccag 960
cctgcccgcc tcggcgcgcg aggccttccg cgctggcctc aaggtgtcct tcgccaactt 1020
catccagtac ctgctggacc cgcacacgga gaagctggcg cccttcaacg agcactggcg 1080
gcaggtgtac cgcctctgcc acccgtgcca gatcgactac gattcctggg gaagctggag 1140
actctggacg aggacgccgc gcagctgctg cagctactcc aggtggaccg gcagtccgct 1200
tccccccgag ctaccggaac aggaccgcca gcagctggga ggaggactgg ttcgccaaga 1260
tcccccctggc ctggaggcag cagctgtata aactctacga ggccgacttt gttctcttcg 1320
gctaccccaa gcccgaaaac ctcctccgag actgaaagct ttcgcgttgc tttttctcgc 1380
gtgcctggaa cctgacgcac gcgcactcca gttttttat gacctacgat tttgcaatct 1440
gggcttcttg ttcactccac tgcctctatc cattgagtac tgtatcgata ttgtttttta 1500
agattaatat atttcaggta tttaatacga aaaaaaaaaa aaaaaaa 1547

<210> 54
<211> 1338
<212> DNA
<213> Homo sapiens

<400> 54
cccacgcgtc cggttccccc atctgtctct caggagcgag atctgatcgc tgaatttgcc 60
caagtcacaa attggtccag ctgctgcttg cgtgtctttg catggcaccc ccacaccaac 120
aagtttgcag tggccctgct agatgactca gtccgtgtgt ataatgccag cagcaccata 180
gtcccctccc tgaagcaccg gctgcagcga aatgtggcgt ctctggcctg gaagcccctt 240
agtgcctctg tcttggctgt ggcctgccag agctgcattc ttatctggac cctggaccct 300
acctccttgt ctacccgacc ctctttctggc tgtgcccaag tgctgtctca ccctgggcat 360
acacctgtta ccagcttggc ctgggccccc agtggggggc ggctgctctc agcttcaccg 420
tggatgctgc tatccgggta tgggatgtct caacagagac ctgtgtcccc cttccctggt 480
ttcgaggagg tggggtgacc aactgctctg gtccccagac ggcagcaaaa tcctggctac 540

```
cactccttca gctgtctttc gagtctggga ggcccagatg tggacttgtg agaggtggcc      600
tactctatca gggcgctgtc agactggctg ctggagccca gatggcagcc gactgctgtt      660
cactgtattg ggagagccac tgatttactc cctgtctttt ccagaacgtt gtggtgaggg      720
aaaggggtgc gttggaggtg caaagtcagc aacgattgtg gcagatctgt ctgagacaac      780
aatacagaca ccagatggtg aggagaggct tgggggagag gctcactcca tggtctggga      840
ccccagtggg gaacgtctgg ctgtgcttat gaaaggaaag ccaagggtac aggatggtaa      900
accagtcatc ctccttttcc gcactcgaaa cagccctgtg tttgagctcc ttccctgtgg      960
cattatccag ggggagccag gagccagcc ccagctcatc actttccatc ttccttcaac      1020
aaaggggccc tgctcagtgt gggctggtcc acaggccgaa ttgcccacat cccgctgtac      1080
tttgtcaatg cccagtttcc acgttttagc ccagtgcttg ggcgggccca ggaacccccc      1140
gctgggggtg gaggctctat tcatgacctg cccctcttta ctgagacatc cccaacctct      1200
gccccttggg accctctccc agggccacca cctgttctgc cccactcccc acattcccac      1260
ctctaagaat aaataagttt tccttttgtt ttccaaaaaa aaaaaaaaaa aaaaaaaaaa      1320
aaaaaaaaaa aaaaaaaa                                                    1338
```

<210> 55
<211> 2071
<212> DNA
<213> Homo sapiens

<400> 55

```
cggcacgagc caaaacaaaa attttgtgca gtcctgtcat ttaatcatct tatcagtgcc       60
ccaaggtgac ttttttcaag agctctgttg ataccatgtg tgtgtgttat tttctggtgt      120
ttttacagat ttgggccagg cttagtcatc tattggtatg gatttatcca ggagctggac      180
tgcaaccggg aaaggggcat cctgctcaaa gcctgtttcc ccacgaacat tgtcacctta      240
tgccacagca tagcttgacc ctgaagatcc tggaagagaa gctgggagga aaaggtgaat      300
ccggaagcaa ttttactttc ctgcactgta agatcctggc aacatctgcc ctgaacttca      360
gctgaactct tgctgcccgt agtcacacca ctacctcttt agacaaacat atcaagagtt      420
tctgttttcc ttcatccctt gctgatgtga acagccaaga actacagaca caacccactc      480
attatcagca tttctgtctc tgtcaaacaa ttagtttata gatagtcata atctttcttt      540
cttccggatg gtttatcctt gtatgctgaa caaaagaaaa aatgtgaaga ctgaaaggtg      600
tgatttttca attctcctcc cagttaccga atcaccctcc ttattttttt ttccctaagc      660
ctccgttcac tgtctctccc tctccctttc tctttccatg ttgcactcca cagagaaccc      720
agcattgcat taccatcgtg gaataatcta gcgcaaacct aggaaagctg aagccacaaa      780
gtccaaagcc acctttgtac tcacctgcag agctccagaa gaccttgatg gcagcctgcc      840
tatgctgtgt gtttgctata ttcaatcttt acggcttcct gacttctgtg acagtaagcc      900
aagtgcaaaa atacacttga tgagaatttc ctcttttaat aatgttattt gaacaccaca      960
tattttagat ttatcttatt tgaaagtatt agttccattg tgcctggaaa ccacactcct      1020
ttagattggg ggccgagagg cgacaaccca acattgagga gagtttattt ttaaacatgg      1080
ctagttgtca gtatgtacgt gagctagtat ttttatgagt cgagtttttt aaaggcacat      1140
tctgtatact gcttagtata tgcattttat accatgtaat tataaaacac tcgagtaagt      1200
tcagcattag aaatgtttag ctttgtatga actgagtgtg ccagaaataa acctggagca      1260
atttttaaat aagcaaaata aaggagattt ttctatttgt tcactttaat ttattcactt      1320
ttgtgtactt ttatgtactg caaatcagat ttcagtctaa agcgaaacat caataagtta      1380
ataataaacc tatcttttgg gaagttgaat attaatctgt acccaaaacg tatttagtaa      1440
aatatttgcc cccgccaccc tgccatgctg acataacaac ttttataatg ttgaatagat      1500
gatatgggaa atactaataa caacaatgta atttttgcag acagctttaa cttatataca      1560
ttggttgatt tttttcaaaa gactaaatat gtcatttata ctttgtttat tttctaccaa      1620
agaaggtttg taaaaatatg cctgctgctt ttccttttga aggacacaaa cctggtccca      1680
acatgtgtgg attttaactc tgagtggggt gcattaaatc aaaagagaga ggcagaagat      1740
gaaatgctaa agaagggtca ggcaaacttc tgtttcagta taaaattcat catgcaggct      1800
tctgagtgaa atagaatgat ttgaaaccac tactgtattg cctggataca cacacacaca      1860
cacacacaca cacactttat acaaaaatgt taaaagcagg tttcctggca tgttctaaac      1920
tgtttttttct ttaggaataa attacattta tctgcacaga tgttgaaaat cctgttaaac      1980
ccttgtcaag gatttgttta ttttacatta aacaaattta ttatgatgaa cgtgaacaaa      2040
taaattaaaa aaaaaaaaaa aaaaaaaaaa a                                      2071
```


<210> 56
<211> 1899
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1439)
<223> n equals a,t,g, or c

<400> 56

```
ccacgcgtcc gcccacgcgt ccgcccacgc gtccgttacg atttataaaa gcaaactttt       60
aatttttcat aatatatcta ttcctaccta ggtttttta atcaaattaa taaaatggta       120
ctccctttg tgttattgtt cagaccaaat tttatcagtg tccttcaccc tttattctac       180
tcacattgtt tatttctata cttaataagt cctgttcact cttcctctat aatatattac      240
aaacctgatc attgtcacta caccccattc attcctggtc tactacaata gccaggtcta      300
cctacttttcc tttcggcatt tggacaatct gtgtttctgg aagtagccca aatgatcttt      360
ttttgttctt atattattca gatcctatta ctccttgatc tcaaccccta caagatattc      420
ctattatatg cttaataaaa tccaatatcc ctaccttggc ctgtatactc aataaagtcc      480
aatatcccta ccttggccta caagatctta gatgactggg atctaggaaa cctattcagc      540
taatttcctg caattctcta tgtttacctg ctcaaggttt ttaccactcc tcaaatattc      600
aaactggttt tgcatctttt tagttctatc tattcttttg cagatgccaa tcttagtaat      660
cataagcagt ttacctctaa attaatgcta aatattgtaa aaggtgtatt ataagttcag      720
tctttcattt attctttcaa ccaccaagtg tcgattgaac acatacattg ggtcacacca      780
atcaaataag atagactccc aggcatcacc gagcatctac tactcaattc atctcaggat      840
ctatacaagg ggtcatttta tcagaaacca aagtcttgat gctgtccgaa aaatcacgtt      900
ttcaccatga tctcctactt ccctaggtgg aagtataact ttttaggata tatcatggtt      960
gctgacttaa cttttgtatt ttttaaatat actcatgaca agtatcatat aaaacctaac      1020
cagcaacttt gcaccagcaa aagtttttca acatttcaat tcttacaaaa tcaaatgata      1080
taatttccta tgtagtaaaa aattcacaca tctgcaaagc ttggtttcac taccacctgt      1140
taaaatctta cctttggaag ctatttatga ttgaaaaaca ctttacctca ctcacaaaga      1200
gctggaagtc tctcttcaat ccaatatgca cacagaagac aaaaagctgt atcattcctt      1260
gatgatatat ttgaaatcat atggccacgt ctgtccattg tcttcagagt ttctaagtat      1320
ttcagaaaat tatgacttgc actgtagaac tattttaaag aaattccatg gtgcaaacag      1380
aaaaactaaa acttttcatg ttaggataat ttattaaaaa tacaaacaaa tcctatgtnt      1440
acataagaag atagtaacta gccttttga gagggaaatt tttctctcat aacttctttt      1500
ctagtaattt caataaagaa taactgccat tccaacgttt agcccatctc actctcttgt      1560
cttcttatgg ccaagtattc aagcttgaaa tttgcagagg aaattcttgt ccgttttta       1620
tatcatgtgg taagcctaat aaaacatctt ctgaaataat tagcccttaa aaggatagta      1680
tcttctacct gacagaggca aatattattg aaaagtttgt accttataag cacattaatc      1740
atggagtcct ggaactggat tctgtctaag actgactttt gcttaattaa gttcacagag      1800
attttccaca tatttttcca gaacattgca tgtagagata ttgtcgatca atcacataac      1860
tagggtcaga aagatgtaac aagggagaaa aaaaaaaaa                              1899
```

<210> 57
<211> 1543
<212> DNA
<213> Homo sapiens

<400> 57

```
ggcacgagat ttgattctca tgctcctttc aaaagagcat actagtttgg ggtggttggt       60
tattttctta accttagcaa gccagcttat ttcctatgga agcagaactg gaaacagcag       120
atgtccacca tgcttataca ggacactaca cactgtctcg acaagccatg ttctttcctc       180
cctcttcgtg agcactttct ctggtgatga gttagtatgg actacttgaa cctcaaaact       240
```

gggcctctca cccaaagcca aatgaagtag cgtatgccag gatgatgttt cttttgggcc 300
gttggcagtg agactgctaa gcaggctgcc ttaggttttg ctgtggcaat gctagcagat 360
tgttcctct ttcaaagggg caaaaatatc attttggtat gataactgac tttctattta 420
cagtttctgg cccccaaaga caaaccaagt ggagacacag cagctgtatt tgaagaaggt 480
ggtgatgtgg acgatttagt aagtactttt aatatgcacc tggtgttctg tgattgaagt 540
cacctgagct gtaaatacag ccacaaaggc tgattatctt acacttgttg cttatttgtg 600
ttttaatttc caatacacca gaagcttcct acaccattat atattgccat tataaattca 660
atcagatagg taatttcata atagaaattc ctgtgtttca tggtgtcggc tatattgttc 720
attcagatta atcctctccc ttgaagggct gaaaaagact agggagctat tccattagta 780
gcaaaatgtt gtaattcact gaaattgctg ttaaccaaaa ataagtaata caacatggca 840
ttttgtgtgg gttgacaaat gaaacaggcc ttaaaagggc tacttcttaa atgttctcaa 900
ttaacttaat gtaaacaaaa tagaccgata ggcatttgag gatttctgga ccccattaca 960
ccatgttgtt gatgtctggg aagctgtgta gtaaatgtct tttgtatcta tccttaatgt 1020
ttggaaactt cccgccttta agcttcatat gacaactgac caacaaacac tacgtactat 1080
gatgtcaatc ttttttagag acattctcat tactaaaatg agtggatact tgaatgttta 1140
actcctaaaa taatgagcgg tgaataaatg agcaagtaca tgcatgcctt ccaatgtaga 1200
gtcattttca ttaaaccctc tctcaccaga gaagcagtgg tatgaaattg gcctgattcc 1260
tttctaagtg tgttgttctt gttcacagtt ggacatgata taggtcgtgg atgtatgggg 1320
aatctaagag agctgccatc gctgtgatgc tgggagttct aacaaaacaa gttggatgcg 1380
gccattcaag gggagccaaa atctcaagaa attcccagca ggttacctgg aggcggatca 1440
tctaattctc tgtggaatga atacacacat atatattaca agggataatt tagaccccat 1500
acaagtttat aaagagtcat tgttaaaaaa aaaaaaaaaa aaa 1543

<210> 58
<211> 1133
<212> DNA
<213> Homo sapiens

<400> 58
ggcacgagct ggagcaaaga tattgtttga aggagagttt atggttttgg attttaaacg 60
ggcagggtct tttttcctct cattttgtg gacaagagag gccttcgcct ttatttttac 120
tctccctctt ctgctgtccc tgtgcagagg aaaaatgaag aattctccca gaagtgactt 180
gtcaagactt aaaaaaaatg tttttaatgc atttcttcct tgtctagtgc ctcggtttat 240
ctctaacagg ggctgtccag tatatcggtc ctgttaggag gggagaaaaa gttcttccaa 300
aggctggaga agtgaacaag gagtcaaatt tattttccca attcaacttc ataattatca 360
tttctttggc ttcatgctct cccgtaactc atgtggttgg gatccatccc atctgggtca 420
cttcagtcta cttcacgtac ttgaaaaggc tttcctttac acttccagga ccaaacagca 480
acttcctgcc acacacttcc accctatcac tgggagaaat ccttttctgg acatgagcct 540
ttgacctggg tggggcagaa agaaccacaa actccatctc ccaatagaac tttgaaattc 600
actcagcttt tcctttcatg ctgtttgttg cctgcttgtt gcactcctcc tgccccagaa 660
ctgcaagatt tttagcttca ccccttttctg agagtaatgt tatcttttat cagaatcagt 720
atcagttccc ctgtattctg tgcttcatcg aatttgcaag actgacctct tttaagcatt 780
taattcactc ccagagtcat ctggtcaggt tgcaatatga ggacttctct gtctcctctg 840
aagcctggga cactgagctt acttaatata ttagatgttc aaaagaggag cgttgtttca 900
tctttcaaaa tgttaggcca ttactttgag tataaaatcg acttattaat gattagtaat 960
ttttctaaag tattgggaaa actttcttat tttataagat cttaacaagc ttaaaaaaga 1020
attttatgac cagaatccaa caagagctct attttggaat tgtgcccaag ttggtgatgt 1080
ttactctaaa attaataata aaactacttg taagcaaaaa aaaaaaaaaa aaa 1133

<210> 59
<211> 1490
<212> DNA
<213> Homo sapiens

<400> 59

ggcagaagtt cctctgcgcg tccgacggcg acatgggcgt ccccacggcc ccggaggccg 60
gcagctggcg ctggggatcc ctgctcttcg ctctcttcct ggctgcgtcc ctagacatca 120
cggctgcagc cctggctacg ggtgcctgca tcgtagaatc ctctgcctcc ccctcatcct 180
gctcctggtc tacaagcaaa ggcaggcagc ctccaaccgc cgtgcccagg agctggtgcg 240
gatggacagc aacattcaag ggattgaaaa ccccggcttt gaagcctcac cacctgccca 300
ggggataccc gaggccaaag tcaggcaccc cctgtcctat gtggcccagc ggcagccttc 360
tgagtctggg cggcatctgc tttcggagcc cagcaccccc ctgtctcctc caggccccgg 420
agacgtcttc ttcccatccc tggaccctgt ccctgactct ccaaactttg aggtcatcta 480
kcccwkctgg gggacagtgg gctgttgtgg ctgggtctgg ggcaggtgca tttgagccag 540
ggctggctct gtgagtggcc tccttggcct cggccctggt tccctccctc ctgctctggg 600
ctcagatact gtgacatccc agaagcccag ccctcaacc cctctggatg ctacatgggg 660
atgctggacg gctcagcccc tgttccaagg attttggggt gctgagattc tcccctagag 720
acctgaaatt caccagctac agatgccaaa tgacttacat cttaagaagt ctcagaacgt 780
ccagcccttc agcagctctc gttctgagac atgagccttg ggatgtggca gcatcagtgg 840
gacaagatgg acactgggcc accctcccag gcaccagaca cagggcacgg tggagagact 900
tctcccccgt ggcacgcact tggctccccc gttttgcccg aggctgctct tctgtcagac 960
ttcctctttg taccacagtg gctctggggc caggcctgcc tgcccactgg ccatcgccac 1020
cttccccagc tgcctcctac cagcagtttc tctgaagatc tgtcaacagg ttaagtcaat 1080
ctggggcttc cactgcctgc attccagtcc ccagagcttg gtggtcccga aacgggaagt 1140
acatattggg gcatggtggc ctccgtgagc aaatggtgtc ttgggcaatc tgaggccagg 1200
acagatgttg ccccacccac tggagatggt gctgagggag gtgggtgggg ccttctggga 1260
aggtgagtgg agaggggcac ctgccccccg ccctccccat cccctactcc cactgctcag 1320
cgcgggccat tgcaagggtg ccacacaatg ttttgtccac cctgggacac ttctgagtat 1380
gaagcgggat gctattaaaa actacatggg gaaacaggtg caaaccctga aaaaaaaaaa 1440
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1490

<210> 60
<211> 1336
<212> DNA
<213> Homo sapiens

<400> 60
ggcacgaggt ccagccaagt tatctaccct caaattctgg actaatcatg tttgtgcttt 60
gggtatttaa aattacatac atatatattc tttttgccaa aaacaaaagt cttgcttctt 120
gtcaaatgat tgctaaagta gatcttacat tttttgttat tatgtatata tttatacaca 180
cccccaacac acttagtgat ttctgttatt tcctagggag cacagcttta aggctatgag 240
atacaactaa aaggagccca tctatttggt tttccagcca attattgtac tcacatttca 300
ggggagaatc tgaaattcct gtcatgttta cagcaacaat ctatcattcc tggctagctc 360
tcagcctctc tctccttcca taggttagaa ttatgtcatt ttgttactta gtggccacgt 420
ctatttctga gaaagactgg ttacatttat gtggcatctc aggtatcatt aaggaaaagc 480
cagagcaggg gtgagcagag gtcaaaacca cagacgcagc agggccattt gccgcctttg 540
gccgggatca caaccactgc agtctcccag caggtaggcc ttgccaagcc taaggctccc 600
catccaatct agacagaggg gcgctcagag cagactttgc cgtagcccat gtctggtgag 660
cacaacaggg aatgaattgg gcactccact cccccgtctc tctggcccag ccctgaacta 720
gatgagctgc atttcatgga gcccatttta aaacctcttt ccttatgact ttgttactca 780
agtccagagt tctctgtgca cttctgctag ataaggagtg taagccctgc cccccagcac 840
tggcagcacg ctgggccctc cccacacagg acaccgtgca gttccggggg aagctgactc 900
aaatcaacct tgaaatctca tgaaaacaaa atgacttgtc tttttatttg atagtgtaat 960
atcatttttat aaatttttta gggtttttct cgttgtaata ttgtacagtt ttgcatggcc 1020
tggtgtgatc atttttggt tagaatataa tgctgacaaa tgtggatgga ggggaagata 1080
ctgctttagc ctatcactcc ttattttatt ttgtttggtt ttatgccctc agtgtcttag 1140
ggaactttat aagagatcct ctgctaccaa acaatgatgt ggattctttt gcacagaaat 1200
atttaaggtg ggatggtaaa aaatgtcaca aaagactcct caccaatact ttatgttgat 1260
atcacttaat attaaccaga ctttgctgta ttgcaataaa acagagaact gttaaaaaaa 1320
aaaaaaaaaa aaaaaa 1336

<210> 61
<211> 1705
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (779)
<223> n equals a,t,g, or c

<400> 61
gaattcggca cagctttaca gtacatagga atttgagaac cacttcacag gaagagggaa 60
acagcccaat atttatttat gtatacacat aatcccaagt gtgtgctggg gccaccaggc 120
ttacctgggg gaacaaggac tgtcgtgcat gtgagtgacg acattaatag catttacata 180
ctgtacagat gcaacctttg atgatacata tatttgataa aaatgagaaa acagatttgt 240
tgtagagtac ctgtccactt ttatagcatg agaacagtac aatcaactat ttattttgca 300
gttactcatt tcagtgattg agaatttctg tgctgtgcag agagacggcc tgtaattggt 360
ctcatcatcc acttgattct aacatgatct ctgcccaaag ttccatttct tgggctttga 420
tatttataat ggcgcctgct cttcatcttg tcttacgctt tccgagcaag ttcaaaccag 480
aaagaaaagg tgaggctaga agcccaaagt gagtgagtgt gaggaccaca aggaagccca 540
ccactccaca gtagatgatc aaaaccacat cctcacgtgg gaggtagcac ttgggagagg 600
gtgtagtctg tgggcgtgat gctaccctgg aaaggaraag ggaaagttat gctgagagca 660
ccaggcacag gttgaacacc gcagtcttag aaacagcaga gggaagactg cyttctcagg 720
tccccctcag gtgaggcagg gaacgggccc tcctcacctg agaccaaggg ggcccagcnt 780
tctccctgca cagctcaccc ccgaccagcc caggctccag caggagagac aagtaaggcc 840
caagtgtgcc tgagtggaaa atgtctggga cactgacctg tcaaaactgg cccctggctc 900
actgggttcc catcaaatat agtgggggat ccataacaga gttsagagag gcaccgtgga 960
gttccagggt catcggtcag cgaggaacaa ggagggaaag gtgtcttcct gccccttgat 1020
gctcaamtaa gcatctgttc cctagaaata catgtgtcca ggtcgtctcc atgggctttt 1080
ctttgcagat acttttatgt ggaacaacag tggcaaatgt tttcatttac tttgaatttg 1140
aaaatgttag ggtttcctcc acctttttat gaagtaaaag amcctgtcgt accagcatca 1200
tgagctggat gcaggagccc atggctgaaa ggagttaaaa cgcccagtgg tcattaagtg 1260
aaacatcttt tatcaacctg caaaagctgc cagcgttctc tgccaggtca aatgggcatg 1320
tttagaaaat aagagaagat ggctgagtat agctaatgaa taaatggttg tttctttaga 1380
aaattaaaca cacacagagt gtaagaggag aggatacggc cctccctgaa ggataaagtc 1440
cmcctggacg gtgccctgcc ctcgcttctc acattaactg cccaggaatg tcatgctgat 1500
tggttcccgg aagggtgttt ggcaaggggc agtgtatgga gctacgtgta gaaggagaga 1560
aatttgtgtg tggcttttgt aaattttgac cgattgcagc aattaaatag ttgattactg 1620
tgttgattta aatacttatg aaagctttca gacaaaaata aactttcacg ttaccatgaa 1680
aaaaaaaaaa aaaaaaaaac tcgag 1705

<210> 62
<211> 1031
<212> DNA
<213> Homo sapiens

<400> 62
ctgacagtca ccgtccggaa tcccgggtcg acccacgcgt ccgggcgtcc gcgtcggcga 60
tccggggtct gggcgcggcg aggtctggtg tggcagatgt ggatagctgg accctcctgg 120
gtgcctctgc gttatgtcgt ttggttgatg catttggaga gaatctgtgc tctccacaac 180
tgcaggggca acatgctttc ctggcctctt cagatcaggg tggctgttct tgggtgctgc 240
accaaaactc cagcagtggg ctttcttcaa gtggccggct cacctcattc ctgccaagac 300
ccaggtccgt gttctcacag tgctgccatc tttcctccgt gtgagcgtgg gctgtgcgga 360
gatggacctc ggtgtgtgcg gggctgcgtg cactgccatc gctcccttct acacgagccg 420
gcgtggaccc agggctgagc tgtgaccacg agggccatcc cgacgagccg ccatggaccc 480

agggctgagc tgtgaccatg agggctatcc cgacgagctg ccgtggaccc agggctgarc 540
cgtgaccatg agggscatcc cgaaactgtg attgttttct gaatgtggaa gcgtcggccg 600
agcgcggtcc ttggagaacc cttgctgcgg agaatgacgc tcactctgcg gcctggcctc 660
gcctcmccat cccttctgca mactcacagg acaggattga tggggagagc ccaggcgaaa 720
cgaagctgac cctastgacc agccctactg gcggctctgg aacaggcccg ggaccggtgg 780
cctggagaca gtggtccttt ctggatgggc tgcagtctcc gaaggcttcc cccactggag 840
tcagcccttt aggagtttgt ccagtgcctc cagaaagctg ttttttgggg gacggaggac 900
ttggcctgga attctggaat tcccaggggg tcagacatgg ttatgggaag tttaataaaa 960
ccggtkaatc acgtgaattc tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
agggcggccg c 1031

<210> 63
<211> 1589
<212> DNA
<213> Homo sapiens

<400> 63
cggcacgagc taagccataa tagaaagaat ggagaattat tgattgaccg tctttattct 60
gtgggctctg attctccaat gggaatacca agggatatta tttttacaga tggttttcca 120
tactggaacc caaaggtaaa gacactcaag gacagacatt tttggcagag catagatgaa 180
aatggcaagt tccctggctt tccttctgct caactttcat gtctccctcc tcttggtcca 240
gctgctcact ccttgctcag ctcagttttc tgtgcttgga ccctctgggc ccatcctggc 300
catggtgggt gaagacgctg atctgccctg tcacctgttc ccgaccatga gtgcagagac 360
catggagctg aagtgggtaa gttccagcct aaggcaggtg gtgaacgtgt atgcagatgg 420
aaaggaagtg gaagacaggc agagtgcacc gtatcgaggg agaacttcga ttctgcggga 480
tggcatcact gcagggaagg ctgctctccg aatacacaac gtcacagcct ctgacagtgg 540
aaagtacttg tgttatttcc aagatggtga cttctatgaa aaagccctgg tggagctgaa 600
ggttgcagca ctgggttcta atcttcacgt tggaagtgaa gggttatgag gatggaggga 660
tccatctgga gtgcaggtcc accggctggt acccccaacc ccaaatacag tggagcaacg 720
ccaagggaga gaacatccca gctgtggaag cacctgtggt tgcagatgga gtgggcctat 780
atgaagtagc agcatctgtg atcatgagag gcggctccgg ggagggtgta tcctgcatca 840
tcagaaattc cctcctcggc ctggaaaaga cagccagcat ttccatcgca gacccttctt 900
caggagcgcc cagccctgga tcgcagccct ggcagggacc ctgcctatct tgctgctgct 960
tctcgccgga gccagttact tcttgtggag acaacagaag gaaataactg ctctgtccag 1020
tgagatagaa agtgagcaag agatgaaaga aatgggatat gctgcaacag agcgggaaat 1080
aagcctaaga gagagcctcc aggaggaact caagagaaaa aaaatccagt acttgactcg 1140
tggagaggag tcttcgtccg ataccaataa gtcagcctga tgctctaatg gaaaaatggc 1200
ctcttcaagc ctgggcctcc cattggccaa acacagcagc aaaccagagg acaagggagc 1260
ccagtggcac tgtccataga ggacagattc ctggggtcca gaagagggtg gagaaagctg 1320
aaggctggag agtgaatcta gggcatataa ggccccacac agagcccagc acagagacgg 1380
ccttgcagct atcaggaaga tgaggagctt ccttcatggc ctgctgtggg ctgagtaaat 1440
aatatgattg ccttctacag cgctagagat tcatatgttt atccccattt ttcaggtgag 1500
gaaatgcttc agatgaggct ccaccttgtt aaataaattg gatgtatgga aaaatagact 1560
gcaaaaaaaa aaaaaaaaaa aaaaaaaaa 1589

<210> 64
<211> 1088
<212> DNA
<213> Homo sapiens

<400> 64
ggcacgagct aagccaaccg cactgaagga gtggggagaa gagcatacgc caggagcctc 60
ctgcctcaaa gtgctcccct aagtcttctt cctcctgtgc tgacctcagg gtggtctgac 120
ccttccctcg gtgtgggggа tgtggccctc tcaggtgccc ctacttgctt tctgcttcct 180
tctggtgaag tccacctcca acattaacct gcccacccca cccccgtcat ccctggagaa 240

```
ttccagcttt gtcgtatctc agagagggaa tctaattgtt tttggggggc aaaagaaagc      300
aacgtttagg tatcacttct acttggaccg catgcctttt tatagccaaa tttctgtgta      360
tttcgtaaat ggatttcgcg ttaatggata tttatgtaat aactagactt ctcagattat      420
tgtgagaagg gtcaggttgg aaggggtgta ggaagagggg tgaggggtag ttttttctg       480
ttctagtttt ttttttttt ttgtcatctc tgaggtggac cttgtcacct gtggttattg      540
gggccaaggc ggactcagct cccggggaga agggcctctc tgccatttcg gtcccaaggt      600
gagctgacac aggcgttcct tttgggactg tggaagcatc agatgccagc actgactcag      660
gaacagcaag tcagggcaga gaggaggagg gaggctgtca ggatggaaat acctggactt      720
ttctttgctt ccctcgcaaa ctggggtctt ctctaccgaa cttcccagga tttcatctca      780
ccatatctgt gtgccgcccc cagcacccca cacccacctc tgggggggccc gtgagcgtgt      840
gtcttcattg cctctctccc cttggcgtct gatgaccaca gcaaagcact gggaatttct      900
actcttcatg cctcatcctg cagcctcggg ttcgcattct ctctttcttt tcctctttcc      960
ctctttccct gggattgact ctgagtggaa taccttggca catccactag gatctactgt     1020
ctgcactgtt ttctttgcat gactttatac gcagtaagta tgttgaaaac aaaaaaaaaa     1080
aaaaaaaa                                                             1088
```

<210> 65
<211> 1256
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1079)
<223> n equals a,t,g, or c

<400> 65

```
gggacaagtc cacgtatatc gagtcctcga aggataggcg ggggaagatt cctgccaccc       60
tgtgctctcg gtccagccgg acgtccatga ccttgggtgg caggaatctt cccccgccta      120
tccttcaagg acaagtccac gtatatcgag tcctcgacca aagtgtatga tgatatggca      180
ttccggtacc tgtcctggat cctcttcccg ctcctgggct gctatgccgt ctacagtctt      240
ctgtacctgg agcacaaggg ctggtactcc tgggtgctca gcatgctcta cggcttcctg      300
ctgaccttcg gcttcatcac catgacgccc cagctcttca tcaactacaa gctcaagtct      360
gtggcccacc ttccctggcg catgctcacc tacaaggccc tcaacacatt catcgacgac      420
ctgttcgcct ttgtcatcaa gatgcccgtt atgtaccgga tcggctgcct gcgggacgat      480
gtggttttct tcatctacct ctaccaacgg tggatctacc gcgtcgaccc cacccgagtc      540
aacgagtttg gcatgagtgg agaagacccc acagctgccg ccccgtggc cgaggttccc       600
acagcagcag gggccctcac gcccacacct gcacccacca cgaccaccgc caccagggag      660
gaggcctcca cgtccctgcc caccaagccc acccaggggg ccagctctgc cagcgagccc      720
caggaagccc ctccaaagcc agcagaggac aagaaaaagg attagtcgag actggtcctc      780
acctgctccg gctcctggcg accactaccc ctgcgtcccg gccccctcgc ctccctccc       840
tgtcgccctt tccctggaca gatcaggccg gggcggtggg aggcccgcct caggtcaggg      900
cccagcgtgt gacgtagggg ccggggcagg ccagggtttg tttgtggagg cgctgtctgt      960
ccctctgtcc ctctgtgttt ccagccatct cgccctgcca gcccagcacc actgggaatc     1020
atggtgaagc tgatgcagcg ttgccgaggg ggtgggttgg gcgggggtgg ggccgggcnc     1080
ccctacggga tgcccacggc cgttcatcat cttgtccctc gtccccctac cacactcccc     1140
ctcctagacc gccgcccttt aacacagtct ggatttaata aattcatatg ggtgtttaac     1200
ttaaamwmaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagggc ggccgc         1256
```

<210> 66
<211> 1602
<212> DNA
<213> Homo sapiens

<400> 66


```
ggcacgagaa aacctgtgga tttgagttgg gatgacatta ttgatgatta gctgagtgtg       60
gatttgagtt gggatgacat tattgatgat tagctggggg agtttttgtc ttcacagtgt      120
tttctcccca tgtatgaatg tttcctgtct ctgtcttttac tgaagtcttg taaagctgtg      180
agtggactta tgtgcctcct gctgccgagg cttggtctgc tgctcctcct accgagtgag      240
cgatgcttct gctggattcc ggtgtactcc ctcattacct gccttgctga gtgctcagtt      300
gttctgcggg atccagggtt tgcgggagct ttccaggtac acaggcgcca ggcctgcttc      360
tccaccctgc gctggtcctg cctgctgctc tggtgggtgt cccgggtgag tgcaggccgc      420
cctctcatag gcagccctca tatgatggct cccagcactt tctgtcccac cgttaggggc      480
cctgggacct gtgcttccag cgacccagat gggtgaggct gtaacagcct gggccggctg      540
cctctgccct ttggtgaccg tgatggggag gtgtccacaa agcaccctat atgttggctt      600
atcctcccgc caggtctgta gtctctaccc ggtcaccccc tcttcctggg accatgcccc      660
agatcagctg ctaccctcaa gctctaccat taggggccc aggcgtgttc agggaaggtc       720
actgggtgcc accttctccc ccatcatcac gctcactgct ttctcttgat gggtaaggct      780
tcccgaatga tgggaactaa cagtggtggt gaagtcgagg cagacttcat caggcattta      840
gcatccaagg ggtggctcat gagtgcagat acagtgcagg ggccggagag gggctgggct      900
gggctgacct gggaggctga ggctgatgga gagtgggcag gtagggtgga gaggcaggaa      960
ggttggtggc agccacatgg ctgagggcta gagcctggcc agggagtctg gagagaggca     1020
gtgggtgggc tgggggttca gcctgctgaa ggggagcact ggtcagtgcc catacccccat     1080
ggggtgaagg cctgggcagg gcccaggggc agcttcgagg gtgacctgga gctgctcagg      1140
aagtgagatg gcccagcctg acctgaccat tggctggcaa ggaacgggat ggagaagttg      1200
tgtcctgggc cttcagcgag tgtgacattg tcattgttgg gatagcttta aagatctgat      1260
tgcttatgac atgccttgta gcgctaccag catcttggca tttggcaggt ctagtccagc      1320
tcgctgtttg cacgtcttct gtcttattcc tagaagagag agttcccagc ttgcttgatt      1380
tccccccatt gatgggaggc tcatcacttt atgggagact cattttactt aggcctttctg     1440
aggatagttt cattctgata gttttttttt ttttttttt ttggagactg agtttccctc      1500
tgtcgcccgg gctggagtgc agttgtgtga tctcggctca ctgcaagctc cacctcccag      1560
gttcatgctc gtgccgaatt cgatatcaag cttatcgata cc                         1602
```

<210> 67
<211> 938
<212> DNA
<213> Homo sapiens

<400> 67

```
ccacgcgtcc gctgccagca gcgcgcagag ggagggatgg gggcgggtat cggcgtaggg       60
ccctcggaaa gaacggatat tgctgtgaca ccgcggggac gctctgaagg ggcgagtgtc      120
ggtgtggcac cggtgcacgc tgaaggagcc ggcggaaccg ggtggccatg gggatgtggg      180
catcgctgga cgctttgtgg gagatgccgg ccgagaagcg tatcttcggg gccgtgctgc      240
tcttttcctg gacagtgtat ctttgggaga ccttcctagc acagcggcag agaaggatat      300
ataaaacaac aactcatgta ccaccggagt taggacagat catggattct gaaacatttg      360
agaaatctcg actctatcaa ctggataaaa gcactttcag cttctggtca ggactctatt      420
cagagactga aggcactctt aatcttctct ttggaggaat accttatctc tggagacttt      480
ctggacggtt ctgtggttat gctggctttg gaccagaata tgagatcact cagtccctgg      540
tgtttctgct gttggctaca cttttcagtg cattgactgg tgtgccatgg agtctttata      600
atacttttgt gataaaaaaa acatggcttc aatcaacaga ctttggggtt cttcacatgg      660
aaatataata aaaataaaaa tctagtttaa tactgcatta tttattttcc taaggctaaa      720
gaggagcagt cctatgcttt tattcagcat cctttatctg tgacttcatg ctctgataac      780
tgccttttct tccttctgtg cctttgaata caaatttcag ttctgcaaaa gtgaaacatt      840
aaacattgcc aacgcaaatt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      900
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa                              938
```

<210> 68
<211> 1585
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (904)
<223> n equals a,t,g, or c

<400> 68
gggttgctgt tggggtgtgt cgrgaggacg tcatgggaat tactgatcgt tcaaaaatgt 60
ccccagatgt gggcatctgg gcgatttatt ggagtgctgc tggctattgg cccttgatag 120
gcttccctgg aactccsacc cagcaagagc cagctctcca ccgagtgggg gtttacctgg 180
atcgtgggac tgggaatgtc tccttctaca gcgctgtgga cggagtgcac ctgcacacct 240
tttcttgttc ttctgtctca cgcctccggc catttttttt ggttgagtcc attagcatct 300
ttagtcattc caccagtgac tgataggaaa tgaggctttt cttcccctga ccaaaactcc 360
ttccctgtag tccagctgag ggacacacat ccctgggccc tcttctgccc ttcatgtctc 420
tatcctggat ggtccatctt ctgggtctcc ctaacggtac cgtttggtat ctgccctttg 480
tgtgcttcac aagaggcagt cccatgggag gtgggtctgg ccaatggaga tgggacagga 540
aattttccaa gacgcttttg ggaaatcttt ttgtagcttt taaagagatg tgcggggaag 600
acatatggat gttagcagcc atattggaac tgagaacaca ggaatggtgg aaaggtagaa 660
gaaacagagt ttttgttgcc gttgtgaaat tgttgaaatt tccttcatgc caagcttctt 720
gttatatgag ataattacgc ccttattgta taagacaatt ttagttgtat ttggttactt 780
gcagcctgaa gtaccgtaac trcactaaag ggacgtagtg tgaacatccc gcagtatagg 840
cttaagtcac ttttgtgaaa tttgacaaag gcatagatct ttttctatcc agtcaggcat 900
tgcntattct ttccagtaac tactgattcc cccacttttc tgtcttagaa aattgtggga 960
atccccccte actctgccta tgttgcactc tctctcctcc caaccataac tctgccctca 1020
gctattaact gtgctgtgta tttatcaagt tggtatgttg tatgtacagt gttattcatg 1080
tcatcatgag aatgttgaac gcttgttaaa tatcttttgc tagcctcttc atatgctgtt 1140
gcatatgact ctcatcacaa ctcagtgaga tggaaagtca aatcctattt gtacaaatga 1200
gaaaactgaa ctctttagag taactagctc agtattggcc agctggtaaa tggcagtgtt 1260
gggattaaaa tccagttctt atctactctc cctttattca gaagcattta ttggatgttg 1320
atctttgttt caggttttga ttttgttact tttttatact gtgtatattt tcctcagtct 1380
acccttctgc tctagattgt ctggactcag gagattgtgg cagttactgg atagttattt 1440
ttaagataat gattgctttt ctctgtttat ataagtcatg tgtacttatt gtagaaagtt 1500
tgtaagatgc aaaaagtata aaaattaaag ttatgcacta ctaaaaaaaa aaaaaaaaaa 1560
aaaaaaaaaa aaaaagggcg gccgc 1585

<210> 69
<211> 1676
<212> DNA
<213> Homo sapiens

<400> 69
ggcacgaggg gacttcagaa ccacagaact gagatgataa atgagtggtg tttcaagttg 60
ctaagtttgt ggtcatttgc ttacagtaat tgtaaactaa tacacaagtg taagtttgtt 120
ttcttaaaga agaaaaaaac ggggaaggag gtaagtgtta aaggatcaaa actctgacaa 180
aaggctggtt gcagaacatg acaggttgtt gcactggaaa ctatttgtca tgcaagttta 240
tgttaaaata agtagctttt gaggactttc atttttggtc ttgtaaacat gccatttaat 300
attgtccmac tgataatact ttttgcaaac agaaactgtt aaaaccttta aagcaaatat 360
tactgtagag aagaagtaat gtgttatgaa actgtgagga tactaagaag gatcctactt 420
aagtttcttc agcataaata aacttgagcg tttcgaccac tgttactgag aatgaaatta 480
tttcttaatc acttttaatg aggtaaaatt tacatacgat aaaatgcacc aattttaaag 540
tatagtttaa tgagcttgca cagatgtaaa tatctgttta acttctactt aatcaagata 600
tagaatattt ccacaatgcc aaaattgcca ttgacccccc tccccttctt tcacccaact 660
gcagacccca ggtcaccacc aacctactct tgctcaatat agatttaatg tgatgtgtct 720
tttctagagt tttatgtcaa tagaattgta cactatgcac tcttccatgc ctggctttct 780
ttgctcagca graggtgttt agattaattc agtagttcat ttctttctag taatgaatag 840
gatcacatta tacattatac cacagagtgt gcatccatta ctttgtkgat tgatatttgg 900

gtcatttcca ggtttttggct attgtgaata aaactgcctt gactattcct gwacaagtct 960
ttgtattaag gaacatacgt tttatttttct cttgaggaag ttcctagcaa taagattgct 1020
gggtcatatg gtaggtatat atttagcttt aaaagcaact aagtgctttc caaagtgact 1080
gtacaattta acattcctac ctgaaatgta agagaattcc agttgctcca cattcttgtc 1140
aacccttggt agcatcagtc tctttaagaa ttctaatgga tatgtaatat ggactatagg 1200
tttaatttgc atttctctgt tgactaatga tgttgcacaa cttttcatat gtctatcaac 1260
cattcttgca tcttcttttta tgaaatgtct gttcaaatca tttgtccact ttttattgtg 1320
tcattttatt cagttgtaag agttctttac atattctgga aacaagtcct ctgtcacata 1380
tataggtact ttgaaaatct gtgctttgcc tttacatttt tttaatggta acttttaag 1440
agtagatagt tttggttttg atgaaattca acttatcagt ttttcagtta tagtatgtat 1500
ttttatgacc catctaagaa gcatctgtct acccagagtt gcaaagatat ccctttttctt 1560
actagaaata ttatagtttt atttaccatt gcttctatga tacattttaa gttaattttt 1620
gtgtattaaa tgaataaaaa gttgaagttc aaaaaaaaaa aaaaaaaact cgtagg 1676

<210> 70
<211> 1344
<212> DNA
<213> Homo sapiens

<400> 70
ggcacgagcg ccagataact caactttccc attggctacc tttgggtcag gtgatctcca 60
ctagacctat cgcctatgcc tgatggtggg tcacatggtg caaatgttgc ctgagagctt 120
agtggattag ggatgtggct gggctcatgg ttgacgtccc tgctgctgag cccttacggg 180
tcaggctggg agaaggtacc atgttgtgtg actggtcatt tgaggtcttg cagctgttgc 240
ttgctgggct tggcaggtgt tcaaagtgac cattttctg aagggttttt ttctgagtat 300
tcctcagatg tactcccctg gggccgacgg tctttccttc cacagggcga tgcttcccta 360
cttgcttgtg aatgtttcct tcatctccag gttgtctggg gacaattctg tcttttggag 420
gcctgggcag gatttacaga gggctccatg ccagctcctt cctgccgggt ccacttctgg 480
tgtagggtaa acacctgccc attcatgtcc tagtgttgat agaataatca ttttctttca 540
gtacagtttc ctttttttt ttttttgccc cagcttttta gatgtagcac ttaatgccag 600
ttctcgagct ccccaaactt aagggacaca ggtcaacaag cagtaggtct ttggaagctc 660
gctctctcac atggtataag gtgaggggga cacatggaat gtaaacctcc aaactaatta 720
tgggggaaaa aggaatgaga aaaacaaaca caagaaggca aaacaaaaac acctggttca 780
attaaaaaca acaacaaagc aaaacaaaaa aaacccaaaa ccaaaccaca caataaatga 840
gaaaaaaatt acataaaaca gatgacatgt atagaaataa aaaaatagaa tggaggaact 900
aattccaaat atataagtaa tcctaagtgg actaaatttg caaagtaaaa ggcaaacatt 960
acactggatt aaaaaacaaa tccagggaat acagttcaca gctgatacat tcaaaatata 1020
aaaacagata aaatataaat aaaatcggta cagtggtgtc tgcctgtaat cccagctagt 1080
tgggaggctg aggcaggaag acccccttgag tctaggagtt agagaacagc ttgggcaaca 1140
aagcgagact gtctctaaaa aaatacacac acacacacac acacacacac acacacacac 1200
acacacacac acacacacac acacacacac acacacacac agactgaaat ggaaatgagc 1260
cgagatcgcg ccactgcact ccagcctggc aacagagtga gactctgtct caaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaa 1344

<210> 71
<211> 1474
<212> DNA
<213> Homo sapiens

<400> 71
ggcacgagct aaaatatgct taaagtaaga tgtttctatg ttatgtggtt atgttatcaa 60
taatatttgg ttgatcttca catattttat atgcatatat atatcaagaa gttatatata 120
tataactcaa gaaactcaag ttatatatat atgtcaagaa atgtatgatt attttggaga 180
gaatgggccc aaatgtgaaa aagatataaa aaaaacaaaa aaaacaaaaa aaaaacacta 240
ttttccccta cgaaatatac tgtatatttc aaaagaagaa aagttaaaag atatttgaag 300

attgcagggg caaaacaaaa acctaccagg gctcagcact taagcacttt tcccacatcc 360
agggtcaaag cagcagtaac tacatggact tttaagtgcg gtatgaaatg caacattacg 420
cttacaaaca gtactgtcaa acctcaaatg ctttctttct tcagatgctt tttcgtgtac 480
atgatactag tagacacttt tctctttata tttactgata gtgaaaatca tacgcaataa 540
aatattgatg tttgaaggca gtggtcacca attggttaaa aaactatgaa atgtaaactg 600
aattgttata tctctatcct ttttgctttt ctctgtgttt ttaatgtatg gaataaatct 660
cataaataga aagaaaaata atctagaaat ttttcaaagc tagtactctt tctccttata 720
aatgtacaca attttaatct ttttacaaat ttatttaact gtacctactg tacttattgt 780
agattcaatg acgcagttaa gtcatcaccc aaggatttat gaatttgaga ttactgacct 840
gttttcttca tattgcattc acatcaatat ttgtgaattt gttgttcagc ttttcattca 900
aacaaaaaat attccctcaa gaaagctccc tttttatcat aaacatttca acttacccaa 960
cattagaaca agtctgccat gttaaaaata atttaaagac ttatctctga aaacggtatc 1020
cagaaacgca ggtgttccca gtaatgtagc ttcaaaaata aaatgtgcta tttatatgac 1080
tgaaattcat aacttttgga agggtatatt tatgacagca taaaaaataa attctgtgct 1140
ataaagaaga tccaacaaat taaccatata agcacagaaa gtagagaaac acagttattg 1200
aatctactct tgtcattaac attttcaaaa aacaaaatgc atattgtaat atttggtaca 1260
tgacacttgc atgttgatat gcctatatac ttacaaagta ttcaatgtgt acttagcggc 1320
gcttaaaata tgtcatgtac aactcttata aacatttta cagggttccc atttgcactt 1380
catctttcag taaagtcttg tcagaaaaaa attgtctgat aaatatggaa aaataaaatt 1440
tgaattttag ttaaaaaaaa aaaaaaaaaa aaaa 1474

<210> 72
<211> 2012
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1468)
<223> n equals a,t,g, or c

<400> 72
aatttttaa aagcaatttt aggttcatag caaaatttag cagaaagaac agagttctta 60
tatacccttt ctgcttttcc ccaagcctct tgcactaata acgttctgta ccagagtggt 120
atgtttgtta caatcagtga acctagactg gacacctcat tatcacccaa gaccaaggtt 180
tacgttaagg ttcgctctta gtgttgtata ttctatgagt ttgacaaatg tttaatgaca 240
tgtatccacc atgatagtat catacagaat agtttcactg ccttcctctg tgctctgcct 300
gttcatccct cccttcctgc tgatcttcta ttgtctccat agttttgtct tttcccaaat 360
gctgtatagt tggaattatc atgtaacctt tcaaatggcc ttttcactta taatatgcgt 420
ttaaggtttt ctacagtctt kgcaggcttg atagctcatt tttctttagt gctgaatact 480
attccattgt ttggatgcat tacagtttat tcattcacct actgaaggaa atcttgcctg 540
cttccaagtt ttgtcaataa agctgctttg taaacatcca tgtgcaggtt tttgtgtgga 600
cataagtttt caactcattt gggtaaatac caagcagcac aattgccgtg ttgtatagta 660
agagaatgtt tagtttcata agacatcacc aagctgtctt acaaagtggc tgtactattt 720
tgcacttcca ccagcaatga atgagagttc ttgttggttc cacatactcg tcagcatttg 780
atgatatcag tgttttagat tttgaccatt taataggtgt gtagtggcat ctccttgttg 840
ctttaacttg taattctcta atgacttata atgttgagca tcttttcata tacttatttg 900
ccatttgtgt ttcttcttcc tttttctttt tcttttttct ttttttttt ttttttgag 960
acagggtatc actctgtctc tcggactgga gtgcagtggt acggtcacag ctcgctgcag 1020
cctcgatgtc ccaggctcag gtgatccctcc catctcggcc tcctgagtag ctggaactac 1080
aggcacatgc caccatgcct agctaatttt ttatattttt agaagagaca ggtttcgtca 1140
tgttagtcag gctggtctca aactcgtggg ctcaagtgat ccacccacct tggcctccga 1200
aagtgccggg attgcaggca tgagccackg tgcccagcca atcaaatgag aaaagggcag 1260
tctcttcaac aaatggtgtt gggaaaattg aatatccaca ttcaaaagaa tgaaattaga 1320
tgcttacctt aaactgtata caaaaattac ctcaaaaaag atcgaagtcc taaatgtaag 1380
acctaaaact ataaaactct tagataaaaa cataggagga cattggattt ggcaatggat 1440

ttcttgggcg tgacaccaaa aacaggcnac mgaagtaaaa atagatggat gacatcaaaa 1500
tttaaaactt ctgtgtatca aagaacacat tcaacagagt gaaaaggccc ataaaatggg 1560
tgaaaatatt tgcaaatgat atatcctgta agaggctaat atccagaata cataaggaaa 1620
tcctaccatt caataacaaa aaacaacctg attttaaagt gaagaagtca agaaaataag 1680
atagactaca tactgggaga aaatatttgc aaaagatata tctaataaag gactgttatc 1740
caaaatatac aaaagaactc taaacgataa gaagacaaat agcctgaata aaatacagca 1800
aaagacttga acacataccc cactaaagaa gattcacaar rttgggtgca gtggttcgcg 1860
cctgtaatcc taacactttt ggaggccaag gtgggagaat cgcttgagcc tgggaggtcg 1920
gggctgcagc gggctgtgat tgtgmcgctg cactccggcc tgggcaacag agggagaccg 1980
tgtctgaaaa aaaaaaaaaa aaaaaccteg ag 2012

<210> 73
<211> 1267
<212> DNA
<213> Homo sapiens

<400> 73
ggcacgagct cactctagct gctatgataa acaagaagac cagtgaggaa gttttgaaac 60
tctcctctgc aagagaatgg tggccagcca ggcgtggtgg ttgtcgaatc tgtggcacct 120
gtgggaagtg ggctcagccc agggactgcc tttggatccc ccagcattgg caccatacct 180
accctgggcc ctaaggtggc catgcttctc tggatttgct tccctagcag gggctctagt 240
gcttgcccac tccctgccca cagcatggcc tgggagcagc tgagactggg ggccagctca 300
tcccgcgtcg attcctggaa gtgttatcag tgcctgttat ggaggctgga cccatgagtg 360
gcagccttcc ctggcagctg ggctgacctg tctgcttttc cattgctcgc tggttttgtt 420
cactgtaggg cgtgaggggt gagtagctgc tggcctccaa gtccatagct actcatgttg 480
tacgctgttc acagggacct ctaaggatgt acatcatcac acattcacac acatgcacca 540
ggatttgctt tttttggcag cttttccctt cctggcttcc tttttgagtg gtggaagtaa 600
aataaaaagc aactagggct gggcacagtg gctcacgcct gtaatcccag tacttttaga 660
ggctgaggcg ggcagattac ttgaggtcag gagtttgaga ccagcctggc caacatggtg 720
aaaccccgtc tctactaaaa atacaaaaat tagctgggag tggtggtgca cccctgtagt 780
cccagctact cgggaggcta aggcaggaga atcacttcaa cctgggaggc ggaggttgca 840
gtgagctgag atcacaccac agcactccag cctgggtgac agagccagac tgtgtctcaa 900
aacaaaacaaa caaacaacaa caacaacaaa aaactgggct ctggtggttg ggaggaggag 960
ggaaggaagc aagtaccagg gtaagcagga tggatggatg gctctccccc agaggggcgg 1020
cagcacacag agttctggag tcagactcag tagagggcca gttttgactc cactgccaac 1080
cacctggctg actccaggca ggttacatca ctgatgaaag cctcagtttc cttgtctata 1140
aattgggggt acaagcgatg aaaagaggct caacatcact aatcactagg gaaatgcaaa 1200
tgaaaatcat aaggaggtac cactttgtac ccttaaaaat agttactaca aaaaaaaaaa 1260
aaaaaaa 1267

<210> 74
<211> 1748
<212> DNA
<213> Homo sapiens

<400> 74
ggcacgagta aagacaaaat aaattcttct gtccacttat ttacctaaca tacacttgct 60
tccttggaag tcataggcat ccacatatct tcagccacaa cttggtattt ctaatataat 120
tcttattttt gaactcctaa actttctggt agaaatcctc agttgaaaat atcctggcaa 180
gtaaaattag aaactcccag aaatgtactt atttctatta tgttgtttta tttctgaaca 240
ttgtgcccaa cattcttttc cacatacttg cccaaattgg aaaactaggg ttctaagttt 300
ccccctccat ccatgcccac atttaattca ccctaataat acctgacatc tttcaagttc 360
attttctact atctatcccc acgcaggcca tatctgggtt gaagcttcat tatctctata 420
gattaaaaac aaaaacaaaa tgcatacaag caaaacaaat aacatacaaa caaaacccac 480
ctaactcatc tttatgtagt cagtcctccc tcaatagttt ggccaaactt cctaaaccga 540

```
aatctgattg tgactatccc cttctaaatg tatttaatca gcataccccct tcaataaatc     600
cattaaccgt tcttgttatc caagacagtt tgtcatctgt cttggataac aagttgcaga     660
ctccatccaa tgccatttttc ccctagaaat atagataatg gcactatagg aacaatgatc     720
tccacatgcc tcatgcattg gtaatttttt taacctttgc tagaaatgtt ctgctccact     780
ctactcatcc accacccatt ctactccacc ttacactacc tcttttccca tttagatctt     840
ccattctata tctccttgca tgaaattgtc catacctgct tagtactcat ctcattattt     900
tgtcattgtg cgcatatctg ttcatatgat ttcttatgga agttattaag tattttgatt     960
tctgtttcag tcagatttcc aacagagaag tagaaccagt agaaaatata tcttaagata    1020
cttattggag ggaattaact tacatggttg tgggaaccgg catagccgac ctaaaattta    1080
tatggctgac tatcaaaaaa gacaggctgg aactcttagg cacaggcaga agttgcagtt    1140
cacaggtgaa atttgttctt tatcctggaa gcctgggctc tgctctttag atttagcagc    1200
tgactgaatc aagtccacct agattaccta ggataatctt gtttacgatt atgattatca    1260
ctaccagtta tcaactgatt ttgaacttca ttcacatcta caaaatacct tcataggaac    1320
atctagatca gtgttggatt aaataactat cagctgtagc ctagccatgt tgacccatca    1380
aaagaccatc acaattgctg atataacttt aataaaattt gcaacatttt cagatggaag    1440
aattgagaaa agggaagcgg gctgacttttt cattttagaa tttattatgc attaacttaa    1500
agtaagtaat aattatgtag gtgatcattt tgatatttta acctacttaa tttagaaaat    1560
catttaaaat cattttgtt aagactacaa aatgattttg ggtaaaaaaa aattttacca    1620
aatatcaaga tcacaataat cacttaaaat agttacatat gtaactaacc tgcacaatgt    1680
gtacatgtac cctaaaactt aaagtataat aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa    1740
aaaaaaua                                                            1748
```

<210> 75
<211> 1570
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (7)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (8)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<400> 75

```
taccggnnan ggaattcccg ggtcgaccca cgcgtccgat tttatgctat ccagtwttta      60
cgtacccatg tgtcaacatt tcatatatcc agttctttgg gtgctggttc actttttttc     120
atttattcaa attcagaaaa atacggacgg atctaatgtt aaattaacca gaaaccctgg     180
aacattcata tcttgagagg gaatttgcta ctcttttact tttgggattt cattataaaa     240
taggctcatt ttatacatat gtcctgtggt ctgtcttcca gagtgtgctg taatcataag     300
tctctagcaa agagtggagg gtggagggtg tgtagaactc cactcagcct catggataca     360
tctacaagtc tctcaaccca tcctgttaca gttctccatg agagtcacct cacacttgga     420
aaagaaggag gtttaaagca gagtattgtt ggcagccagc tatgcccatc ctcttgtaaa     480
taactttcca acacacccat ttccttgcct taaggtgcag gttcctactt ctacaaaatt     540
tcaaatgatt gcaggtcaaa aacctttgga gttactcaca aataataata aaatttcaaa     600
taactagggt ctacttgtcc atcaagatga cattaccagt ggaacccacc tgttaatttt     660
aaagtagctt cagaacccaa caaaaattat gtaagcctgg ttaaatgtcc ttttttcttc     720
ttgcctctaa taraatcagg atcttcggcc ttgatactaa atatgtgtat atttagttat     780
```



```
gatggtactt gtagatgctc acatttccag ttccaaactc gcccgtactt tttatgtgct      840
tcaaaatatt ggacacattt ctgttaatat atgatttctg tatccacaaa ccgctgtttg      900
cttatgctga gtcaatttag aagttaattt ccaatctagt ctcaactgca atgcatttaa      960
aataggtaaa acaagtaaat gagtttggga cattttgaga ttaatgttac tgcccacttg     1020
actgtcaatt tcaaatggct cctaatgcaa ccaaaattat aaccaatgta gcatgtgtag     1080
gaaaggtatt tttaattatt taaaatcatt gtgtatatta cagcagtatg aggaatgcct     1140
ggctaaagag gatttttaa aagatgaaga atggttttgc ttgtattata taggcttact     1200
gagtttgtga gcagcataaa aacaatcatt ccttaattct tcattgtgga actgaaatat     1260
ttctgkaatg cattttttaa aaggagactc ctagacacag cygtaatagg ggaatagaaa     1320
tgtagagctt ttctcataac acaaaaccag aaaataattt tcagcacttt gacttactct     1380
atgtaataag gaaaaaaatt gtttccacaa agttgaacta tgtagtaata tttggtaaca     1440
tatggcatgg ccactttata tcacagaatg tgtgtcaagt tgcaaagcat acttgggcca     1500
tagtagacac taagaattaa aactcttaaa tcagtgaaac aaaaaaaaaa aaaaaaaaaa     1560
gggcggccgc                                                           1570
```

<210> 76
<211> 524
<212> DNA
<213> Homo sapiens

<400> 76

```
ggcacgagcg gcacgagcgg cacgagacgg cctcccctcc gccctgcggt cccgcgcgga      60
tgcagatctg tggatccagc gtagcatctg tagcagctgg gacatcattc caggttttgg     120
gcccggtgtg ttggcaacaa ctggatctga agatggcagt cagggtgctt tggggtggtc     180
tcagcctgct ccgagtgctg tggtgtctcc ttccgcagac gggctatgtg cacccagatg     240
agttcttcca gtcccctgag gtgatggcag gtaaaactcc gcatgtgtgg ctgagacaag     300
ctgcagcaga gtctgcttga gaagctgacg ggagactttg tggggaggga gtagcatgtc     360
tgggtagatg agtagtaaat ccacaagcag agcagcagcc tctctctctg gggtaagaac     420
ttggaagtgg ggacttcata tctccttccc gagtggtgac actgaccttc tgggtaatgc     480
taataaacca ccagtctctt tgatgtaaaa aaaaaaaaaa aaaa                      524
```

<210> 77
<211> 1306
<212> DNA
<213> Homo sapiens

<400> 77

```
gaagctcgaa attaaccctc actaaaggga acaaaagctg gagctccacc gcggtgggcg      60
ggccgctcta gaactagtgg atcccccggg ctgcaggaat tcggcasrrg gcaagctgag     120
atcttcaacg cttcctacaa gaagtaccta gatagggagt gggaggaaga gccactcagg     180
accaagactc tgccagcagc tctccttgcc agggagtcta catggctctg aactcgtgtg     240
tctttctttc ccagtacggc caccttctat ttccttcttc ctagctgcct atttgcaatg     300
ccaccggaag tcaagggccc ctcaggcaag gagaatagca cttcataaag agaaggatga     360
tgaccccgag ggtgtgtggc cctgtgctgc gcccattgca gtctctcagc tcagctgctc     420
ctcctcctac ctggtgctgg cctgcgagga atggtgtgct cacgctgtgg gacctggcca     480
aaggattccc tcttggggtc gctgctcttc ctcaaggatg tttctgccaa agcattcact     540
tcctaaaata tttctcggtc cacaaaggac agaatatgta tcctgaaggt caagtgaaat     600
cccaaatgaa atgtgtggtg ctgtgcacag acgcctccct ccatctggtg gaggctagcg     660
ggacccaagg acccaccatc agtgtgcttg ttgagatgtg ctcatctttt ccaagaatgg     720
ctctgtgtgc cttatggatg tggccaagcg tgaaatcatc tgtgcctttg cccctccggg     780
agcctttcct ctggaggtcc cctggaagcc agtgtttgct gtgtctccag accatccatg     840
tttcctgctc cgaggcctgc ccactcctgg aaaatatctc aaaaaattgt accattcctc     900
aaagggactt ggataacatg gccttccccc aagcactgcc actggagaag agatgtgagc     960
gtttcctcca gaagagctat cggaagctgg agaagaaccc agagaaggag gaggagcact    1020
gggcccggct tcagaggtac tccttgtcgc tccagagaga gaacttcaag aagtgaggct    1080
```

gccaccgccc tgggatctct gaaaaggagg tttcagccac gaggcagctg cttccaggac 1140
actgaggcca agagaaatgt aacagarcca cagctccaca ggcctgcact cggagtctgg 1200
ggcctctgca gaaccagcaa ggggaaaagt ataatctggg ggaccttcaa ccactaagcc 1260
tcttgtcaga accctcaggc agggcagatg tgtcaccaaa taaaac 1306

<210> 78
<211> 1479
<212> DNA
<213> Homo sapiens

<400> 78
acgagaagct cgaaattaac cctcactgaa agggaacaaa agctggagct ccaccgcggt 60
ggcgggccgc tctagaacta gtggatcccc cgggctgcag gaattcggca cgagcttgtt 120
tcatgccctt ccaattacct ctccagcttt tactacttag gttaatttgt gaattctttc 180
ttgcccctgc cttaaattgt aatctcactg ggactgtgat tttctttaca ctcatgattt 240
ctttacagct catgattttc tttacactgc agtttgctga tggcttccaa attggtgttg 300
atcttcagct ttcagagttg aatattctgt aggtggcttc atatgtcatt cattccgtct 360
tctcagttta ttcttaaata tgacccaact ccagccttta tcccaattta tactacctct 420
gtcctgattc aaggcttcat tatctgtcac ctaaatgtac ttgaagctgt agtgccctgc 480
ttcattcttg atctcttcaa atctgctttt ttataaggcc agcaggatgc tttggcaaaa 540
atactgatct tagtgactgg tctttttaaa agcagaaatt atcagatctc tgataagaat 600
ccccaagagt aggatacctt gaagtctatt ttgtatacaa gttcattcca tacctgcaga 660
tctggtttta atcagattga gaaacttgca gtctaccaga attaagtttg agcccctctg 720
cctggtgcat aaagtcctcc atgacctggt tttgctttac ctgtagttca catttcccac 780
tatggcctaa tttgcagcag tattgaagaa cacactctct tactgtcctg tccccctacc 840
tgctgtatcc tttgcataga ataagtgcca ttctcttcca gtctacataa cgtaccttca 900
ctttttttg tggcagctgt tattgcactt tgcaacattt gccaaaacgt ttctgactcc 960
ccagcctgtt ttatagtaac actcatatgg acaccttgaa aatttataaa atattatttc 1020
attggatgag aaaatgaatc aattttaata aaaataattt acaccaatgt taacattaaa 1080
gattgcacta gagttcaaaa ttagtatatt tttatgttta aagaaatttt aggccaagtg 1140
cagtggcctg agcctgtaat cccagcactt tgggagactg aggcaagtgg atcacttgag 1200
gtcgggaagt tcaagaccag cctggctaat atggcaaaac cccatctcta ctaaaaatgc 1260
aaaaattaac aatgcttgat ggcaatgcct gtaatcgcag ctatttggga ggcagaggca 1320
ggagagtcac ttgaacttgg gagttgccgt gagctgagat agcgccagtg cactccagcc 1380
tgagtaactg agactcctat ctcaaaaaaa aaaaaaaaaa aaaaactcga ggggggccc 1440
gggtacccaa ttcgccctca tcagtgcagt cgtattaca 1479

<210> 79
<211> 1794
<212> DNA
<213> Homo sapiens

<400> 79
ggcacgagaa gcatttagta ggattttaaa gaaacttgag aactgttaca taaggtgatg 60
aattgggcat agcatgtaaa attatattta agcaaggaaa tgatctctgg tgttttaata 120
ttcaacttga ttgcttcctc ttgggttctg tgtttcccac tgtgtgacct gagctgtcag 180
aaaaccttaa gaattttctt tgcatcattt ttccatgcag tttgtgtaca tgtctcatgt 240
acctcgtggc agccactggt tttgttcatc aaatggtggg ttgtgggatg ctctcctgca 300
gtctccctct aattaaagag gttaaattgc cgtttgctca gcctttagtt cctttccaca 360
gcttcctagg ctcttaaaaa ttagcactat attcctttca gattaaaaaa aaaacaaaaa 420
caaaaacctg tttgctgtct ttactgctgt ggtcttgtct agagcaaatc tgaacaaact 480
gattgaaagg ggtgtttggt ggctggtgtt ctctttgact aaagaggctt acatgtactg 540
tggtacagtc tgcttactta aaaggtgagg cttgaattaa aatacagcca gatagaagcc 600
agactctaat caaatgaggt gattagatca atgaatgaag agaggagagg agtcaggtgt 660
tgcctttccc tggctgttga atagctgatg ttccagattg ccctacagtg ttgtgttagg 720

gcatccagga gggatacttt tcaggcttag gtacacctca gtctttaaaa tgaggaatta 780
ggacacattc atgtgtgtgt ccctaatctg ctcctgagaa gagaagtgca atcagggtct 840
tattttgtga ccactgactt gcacactgag acaaaagggc catctgcaag ctgaaaatag 900
tggattcctt aaataaaaac tattcacatt tgatggtgtg gtagttttaa taaaatgttc 960
aagtgtcaag ttcattttca tttataatct gagacagttt tataagtcac ctccctgggg 1020
gtaaaaatgc atgttctgtc ctcatagtga gacacatctt ctgcttagag tctagaaagc 1080
tctaagaaag atttatgcca tctgtgcagc tggcattttt atagtaaaat ttttttact 1140
ttgctccaag tttaagttat ctcatgacaa actttcttga aagaggcatt cactattatt 1200
ataggaagta tacttcttta ttgaaaagga gataatgtat caggtaactt attaaagtat 1260
tttctcaaag tttagtatct ttaggaatac agtgcctcaa tacaatataa aatattttgt 1320
aaataataga atgaattcat tttagaattt aaatgatgct aataaaatag accattattc 1380
taaaagttta actaatttag aatcaaccct ggttgaaaat aaagccttaa gctgtttttt 1440
tggaagactt taaatccttt atggctaaga gatgacagac agggccgagt gcggtggctc 1500
atgcctgtaa tcccagcact ttgggaggcc gaggcgggcg gatcacgagg tcaggaaatc 1560
aagaccatcc tggctaacac ggtgaaaccc tgtctctact aaaaaatata aaaaaaatta 1620
gccgggcgtg gtggcgggcg cctgtagtcc cagctactca ggaggctgaa gcaggagcat 1680
ggtgtgaacc caggaggcag agcttgcagt gagctgagat cacaccactg cactccagcc 1740
tgggcaacag agcgagagag tgagactctg tctcaaaaaa aaaaaaaaaa aaaa 1794

<210> 80
<211> 1280
<212> DNA
<213> Homo sapiens

<400> 80
ggcacgagta taaaggcccc tccacccagc ctctagccca tttctttctc tggcttttgc 60
aggattcctc attctccctg aggtcttaac tatcacatca tgcacgttct gccactgctg 120
ttatcactgc tgctgctgct gctgctgctg tcagctagct ttgtgacttt cagcaccccc 180
acttccagca gaaattctag ctgccctgat tgtgagagtc tgaacaccgg tcttccatcc 240
ctgatgatgt ttggtggatc tctgctcaaa tgggttcaga acacacacgg ggtggaatca 300
ctctttgtcct ctgccaaggt gcgcctgctt ccaccagccc taggggttct gttcccaaga 360
ctacaccctg gcactctgac ccttgtcttc cttttaattc ccttcctcac agtgtcttct 420
tccacatctg acgttcttag ctctttagag tccccaaaac tatctgttac catatttcat 480
tattgttaac tctaaagatt ttggcatcaa acaccctgca tttgaatgct agctgtgtca 540
cacatcagat gctttacttt ggcaaatcat agaactttct gtcaatagag ataataatgg 600
tacctatatt gtaatattgt gagtgttact tggataataa agtacatagc acagtatttg 660
gcacatagta attgctcaac aataccaatt gttattatta ttagactgtg ccctctaaat 720
tatttgtcta cggattatga tctgtataaa tgacttatca attaagaaga ccacaggtat 780
gcagagtctc atcactcata caagactgat gtcaattaac taagagaagt ttcgtcacta 840
accaggagtt tcacatcata gttccacact ttgcttctac tcccaatatg gcttgttgac 900
ttttcactct ctttaccctg ttttctttct atggttccca gggctatcac ttttctttat 960
tttggttaat acatatagct gtacactgac ccagtctcca tgaaaaatac tgtcatatac 1020
tccctctttc cctctttccc taatatcatc atctcataga gatcaaactc acattttctg 1080
gcaccattat tctttttata aaatacttta cttttaaatt tttacccaac tacgtctatg 1140
ttattttagc tagctaagct gctataacaa agagatctaa atacagtggc ttaaatataa 1200
cagaagcata tttttctctc atgtaacagc tagaggaatg tgtgtagtcc agagcataca 1260
aaccacaagt cattcatgac 1280

<210> 81
<211> 974
<212> DNA
<213> Homo sapiens

<400> 81
ggcacgagcc acaactacca gaactggagg gtgtacgacg tcttggtgct caaaggatcc 60

```
cagttatctg caagggctgc agatggatcc ccctgcaatg tcctcctgtg ctctgtggtc      120
cccagcagac gcatggactc tgtgacctgg caggaaggga agggtcccgt gaggggccgt      180
gttcagtcct tctggggcag tgaggctgcc ctgctcttgg tgtgtcctgg ggaggggctt      240
tctgagccca ggagccgaag accaagaatc atccgttgcc tcatgactca caacaaaggg      300
gtcagtttta gcctggcagc ctccatcgat gcttctccctg ccctctgtgc ccttccacgg      360
ctgggacatg ccttggattc tgatgctgct gttcacaatg ggccagggag ttgtcatcct      420
ggccttcaga tcgtgtctgg aggcagaggt ccgtggggtt ccaggcagag gaaaccgaag      480
cggtgttaaa actgtggtgg aagccccagc agtttttgca aagaggccgt gaccacctgt      540
ggcgagggca gaccccagcc aggcctggaa cagatcaagc tacctggaaa ccccccagtg      600
accttgattc accaacatcc agcctgcgtc gcagcccatc attgcaatca agtggagaca      660
gagtcggtgg gagacgtgac ttatccagcc cacagggatg tacctgggag acctgtgcaa      720
cagcgccgtg gcaagccatg tggcccctgc aggcattttg gctgcagcag ctaccgccct      780
gacctgtttt ttgccaggac tgtggagcgg ataggggggag taggagtaga gaagggaaca      840
agggagcaag ggaacaaggg acatttgaac atttaatgtg agaagacaaa catccttttgt      900
gagtcattaa aatttatgaa ccacttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      960
aaaaaaaaaa aaaa                                                        974
```

<210> 82
<211> 1955
<212> DNA
<213> Homo sapiens

<400> 82

```
ggcagtgtcc ccaaggcacc gaaaccgagg cgggggtctc ggtccctccg cgcaaggagg       60
gaggcggacc gtacgtggca ggactcaccg ccccgcacgt ggcaggactc accgccccgc      120
gccgtgttct ccgagccatg gcgccagcgc tgtggcgggc ctgcaacgga ctcatggccg      180
ccttcttcgc gctggcggcc ttggtgcagg tggtgtacac aatccctgca gtactgaccc      240
tgcttgttgg acttaaccct gaagtcacag gtaatgttat ttggaaaagt atctctgcaa      300
tacacatact cttttgtacg gtgtgggctg ttggcttggc gtcctacctc ttgcatcgta      360
cacaacagaa catcttacat gaggaagaag gcaggagctg tctggtctgg tgattattac      420
agcatggatt atcctgtgcc acagttcctc aaagaatcca gttggtggaa gaattcaatt      480
ggctattgcc attgtaatca cacttttccc atttatctca tgggtctaca tatatattaa      540
caaggaaatg cggtcctctt ggccaactca ctgcaagaca gtaatttaaa taaattcaag      600
aacttcgttt ttaaaatgaa tattttcaat caatttttta taaacattag gggaacaagc      660
caggaattta tttcaggtaa tttgggctaa tagttttaaa actccaaata acttttttaag      720
ggtgcatata attcgatgta agattggatg ggacaagtaa gaaatggtct gatattttcc      780
agacactttc tgcagggtct tgtgtcataa tgtagtggaa aaggctagaa ataaagttta      840
aaaatacagt tctaacttaa ctttgtacta tgttatttgg gcaatatata aacctcctgg      900
tggatattat ctataaaata ggataatgcc agatctactt acttacacag taacaaggat      960
caatctagat aatgtaagaa cactctgaag atataaagtg tttggaaaga ttacggaggg     1020
ctgcccatga ttaaaataga ggggagcagg gattggtaat atactgaaat agacattcaa     1080
gagagggtat accccgatct ttttttttt ttttaagaca gtcccactct attgcccagg      1140
ctggagtgca gtggcatgat catggctcac tgcagtcctg acctcccggg gctcaggtga     1200
tcctcctacc tcagcctccc aagaagctac gactacaagt gtgcaccacc atgcccggct     1260
aaatttttt aaatttttg tagaggcagg gtttcaccgt gttgtccagg ctggtcttga      1320
attcctgagt tcaagcgatc tgtccacctt ggcctcccaa agtgctggga ttacaggtgt     1380
gagccaccat gcccagtcca gccctaaact aatcttatcc agagctggca tagtgcagtg     1440
aactaaagga gaactctaga tgaatcaaat gagcaggcat gtcttggaaa gaaagggaag     1500
ctggatagaa taaaggaatt agggaccaaa caagaaggca atagggacta taactacatt     1560
ctaaatgaga aataaggtca aaatctatat acattcttta taaatggatg tccaaagtaa     1620
tcctagggag gagagctttt ttttttcat ttccattttc atttaaaaat ggatacttga      1680
ttattggaaa acttacaatt gtgtttggaa caacttgggt atttgaatct aattttccaa     1740
ttgcaaattt tatgatacct aaatacagat aaagtatttc caatgaaaat ttagtgtcca     1800
aatgagtggg gctataaatg taaaatacac tggattttaa agacatggta gaaaaagaac     1860
agaaaatatt ttttgtattg attacatgtt gaaacaatat tttggctata atgggttaaa     1920
tatactatta aagttgaaaa aaaaaaaaaa aaaaa                                1955
```


<210> 83
<211> 638
<212> DNA
<213> Homo sapiens

<400> 83

```
ggcacgagag aggtcctggg gtaagagaaa aaaagtagtt atagcacttc gtccagcact       60
gacagcagcc gaacaaatgc tgaaaatctg actgtgtgac agaacgtatc actgatgact      120
gatagaaagc cctctttcac tctgattacc cactcactac atgaagtcct gaaaataaca      180
gagaaactgt tatatctttt taatgattta tttgcaagta ttgagatttg acctgaaaaa      240
caatgaaaca catgaacaca cttccgattt tctcctcgct gattagcttc ctgcctgctg      300
tcagtgctgg acgaagtgct ataactactt tatgtaacat tacagaacag ctagaggtcc      360
tggggtaaga gaaaaaaagc acatcacaac aaatgtgaaa gccttcatta ttacacgttc      420
cagtttgtct cgctgtgtag gcataagcta atggtttatt ttcagaaagc tgcctgaaac      480
gttgctttgt attcttctag gaagaacttt aattcctcct gaggaactct actttctgag      540
ccaaactgct aatttttctgc ggaactgtct agaagatcat tcaagagacc ctgcagttgc      600
actttctcgt aaaagttaaa aaaaaaaaaa aaaaaaaa                              638
```

<210> 84
<211> 859
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (27)
<223> n equals a,t,g, or c

<400> 84

```
ccgggtcgac ccacgcgtcc ggcagangcg ggactgtcgt ctgggggagc cgcccaggag       60
gctcctcagg ccgaccccag accctggctg gccaggatga agtatctccg gcaccggcgg      120
cccaatgcca ccctcattct ggccatcggc gctttcaccc tcctcctctt cagtctgcta      180
gtgtcaccac ccacctgcaa ggtccaggag cagccaccgg cgatccccga ggccctggcc      240
tggcccactc cacccacccg cccagccccg gccccgtgcc atgccaacac ctctatggtc      300
acccacccgg acttcgccac gcagccgcag cacgttcaga acttcctcct gtacagacac      360
tgccgccact ttcccctgct gcaggacgtg ccccccctcta agtgcgcgca gccggtcttc      420
ctgctgctgg tgatcaagtc ctcccctagc aactatgtgc gccgcgagct gctgcggcgc      480
acgtggggcc gcgagcgcaa ggtacggggt ttgcagctgc gcctcctctt cctggtgggc      540
acagcctcca acccgcacga ggcccgcaag gtcaaccggc tgctggagct ggaggcacag      600
actcacggag acatcctgca gtgggacttc cacgactcct tcttcaacct cacgctcaag      660
caggtgcgct ggactggggt cacctgatcg gggccacctg tccttcttgt ccaaattacc      720
actccactcc agcctgggca acaaaagcga aaactccatc tccaaaaaaa taataataat      780
aataataaaa taaaaatcac acaaaggcca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      840
aaaaaaaaaa aaaaaaaaa                                                   859
```

<210> 85
<211> 1129
<212> DNA
<213> Homo sapiens

<400> 85

```
gctgcttccc aaggaccatg aaactcctgc tgctggctct tcctatgctt gtgctcctac       60
cccaagtgat cccagcctat agtggtgaaa aaaaatgctg gaacagatca gggcactgca      120
```

```
ggaaacaatg caaagatgga gaagcagtga aagatacatg caaaaatctt cgagcttgct     180
gcattccatc caatgaagac cacaggcgag ttcctgcgac atctcccaca cccttgagtg     240
actcaacacc aggaattatt gatgatattt taacagtaag gttcacgaca gactactttg     300
aagtaagcag caagaaagat atggttgaag agtctgaggc gggaagggga actgagacct     360
ctcttccaaa tgttcaccat agctcatgac ttcctctcgg ctatcactca cccctgtcct     420
cagagtgata aactaagtca catacagata aagcactgaa aacaccacag tgaccctccc     480
acccccacc aatatgtaat tctattaata gaaacagctg tgtaaagaag tctaaaattt     540
tcactatttc caatgataaa ctcttcagtg ctcttcttga aatgtcacat tatttcccaa     600
caagttatac ctatttttag tattcttgtt gctagtgcca tgcacaactt caatagctag     660
ttgctattcc aacaacaatt tcttcatgta tcgttctgtc ttctcaacag ctgtctttca     720
tggcagcata agtggtcatg atcaaaattc taaatcttgc atctgtgaga gtagctacta     780
tgacactaaa agctttttt ctagaacagg agacacttca ggtgaagcat tcattctcct     840
actaactatg gccttggagc caggttttat ctctcactgt aggaaattgg ccgccccagg     900
tgtgagctat gaagactcct ttttgcccca gtggctttgg ggttgaaatg ctgtcgaaaa     960
gcttttatgg ctctgtagac ccatcttttt gaccaagcct tgatcacaca tggacatcca    1020
agggtaatca tggaccccca attgtgggtg aaaggatgga tcatttatct acctgattac    1080
tgagagcttt atttgtctcc ctctgatagc aaaaaaaaaa aaaaaaaaa                1129
```

<210> 86
<211> 2674
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2607)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2611)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2621)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2634)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2650)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2660)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2669)

<223> n equals a,t,g, or c

<400> 86

```
gatccctccc atctcacagt acctcacagg tctcttcccc cgagcagtgc attgctggag      60
cgaggagaag ctcacgaatc agctgcaggt ctctgttttg aaaaagcaga gatacagagg     120
cagaggaaaa gggtggactc ctatgtgacc tgttcttaga gcaagacaat caccatctga     180
attccagaag ccctgttcat ggttggggat attttctcga ctgcatggaa tcagaaagaa     240
gcaaaaggat gggaaatgcc tgcattcccc tgaaaagaat tgcttatttc ctatgtctct     300
tatctgcgct tttgctgact gaggggaaga aaccagcgaa gccaaaatgc cctgccgtgt     360
gtacttgtac caaagataat gctttatgtg agaatgccag atccattcca cgcaccgttc     420
ctcctgatgt tatctcatta tcctttgtga gatctggttt tactgaaatc tcagaaggga     480
gtttttatt cacgccatcg ctgcagctct tgttattcac atcgaactcc tttgatgtga     540
tcagtgatga tgcttttatt ggtcttccac atctagagta tttattcata gaaaacaaca     600
acatcaagtc aatttcaaga catactttcc ggggactaaa gkcattaatt cacttgagcc     660
ttgcaaacaa caatctccag acactcccaa aagatatttt caaaggcctg gattctttaa     720
caaatgtgga cctgaggggt aattcattta attgtgactg taaactgaaa tggctagtgg     780
aatggcttgg scacaccaat gcaactgttg aagacatcta ctgcgaaggc cccccagaat     840
acaagaagcg caaaatcaat agtctctcct cgaaggattt cgattgcatc attacagaat     900
ttgcaaagtc tcaagacctg ccttatcaat cattgtccat agacactttt tcttatttga     960
atgatgagta tgtagtcatc gctcagcctt ttactggaaa atgcattttc cttgaatggg    1020
accatgtgga aaagaccttc cggaattatg acaacattac aggcacatcc actgtagtat    1080
gcaagcctat agtcattgaa actcagctct atgttattgt ggcccagctg tttggtggct    1140
ctcacatcta taagcgagac agttttgcaa ataaattcat aaaaatccag gatattgaaa    1200
ttctcaaaat ccgaaaaccc aatgacattg aaacattcaa gattgaaaac aactggtact    1260
ttgttgttgc tgacagttca aaagctggtt ttactaccat ttacaaatgg aacggaaacg    1320
gattctactc ccatcaatcc ttacacgcgt ggtacaggga cactgatgtg gaatatctag    1380
aaatagtcag aacacctcag acactcagaa cgcctcattt aatttctgtct agtagttccc    1440
ascgtcctgt aatttatcag tggaacaaag caacacaatt attcactaac caaactgaca    1500
ttcctaacat ggaggatgtg tacgcagtga agcacttctc agtgaaaggg gacgtgtaca    1560
tttgcttgac aagattcatt ggtgattcca aagtcatgaa atggggaggc tcctcgttcc    1620
aggatattca gaggatgcca tcgcgaggat ccatggtgtt ccagcctctt caaataaata    1680
attaccaata tgcaattctt ggaagtgatt actcctttac tcaagtgtat aactgggatg    1740
cagagaaagc caaatttgtg aaatttcagg aattaaatgt tcaggcacca agatcattca    1800
cacatgtgtc cattaataag cgtaattttc tttttgcttc cagttttaag ggaaatacac    1860
agatttacaa acatgtcata gttgacttaa gcgcatgaga caccaaattc tgtggctgcc    1920
atcagaaatt ttctacagta catgacccgg atgaactcaa tgcatgatga ctcttcttat    1980
cacacttgca aatgaatgcc tttcaaacat tgagactgct agaaccaagc actaccagta    2040
tctccatcct taactgtcca gtccagtgat gtgggaagtt acctttata agacaaaatt    2100
taattgtgta actgttcttt gcagtgaaga tgtgtaaata agcgtttaat ggtatctgtt    2160
actccaaaaa gaaatattaa tatgtacttt tccatttatt tattcatgtg tacagaaaca    2220
actgccaaat aaaatgttta cattttcttt cataaaaaaa aaaaaaaaaa aactcgaggg    2280
ggggcccggt acccaattcg ccctatagtg agtcgtatta caattcactg gccgtcgttt    2340
tacaacgtcg tgactgggaa aaccctggcg ttacccaact taatcgcctt gcagcacatc    2400
ccccttcgc cagctggcgt aatagcgaag aggcccgcacc gatcgccctt cccaacagtt    2460
gcgcagcctg aatggcgaat ggcaaattgt aagcgttaat attttgttaa aattccgcgt    2520
taaatttgt taaatcagct catttttaa cccaataggc cgaaattcgg caaaaatccc    2580
ttattaatca aaagaaatag aaccganaat nggggttgaa ntgttgtttc caantttggg    2640
aaacaaaaan tcccacttan tttaaaagna aacg                                2674
```

<210> 87
<211> 1636
<212> DNA
<213> Homo sapiens

<220>
<221> SITE

<222> (1624)
<223> n equals a,t,g, or c

<400> 87
tcgacccacg cgtccggctg agtgtgagct gagcctgccc caccaccaag atgatcctga 60
gcttgctgtt cagccttggg ggccccctgg gctgggggct gctgggggca tgggcccagg 120
cttccagtac tagcctctct gatctgcaga gctccaggac acctggggtc tggaaggcag 180
aggctgagga caccagcaag gaccccgttg gacgtaactg gtgccctac ccaatgtcca 240
agctggtcac cttactagct ctttgcaaaa cagagaaatt cctcatccac tcgcagcagc 300
cgtgtccgca gggagctcca gactgccaga aagtcaaagt catgtaccgc atggcccaca 360
agccagtgta ccaggtcaag cagaaggtgc tgacctcttt ggcctggagg tgctgccctg 420
gctacacggg ccccaactgc gagcaccacg attccatggc aatccctgag cctgcagatc 480
ctggtgacag ccaccaggaa cctcaggatg gaccagtcag cttcaaacct ggccaccttg 540
ctgcagtgat caatgaggtt gaggtgcaac aggaacagca ggaacatctg ctgggagatc 600
tccagaatga tgtgcaccgg gtggcagaca gcctgccagg cctgtggaaa gccctgcctg 660
gtaacctcac agctgcagtg atggaagcaa atcaaacagg gcacgaattc cctgatagat 720
ccttggagca ggtgctgcta ccccacgtgg acaccttcct acaagtgcat ttcagcccca 780
tctggaggag ctttaaccaa agcctgcaca gccttaccca ggccataaga aacctgtctc 840
ttgacgtgga ggccaaccgc caggccatct ccagagtcca ggacagtgcc gtggccaggg 900
ctgacttcca ggagcttggt gccaaatttg aggccaaggt ccaggagaac actcagagag 960
tgggtcagct gcgacaggac gtggaggaac gcctgcacgc ccagcacttt accctgcacc 1020
gctcgatctc agagctccaa gccgatgtgg acaccaaatt gaagaggctg cacaaggctc 1080
akgaggcccc agggaccaat ggcagtctgg tgttggcaac gcctggggct ggggcaaggc 1140
ctgagccgga cagcctgcag gccaggctgg gccagctgca gaggaacctc tcagagctgc 1200
acatgaccac ggcccgcagg gaggaggagt tgcagtacac cctggaggac atgagggcca 1260
ccctgacccg gcacgtggat gagatcaagg aactgymctc cgaatcggac gagactttcg 1320
atcagattag caagktgkwg cggcaggtgg aggagctgca ggtgaaccac acggcgctcc 1380
gtgagctgcg cgtgatcctg atggagaagt ctctgatcat ggaggagaac aaggaggagg 1440
tggagcggca gctcctggag ctcaacctca cgctgcagca cctgcagggt ggcatgccga 1500
cctcatcaag tacgtgaagg actgcaattg ccagaagctc tatttagacc tggacgtcat 1560
ccgggagggc agagggacgc cacgcgtgcc ctggaggaga cccaggtgag cctggacgar 1620
cggnggcaag ctggac 1636

<210> 88
<211> 1639
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (12)
<223> n equals a,t,g, or c

<400> 88
gtgacactat anaagtacgc ctggcagggt accggtccgg caattcgcgg ccgcgtcgac 60
gtcaggcggg ccgtgggttc ccggaggggs tcttgaggcg ccatttcaag tcgcccccag 120
cctctcccac agcactcctg ttttcccggg cctcatcatg gcccacggcc ctcagtcgct 180
gtggagcctg ggcttcacag tgacactcac gtttgaactc ccggtcggct gtgtgcttgg 240
tagaatttgt catccaatac aggcgtgtaa cacgggcttg atgacaccca ccccacaggg 300
cccctgcagg accgagatga tgtccaatga caagccctgg cttccagcca atgctcctgc 360
ccacatctct ctcccaggag ccaggcttac ctctacctgt gcacctgggc tgtgactcat 420
gactggaatg atctggctgg gcctgttccc ccaccagact tattttcagg cgccccagca 480
gccaccaaac atctgtcaac tgaagtaatg aacctgcagt tgagaggcag ctaaacctag 540
gttgaaggtt agggagacag ctgagttgag gtcaaatccc cccggccagt tagcctttct 600
gagcctattt cctcaattgt aaaaggaaga caatcatgat gctgacctca gaatcsagcg 660
aggaggaagt gaggaggtgc atgtgaagca ttgtgcgtga ctggtggggc taactgggct 720

ctggaagcgg tarctctggg gccctaaccc ctttctgcct catgctaatt gacctatggc 780
atgtccagtg acatcatgac tgaaaaaatg atttgaaart ataatcgctg tcaggaattg 840
tctcctggtc tcaaactcct aggcttaagg aatttgccca ccttagccta ccaaagggcg 900
gggcttacaa gcatgarcca tggcacccgg ccccaaagtg ttttttctat tctctcagtc 960
macagttaca cagaaaattt ctgtgaccac tggtcacgaa agggagtgga ggtctctccc 1020
taccggcaac caagcagtcg attctgcagt ggacaccagc tgggtgttct cttattgaat 1080
taattctgac actatctgtc cagagatagc attagattcc acaggttgag gacttagtcc 1140
ccacttgtcc cttatttctg atgctgatca caagamctar gttattttgc cggtgattct 1200
gactgactgg ctattaatta gggtttctgt gacccactcc ttgggttcaa ttaatttgct 1260
agagaactcc ctcatggaat tcagagaaac acatttacca gcttattata aaggctgcta 1320
caaaggatac agatgagatg cgcagagcaa cgtgtgggat ggagtgcaga gcttccgcgc 1380
cctctcctgg agcaccactc ttcaggaacc tccatgtgtt cagctattca gaagctccct 1440
ggacccagtc ctttcgggtt tttatggaag cttcattatg tagacatgat taattatacc 1500
attggtcatt ggtgatcaac ttaaccttca gcccttctcc cctcccggag gttggagggt 1560
ggggctgaaa cattccaact tacaggcccg tcgacgcggc cgcgaattcc cgggtcgacg 1620
agctcactag tcggcggcc 1639

<210> 89
<211> 1860
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1846)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1848)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1853)
<223> n equals a,t,g, or c

<400> 89
ctcaccagms ggaaagtacg agtcggctca gcctggaggg acccaaccag agcctggcct 60
gggagccagk atggccatcc acaaagcctt ggtgatgtgc ctgggactgc ctctyttcct 120
gttcccaggg gcctgggccc agggccatgt cccacccggc tgcagccaag gcctcaaccc 180
cctgtactac aacctgtgtg accgctctgg ggcgtggggc atcgtcctgg aggccgtggc 240
tggggcgggc attgtcacca cgtttgtgct caccatcatc ctggtggcca gcctcccctt 300
tgtgcaggac accaagaaac ggagcctgct ggggacccag gtattcttcc ttctggggac 360
cctgggcctc ttctgcctcg tgtttgcctg tgtggtgaag cccgacttct ccacctgtgc 420
ctctcggcgc ttcctctttg gggttctgtt cgccatctgc ttctcttgtc tggcggctca 480
cgtctttgcc ctcaacttcc tggcccggaa gaaccacggg ccccggggct gggtgatctt 540
cactgtggct ctgctgctga ccctggtaga ggtcatcatc aatacagagt ggctgatcat 600
caccctggtt cggggcagtg gcgagggcgg ccctcagggc aacagcagcg caggctgggc 660
cgtggcctcc ccctgtgcca tcgccaacat ggactttgtc atggcactca tctacgtcat 720
gctgctgctg ctgggtgcct tcctgggggc ctggcccgcc ctgtgtggcc gctacaagcg 780
ctggcgtaag catggggtct ttgtgctcct caccacagcc acctccgttg ccatatgggt 840
ggtgtggatc gtcatgtata cttacggcaa caagcagcac aacagtccca cctgggatga 900
ccccacgctg gccatcgccc tcgccgccaa tgcctgggcc ttcgtcctct tctacgtcat 960
ccccgaggtc tcccaggtga ccaagtccag cccagagcaa agctaccagg gggacatgta 1020
ccccacccgg ggcgtgggct atgagaccat cctgaaagag cagaagggtc agagcatgtt 1080

```
cgtggagaac aaggcctttt ccatggatga gccggttgca gctaagaggc cggtgtcacc     1140
atacagcggg tacaatgggc agctgctgac cagtgtgtac cagcccactg agatggccct     1200
gatgcacaaa gttccgtccg aagagcttac gacatcatcc tcccacgggc caccgccaac     1260
agccaggtga tgggcagtgc caactcgacc ctgcgggctg aagacatgta ctcggcccag     1320
agccaccagg cggccacacc gccgaaagac ggcaagaact ctcaggtctt tagaaacccc     1380
tacgtgtggg actgagtcag cggtggcgag gagaggcggt cggatttggg gagggccctg     1440
aggacctggc cccgggcaag ggactctcca ggctcctcct ccccctggca ggcccagcaa     1500
catgtgcccc agatgtggaa gggcctccct ctctgccagt gtttgggtgg gtgtcatggg     1560
tgtccccacc cactcctcag tgtttgtgga gtcgaggagc caaccccagc ctcctgccag     1620
gatcacctcg gcggtcacac tccagccaaa tagtgttctc ggggtggtgg ctgggcagcg     1680
cctatgtttc tctggagatt cctgcaacct caagagactt cccaggcgct caggcctgga     1740
tcttgctcct ctgtgaggaa caagggtgcc taataaatac atttctgctt tattaaaaaa     1800
aaaaaaaaaa aaaaaaactc gaggggggge ccgtacccaa tcgccngnga tgntagtata     1860
```

<210> 90
<211> 839
<212> DNA
<213> Homo sapiens

<400> 90

```
ggcacgaggg ctacgatcct acagtggaga atagatgagt acagcattct gccctattca       60
ttcatcattg gggtccatgg ttatgtgctt gtgtattctg tcacctctct gcatagcttc      120
caagtcattg agagtctgta ccaaaagcta catggaaggc catgggaaaa cccgggtgcc      180
agtggttcta gtggggaaca aggcagatct ctctccagag agagaggtac aggcagttga      240
aggaaagaag ctggcagagt cctggggtgc gacatttatg gagtcatctg ctcgagagaa      300
tcagctgact caaggcatct tcaccaaagt catccaggag attgcccgtg tgggagaatt      360
cctatgggca agagcgtcgc tgccatctca tgtgagccct tgggtgtggg gtaactgcct      420
tgcttctgcc cccggcactt gccatgttcc agtgggggge agatcctcag gacttcacgg      480
gtatggttgc cagctgtgtt cctggcccct ggacacacag tgtggcatcc tcatgtttgc      540
acactttccc caggctccag tggcctggat gtcaatgttt acaaaggggc aaggacctct      600
catggacact ggcctctagc cctctgtttt tgtttgatga attctgttat aacctatggg      660
gtcaggatat gagtcctggg cattatttat ccaggaccca tcctcttggg tgggttttgg      720
gtgttggctg ggtaagggga gccggggact tctgaaatag agctggctcc ctggggtgac      780
aatgtatata tgcaaataaa ttgagaaatc ttttgttgtt gaaaaaaaaa aaaaaaaaa       839
```

<210> 91
<211> 1145
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (386)
<223> n equals a,t,g, or c

<400> 91

```
aattcggcac gaggacatat tggccattta ctctactaat aaaagagtac tatctactca       60
gtgtcattta ctgttactgt agtaattaat gcctttggaa gaatcttttg aaatagttct      120
caaattggta ccactacttg gtttggaatt attttttttt cttttcataa tcaatggtta      180
tataaatgta tattgtccta gtcagtattt tatatatgct aaggactcac tagctggctt      240
ggcactaata cctcaataaa aggaatactt cttttggaat catgaaacaa aagtgartaa      300
acctccaagt tatttttcca accaaccttc tttgaaaaat cttggatgag tcactcaaat      360
caagacatgt tataaaatta tctgtnattt tggtagaaca tatacattgt yctaataata      420
atttycaaat attcagtgka acygtaagka tgagaatаca ggttgaatat cycttatcca      480
aaatgcttgg gaccagaagt cttttggatt ycaaattttt aaatatttac atcatactta      540
```



```
ccagtttaac atccctaatt caaaaattca aaattcagaa tgctccaata atcgtttcct       600
ttgascatca tgtcagtgct caaaaagttg cagattttga ggtatttcag atttttgaat       660
taggaagact caacttgtac tatcattcta tagactttat gattgggtag actacatgag       720
tattgaaccc agaaatcatt gtctagcaaa agccagtata gtgattaatt accctgtgac       780
tattatataa tgttcaaaaa agctaacata ttagaatgtc cttagcgtgc agagagcaaa       840
cagagacaaa aagaaaagtt accctgaaaa gtttgtcaga aaaatagaat atcagacgct       900
raactactca tccagaattt tgtcraaaaa gaaaaataag ataaaattca ctggtagaca       960
aaaagtagta acataccagt ttgtaatttc tcagtttcaa accatgaata tgtatttgta      1020
taccaaaaat catttcagga gtcagagaag gaggatatgc cttttatgtg gagactttaa      1080
acataaaatt ggaaaaaaaa aaaaaaaaaa actcgtaggg ggggtcccgt acccaatcgt      1140
cctgt                                                                 1145
```

<210> 92
<211> 2050
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (515)
<223> n equals a,t,g, or c

<400> 92

```
aagaatggca taaattcatc cagcttctta cagaattcca aatgcggaat gtagattttt       60
tatatagtaa tcttgagttt attctaccat taccagttga taccattcca gaaactaaaa      120
acttttgtgg cccatcagta actgtggatg ccagtgcagc aacaaaaagt atgaattgtc      180
ttgctaggaa acactctgaa agagaacagc cattgaaaaa gtcccagaaa aagaaacaaa      240
agaaaacatt ggtaatatta gatgatagtg atctatttga cactgacttg gactttcctg      300
atcaatctat tagcctgtcc tctgtatcat cttcctcaaa tgcagaagaa agcaaaaccg      360
gagacgaaga aagcaaagcc agagacaaag gaaacaatcc agagacaaag aaatctattc      420
cttgtcctcc taaaacaact ggcaggaaaa aaatgttctg ccctgtttct cattgtttaa      480
attctctctc tgagttcatg ggataacatg tcctncttag atgcactttt aactgatgta      540
agggracaaa acaaatacgg tagaaatgac tttagttgga caaatggaaa ggttacaagt      600
ggactttgtg atgagtttag tcttgagagt aatgatggat ggacttctca aagctctgga      660
gaattaaagg cagctgcaga agctctcagc tttactaaat gttcttctgc tatttcaaaa      720
gcatkggaaa ccttgaattc ttgcaagaaa ttaggaagag atccaaccaa cgatcttact      780
ttttatgttt cacaaaagcg caataatgta tactttagtc agtcagcagc taatttagac      840
aatgcttgga agaggatatc agtcattaaa agtgtatttt cgagtcgatc tcttctctat      900
gtgggtaata gacaagctag tataattgaa tacctgccaa cccttcgaaa catctgtaag      960
actgagaagc taaaagaaca aggaaaaagt aaaagaagat tcctgcacta ttttgaagga     1020
attcatcttg acattccaaa agagactgtg aatactttgg cagctgactt cccttaatgt     1080
tccatactaa caatgctttg tatagattat catgtggtcc ttaagataca tttttatatt     1140
atgtggatct tcatggaaaa gtatatttct cgatgtacat tttaaacaaa caatttgtat     1200
atttttttat tggcgggtaa atatttaaaa tatttgagtt acaaatttta tatatgattg     1260
taatttttt tctgaatttt ttgtattatc tgatttagct ttgttggagt atttttgta      1320
tgtgagtgaa ctgtttctgg aaggtaragt tcattaagat gaactcccta tttcaagtgt     1380
ttatattata tattagctta atattcagat acattatctt ggctgctaac attagtgtca     1440
ctaaagttgg tatacaatct cccactgcta aatttgactg gctttacaaa aacaaaaaca     1500
ttatctggtg aattatattt ttaacctaaa agttaaggat cctcatattg tacagttttt     1560
tttgtgtgct ttttttttt tttttgagac ggaatcttgc tctgtcaccc aggctggagt     1620
gcagtggcct ggtatcggct cagtgcaact tttgcctccc gggttcaagc gattatcctg     1680
cctcagcctc ctgaatagck gggattacag gcatgtgcca ccttgcccag ctaatttttg     1740
tatttttaga agagacaggg ttttaccatg ttggttaggc tggtctctta actcckgacc     1800
tcaagtgatc catctgcctc ggcctcccaa agtgctggga tcacaggcgt gagccacctc     1860
acctggccta tattgtacag ttttgaacag tatagatgca tacctgttta caaatgtgta     1920
tgaagataga tatttttacc tcttatttgt tcaatttact ttktcttgta ttaattagta     1980
```

tattgatcta attaaaggtt aaagctaaag gctttatgaa atgtttaaaa aaaaaaaaaa 2040
aaaactcgag 2050

<210> 93
<211> 1173
<212> DNA
<213> Homo sapiens

<400> 93
tcgacccacg cgtccgaaac aaaggaaaat atccccaaag ttgttttcta gatttgtggc 60
tttaagaaaa acaaaacaaa acaaacacat tgtttttctc agaaccagga ttctctgaga 120
ggtcagagca tctcgctgtt tttttgttgt tgttttaaaa tattatgatt tggctacaga 180
ccaggcaggg aaagagaccc ggtaattgga gggtgagcct cgggggggag gcaggacgcc 240
ccggtttcgg cacagcccgg tcactcacgg cctcgctctc gcctcacccc ggctcctggg 300
ctttgatggt ctggtgccag tgcctgtgcc cactctgtgc ctgctgggag gaggcccagg 360
ctctctggtg gccgcccctg tgcacctggc caggggaagc ccgggggtct ggggcctccc 420
tccgtctgcg cccacctttg cagaataaac tctctcctgg ggtttgtcta tctttgtttc 480
tctcacctga gagaaacgca ggtgttccag aggcttcctt gcagacaaag caccccctgca 540
cctcctatgg ctcaggatga gggatgcccc caggcccttc tggttggtag tgagtgtgga 600
cagcttccca gctcttcggg tacaaccctg agcaggtcgg gggacacagg gccgaggcag 660
gccttcgggg ccccttcgc ctgcttccgg gcagggacga ggcctggtgt cctcgctcca 720
cccacccacg ctgctgtcac ctgaggggaa tctgcttctt aggagtgggt tgagctgata 780
gagaaaaaac ggccttcagc ccaggctggg aagcgccttc tccaggtgcc tctccctcac 840
cagctctgca cccctctggg gagccttccc caccttagct gtctcctgcc ccagggaggg 900
atggaggaga taatttgctt atattaaaaa caaaaaatgg ctgaggcagg agtttgggac 960
cagcctgggc tatatagcaa gaccccatca ctacaaattt tttacaaatt agctaggtgt 1020
ggtggtgcgc acctgtggtc ccagctactc gggaggctgt ggtgggagga ttgcttgagt 1080
ccaggaggtt gaggctgcag tcagctcaga ttgcaccact gcactccagc ctgggcaaca 1140
gagcgagacc cggtctccaa aaaaaaaaaa aaa 1173

<210> 94
<211> 822
<212> DNA
<213> Homo sapiens

<400> 94
ggcacgaggt tccctctccc cagagccatc ggccaggtac caaagctcag ctgtatggat 60
tcccaacagg aggacctgcg cttccctggg atgtgggtct cattgtactt tggaatcctg 120
gggctgtgtt ctgtgataac tggagggtgc attatctttc tgcactggag gaagaacttg 180
aggcgggaag agcatgccca gcagtgggtg gaggtgatga gagctgccac attcacctac 240
agcccattgt tgtactggat taacaagcga cggcgctacg gcatgaatgc agccatcaac 300
acgggccctg cccctgctgt caccaagact gagactgagg tccagaatcc agatgttctg 360
tgggatttgg acatccccga aggcaggagc catgctgacc aagacagcaa ccccaaggcg 420
gaagcccctg ctcccctgca acctgcactg cagctggctc cacagcagcc ccaggccaga 480
tccccattcc cacttcccat ctttcaggag gtgccctttg ccccaccctt gtgcaaccta 540
ccccccctgc tgaaccactc tgtctcctat cctttggcca cctgtcctga aaggaatgtt 600
ctcttccatt ccctcctgaa tctggcccag gaagaccata gcttcaatgc caagcctttt 660
ccttcagaac tgtagcctcc tctcactgaa ggtgggagct gcaggaatca ggtgcagagt 720
aggaaatgga actaacctca ggaaggtggt attgacagaa gtcaggaccc acctggatgt 780
catgctatga aacatttgaa gcaaaaaaaa aaaaaaaaaa aa 822

<210> 95
<211> 1077
<212> DNA

<213> Homo sapiens

<400> 95
ggcacgagtt ggtgggcaat agcgcttttc tctcaagggg cttttggcta tgtgctgccc 60
atcatttcat tcatccttgc ctggattgag acgtggttcc tggatttcaa agtgttacct 120
caagaagcag aagaagaaaa cagactcctg atagttcagg atgcttcaga gagggcagca 180
cttatacctg gtggtctttc tgatggtcag ttttattccc ctcctgaatc cgaagcagga 240
tctgaagaag ctgaagaaaa acaggacagt gagaaaccac ttttagaact atgagtacta 300
cttttgttaa atgtgaaaaa ccctcacaga aagtcatcga ggcaaaaaga ggcaggcagt 360
ggagtctccc tgtcgacagt aaagttgaaa tggtgacgtc cactgctggc tttattgaac 420
agctaataaa gatttattta ttgtaatacc tcacagacgt tgtaccatat ccatgcacat 480
ttagttgcct gcctgtggct ggtaaggtaa tgtcatgatt catcctctct tcagtgagac 540
tgagcctgat gtgttaacaa atagtgaag aaagtcttgt gctgtattcc taatcaaaag 600
acttaatata ttgaagtaac actttttag taagcaagat acctttttat ttcaattcac 660
agaatggaat ttttttgttt catgtctcag atttattttg tatttctttt ttaacactct 720
acatttccct tgtttttaa ctcatgcaca tgtgctcttt gtacagtttt aaaaagtgta 780
ataaaatctg acatgtcaat gtggctagtt ttatttttct tgttttgcat tatgtgtatg 840
gcctgaagtg ttggacttgc aaaaggggaa gaaaggaatt gcgaatacat gtaaaatgtc 900
accagacatt tgtattattt ttatcatgaa atcatgtttt tctctgattg ttctgaaatg 960
ttctaaatac tcttattttg aatgccaaaa tgacttaaac cattcatatc atgtttcctt 1020
tgcgttcagc caatttcaat taaaatgaac taaattaaaa aaaaaaaaaa aaaaaaa 1077

<210> 96
<211> 2092
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (637)
<223> n equals a,t,g, or c

<400> 96
gaattcggca yggcgacctt tgtgagcgag ctggaggcgg ccaagaagaa cttaagcgag 60
gccctggggg acaacgtgaa acaatactgg gctaacctaa agctgtggtt caagcagaag 120
atcagcaaag aggagtttga ccttgaagct catagacttc tcacacagga taatgtccat 180
tctcacaatg atttcctcct ggccattctc acgcgttgtc agattttggt ttctacacca 240
gatggtgctg gatctttgcc ttggccaggg ggttccgcag caaaacctgg gaaaacccaa 300
gggaaagaaa aagctttctt ctgttcgtca gaaatttgat catagattcc agcctcaaaa 360
tcctctctca ggagcccagc aatttgtggc aaaggatccc caagatgatg acgacttgaa 420
actttgttcc cacacaatga tgcttcccac tcgaggccag cttgaaggga gaatgatagt 480
gactgcttat gagcatgggc tggacaatgt caccgaggag gctgtttcag ctgttgtcta 540
tgctgtggag aatcaccttа aagatatact gacgtcagtt gtgtcaagaa ggaaagctta 600
tcggttacga gatggtcatt ttaaatatgc ctttggnagt aacgtgaccc cgcagccata 660
cctgaagaat agtgtagtag cttacaacaa cttaatagaa agccctccag cttttactgc 720
tccctgtgct ggtcagaatc cagcttctca cccacccccc gatgatgctg agcagcaggc 780
tgcactcctg ctggcatgct ccggagacac tctacctgca tctttgcctc cggtgaacat 840
gtacgatctt tttgaagctt tgcaggtgca cagggaagtc atccctacac atactgtcta 900
tgctcttaac attgaaagga tcatcacgaa actctggcat ccaaatcatg aagagctgca 960
gcaagacaaa gttcaccgcc agcgctttgc agccaaggag gggcttttgc tgtgctaaat 1020
taggatttga gggtgtggga ccctcaccra attcattgat tactgaaaat tgaatgtttt 1080
ttgggtccac atttcaaggc tgaagtgtgt agtgtatata taacctttcc tatggaaatg 1140
tgacattgag tacattttgt gttgctgttg tgaagccatt aatataaatc tttggtaatg 1200
acccatatct ctatatgtat gtgttcccag ttgtgggagc aggcactaat gaaatcctgt 1260
gcctggaatg gagatattta ggtacctgag gcttagtgtc ctgtggtctg catgtaagat 1320
agatgacatc ctagaacaaa gaagctgttt taacttaatc cccctgatca gcaggatatc 1380

```
tgtgtgttca gtgacatcat acattctgta tctagaagtc taaaatttct gccttttctcc    1440
taaagaatgt gttcttgcat tttggttgaa ataacctaca cagtgttaaa aatcagatac    1500
ctccttttagt gaccagttca aattttaata gcgataggta gcccctgaga aatttatcac    1560
tataactcca caggaaatat gacttggaag tgctctgtgt actaaacaaa ataaagcccc    1620
tctttgcatt taaaaccaaa gtcaaaacaa aactcttgta atgcaattaa ttaacttyat    1680
gtcttcccat gactcaagtt ttgttaaata tgcccaaaaa ctttgattgg cagtttcttc    1740
ggttaattat tcctatagaa tgtattttaa gaaatctata caaattggat atatgcttgg    1800
taattctcca gtttctagga ggtacctatt tctaccgttt caagtgatga agtgaaaata    1860
atttacattc gatagtgtta ctgataacaa acctacttaa gagatatgtt gctttttact    1920
taagggatag tgttgataga taaattagaa tgtatagata ggtttgtgaa agtctaaata    1980
atggctgtat agatatgtat atatggttca cayatctgga tctgtgtatt tgattttgta    2040
ctttaaatgt gacaaataaa ccttttggga gaaaaaaaaa aaaaaaaaac tc            2092
```

<210> 97
<211> 1352
<212> DNA
<213> Homo sapiens

<400> 97

```
ggcacgaggt gatccaccca cgttggcctc ccaaagtgct gggattacag gtgtgagccg      60
ctgcccctgg ccctaaatag attttaaata agttttctgg atgcacacac tagtaaacac     120
aaatgccaaa gacttgcctt ccaattctct gtctacctct aactcaggct gttgtcttgg     180
cacagttaaa caacttttct agcctcaata ttttcatctt caaaatcaaa aataaaatgt     240
attacatatg gatctatgac aaatagtgat atattccatg tgcacgttat cattaaacat     300
gaattaacca atatttaaat ctttttttct ttttttttct ttttgagacg gagcctgggc     360
gacagagaga gacaccgtct caaaaaaaaa aaaaaaaaaa aaaaaaggta attatggtaa     420
aatgaggtca ttagggtggg ccctaattct aattcagtac aactgatgtc tttattagaa     480
ttgcaagttt gggcatcaag agacacactc acgcggggaa gaacacgtga agacacaggg     540
aggagacagg gtttacataa agtcaaggag aagggcctga aacattcttc tttcacagtc     600
tcgcataagg aaccaaccct gccgaaacct tgatctcaga cttccagcct caagaactgt     660
gagaaaataa atttctgttg tttaagccat tcagcttgtg gaacttttat atgatgactc     720
tggcaaacta atatggcatt acacacaggg gataagaaaa taatccaaat aagtatatgt     780
atcaactacc ataagagcag attgagttcc tatcctaaag gaaaatacta ctattagata     840
aattttagaa atttatctaa taaagctata acaatcggta aagctcataa attttcttac     900
tgtgaactta tatatgaatt taaaatggaa aggtattatg tactaattct tgtcccgatc     960
agaaggttta cctgtacccc tcaaataact atcaccagaa tgaaggcagc agttacatga    1020
agaagcacaa agaaccacca ctaaagatct aatggtaccc aatccctttt aaagtatgtc    1080
tgtgtctata ttggttaacc ttttcttatc tgaaatacaa atgccacatg atctcactta    1140
taagtggaag ctaaacattg agtacagatg gacacacaca aaaagaacaa cagacacagg    1200
ggtttacttg agagagaagg gtgggagaag ggtgagggtg gaaaagatac ctattgggta    1260
ctatgctcac tacctgggtg atgaaatcat ttgtacacca aactccagtg acacacaatt    1320
tacttatgta gcaaacctgc acaaaacaac cc                                  1352
```

<210> 98
<211> 913
<212> DNA
<213> Homo sapiens

<400> 98

```
ggcacgagtg aatattttta aggctcttga tttgctggag gactgaaaaa aatgaagtga      60
tagtgtctga gaatattcat ttgacttatt ttttacagca tccattccct ttcatgttgg     120
gagtgttctc tttagtggct taaattcttt gcctgccttt gggagtgtgg agggtggagt     180
ggacctttg agggtcgagg gtgaatgtgg ccttgctgtt tggatagcct tttgtttgga      240
ttctggctct gggcacaggg aataacacta ctttctgagg acagtatcag gattgtctgt     300
agttcctgtg agcctgaggt gctgcatgtg cccacccccg tgtacaggcc ctgccccagc     360
```



```
cacagcccac tcacctttg accctcctgc tctgcctata cagtttgaat accagcaggc      420
tcagctggag gctgagatcg aaaacctctc atggaaagtg gagcgtgcag acagctatga     480
cagaggggac ttggagaacc agatgcatat agcggagcag cggaggagaa ccctgctgaa     540
agatttccat gacacctaag ttgggatgtg gatgtgccgg ggtgaggaag atgtggctgc     600
aaggtctccc ggctgccata ctgcatgctg caggctctgc ctttcatgac cccaggcaac     660
agccagggcc ccactcctga gagacactgg caacacctct tagttgattt ctgttttctt     720
ctcttttcac tttttgtttc taccagggta gaggccatgt tgaactggcc tcttttcagg     780
acttttattt ccccctggat ggttgttggg agggagggaa agtgttttct gaatggctat     840
taatagtatt agatcattac aacttatgta actttcaaag gttgtacaat tatacaaaaa     900
aaaaaaaaaa aaa                                                        913
```

<210> 99
<211> 721
<212> DNA
<213> Homo sapiens

<400> 99

```
ggcacgagct taaatacact tttatttgct atttctgtga agcaaactgc cgttggactt      60
cccattaaac aatgtctaga atctttgcca ttgtctctct atgctagtca cacttacagc     120
acctactttc agactcctca tctttcaacc tgttgtctcc tttcagttgc tggattaagt     180
atcatttggg ctacatgttc ccccccttgtc cctaaaattc cttcccattc caccccagct     240
attctaatgc atttaataat atgtctttgg atatgtatga tttcttcaat gtacagtgga     300
atgtattcca atttacataa atagttctac gttatttttct gttatggccc ttcaatcaat     360
tccaagtttc accttattga tctcattctt tctttccact cagtgcttaa gatgtgtgta     420
caactatgaa tgcatcctat tcatggcatt taactgcagg atggtgttct agtattcatc     480
cgaatttccc ttatctgatc cactagtgat ggtcattgtg tcaattaagg taatgttagc     540
taatggatca aacacgatga gtttactaat aggagtatca gtcatttctg gctggatgca     600
atagctcata catgtaatcc cagtgctttg ggaggctgag cagagggatt gcttgacccc     660
agattggaga ccagtctggg caacataatg aaatcctatc tctacaaaaa aaaaaaaaaa     720
a                                                                    721
```

<210> 100
<211> 645
<212> DNA
<213> Homo sapiens

<400> 100

```
ccccccccc cccccaagac tgcaatgaca aatgctcaca caacaccgag gtcggggaga       60
cgcggagcag aactccagaa atgcctgccg tgtctgcgtt ctttagcctc gctgcgctgg      120
ctgaagtggc agccatggaa aatgtgcaca gaggtcagag gtcaactccg ctcacccatg      180
atggacagcc aaaagaaatg ccgcaggctc ctgtacttat ttcctgcgct gaccagtgaa      240
gcgccctttc attgtaaaac attgtgcttt acctactacc ctagccttgt ctttaccgag      300
ggatgctagt gagtccaagt ggtggaaaat atagactgca aacaagtgct tgttgcccca      360
cacggcccag attcacttga agcagaagtt agcatcctgg gccagtttgt tctctcagaa      420
cccagaatct ttgagggtaa ggttatctgt ctgatactga gcagaaacag aatgatcctg      480
gagctttgct ttctattgaa ggcttttgac ggtaataggt ggtaacttgg taaaaggctg      540
cctttactgt agctcaccca gcatctcttt taccaaccag agagtgtgaa actagtttca      600
tatattacct agttattctt tcaaaacaaa acaaaaaaaa aaaaa                     645
```

<210> 101
<211> 563
<212> DNA
<213> Homo sapiens

<400> 101
ggcacgagat aagatcgcct taataccaga aatgattaga agtgctgatt tagattcaac 60
aaataccata tgtccttatc attttttgta agaagaaatt ggttaagtcc taactttcaa 120
tgtgtaccca aatacttgta tttatgcttt tgataaaatg tattttcagc attaatacac 180
atccgattat gccttattta tatatgaaga ataaagttac catgttatac tgttatgtcc 240
taaaattcaa atcactattt gagaaaccct caaattggtg ctttcattat ataatgatac 300
atttagacaa aaccccaaac taagccattt gaaacaagat tctctccatt gcagtttgta 360
gcaatgttat ttctgtgtat gtcatgagaa ggctaaatat cagtgttaat ttcttgtttg 420
aatccgtgaa atcatgcctg taaagcccaa acatttgtaa caaactccct aataaattta 480
gagaaagtca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 540
aaaaaaaaaa aaaaaaaaaa aaa 563

<210> 102
<211> 1324
<212> DNA
<213> Homo sapiens

<400> 102
gacagactgt tttttgcaag accacattat attactttat tattttctgc ttttttcttt 60
aacgacatta gtgtttttga tcactatatt ttaaaatgct ttttgtgagc cttttggtta 120
tgtggaatct gttccttagc tctgattttt tattcttacg gagcgtctta ggttactaca 180
tgaaggtaag actgccacag tcccccaggg aggcacactg tgtttttactg attgatttga 240
agatgataga gagcctaggg ggatgagtct attggactca aaggttacat tttgtttttc 300
catttaattt aataatcaac aaaacgacaa agtcagttta atatctttct tctgctgagt 360
cttcaggatg ttagctagtc tttcaaaagc cattgctaca aaagtgcaaa tttctcattt 420
cctgtgggtc tctasaaact ctctcaatat ttaaagccaa acaaatccat cttttctgag 480
agacagaaac taaaaaattc agagttaatt cactattaaa aacagcaagg ccctgctatt 540
tcccaagaat aaagaaattt aaaattctca ttgtaagaag tatgaacttg aagctagaat 600
tggtttattt ctggcagcta cttacaatat taagaacttt acttttttaaa tttgagacaa 660
tttcacagga aagcaagaaa ttagtctatt gtgaaatgtt tttacaacta acttggaata 720
tactgcaaat cactagtaag tagagacaca tttaagataa aatgattaat aaaacaattg 780
gtaattctga ataaggatct gaataaatcc agatcacaga ctgttccttt accaatatgt 840
aaaagaatgt gcaaaattmg taaaaatata cccaaaaatt taccagcaac agagaagcaa 900
agaatggagt tcaaccttac actataaaca tctaatagat atgtatgaaa atttaaaaac 960
tagaaaaggt tgggcatggt ggctcatgct tgtgatccca ggacttttagg aggccaaggt 1020
gggaggattg tttgagccca ggagttcaag accagcttga gcaatatagt gagaccctgt 1080
ctctacaaaa acaaacaaac aaacaaacaa ataaataaat aaataaaatt agctgggaat 1140
ggtgatgcac acctggagtc ctagctactc agaaggctga ggcaggacga tcacttgacc 1200
tcagaagtct gaggttacag tgagctatga tcataccagt gcactccagt ctgggtgaca 1260
gaacaagacc ctgtctccaa aaattaaata aataaaacaa aaaaaaaaaa aaaagggcgg 1320
ccgc 1324

<210> 103
<211> 1731
<212> DNA
<213> Homo sapiens

<400> 103
cccgggtcga cccacgcgtc cgtaaaattg aattttgcag actaaattat tttataaggc 60
tgttgctatt gaaagatcaa ttttgtcttt acctgcattt aaaatggaac agctcttagc 120
agctgtggtt ttttttttca tatttttttt aaatttgttg gctcttaaga tgaataaagt 180
ttataggtgc atctgcctcc tcttctctaa gaatatgcat actaatgttt gtttctataa 240
atcaaatata catgtgataa tatgcatgta aatacataac tatcctcatc atgtatggct 300
ctcagttctt aattgatgat aacatgattg aattgccata tatctgtatt acttgtgtga 360
atggttgtgt tgaacacgct aagaacaatt tgaattttat taagtacaaa aatccttaac 420

gtttgtatgg gaacattggc aagaaagaat agtgtgaaag ggaactgttt tagtttccta 480
tcagtaattg tacatgcagt taaatgttta aggtaaaatg attggtctct gtcacagcta 540
aaagatttca gtagccttca ttgagtttgg gtaaaataag ttgctgttct tttgtcttct 600
ttttaatata taaaagttat atttaaaaag tatataacat actatatatg ttacatacta 660
acatatatat acacaacaga aagtttattg gatttagtac tgatatttac tgtctatttt 720
tgttactttg ttcttagtaa tctattatag ttacctattt taaggtaagg tctgtaggca 780
agatatgtaa gtaaaggcaa gccctacaat tttaaaataa caaagcttat gtcttaagtt 840
gtatttttc aaaggttcat gtttttctga gtaaatgtgg tttattagca tgaaatatta 900
tgccttttac ttaaattatt ttatgtaaaa tagggcactg tttaattatg aaaggggaa 960
aatcattcca aataagagtt taatttttat taattataaa aaactctgta ttagtttcct 1020
agatgtgcta gaacaaatta ccacaaactg ggtggcttta aacaacagaa atttattctc 1080
ttaacagttc cagagactaa atgtccagac tcacaatgtc ccagtgccat gcttcctcct 1140
taggccctag gaaagaatac ttcctagcct cttcctggct tttggtggtt gccagcaatc 1200
cctgctgttc cttagcctat agtggcttga ctccaatctc agttttgttg tcaagtggtc 1260
ttctaccctg tcttctatgt ttgtatccgt gtccaaactc tttttctagg gagaccagca 1320
ctggattaga gttcaccatg atccaatatg acctcatctt gactacatcc gcaaagaccc 1380
tgtctccaaa taaggtcaca tttacagggt accatgtgtt aggatttgac atatcttttg 1440
ggggacacaa ttctacccac tacaggccca tatcttatct aggatgttgg tggcaagaag 1500
gtgaagatta ctacctcttt tgatataact agtttctgag gtatttaaaa atttggtttt 1560
aaaaatatta agctttttgc tcatttgcat gtatactttt ctctcaacat tgttttggtt 1620
tatttaggtt atttgttaaa acttcagtaa atactaaagt tacttgtatt agaacataat 1680
aaaagtagag aattaaacta cctaaaaaaa aaaaaaaaaa aaaaaaaaaa a 1731

<210> 104
<211> 1466
<212> DNA
<213> Homo sapiens

<400> 104
ggcacgagct ctacctgaat gttcccctag agtttcatac acaatgtgtt ggaaacctaa 60
atgtatcctt ctcctcagtt ttgtatttca gtgtgtggca tcatcaacat ttgacccctt 120
aggtagtgag agaccttgga gtcaacctca atgtcccatc tccttcctc tccttatcac 180
agggtgttgt tggttctcta tgtcccgggt ctcttaaaac cacctcttct cctccgcctc 240
tacagacacc aacataaatc aagtttccat cttcgtttgc ctggacaagt ggcaaggcag 300
cactgaaagg atactccttc ctctagtctt ctctgccttt tgcctactga gcccactctt 360
ctgagctgct gataaaggaa tttacatacc acacatcctt tgatgggatt gccatgctac 420
aaagcagaac ctaaatccca tgcctggacg ttaggcagtc tacattctgg cttctgtgac 480
ttttggccta atttttgcat cagccccaaa tttctgttgt gccaccatcc cagtggattc 540
tagaatttag tcttacacaa tcattccata ttcctttaat gagtccttta gcatttgttc 600
attcctttca tgtgccctat ccccgtacct ggaattactt ttcctctttt acttactcaa 660
gtcctgcaaa agccagttcc attatgctgg tctcactgac ctctttctac atatttctgg 720
taagaatgaa ttacttttctc ctgaaatacc tctgccatat tgtttaaaaa ttgccatatg 780
gtgctggaca tgagtatgtg ttcacatgtt tattatctac tctagtctca atttctaagg 840
tcttgaatat aggaaccaat ttattcatca ccttattcca gacatgatgg aactcagctt 900
tattgagaat caagtgatta tagtagatag tgaccatcct gagtatgttc atgtgttaca 960
taacaatgtt ttggtcaacc aaggactgca tataggaagg tgggctcata agattaatat 1020
ggagctgaaa aattcctaat gcttagccat atcgtagcca tgatattgta gcacaatgct 1080
ttactcacgc ggtgatgcta gtgtaaatgc tgccttacca gtcatataaa tgtatagcac 1140
aaggggccag gtggggtggc ttacaccttgt aatctcagca ctttgggaag ctgaggggggg 1200
aagattgctt gagcacagga atacaagtct agcctggtta atgtagggag ggcacgtttc 1260
tacaaaaact aaataaaatt agcctggcat ggtggcatgc acctgtagtc ccagctactc 1320
tggaggctga gacggaagga ttgtttgagt ccctggaggt tgagctgcag tgagccatga 1380
tcatgccact gcactccagt ctgggcgaca gagcaatccc ctttttcaaa aaaaaaaaaa 1440
aaaaaaacaa aaaaaaaaaa aaaaaa 1466

<210> 105
<211> 1303
<212> DNA
<213> Homo sapiens

<400> 105
aggttaaatg cgtacttttc taacctttgt tattttgaaa gttattctga tattcctatc 60
cagttgtgcc tcatttacta gaaatttgct cacatggcca aatgatgtat ccacagaaca 120
atttgaaact agacctttg gaagcgaact cctacaaact gtcatcaatg ttagcagaac 180
ttgagcaaag acctcaaccc agccatcctt gtagtaattc catcttcagg tggagggaaa 240
aggtaacatt taaggagact ggttgtaatt tcttgattgg gcctgctggg tggagtggct 300
taaagtagca tcagggcaaa aaaggtgtta ggaattctat gtgatattaa tattcatgca 360
gttagttaag aagataaatg ttttwatttt tcttttgagc acaataacaa gagctagaca 420
aaaccgaata cattctgtgt acaccaaact tctatgagaa gctaaaaaac acttttgatt 480
tcttctttct catcatacct gaatttcatc ctttggatgt gcttttacag taaaatttct 540
attaaattga aattttaata ttcgttcaga cctaaattat aagattttgt ggtatgtatt 600
agtctcatct gtttaagatg gtgcctaatg cagataatgc atcagtacag ctctgaaatg 660
cttgtagcta tttttattac tgatcagaag ggggaactgt aatcatcttg tgaagggaca 720
gttttctaag gctcaagagc tcgaaaacaa tctcaatcat ttacagggtt gtgatcattt 780
cacttgcatt aagccaacta aagttgtatt tgtaaaagta atgctatgaa tattactatt 840
tgacctagac acataggtta gaattggaaa cacaggctat aaagtatagt aattgtgtaa 900
ttgtgaaaat attaaggctt caactcaaaa ctgaaacaca gtagggctta gaaatctttg 960
aattatttat acccctcagt ttaaaaactt ccagtccagg cgcagtggct catgcctgta 1020
atcccagaac tttgggaggc caaggcaggc ggatcacctg aggtcaggag ttcgagagca 1080
gcctggctga cacggtgaaa ccccgtctct actaagaata caaaaattag ccaggcatgg 1140
tggtgggcac ctgtaatccc agctacgggg gaggctgagg caggagaatc acttgaaccc 1200
gggaggtgga ggttgtagtg ggccaagatc atgccactgc actccagcct gggtgaacag 1260
ggcaagactc tgtctaaaaa aaaaaaaaaa aaaaactcgt agg 1303

<210> 106
<211> 1516
<212> DNA
<213> Homo sapiens

<400> 106
ggcacgagag gaattgatgc tttaattttt ggatactttt tcagaatttt taatttacta 60
tggtccggcc taagatcctc tgttgtatca ggttttgtgc acaaaagaaa agcacaaaag 120
ttgaatgcac atggggcatg tgcttttctgt gcaccaaata tctggatgag gttcttttt 180
caggcctaca gtcaaatctg tgtccagaat tttttgactt ttttgctttg tataatcata 240
gaattcattg ctgctgattt ctataatgat tcatgttgtc atgtgtctct taataactga 300
gggctgtcag taacctgtga ttttgccttt tctatagtct tactcccatg aagaaccttg 360
gttctgatgg agaaagtgaa aagctttatt tcttccccta gatatcttta tatttctatt 420
atatttttta gttgtgtact gtgtactaga gatttttttc agtttgttat gaacacaatt 480
tggtaagccc taaattggtt ctgcctgtct ccaaacagaa acatctgtac aaatcttgtt 540
ggtatagact actttctgga aaatggtcaa gataagttca tgttttcttg aaatttctaa 600
gatagtatat ggtatcactt gtttaaagca aatcagactg agtttgacat ttaattcaat 660
atttctggta ttcagtaacg ggtatatatg tttgttcttc cagtttgggt cagtttaaaa 720
gatatgttgc aaagtataca tagaaaatgt gagcaatgcc tctctttgcc ttttgatcag 780
aaacttcagc agagcggtaa ggattccaca tgatttaaac tgaaatgctt ttctttgttg 840
ctgtaagaac ttaaaatgta aaatacctt ttcagtttaa gtcctgtaaa caacattgaa 900
gcatggagat gaggcaagga atagtactca ctgaagttga aatgactgcc cacttcaaaa 960
tcttcattgt gtttacacac cagtgtattt atacaaatca gaggcatttt gtagatgctt 1020
tgctgacttg ttcagctctg taaaaacaca gaaatcagac ccattttgta aagcggaaaa 1080
tcatgttaca tggaacatgt cctgtatata tcacatacat ggtaatggag tcttaatgat 1140
aagtgcaaga taataattta atgatgggat tagtctgatc gcttaatatg cacaatcctg 1200
gaagtgaatt acttgcatca gatatagtga tatttattat tctgtacaga gagaaaaata 1260

catataaaac atatgcttac attacatgca cgcggatttc atgctccata atctttttcta 1320
ttttttaatt tacctttctg taaatgatgt gcatggaata tgccttatag aaaaatgctg 1380
ttcataattt gactacgtgg aaaagtgcct atatggtggt aatgctagta aggcaaataa 1440
gacaaattat catgttggtt tactacatca ccagttaaca ttttatattg tgatgtttaa 1500
aaaaaaaaaa aaaaaa 1516

<210> 107
<211> 1689
<212> DNA
<213> Homo sapiens

<400> 107
actatagaag tcgcctgcag taccggctcc ggaattaagg gtcgacccac gcgtccgggc 60
taattgtttg gtcagaaatt cctaaggcca cagctttggg gggttcgtgt agatgtacat 120
ggtgggtggg ttataaatat tgggacttaa ggcagcttgt tctatgtatt tatctttgct 180
cttgggtgac ttagggaatg attttatttg atttaaccct ctttctgttt gccccgagaa 240
tactcgccag tggcgcttgc agttgtagca tttaccccaa gataactttg cctacgaaat 300
atttcgcttt tattatttyc acatcattct agtatatgga ctttggaaac aaaagacatt 360
gttctattta tagcattctt ttttttttt tagtagcggt atttccattt acaaaatata 420
gtaactcttg attactgaaa atgtcaaatc ctagaaaacg tagcatgcct atacatgatg 480
ttaacatcat tctcgaacag ttgttggccg aagattcatt tgatgaatcc aatttttttg 540
aaatagacaa ttctgatgtt ctctttagaa ataactcagt ttttatcttt tttcacattg 600
aaaatcagtt agatttgctt aagcctcaaa gagaatgttt atgtaaatta gcgctggcaa 660
ttttttttt tctaaacagg aaaagggtta aatgaaggtt gataaaatgg atgttcaatt 720
gtctttctga aagtgagtgg cttgaaggga tgaataaata ttttcttaat atattcaaaa 780
aagtgcattg ctttctgtga tggaagttaa gacctaaatg tctggaagtt gtaaccctca 840
acacagcttt tcctgatttg ctgcaaaggc acatagctga ttatagaagt gaagacggca 900
aggacgggga ctccaacaaa ggaaaccctg ttgcaggatt tgggaacttt catgcttcag 960
atgaaattca ggcatgtgag catcactgca gaatgtggtg catcattgcc atcatgagta 1020
atcacttgct gctcctactt ctgagaccaa gactcttttg tcatattctt tagcaatagg 1080
acgggtaaag actggattta attgctgttc agagtataaa aactcaattg attccaacat 1140
atctgaatgt gcagtaaagt cttaaaagtc aaccgttaat cattaagtct tttgcctcta 1200
aagtcttttg cctctgaaga agtttattac atgagttgat tttcatattt tcattttggt 1260
ggggttttcc tgttgttggg caaggtgggg tcacaggaca tgggactagt aagcatttta 1320
ctgtttacta tatttgtctt tttataaaca gtatctccca aaatgtgatt agaaggctac 1380
caagcctgta tttggacatt taattgtgtg ctttatataa tgtaactact aacagtattt 1440
ggactgcctg ttcattcctg gagacaaaaa tgaaaatctg tcagttcaag ttcttgggta 1500
acatcaagtc attagaattt atctaaagct tatcatgatt tgataagaca tccattgcat 1560
gcagctgttt tagctcagtg caaaacactg aaattgtgat tcttagactg tttctgagac 1620
atttggatgg aaataaatgt ataaatgtta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1680
agggcggcc 1689

<210> 108
<211> 1943
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (161)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1926)

<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1928)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1934)
<223> n equals a,t,g, or c

<400> 108
ggcacgaggc ttggctaagg tccgcgggaa cccgtgagcc accgagagag cagagaactc 60
ggcgccgcca aacagcccag ctcgcgcttc aggtcccggc gccgtcgcgc actcctccga 120
tggccacaga tgtctttaat tccaaaaacc tggccgttca ngcacaaaag aagatcttgg 180
gtaaaatggt gtccaaatcc atcgccacca ccttaataga cgacacaagt agtgaggtgc 240
tggatgagct ctacagagtg accagggagt acacccaaaa caagaaggag gcagagaaga 300
tcatcaagaa cctcatcaag acagtcatca agctggccat tctttatagg aataatcagt 360
ttaatcaaga tgagctagca ttgatggaga aatttaagaa gaaagttcat cagcttgcta 420
tgaccgtggt cagtttccat caggtggatt atacctttga cggaatgtg ttatccaggc 480
tgttaaatga atgcagagag atgctgcacc aaatcattca gcgccacctc actgccaagt 540
cacatggacg ggttaataat gtgtttgatc atttttcaga ttgtgaattt ttggctgcct 600
tgtataatcc ttttgggaat tttaaacccc acttacaaaa actatgtgat ggtatcaaca 660
aaatgttgga tgaagagaac atatgagcac atgagttaag attgtgactg atcatgattt 720
atttgaagat ggagcactgc tgatttatga aggaaaaaag aagaattttc taaagattac 780
acatatttca gaaagacttt acccaattca gttgtcagac ataatgattt atttgaaggc 840
ttgttttatt tgaagaaaag catattgcca aaaattctgg ttaaaagctt cctaacgggt 900
aacagaccat gggagagata tgtggttggg taatgcaaat gtagttatac aaagaaaaat 960
acagatgtct ccagacctga ggacttttta atagggcagt tgttgtgttg gtggcacatt 1020
ggatatttct aacatgtaca aagctatgta ttttgattta ctttcatttc ttgctatgta 1080
tatgtacttt tcttaaaatg ccaagaactt tctcttgcta tcattgctcc ttttgaaaca 1140
attcaatttt catgtctaca gctgactgtt ttgttaagat tgagtcatcg acattcagga 1200
tttaagtctg aggtagtcaa ccctcaggaa aaaaaaaatg gcttatctga aatcagtact 1260
gtggaaatga actatattag ctattatgaa taatgtccag tataagaata tgcttctgga 1320
attgagttct ccttttaagt accaatgata cttaaatttc tcagaaatgt aatggtgtgt 1380
cattgccttg aaatgcttgc ttagggcttc ttttatgtta tcttaaaaag tgctggtgaa 1440
ttttccattt tttacatcca tttcacatgt aagagacaaa aaagtctaga ttggtcttga 1500
tattgagata ataaaaagta agtagcatta agaaaggtaa caatcttcat tctacagatg 1560
aactcattga aacaatttag gggaatgagg ggcaaaaggg gagaaatact gctaaagaac 1620
atgagcataa aaatgcgtgc gtttcagtgt ttaagaaggc ttgataaaga atgtcacttt 1680
tttatttaac tgataagatt tttgttattt tttactttga taagtaaacc aaagaatatt 1740
tgtatttcaa gcagtttgtg tggtgtttct atataatttt ctgtgtataa ataataaagt 1800
aggcatttgt ttattttgta aaaaagaaat gaaaatctgc tggccagcta tgtcctctag 1860
gaaatgacag acccaaccac cagcaataaa catttccatt gtcactgtaa aaaaaaaaaa 1920
aaaacncngg ggtnctttg ggg 1943

<210> 109
<211> 1594
<212> DNA
<213> Homo sapiens

<400> 109
ggtggattat ctataaattt tggaataaat gacttttcta ttttttttct tattttccag 60
aatactttgc attaaaaatt tagatcttct tacatggaag aggtcaaatc cagttatagc 120
aaaacacctt tactgcagag gccatataac caaaaagtcc aaaggcccag cccagtggac 180

catttacttc agtgatgttc agtacaaaat ttcactgcca ttaaagactt tggaaagtcc 240
cttttaagtt gtaacaggat ttgactatta gtgtggattt cgataaccct tctttagtta 300
atgtaataaa tgctctttga agctggaaat atactggttt cttgcaccct tgtagttttc 360
tctgggcttt atgcaaaaga tgtattttct gaatgtctta gtatgttgct gtcttttac 420
ctgcctgggg ttgccttcag atgtgggtga ggacttgttt acaaaaagtc ctagaagacc 480
ttaagttaaa attagctctc caatttttcaa gtgtttttctt ttggcagaat aagttttggg 540
tcctatgaga ggtaaatagg ttggktgcct ctcttgctat agcccatcta gagcagaaca 600
aaaactttgt ttttgagggg gatggagtta ctttttacct tgtcccctaa ttgaatatat 660
ttaggacttt tggttttaga aatctcagag ttctatagtt ggaatagtgt cacagagata 720
gtgttaggtt tcttaggcaa caaaattgga gtgttaccta ttgcccatct gggcatggct 780
ttgatgagtt ctatataaat aatgagtgta gcctaatttt ctgtcatgtg ctacctagca 840
tatacatttc tgacagtcag gtggattatc ttgaaatttt agacaaactt tctgcctcct 900
tggaaagctc tacatctcct tgtgattgga gtgtgggttt caagattcca gaargtgggt 960
gtmttcattt tctattttca atgcactcta aagatgacct gcttacaggt tctctgaggc 1020
agacctcagt tgctcttgtg atatgtaact ttgctttgat aaggaataaa caattacata 1080
tccagataat gatacagaat tgtcaaaatg tttaatcatt aagccactac aaatagacat 1140
tttcgtggaa taaactgatt ttgaaatgtc tttcaattta tattgaaata tctgaaggca 1200
cctctaaaat ttgggtgatg acacagaggt atagattata agatttaatt atgaatgggt 1260
ggtatactgt gaagactacg gaagtgagca gaaagatatg tttggctttt ttggttttta 1320
gttagagatt ttaaaaaggt ctgtgaaggt caagttgatc attggttttg attgcatccc 1380
acaggtttct ataaactggc ttaaaaatgg catactccat tttctggtgt attcattgta 1440
actttaggaa gtatttgaaa tggtcacatt aaagtctagg aatgtcaaat tgtattttaa 1500
tgcgttagtt ctttttcttt ttctttttt ttggagacag cctgggcaac aagagcaaaa 1560
ctctgtctca aaaaaaaaaa aaaagggcgg ccgc 1594

<210> 110
<211> 1742
<212> DNA
<213> Homo sapiens

<400> 110
ggcacgagct cgtgccgctt tgtagtctag ggagtttaat taaagtaagt ggagacaaaa 60
gtactctttt gagagctgtc atttctctta gtgtgacgct attaataatg tagtgtaatg 120
ctattttgga agtttggttc tttccttttc ttttgtcttc ctctgactct tttctgtatt 180
ctaaatgaaa ggggaataat gcacttagag gggggcactc tcctaaattc actgtctcat 240
gtacgacatt atctccgact tcggctctca tgttttgaaa aaatacctct tcatcgctct 300
atttttattt ttcttcttct tttattgtga atctctttta ccaaaaacat ttgtagggtt 360
cttcacaaag attttttttt tcaatcagga tgaaaactag atcatgatgt gaccatttca 420
ctgtgagtgt aacttccctt tttgacagct ccattagatc tgccaggtta taaatcttca 480
tatttctgac ttgccttgaa atcagaaagt gttttcatta tgctagtctc tgtgagcaac 540
aagcatgaag gaaggcatgg caggtatcat agccccttg atgaacttac ctgtttcaac 600
tcagtgccag ggcagaacat ttactgctaa ccctgatggg tcaactttga ttgcaaatta 660
tgtgtggtac attttgaatt taaagaatgt ttctgagatt attctacgat cacttgtcat 720
ttttatgtgt gcagtaatgt gttgtgtata acttggattt caacaatatc cattgtttga 780
aagttagaaa atattctaag aatactaatt atcttgctca aataatcatt taagtacaac 840
tgtcacttga ttatggtgaa tatttttaag taaaattata tatttaaggt gtgctacctc 900
taattttatt gtcatacaaa aagcagatta ttgaacatgt taatgtaaat tgtactttta 960
atttttcca gtactctaga acatgtgtaa ggttaaaaga atttaaatta cccaggtttt 1020
tctttttaca taataaataa gaagaaatca caaaggaagc agatattata ttgtttttaa 1080
tatacacatg aaattgtttg actttatttt gagacctcac acaagtataa acatggcagt 1140
ggtgtgtatg atcaaagtaa gaaattaaag agttaccggt tctttataaa ccagaagtcc 1200
attgactttt aataatgctg tctcaaatat ttgatagtaa attgtggaaa taatcaaagc 1260
tgagcctatg ggactgtact ttgtagtact gtttaattta ataactctaa taatccctta 1320
agaatattag gaaaaatagg ccgggtgcag tactcacgcc tgtaatccca gcactttggg 1380
aggccgagga gggcggatca cctgaggtca ggagttcaag accatcctgg ccaacatggt 1440
gaaaacccat ccctacaaaa acacaataat taggcaggca tgatggtgag tgcctataat 1500

```
cccagctatt caggaggctg aggcgggaga atctcttgaa cccaggaggc ggaggttgca    1560
gtgagccaag attgcgccat tacactccag cctgggcgac agagcgagac tcctctcaa     1620
aaagaaaaag aaaaaagaaa aaagaatatt aggaaaaata tcttaatgca aaatatatta    1680
attagtaatc tgccaacact gagatgtact ataaggccaa gaagaaaaaa aaaaaaaaaa    1740
aa                                                                  1742
```

<210> 111
<211> 1501
<212> DNA
<213> Homo sapiens

<400> 111

```
ggcacgagcc tattttctgct tactgtgtta ccagagagcc tgggggtctg gatcctatct      60
ggccccgtca gggtggattg ccaaatgagc agttctcttg ccccagtccc tttcctgtgc      120
tataaataag ccccatgttt attttcttat gttattgaaa tgagcacttg tgatttgggc      180
ctcttttgag gagtccagag agcgtccatc cggtgcctgg tgagggccct gcatggctgg      240
ctgctgtctg aagctatttg gagtcctctc cctgtgtttt ctatgtggct taatttcaat      300
agaaagggtt atatgcaacc ctgtatctgc tgattttcag gtttcaactt tctgccagcg      360
tcactgcctg cttagaagta aagttatgtt tcccataagg ggataacagc cacaattgag      420
gtaattaacg aaaattgtac attggtggca gcacctccta taggatttcc aatagtcttt      480
ctctagtaga tcattggggg ctcaccttga tctcctctct tctgtctacc ctgcaccaaa      540
ataccttgtc ctgttttctg gatatagttc caataatttt tttcctaaca gccttttttgt      600
caccagttgg tttgatatct tacaacttgg ccaaatgagg gttccattaa ctccatcttg      660
tctaatgcat ggagaattca aggatttttt ttttcctctt ttcatagcac cttccagttg      720
ccagttgtac cctggccctt ctttggaagt cataatgatg aatatccatt aataagagat      780
tgatgctctt tcaactctca tgtcatctat accatctcag tggagaggat gactttggat      840
gaggttggaa tacaaaggaa acatttggaa gtccactgca gtgtattata tgctgtgtgg      900
aagtctgggg gttaggaaat acctggaggg agaacttcct aagaaatgat ttttggttct      960
tttaggcctt aacagcacaa taaaagtatc ccatgagacc attatgagca ggacacgaca     1020
ttgtttcaca ccttgggctg tgactattta cttctcggta cagattactc tggttaaatc     1080
actcagtaaa gaaatctttt catgctcaca atctgaacct gaaggctatt actgaagaga     1140
attgcatctg acaacaaaat ttaatttact tccagagaaa ggaccagaag aaagtaaatt     1200
ttcatttatg tttttaagtc tattgtctta aaaagattct tttcccttaa aaaataaaaa     1260
aacctgatgt gatgggttcc ttcagtcaac aaatacttat tgagcagtta ttgtgtgcca     1320
gatactgttc ttggtgtgag gatatggcac tgaacaaaac aatgtaccta ctttcgtcaa     1380
gcttacattc tagtgaggaa gataaccaaa acaagtgact gaatataatt tcaaatgtca     1440
ataaatgctg tgaagaaaat aaagtcagag tattatatgt aaaaaaaaaa aaaaaaaaaa     1500
a                                                                    1501
```

<210> 112
<211> 791
<212> DNA
<213> Homo sapiens

<400> 112

```
ggcacgagct gcatttgatc tcattcttta gtccaatgta agtaagagta aaacaatgac      60
atttaaggcc accaggctat tctcattttt ggaaaaatgc tggattacat taccagcata      120
ttaaatgaga atatcaaggt gtaatatctc cctagaaatt gtctcacctt caatactatt      180
gacatttttg gacctgataa ttttgttgtg ggctctagcc tcatgttata ggaggtttac      240
cagttttcct gccctaaact taccggatgt gaatagcaca ctccactacc tacagcagta      300
aaaactaaaa ttgtctctaa acattgacaa attgtccctg gtagtgaaaa tcacccctgg      360
ttgagaccgt gttgttgaaa ataaaacaaa aactttcaca tcaataaata tgttaggctg      420
tgtatgttaa ggattaacat taagacaata tggagcaagc actacatgaa agcagtgacg      480
attggggaat tagtggcaca ttatcctaat agttaatata gtgactgtaa tatctaaata      540
tcatcctata gagtttttct tagatttttt cattagtata acaggatgtt gtgtatgtta      600
```



```
cactgtatat actgttattt tgagagacaa ttttgggaat tttgccaagg tattttcaat      660
tataggtctt taatacattc taagcaagtg ggtctcaaaa atgggaattt tacaccccac      720
attcttcttc ccatccggtg gacatttgtc aatgtgcgca aatatttcctg attaaaaaaa      780
aaaaaaaaaa a                                                           791
```

<210> 113
<211> 1637
<212> DNA
<213> Homo sapiens

<400> 113

```
ggcacgagca ccactccctg ctcttctgca ccccaaatct tctttgttgg gaaaagaggt       60
aggagggagc tggctgggag gctcctagtc tgttgggaag cagtggatgg tggctcctct      120
ccatctcttc atccctttct cttggctagt gaggacaata gggcaattac tgagtcctgt      180
gggcaaggca ctgagtcatc ggtcgaatca gatgatgccc aggtcctggg gatgagtgag      240
tcactcttaa tgggcagctc ccaagatgaa tgttgagagc atcctgcctg gctttatgcc      300
tgcaagccct ccccgtaatc tccttccttc ttgcaggtgg gcaggaagaa gcagggtaga      360
aaagttagat tcctaatcta actcctaccc ctcaacccca agggaccttg ttggtcaata      420
gcgaaggaac tgggaaggat gttcaaaggc tgaggcaggg cacagatgtc acatttcatc      480
tctgtggaag gtgggctgct caggccagat ggatgagctt gtttgtgtgt gaatgttcct      540
ctcaccttcc tgatggtgag gggggcgatg tccacttcca gatgctgcca agtagacttc      600
ctgttttctt cctcttgtcc ccccccgct tccttttat atttacaaag ctctctggtt      660
atgtacagca gggaaatggt gcctgagaga ctccttcaga tagcagttcc ttctagtttg      720
agtcaggagg cactgcgtcc ccagagtccc tgcatcctca ttcatgaaat gctggcagtc      780
aagggaacag ccctggctat ctcatgaggt tggccttagg atttaagtga gataatgtgt      840
ttgacaatgg aatcccagca tgagcttggg tttcggcttc attaaaaaat tagaatttat      900
tgtagaaaat ttagaaaata gacagaaaaa ataatcctag taccttctct tactatttga      960
tgtatatccc atatttttt caaaaaaaag aaataatgat aataacatga tagtcatgta     1020
tcaatgcatt ttctacttt gatggttaca ttattattat gtgagagaag gtcttatttg     1080
tggagataac aactacaaaa agtatttggg ggggtgatgg agcatcaggt actcactcaa     1140
atggttgaga gcaaaaagtt atttgtactg tacttttct taactttgtg aatattttga     1200
aataaaagta cgtatgccat ttggagaaaa gaagatagca tagtggtggt tttttatgtc     1260
tggaatatcc atgtctgtct attccagtgt ctggaatatc catgtctatc tatccactgg     1320
aatatccagt gtctcagttg agggtactta aagggaaaaa cctcccacac ttgactttct     1380
ttgaagagtt tacaaagatt tgtaatttca gcctgggcaa catggtgaga tcttgtctct     1440
atatgaaata aaaaaaattt aaaattagct ggatgtagtg atatgtgcct gtggtcctag     1500
ccctaggag gctgaagcca ggaggattgc ttgagcacag aagttcaagg ctgcagtgag     1560
ccatgaagtc tctcttgtat tccagcctgg gtgacagagc aagaccctga ctcaaaaaaa     1620
aaaaaaaaaa aaaaaaa                                                    1637
```

<210> 114
<211> 1588
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (778)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1150)
<223> n equals a,t,g, or c

<400> 114

gggaacgttt tcccagctga accacatgtg acgaaccaac ccatttatag tctaaaaatt 60
atgagaacaa gtctcttttt tttcttttct aaaaacatct tggtactttg tggtacattg 120
ctcatctcca gaagttccca ttcccagagt gccccgcgag gctgttggtg gccacataag 180
tgaccacagc aggccctgga atgcaagctc ttttccccgt ggctttggag cagaggggag 240
tcagctgggt ggccttgtct cctgaggggc attggccagg gtcacactcg gttttctagg 300
gaccaggctg ttccatgggg tggagaggca gtaggccatc cctttctctt catcttttat 360
ctagcccttc cccatacaaa cactttctca cagaaagact tgtttgttgt cccctgagca 420
aggccacagc tctcccacct atcttctgtt caggttggca gatgggttca ggcaagggtc 480
attctgagag gagacctcca cccaatgctc ccgtctgctg gcttggtcac cctgagctgc 540
tgcctgaggg gccaggaaag tggctggtgt ccccggcctg tgagagatgg ccagagcctc 600
agccagaccc accctgccag gagaaaaggg gagtggccgg agaagccacc ccttgagagc 660
aggctgggct cgcccttgtg cccaggaggg ctgcacaggt gcagttgcca ctttcagacc 720
acacacttca agctagagct tggcctgtgc ccctggtggt tgggggttgg aagarcanac 780
tgtgttgaca gggtctktaa ttcmcgattc caggtgcttc tgawttgttg gatcctgatg 840
aatcgcaatc aggactatgt ttggcttgag ctccagcctc atgaccacca accccatcga 900
atgactgaga gctgccaggc tcctgccacg ttggagctca saatcctccc gtggggacac 960
tgtgctgcag ccagcctcca gggagccgct tgttttatgg cctaaaaagt ctctttatgc 1020
tgagaaggtc acactggact ttgctcacac agagatttga cccaagaaaa ggaataaaga 1080
kgccttggat accctgtctt gcccctgttc ctgcccccgc cgtaccctgc tggctcatgs 1140
cagaagamtn ggaacttgct gtctgtgggc atgtttgttg tcggctgamg gtagcaccca 1200
cagcactggc cgtgtgtgtg ccacagtcag gaacgargtc ctgcccccca cccattaacc 1260
cattagcttt gtccttactc cttgaggccc tgcttgaaaa gattaatggt gctttgggar 1320
gctgaggcag gaggattgct tgaggccggg agctcgagac cagcctgggc gacatagcaa 1380
gaccctgtac ctccaaaaaa taaaatataa acattagtca ggcatagagg cacacacaca 1440
cataggccta gctactcagc tgaggtagga ggattgcttg agcccaggag ttcaaggtta 1500
cagtgagcta tagtcatgcc atcatacact cagcctgggt gacagagtga gtccttgtct 1560
ctggaaaaaa aaaaaaaaaa aactcgag 1588

<210> 115
<211> 1926
<212> DNA
<213> Homo sapiens

<400> 115

taaccatgtt cttaacatct agatgcagaa atggatttga atgtgatctg cagtttctgt 60
cgtagttatg aaatggcttt tgccaacatg ggttacccca aagcaaacat tgcatgctat 120
ggaaatactt cttgtctctt tttctcccat ggtatctgta ttgcttcttt aataataaca 180
tcatgtttta cagcctgcac tctgtgccca tgtttattca acccttttta ctttggtgac 240
tgtttatcag atgtgttgcc ttgttcttcc tgccctccag agcccatgtt tttaattata 300
actgaaatat gaaatgataa tatttgggct ttatttcttt tctttaaagg acagtactgc 360
tttaaagaga cagtgttaag gatcttggaa gcacagccaa catgtgtgtg acatggaaga 420
agccactaac caactcctag atgtgaacct acatgagaac cagaagtctg ttcaagtgac 480
agaaagcgac ctcggaagtg aatctgagct tctagtcact attggagcca ctgtacctac 540
tggctttgag caaacagctg cagatgaagt cagagagaaa cttgggtcat catgcaaaat 600
cagcagagac cgtggcaaga tatattttgt catttcagtg gaaagtctgg cacaggtttg 660
aatggagcaa tacttaaaat agttttctaa gttgatcatt ttatggttac ttttcatttt 720
atagaccctt ctggaatcct ttctgatttt cattgctctg ccccaaatca ggtgatttta 780
aagttactgc attttctatt gagtactgat ttgtaatttt gactgtagtt tcagtatccc 840
ttaggaccaa aagtgtttca gatttttgga ggggggtggg gggagttttg gaatatttgc 900
attatacttg ccagttgagc atttcttttt ttttttcttt tctttgagac agagtcttgc 960
tctgtcatca ggctggagtg caatggcgcg atcttggctc actgcaacct ccgcctccca 1020
ggttcaagca attctcctgc ctcagcctcc ccagtagctg ggactacagg cgcccgccac 1080
cgcatctggc taatttttgt atatttagta gaaacggggt ttcaccatcc tggccaggct 1140
ggtctcgaac tcctaacccc gtgatccacc cgcctcgacc tcccaaagtg ctgggattac 1200
aggcctgagc cactgcgctc ggcctgccag ttgagcattt ctaatctgaa aatccgaaat 1260

gctgcactga gcatttcctt tcagcattgt gttggggctc aaaaagtttc agatttttag 1320
atgtgggctg ctcaacctgt agtaggattg ctacattttt agaggtgatc tagtatttct 1380
tgaggattga attcaccaga aagaatactg ttcaacttaa gaaattctct aagtatctca 1440
gtatttattt acttcagcat atagcagatg tttaaccttt ggtgatgaaa cataaaagag 1500
attttccttt taatttgcat caaaaattct tgctcagaag taattaggac tcactcaagg 1560
taaaaagtga aggtcagaaa actgcaatct cactatcata aagctgatat atctcattac 1620
cacataagca gtgagagggc aaggattgtt gtctattttt ttttccacca atatatccca 1680
cgctcttagt gtctggcata tagtaggtac ccagaaaata tctgtgggat gaattggtaa 1740
gcaaatgttt tccatccaat attttagcca ataccctcag cagctttgtg aagataggca 1800
ctattattat cctcattaat cattaggctt aggacacata aataatttcc ccagggccac 1860
tcagctagta atcacagaac tggagctcaa atccccctgca aaaaaaaaaa aaaaaaaaaa 1920
aaaaaa 1926

<210> 116
<211> 1063
<212> DNA
<213> Homo sapiens

<400> 116

ccacgcgtcc gaggagaaca agtggactcg ggtagcttct atgagtacca gaagactagg 60
tgtggctgtg gctgtgttag gagggttctt atatgctgta ggtggctctg acgggacatc 120
tcctctcaac acagtggaac gttacaatcc tcaggaaaac agatggcaca ctatagcccc 180
tatggggacc cggaggaaac acctaggctg tgcagtatat caggacatga tctatgctgt 240
aggaggtaga gatgacacta cagagctgag cagtgctgag agatacaacc ccagaaccaa 300
ccagtggtct ccagtggtgg ccatgacatc acgccgtagt ggagttggcc tggcagtggt 360
caatggacag ctcatggcag taggaggttt tgatggcaca acatacttga agaccataga 420
agtttttgat cctgatgcca atacatggag gttatatggc gggatgaatt accgtcggct 480
agggggtggc gtaggagtta ttaaaatgac acattgtgaa tcccatattt ggtgaacaca 540
gagaagacag tcttgtatat attcctctgt attctgggga gctttgacct tggagctttg 600
tacagcttga gaaaacatta gaacaaattt tattatttgc cggtgcctca acaaatggaa 660
atacaatcca atgaaagtac ttcacctgca agatgcacaa taattttcaa ctctgtgcag 720
aagaatattt atttttggtt ttaatttatc atggtttttt gttgttttcg ttttgaactt 780
atccttcctc ccacaaaaaa agaaaagaag aaaaaattcc aagcagcaaa acttactttg 840
tttgtaaggt attcatttag gtttgaaaat actatttaat aagggcagaa gggctatata 900
tgatttggct attatttcta gacactccat ccacatgatt ccactaacaa ggattaccag 960
gaataaaggt aggtatgcaa aatgtattag ctacccatta ttctcgcact aaccaccaga 1020
agacttgaaa atcttaaaaa aaaaaaacaa aaaaaaaaaa aaa 1063

<210> 117
<211> 1615
<212> DNA
<213> Homo sapiens

<400> 117

ggcacgagct cgtgccgctt aagtttacag gttcagatag cttttctcac accataggac 60
tcgtctatca tttttgtgta gtttttcttt tttaatatgg cttgtcttat cagatttcct 120
gctattggtt ccctccctta ttccacctgg ccctttcttt tctttatctt tttatttttc 180
tcctgtttaa cttttattcc attttctcca ctttcttctt tctgtgagcc atacctaga 240
aaagaaccct agtgggccag agttgagatg caaattctta gactactcta gcccccttgaa 300
ctcactccat attggcaaag ccagaaatcc tgactgtttt acttgctgtt ctcaaatcaa 360
tccatcttac tttccaggga atatcttctg tctgctttgg atatgattcc agaagccatg 420
tcacttctag taaattactc tgccttccct gtacactttc aaatttccta gggcctcttg 480
catataaagt ggaaggtctc atctctaaat ttctagtaga atccaactaa aaacacatac 540
cctgagctga gacccttctc tgagcaaagg aactcaccca gtcactcttt ggaactttca 600
agtcgtgctc tttgtacgta tcatatatac tatgaacttg ttttctcctc attgaaagat 660

```
aagatgtcag ctttgcatgt ttcctttatt ccagtggaga tccttcaggg tttggtgagt      720
ggaaatctgg gaggcacact tgggccgact gtcagcagcc ccattgagca agatgtggtc      780
agtcccgttt ccctgccccg gagagcaaag acctttggag gatttgacag ccgcttcagc      840
aaggtggtga ctattctggt aactatggtt acaataatga caaccaggaa ttttatcagg      900
atacttatgg gcaacagtgg aagtagacaa gtaagggctt gaaaatgata ctggcaagat      960
acgattggct ctagatctac attcttcaaa aaaaaaaatt ggcttaactg tttcatcttt     1020
aagtacattt tgctgccatt tgtattgggc tgaagaaatc actattgtgt atatactcaa     1080
gtctttttat ttttcctctt ttcataaatg ctcttggaca ttattgggct tgcagagttc     1140
ccttattctg gggattacaa tgcttttatc gtttcaggct tcattttagc ttcaaaacaa     1200
gctgggcaca ctgttaaatc atgattttgc agaacctttg gttttggaca gtttcatttt     1260
tttggatttg ggatagatta cataggagta tggagtatgc tgtaaataaa aatacaagct     1320
agtgctttgt cttagtagtt ttaagaaatt aaagcaaaca aatttaagtt ttcttgtatt     1380
gaaaataacc tatgattgta tgttttgcat tcctagaagt aggttaactg tgtttttaaa     1440
ttgttataac ttcacacctt tttgaaatct gccctacaaa atttgtttgg cttaaacgtc     1500
aaaagccgtg acaatttgtt ctttgatgtg attgtatttc caatttcttg ttcatgttaa     1560
gatttcaata aaactaaaaa atctattcaa aacattaaaa aaaaaaaaaa aaaaa          1615
```

<210> 118
<211> 1221
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (697)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (700)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (701)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (712)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (720)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (722)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (742)
<223> n equals a,t,g, or c

<400> 118

```
cactagtgga tccaaagaat tcggcacgag gagagacttg catagatcag ggagtatgtg       60
aaaataaatg tcagttgcca gagaaagaat agatcaaaca gtttatttga atttctgatg      120
agtttggtga ggaagtgtat agcacttaac atttggaagg cagacaaaag gttttgttgt      180
tggtgttatg ttccttttga attttagata cataatgcga ttttttttct ggccaatgct      240
ccaggcaaaa ttgatgtctt tccactttct aaaacccatc atatttatga actctctgat      300
actctgtctg aaacagtcgt gctcctgtga ggttgaaata tctctcctgc ctctatcaca      360
gcagacgcac agaactgatc tgggattttc tcactcagga tcccaaaatg agccctttct      420
caatcttgac aaacgtgcag cagaagccca ttgtgcagtt atggttctgt gcctgctggg      480
cagggattta aaggccagga gaagcaggga aggccctgct ctctgctcca gccaggtggt      540
aatatgcatt ctcaaactag ctaggaaaag gttctagatt cctttgaatc tattgctgaa      600
tcccactgat tagcttttcc cactgacaga cattcaaatc tttgtttttg gagcttcctc      660
tgcagacttg gtgtaaattt caaaaaaaga aaacaangcn ntgaagctta anacaggcan      720
anacagttgg cttcctacct angcatgctt caaactcact atatgacttg gtaaattctg      780
ttactttaat gcatgcttgt tttcacatgt gtaaaatgag agagtatcag actagatcat      840
ggatttgttt cccctctttt tccccttctc tctcgaagag tagaaccctt taaattaaat      900
cttttataaa agttaagtgg ccgggagctg tggcccatgc ctgtaatccc agcactttag      960
gaggccgaag cgggtggatc acctgaggtc gggagttcaa gaccagcctg accaacatgg     1020
agaaaccctg tctttactaa aaatacaaaa aattaggcag gcatggcggt gcatgcctgt     1080
aatcccagct actcgggagg ctgaggtagg agaatcgctt gaacctggga ggcagaggtt     1140
gcggtgagcc gagatcatgt ccattgcact ccagcctggg caacaagaac aaaaatccgt     1200
ctcaaaaaaa aaaaaaaaaa a                                               1221
```

<210> 119
<211> 1149
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1120)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1140)
<223> n equals a,t,g, or c

<400> 119

```
gggtttctgg ggattggatt caaagagcag aagtatgatg ccaggggctg gtaaggactc       60
agccatatag agatttcagc tgcattataa tgtatatttg agaaattgag ttcttattat      120
cagaaaattg acctatgtaa tgaaatacta gaagaaaact ctaaattaga atggctttgt      180
tatgaatttt taatgataag tactaacact taaaagggaa aaaatttttc aaagaaaatg      240
cctaaaaatg tgttgtatct gagatcatca tatatgtagt attacagtgc aaacactatt      300
aatgttaatg aggtaggtgg attttttaa tgaaaaaact tgaaatatta tcaggttgtc      360
cccatttatg gaatttaagc ttgtcagaaa gatccagata gctatattaa tattttatct      420
gtatttggtt gcggttgctt ttaaaaataa gttttcttat aagtcatttc aatttttgg       480
tttagagtcc atatttcaaa ataaaaagtt aaaaaaagag taccttatgt aatttagcaa      540
ggtattccat aaactcaggg aggaaaaaaa aaaaactaag atgagaggct agttataatg      600
atctttattt atatattgca ggaaatgatt tcctctctca caacttagca taatttactg      660
ctaatatttt tagccatggg ttgaaaaaaa ttaartggtt ttgtaagtgc taatcctttg      720
ttactcattt aaactggtaa aatgtagtcc ccgctccctg aggaggacct gtccaaactc      780
ttcaaaccac cacagccgcc tgccaggatg gactcgctgc tcattgcagg ccagataaac      840
acttactgcc agaacatcaa ggagttcact gcccaaaact taggcaagct cttcatggcc      900
caggctcttc aagaatacaa caactaagaa aaggaagttt ccagaaaaga agttaacatg      960
```

```
aactcttgaa gtcacaccag ggcaactctt ggaagaaata tatttgcata ttgaaaagca    1020
cagaggattt ctttagtgtc attgccgatt ttggctataa cagtgtcttt ctagccataa    1080
taaaataaaa caaaatcttg aaaaaaaaaa aaaaaaaaan gggsggccgc tctaaggggn    1140
tccaagctt                                                           1149
```

<210> 120
<211> 1515
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> n equals a,t,g, or c

<400> 120
```
aattcggcac gagggaaatt caagcacttt tcctaaaaga agggggaatg gatgctgaaa      60
caacacgtnt cccacaaagg gagcagacac tgggcttgtg aagctgcccc ataccttccc     120
cacagaactg gggtccggcc tccctgacat gcagatttcc acccagaaga cagagaagga     180
gccagtggtc atggaatggg ctggggtcaa agactgggtg cctgggagct gaggcagcca     240
ccgtttcagc ctggccagcc ctctggaccc cgaggttgga ccctactgtg acacacctac     300
catgcggaca ctcttcaacc tcctctggct tgccctggcc tgcagccctg ttcacactac     360
cctgtcaaag tcagatgcca aaaaagccgc ctcaaagacg ctgctggaga agagtcagtt     420
ttcagataag ccggtgcaag accgggggttt ggtggtgacg gacctcaaag ctgagagtgt     480
ggttcttgag catcgcagct actgctcggc aaaggcccgg gacagacact ttgctgggga     540
tgtactgggc tatgtcactc catggaacag ccatggctac gatgtcacca aggtctttgg     600
gagcaagttc acacagatct cacccgtctg gctgcagctg aagagacgtg gccgtgagat     660
gtttgaggtc acgggcctcc acgacgtgga ccaagggtgg atgcgagctg tcaggaagca     720
tgccaagggc ctgcacatag tgcctcggct cctgtttgag gactggactt acgatgattt     780
ccggaacgtc ttagacagtg aggatgagat agaggagctg agcaagaccg tggtccaggt     840
ggcaaagaac cagcatttcg atggcttcgt ggtggaggtc tggaaccagc tgctaagcca     900
gaagcgcgtg accgaccagc tgggcatgtt cacgcacaag gagtttgagc agctggcccc     960
cgtgctggat ggtttcagcc tcatgaccta cgactactct acagcgcatc agcctggccc    1020
taatgcaccc ctgtcctggg ttcgagcctg cgtccaggtc ctggacccga agtccaagtg    1080
gcgaagcaaa atcctcctgg ggctcaactt ctatggtatg gactacgcga cctccaagga    1140
tgcccgtgag cctgttgtcg gggccaggta catccagaca ctgaaggacc acaggccccg    1200
gatggtgtgg gacagccagg yctcagagca cttcttcgag tacaagaaga gccgcagtgg    1260
gaggcacgtc gtcttctacc caaccctgaa gtccctgcag gtgcggctgg agctggcccg    1320
ggagctgggc gttggggtct ctatctggga gctgggccag ggcctggact acttctacga    1380
cctgctctag gtgggcattg cggcctccgc ggtggacgtg ttcttttcta agccatggag    1440
tgagtgagca ggtgtgaaat acaggccttc actccgttaa aaaaaaaaaa aaaaaaaaaa    1500
aaaaaaaaaa aaaaa                                                     1515
```

<210> 121
<211> 1025
<212> DNA
<213> Homo sapiens

<400> 121
```
ggagaattgt tactggtgaa ttggttttca ggttttgagc atacatatac aatgtgtttc      60
aaatgctgct tgtaaaatta aaccatcatc tagaatagag ttaatttatt ataatcaagc     120
tacaaatagg ttttcttaaa ccagagatgc actgcccttg tctaaagttc ttattgcact     180
ggtttatatg tgtatgtgtg ttttattgtg tgtttttta atttgtaagt attctaagag      240
tttcctaata ctaaggttaa aattttcatg ttgacctgag ccttttgcaa atttgctttg     300
gctctattga tttgtccatt atgtgttagg caaatataac ttaagtggag ggggaagttt     360
```



```
atgaatataa tatagctctg tgttttaaac ctcagaaaca gatttgagtg tttcagtatt      420
atagaaacag tgatgactat tcatgctctg ctagtctatg cctgcaactc caaatgtttg      480
tggttcagta tttcccacct acatttctgt ttggtgacat tgctcatttt aacaaatatg      540
accgagtcta gtttttcttt aaaaggatag tttatgagta atctttaaaa ccatttccat      600
accatctgta tataaccatt tcggtagaga acacactaca ctgaaccctg ctttagagct      660
gtgtgttgag ctaaaaatat aatttttaa aaattgacta gcaaaatcta tggccacact      720
gagaagcctt tgaaaatggc aaatactttt catcaccaat tgcccaattc atcttttcttc     780
tgcttcctca gccttgtagc aaaggctaca cagcagccca cagtccacag tcttttttggg     840
aaaattggcc tgccaccttc tttaagctca gtttatttttt gacttacttt ctttgctgta     900
gttatgaacc ttggggcatt aaaatcccat ggcaaggagc ataagagatg ttctcgtagc      960
tctgcgttgt gtgaaatgtc catcttagtt ttgttaaaaa aaaaaaaaaa aaaaaaaaac     1020
tcgag                                                                1025
```

<210> 122
<211> 2207
<212> DNA
<213> Homo sapiens

<400> 122
```
ggcacgagca cgaatcagct gcaggtctct gttttgaaaa agcagagata cagaggcaga       60
ggaaaagggt ggactcctat gtgacctgtt cttagagcaa gacaatcacc atctgaattc      120
cagaagccct gttcatggtt ggggatattt tctcgactgc atggaatcag aaagaagcaa      180
aaggatggga aatgcctgca ttcccctgaa aagaattgct tatttcctat gtctcttatc      240
tgcgcttttg ctgactgagg ggaagaaacc agcgaaccaa aatgccctgc cgtgtgtact      300
tgtaccaaag ataatgcttt atgtgagaat gccagatcca ttccacgcac cgttcctcct      360
gatgttatct cattatcctt tgtgagatct ggttttactg aaatctcaga agggagtttt      420
ttattcacgc catcgctgca gctcttgtta ttcacatcga actcctttga tgtgatcagt      480
gatgatgctt ttattggtct tccacatcta gagtatttat tcatagaaaa caacaacatc      540
aagtcaattt caagacatac tttccgggga ctaaagtcat taattcactt gagccttgca      600
aacaacaatc tccagacact cccaaaagat attttcaaag gcctggattc tttaacaaat      660
gtggacctga ggggtaattc atttaattgt gactgtaaac tgaaatggct agtggaatgg      720
cttggccaca ccaatgcaac tgttgaagac atctactgcg aaggcccccc agaatacaag      780
aagcgcaaaa tcaatagtct ctcctcgaag gatttcgatt gcatcattac agaatttgca      840
aagtctcaag acctgcctta tcaatcattg tccatagaca ctttttctta tttgaatgat      900
gagtatgtag tcatcgctca gccttttact ggaaaatgca ttttccttga atgggaccat      960
gtggaaaaga ccttccggaa ttatgacaac attacaggca catccactgt agtatgcaag     1020
cctatagtca ttgaaactca gctctatgtt attgtggccc agctgtttgg tggctctcac     1080
atctataagc gagacagttt tgcaaataaa ttcataaaaa tccaggatat tgaaattctc     1140
aaaatccgaa aacccaatga cattgaaaca ttcaagattg aaaacaactg gtactttgtt     1200
gttgctgaca gttcaaaagc tggttttact accatttaca aatggaacgg aaacggattc     1260
tactcccatc aatccttaca cgcgtggtac agggacactg atgtggaata tctagaaata     1320
gtcagaacac ctcagacact cagaacgcct catttaattc tgtctagtag ttcccaacgt     1380
cctgtaattt atcagtggaa caaagcaaca caattattca ctaaccaaac tgacattcct     1440
aacatggagg atgtgtacgc agtgaagcac ttctcagtga aaggggacgt gtacatttgc     1500
ttgacaagat tcattggtga ttccaaagtc atgaaatggg gaggctcctc gttccaggat     1560
attcagagga tgccatcgcg aggatccatg gtgttccagc ctcttcaaat aaataattac     1620
caatatgcaa ttcttggaag tgattactcc tttactcaag tgtataactg ggatgcagag     1680
aaagccaaat ttgtgaaatt tcaggaatta aatgttcagg caccaagatc attcacacat     1740
gtgtccatta ataagcgtaa ttttcttttt gcttccagtt ttaagggaaa tacacagatt     1800
tacaaacatg tcatagttga cttaagcgca tgagacacca aattctgtgg ctgccatcag     1860
aaattttcta cagtacatga cccggatgaa ctcaatgcat gatgactctt cttatcacac     1920
ttgcaaatga atgcctttca aacattgaga ctgctagaac caagcactac cagtatctcc     1980
atccttaact gtccagtcca gtgatgtggg aagttacctt ttataagaca aaatttaatt     2040
gtgtaactgt tctttgcagt gaagatgtgt aaataagcgt ttaatggtat ctgttactcc     2100
aaaaagaaat attaatatgt acttttccat ttatttattc atgtgtacag aaacaactgc     2160
caaataaaat gtttacattt tctttcataa aaaaaaaaaa aaaaaaa                   2207
```

<210> 123
<211> 1770
<212> DNA
<213> Homo sapiens

<400> 123
gctgagtgtg agctgagcct gccccaccac caagatgatc ctgagcttgc tgttcagcct 60
tgggggcccc ctgggctggg ggctgctggg ggcatgggcc caggcttcca gtactagcct 120
ctctgatctg cagagctcca ggacacctgg ggtctggaag gcagaggctg aggacaccag 180
caaggacccc gttggacgta actggtgccc ctacccaatg tccaagctgg tcaccttact 240
agctctttgc aaaacagaga aattcctcat ccactcgcag cagccgtgtc cgcaggagct 300
ccagactgcc agaaagtcaa agtcatgtac cgcatggccc acaagccagt gtaccaggtc 360
aagcagaagg tgctgacctc tttggcctgg aggtgctgcc ctggctacac gggccccaac 420
tgcgagcacc acgattccat ggcaatccct gagcctgcag atcctggtga cagccaccag 480
gaacctcagg atggaccagt cagcttcaaa cctggccacc ttgctgcagt gatcaatgag 540
gttgaggtgc aacaggaaca gcaggaacat ctgctgggag atctccagaa tgatgtgcac 600
cgggtggcag acagcctgcc aggcctgtgg aaagccctgc ctggtaacct cacagctgca 660
gtgatggaag caaatcaaac agggcacgaa gttccctgat agatccttgg agcaggtgct 720
gctaccccac gtggacacct tcctacaagt gcatttcagc cccatctgga ggagctttaa 780
ccaaagcctg cacagcctta cccaggccat aagaaacctg tctcttgacg tggaggccaa 840
ccgccaggcc atctccagag tccaggacag tgccgtggcc agggctgact tccaggagct 900
tggtgccaaa tttgaggcca aggtccagga gaacactcag agagtgggtc agctgcgaca 960
ggacgtggag gaacgcctgc acgcccagca ctttaccctg caccgctcga tctcagagct 1020
ccaagccgat gtggacacca aattgaagag gctgcacaag gctcaggagg ccccagggac 1080
caatggcagt ctggtgttgg caacgcctgg ggctggggca aggcctgagc cggacagcct 1140
gcaggccagg ctgggccagc tgcagaggaa cctctcagag ctgcacatga ccacggcccg 1200
cagggaggag gagttgcagt acaccctgga ggacatgagg gccaccctga cccggcacgt 1260
ggatgagatc aaggaactgt actccgaatc ggacgagact ttcgatcaga ttagcaaggt 1320
ggagcggcag gtggaggagc tgcaggtgaa ccacacggcg ctccgtgagc tgcgcgtgat 1380
cctgatggag aagtctctga tcatggagga gaacaaggag gaggtggagc ggcagctcct 1440
ggagctcaac ctcacgctgc agcacctgca gggtggccat gccgacctca tcaagtacgt 1500
gaaggactgc aattgccaga agctctattt agacctggac gtcatccggg agggccagag 1560
ggacgccacg cgtgccctgg aggagaccca ggtgagcctg gacgagcggc ggcagctgga 1620
cggctcctcc ctgcaggccc tgcagaacgc cgtggacgcc gtgtcgctgg ccgtggacgc 1680
gcacaaagcg gagggcgagc gggcgcgggc ggccacgtcg cggctccgga gccaagtgca 1740
ggcgctggat gacgaggtgg gcgcgctgaa 1770

<210> 124
<211> 1034
<212> DNA
<213> Homo sapiens

<400> 124
ggcacgagga aagtacgagt cggctcagcc tggagggacc caaccagagc ctggcctggg 60
agccaggatg gccatccaca aagccttggt gatgtgcctg ggactgcctc tcttcctgtt 120
cccaggggcc tgggcccagg gccatgtccc acccggctgc agccaaggcc tcaacccccc 180
gtactacaac ctgtgtgacc gctctggggc gtggggcatc gtcctggagg ccgtggctgg 240
ggcgggcatt gtcaccacgt ttgtgctcac catcatcctg gtggccagcc tccccttgt 300
gcaggacacc aagaaacgga gcctgctggg gacccagcta agaggccggt gtcaccatac 360
agcgggtaca atgggcagct gctgaccagt gtgtaccagc ccactgagat ggccctgatg 420
cacaaagttc cgtccgaagg agcttacgac atcatcctcc cacgggccac cgccaacagc 480
caggtgatgg gcagtgccaa ctcgaccctg cgggctgaag acatgtactc ggcccagagc 540
caccaggcgg ccacaccgcc gaaagacggc aagaactctc aggtctttag aaacccctac 600
gtgtgggact gagtcagcgg tggcgaggag aggcggtcgg atttggggag ggccctgagg 660

acctggcccc gggcaaggga ctctccaggc tcctcctccc cctggcaggc ccagcaacat 720
gtgccccaga tgtggaaggg cctcccctct tgccagtgtt tgggtgggtg tcatgggtgt 780
ccccacccac tcctcagtgt ttgtggagtc gaggagccaa ccccagcctc ctgccaggat 840
cacctcggcg gtcacactcc agccaaatag tgttctcggg gtggtggctg ggcagcgcct 900
atgtttctct ggagattcct gcaacctcaa gagacttccc aggcgctcag gcctggatct 960
tgctcctctg tgaggaacaa gggtgcctaa taaatacatt tctgctttat taaaaaaaaa 1020
aaaaaaaaaa aaaa 1034

<210> 125
<211> 353
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (353)
<223> Xaa equals stop translation

<400> 125
Met Leu Cys Arg Leu Cys Trp Leu Val Ser Tyr Ser Leu Ala Val Leu
1 5 10 15

Leu Leu Gly Cys Leu Leu Phe Leu Arg Lys Ala Ala Lys Pro Ala Glu
20 25 30

Thr Pro Arg Pro Thr Ser Leu Ser Gly Ala Pro Pro Thr Pro Arg His
35 40 45

Ser Arg Cys Pro Pro Asn His Thr Val Ser Ser Ala Ser Leu Ser Leu
50 55 60

Pro Ser Arg His Arg Leu Phe Leu Thr Tyr Arg His Cys Arg Asn Phe
65 70 75 80

Ser Ile Leu Leu Glu Pro Ser Gly Cys Ser Lys Asp Thr Phe Leu Leu
85 90 95

Leu Ala Ile Lys Ser Gln Pro Gly His Val Glu Arg Arg Ala Ala Ile
100 105 110

Arg Ser Thr Trp Gly Arg Trp Gly Asp Gly Leu Gly Pro Ala Leu Lys
115 120 125

Leu Val Phe Leu Leu Gly Val Ala Gly Ser Ala Pro Pro Ala Gln Leu
130 135 140

Leu Ala Tyr Glu Ser Arg Glu Phe Asp Asp Ile Leu Gln Trp Asp Phe
145 150 155 160

Thr Glu Asp Phe Phe Asn Leu Thr Leu Lys Glu Leu His Leu Gln Arg
165 170 175

Trp Val Val Ala Ala Cys Pro Gln Ala His Phe Met Leu Lys Gly Asp
180 185 190

Asp Asp Val Phe Val His Val Pro Asn Val Leu Glu Phe Leu Asp Gly

195 200 205

Trp Asp Pro Ala Gln Asp Leu Leu Val Gly Asp Val Ile Arg Gln Ala
210 215 220

Leu Pro Asn Arg Asn Thr Lys Val Lys Tyr Phe Ile Pro Pro Ser Met
225 230 235 240

Tyr Arg Ala Thr His Tyr Pro Pro Tyr Ala Gly Gly Gly Gly Tyr Val
245 250 255

Met Ser Arg Ala Thr Val Arg Arg Leu Gln Ala Ile Met Glu Asp Ala
260 265 270

Glu Leu Phe Pro Ile Asp Asp Val Phe Val Gly Met Cys Leu Arg Arg
275 280 285

Leu Gly Leu Ser Pro Met His His Ala Gly Phe Lys Thr Phe Gly Ile
290 295 300

Arg Arg Pro Leu Asp Pro Leu Asp Pro Cys Leu Tyr Arg Gly Leu Leu
305 310 315 320

Leu Val His Arg Leu Ser Pro Leu Glu Met Trp Thr Met Trp Ala Leu
325 330 335

Val Thr Asp Glu Gly Leu Lys Cys Ala Ala Gly Pro Ile Pro Gln Arg
340 345 350

Xaa

<210> 126
<211> 158
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (156)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (158)
<223> Xaa equals stop translation

<400> 126
Met Ser Trp Val Gly Leu Gly Arg Arg Gly His Leu Leu Leu Leu Ile
1 5 10 15

Asn Pro Arg Ala Leu Ala Gly Ile Arg Leu Pro Ser Pro Thr Gly Ala
20 25 30

Pro Ala Pro Gly Pro Cys Pro Pro Leu Cys Thr Pro His Cys Ser Arg
35 40 45

Glu His Pro Ala Gly Gly Thr Gly His Pro Ala Gly Val Trp Trp Arg
50 55 60

Arg Gly Cys Tyr Gly Gly Ser Cys Pro Met Gly Pro Val Arg Gly Ile
65 70 75 80

Leu Gly Gly Leu Pro Cys Arg Glu Glu Ala Leu Arg Arg His His Ser
85 90 95

Lys Pro Cys Trp Arg Pro Gly Gly Gln Ala Arg Xaa Leu Gly Ser Trp
100 105 110

Pro Leu Thr Ala Gly Arg Glu Pro Pro Arg Thr Ala Ser Thr Ala Pro
115 120 125

His Thr Ser Glu Pro Thr Ser Ser Phe Pro Arg Phe Pro Arg Ser Gln
130 135 140

Ala Trp Glu Asp Leu Pro Asp Ala Ala His His Xaa Ser Xaa
145 150 155

<210> 127
<211> 554
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (199)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (201)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (202)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (228)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (420)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (434)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (440)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (452)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (554)
<223> Xaa equals stop translation

<400> 127

```
Met Lys Ile Ala Thr Val Ser Val Leu Leu Pro Leu Ala Leu Cys Leu
 1               5                  10                  15

Ile Gln Asp Ala Ala Ser Lys Asn Glu Asp Gln Glu Met Cys His Glu
            20                  25                  30

Phe Gln Ala Phe Met Lys Xaa Gly Lys Leu Phe Cys Pro Gln Asp Lys
        35                  40                  45

Lys Phe Phe Gln Ser Leu Asp Gly Ile Met Phe Ile Asn Lys Cys Ala
    50                  55                  60

Thr Cys Lys Met Ile Leu Glu Lys Glu Ala Lys Ser Gln Lys Arg Ala
65                  70                  75                  80

Arg His Leu Ala Arg Ala Pro Lys Ala Thr Ala Pro Thr Glu Leu Asn
                85                  90                  95

Cys Asp Asp Phe Lys Lys Gly Glu Arg Asp Gly Asp Phe Ile Cys Pro
            100                 105                 110

Asp Tyr Tyr Glu Ala Val Cys Gly Thr Asp Gly Lys Thr Tyr Asp Asn
        115                 120                 125

Arg Cys Ala Leu Cys Ala Glu Asn Ala Lys Thr Gly Ser Gln Ile Gly
    130                 135                 140

Val Lys Ser Glu Gly Glu Cys Lys Ser Ser Asn Pro Glu Gln Asp Val
145                 150                 155                 160
```



```
Cys Ser Ala Phe Arg Pro Phe Val Arg Asp Gly Arg Leu Gly Cys Thr
                165                 170                 175

Arg Glu Asn Asp Pro Val Leu Gly Pro Asp Gly Lys Thr His Gly Asn
            180                 185                 190

Lys Cys Ala Met Cys Ala Xaa Leu Xaa Xaa Lys Glu Ala Glu Asn Ala
        195                 200                 205

Lys Arg Glu Gly Glu Thr Arg Ile Arg Arg Asn Ala Glu Lys Asp Phe
    210                 215                 220

Cys Lys Glu Xaa Glu Lys Gln Val Arg Asn Gly Arg Leu Phe Cys Thr
225                 230                 235                 240

Arg Glu Ser Asp Pro Val Arg Gly Pro Asp Gly Arg Met His Gly Asn
                245                 250                 255

Lys Cys Ala Leu Cys Ala Glu Ile Phe Lys Gln Arg Phe Ser Glu Glu
            260                 265                 270

Asn Ser Lys Thr Asp Gln Asn Leu Gly Lys Ala Glu Glu Lys Thr Lys
        275                 280                 285

Val Lys Arg Glu Ile Val Lys Leu Cys Ser Gln Tyr Gln Asn Gln Ala
    290                 295                 300

Lys Asn Gly Ile Leu Phe Cys Thr Arg Glu Asn Asp Pro Ile Arg Gly
305                 310                 315                 320

Pro Asp Gly Lys Met His Gly Asn Leu Cys Ser Met Cys Gln Ala Tyr
                325                 330                 335

Phe Gln Ala Glu Asn Glu Glu Lys Lys Lys Ala Glu Ala Arg Ala Arg
            340                 345                 350

Asn Lys Arg Glu Ser Gly Lys Ala Thr Ser Tyr Ala Glu Leu Cys Ser
        355                 360                 365

Glu Tyr Arg Lys Leu Val Arg Asn Gly Lys Leu Ala Cys Thr Arg Glu
    370                 375                 380

Asn Asn Pro Ile Gln Gly Pro Asp Gly Lys Val His Gly Asn Thr Cys
385                 390                 395                 400

Ser Met Cys Glu Val Phe Phe Gln Ala Glu Glu Glu Glu Lys Lys Lys
                405                 410                 415

Lys Glu Gly Xaa Ser Arg Asn Lys Arg Gln Ser Lys Ser Thr Ala Ser
            420                 425                 430

Phe Xaa Glu Leu Cys Ser Glu Xaa Arg Lys Ser Arg Lys Asn Gly Arg
        435                 440                 445

Leu Phe Cys Xaa Arg Glu Asn Asp Pro Ile Gln Gly Pro Asp Gly Lys
    450                 455                 460
```

```
Met His Gly Asn Thr Cys Ser Met Cys Glu Ala Phe Phe Gln Gln Glu
465                 470                 475                 480

Glu Arg Ala Arg Ala Lys Ala Lys Arg Glu Ala Ala Lys Glu Ile Cys
                485                 490                 495

Ser Glu Phe Arg Asp Gln Val Arg Asn Gly Thr Leu Ile Cys Thr Arg
            500                 505                 510

Glu His Asn Pro Val Arg Gly Pro Asp Gly Lys Met His Gly Asn Lys
        515                 520                 525

Cys Ala Met Cys Ala Ser Val Phe Lys Leu Glu Lys Lys Lys Lys Lys
    530                 535                 540

Lys Lys Lys Lys Lys Gly Arg Pro Leu Xaa
545                 550
```

<210> 128
<211> 308
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (308)
<223> Xaa equals stop translation

<400> 128

```
Met Asn Thr Val Leu Leu Ser Leu Leu Phe Ser Leu Pro Arg Ile Val
  1               5                  10                  15

Tyr Ala Met Ala Ala Asp Gly Leu Phe Phe Gln Val Phe Ala His Val
             20                  25                  30

His Pro Arg Thr Gln Val Pro Val Ala Gly Thr Leu Ala Phe Gly Leu
         35                  40                  45

Leu Thr Ala Phe Leu Ala Leu Leu Leu Asp Leu Glu Ser Leu Val Gln
     50                  55                  60

Phe Leu Ser Leu Gly Thr Leu Leu Ala Tyr Thr Phe Val Ala Thr Ser
 65                  70                  75                  80

Ile Ile Val Leu Arg Phe Gln Lys Ser Ser Pro Pro Ser Ser Pro Gly
                 85                  90                  95

Pro Ala Ser Pro Gly Pro Leu Thr Lys Gln Gln Ser Ser Phe Ser Asp
            100                 105                 110

His Leu Gln Leu Val Gly Thr Val His Ala Ser Val Pro Glu Pro Gly
        115                 120                 125

Glu Leu Lys Pro Ala Leu Arg Pro Tyr Leu Gly Phe Leu Asp Gly Tyr
    130                 135                 140
```



```
Ser Pro Gly Ala Val Val Thr Trp Ala Leu Gly Val Met Leu Ala Ser
145                 150                 155                 160

Ala Ile Thr Ile Gly Cys Val Leu Val Phe Gly Asn Ser Thr Leu His
                165                 170                 175

Leu Pro His Trp Gly Tyr Ile Leu Leu Leu Leu Leu Thr Ser Val Met
            180                 185                 190

Phe Leu Leu Ser Leu Leu Val Leu Gly Ala His Gln Gln Gln Tyr Arg
        195                 200                 205

Glu Asp Leu Phe Gln Ile Pro Met Val Pro Leu Ile Pro Ala Leu Ser
    210                 215                 220

Ile Val Leu Asn Ile Cys Leu Met Leu Lys Leu Ser Tyr Leu Thr Trp
225                 230                 235                 240

Val Arg Phe Ser Ile Trp Leu Leu Met Gly Leu Ala Val Tyr Phe Gly
                245                 250                 255

Tyr Gly Ile Arg His Ser Lys Glu Asn Gln Arg Glu Leu Pro Gly Leu
            260                 265                 270

Asn Ser Thr His Tyr Val Val Phe Pro Arg Gly Ser Leu Glu Glu Thr
        275                 280                 285

Val Gln Ala Met Gln Pro Pro Ser Gln Ala Pro Ala Gln Asp Pro Gly
    290                 295                 300

His Met Glu Xaa
305
```

<210> 129
<211> 167
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (167)
<223> Xaa equals stop translation

<400> 129

```
Met Ala Ala Ala Val Leu Ala Met Thr Leu Ala Pro Thr Val Ser Gly
  1               5                  10                  15

Thr Thr Ser Lys Cys Ser Ser Arg Arg Trp Cys Pro Val Pro Ala Ser
             20                  25                  30

Ser Ser Cys Val Ser His Leu Leu Gly Ser Gly Cys Ala Pro Cys Ala
         35                  40                  45

Pro Trp Thr Ala His Pro Arg Gln Pro Ser Gln Cys Trp Ser Ala Arg
     50                  55                  60
```

```
Ala Pro Arg Arg Leu Gly Ser Arg Pro Arg Arg Tyr Leu Leu Thr Gly
 65                  70                  75                  80

Gln Ala Asn Gly Ser Leu Ala Met Trp Asp Leu Thr Thr Ala Met Asp
                85                  90                  95

Gly Leu Gly Gln Ala Pro Ala Gly Gly Leu Thr Glu Gln Glu Leu Met
            100                 105                 110

Glu Gln Leu Glu His Cys Glu Leu Ala Pro Pro Ala Pro Phe Ser Ser
        115                 120                 125

Leu Met Gly Leu Ser Pro Gln Pro Leu Thr Pro His Leu Pro His Gln
    130                 135                 140

Pro Pro Leu Ser Leu Gln Gln His Leu Leu Val Trp Pro Pro Trp Glu
145                 150                 155                 160

Pro Lys Pro Pro Ala Gly Xaa
                165
```

<210> 130
<211> 306
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (306)
<223> Xaa equals stop translation

<400> 130

```
Met Ala Ala Gly Leu Ala Arg Leu Leu Leu Leu Leu Gly Leu Ser Ala
  1               5                  10                  15

Gly Gly Pro Ala Pro Ala Gly Ala Ala Lys Met Lys Val Val Glu Glu
            20                  25                  30

Pro Asn Ala Phe Gly Val Asn Asn Pro Phe Leu Pro Gln Ala Ser Arg
        35                  40                  45

Leu Gln Ala Lys Arg Asp Pro Ser Pro Val Ser Gly Pro Val His Leu
    50                  55                  60

Phe Arg Leu Ser Gly Lys Cys Phe Ser Leu Val Glu Ser Thr Tyr Lys
65                  70                  75                  80

Tyr Glu Phe Cys Pro Phe His Asn Val Thr Gln His Glu Gln Thr Phe
                85                  90                  95

Arg Trp Asn Ala Tyr Ser Gly Ile Leu Gly Ile Trp His Glu Trp Glu
            100                 105                 110

Ile Ala Asn Asn Thr Phe Thr Gly Met Trp Met Arg Asp Gly Asp Ala
        115                 120                 125
```



```
Cys Arg Ser Arg Ser Arg Gln Ser Lys Val Glu Leu Ala Cys Gly Lys
    130                 135                 140

Ser Asn Arg Leu Ala His Val Ser Glu Pro Ser Thr Cys Val Tyr Ala
145                 150                 155                 160

Leu Thr Phe Glu Thr Pro Leu Val Cys His Pro His Ala Leu Leu Val
                165                 170                 175

Tyr Pro Thr Leu Pro Glu Ala Leu Gln Arg Gln Trp Asp Gln Val Glu
            180                 185                 190

Gln Asp Leu Ala Asp Glu Leu Ile Thr Pro Gln Gly His Glu Lys Leu
        195                 200                 205

Leu Arg Thr Leu Phe Glu Asp Ala Gly Tyr Leu Lys Thr Pro Glu Glu
    210                 215                 220

Asn Glu Pro Thr Gln Leu Glu Gly Gly Pro Asp Ser Leu Gly Phe Glu
225                 230                 235                 240

Thr Leu Glu Asn Cys Arg Lys Ala His Lys Glu Leu Ser Lys Glu Ile
                245                 250                 255

Lys Arg Leu Lys Gly Leu Leu Thr Gln His Gly Ile Pro Tyr Thr Arg
            260                 265                 270

Pro Thr Glu Thr Ser Asn Leu Glu His Leu Gly His Glu Thr Pro Arg
        275                 280                 285

Ala Lys Ser Pro Glu Gln Leu Arg Gly Asp Pro Gly Leu Arg Gly Ser
    290                 295                 300

Leu Xaa
305
```

<210> 131
<211> 220
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (204)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (209)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (220)
<223> Xaa equals stop translation

<400> 131
Met Pro Cys Leu Glu Ala Val Ala Leu Ile Leu Leu Ile Leu Leu Val
1 5 10 15

Pro Asp Pro Pro Arg Gly Ala Ala Glu Thr Gln Gly Glu Gly Ala Val
20 25 30

Gly Gly Phe Arg Ser Ser Trp Cys Glu Asp Val Arg Tyr Leu Gly Lys
35 40 45

Asn Trp Ser Phe Val Trp Ser Xaa Leu Xaa Val Thr Ala Met Ala Phe
50 55 60

Val Thr Gly Ala Leu Gly Phe Trp Ala Pro Lys Phe Leu Leu Glu Ala
65 70 75 80

Arg Val Val His Gly Leu Gln Pro Pro Cys Phe Gln Glu Pro Cys Ser
85 90 95

Asn Pro Asp Ser Leu Ile Phe Gly Ala Leu Thr Ile Met Thr Gly Val
100 105 110

Ile Gly Val Ile Leu Gly Ala Glu Ala Ala Arg Arg Tyr Lys Lys Val
115 120 125

Ile Pro Gly Ala Glu Pro Leu Ile Cys Ala Ser Ser Leu Leu Ala Thr
130 135 140

Ala Pro Cys Leu Tyr Leu Ala Leu Val Leu Ala Pro Thr Thr Leu Leu
145 150 155 160

Ala Ser Tyr Val Phe Leu Gly Leu Gly Glu Leu Leu Leu Ser Cys Asn
165 170 175

Trp Ala Val Val Ala Asp Ile Leu Leu Ser Val Val Val Pro Arg Cys
180 185 190

Arg Gly Thr Ala Glu Ala Leu Gln Ile Thr Val Xaa His Ile Leu Gly
195 200 205

Xaa Leu Ala Ala Leu Ser His Arg Thr Tyr Leu Xaa
210 215 220

<210> 132
<211> 99
<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (99)
<223> Xaa equals stop translation

<400> 132
Met Met Asn Gln His Leu Leu Glu Ser Phe Gly Ser Pro Ser Ser Leu
1 5 10 15

Phe Ile Val Phe Ile Leu Leu Ile Trp Met Leu Gln Arg Cys Lys Asp
20 25 30

Phe Phe Leu Cys Cys Tyr Arg Val Val Leu Thr Pro Ser Phe Trp Gln
35 40 45

Lys His Gln His Pro Asp Pro Lys Ile Lys His His Leu Lys Leu Tyr
50 55 60

Ser Leu Lys Tyr Ser Ser Ser Gly Gln Asn Asn Phe Arg Lys Asp Lys
65 70 75 80

His Trp Leu Ser Gly His Thr Glu Glu Ala Asn Leu Ile Lys Glu Glu
85 90 95

Trp Lys Xaa

<210> 133
<211> 61
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (61)
<223> Xaa equals stop translation

<400> 133
Met Thr Ser Ser Leu Phe Ile Phe Leu Phe Leu Trp Phe Cys Pro Pro
1 5 10 15

Pro Arg Ile Ser Phe Val Leu Cys Trp Pro Gln Pro His Ser Gln Val
20 25 30

His Ile Gln His Glu Lys Ala Asp His Leu Phe Gln Ser Leu Lys Gln
35 40 45

Lys Ala Pro Gly Leu Leu Gln Trp Ala Arg Ile Val Xaa
50 55 60

<210> 134
<211> 248
<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (141)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (248)
<223> Xaa equals stop translation

<400> 134
Met Ala Val Pro Ala Leu Thr Pro Ala Ala Val Arg Ala Xaa Gly Leu
1 5 10 15

Leu Gly Val Ser Trp Thr Trp Ala Leu Phe Thr Pro Leu Val Ala Leu
20 25 30

Gly Arg Glu Gly Gly Ser Gln Asp Ser Ala Thr Thr Pro Ser Arg Pro
35 40 45

Pro Gly Arg Pro Arg Ile Val Asp Ile Ala Thr Ile Val His Cys Tyr
50 55 60

Ala Glu Glu Arg Gln Ser Ala Glu Asp Tyr Glu Lys Glu Glu Ser His
65 70 75 80

Arg Gln Arg Arg Leu Lys Glu Arg Glu Arg Ile Gly Glu Leu Gly Ala
85 90 95

Pro Glu Val Trp Gly Pro Ser Pro Lys Phe Pro Gln Leu Asp Ser Asp
100 105 110

Glu His Thr Pro Val Glu Asp Glu Glu Glu Val Thr His Gln Lys Ser
115 120 125

Ser Ser Ser Asp Ser Asn Ser Glu Glu His Arg Lys Xaa Lys Thr Ser
130 135 140

Arg Ser Arg Asn Lys Lys Lys Arg Lys Asn Lys Ser Ser Lys Arg Lys
145 150 155 160

His Arg Lys Tyr Ser Asp Ser Asp Ser Asn Ser Glu Ser Asp Thr Asn
165 170 175

Ser Asp Ser Asp Asp Asp Lys Lys Arg Val Lys Ala Lys Lys Lys Lys
180 185 190

Lys Lys Lys Lys His Lys Thr Lys Lys Lys Lys Asn Lys Lys Thr Lys
195 200 205

Lys Glu Ser Ser Asp Ser Ser Cys Lys Asp Ser Glu Glu Asp Leu Ser
210 215 220

Glu Ala Thr Trp Asp Gly Ala Ala Lys Cys Gly Arg Tyr Tyr Gly Phe
225 230 235 240

Asn Arg Ala Arg Ser Thr Tyr Xaa
245

<210> 135
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 135
Met Val Cys Phe Tyr Ala Leu Leu Leu Cys Phe Leu Ser Ser Val Glu
1 5 10 15

Ile Gly Pro Leu Ser Trp Leu Leu Cys Leu Ser His Ile Lys Cys His
20 25 30

Phe Thr Ala Leu Pro Phe Glu Ala Xaa
35 40

<210> 136
<211> 75
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (75)
<223> Xaa equals stop translation

<400> 136
Met Leu His Leu Phe Cys Ser Gln Pro Leu Gly Leu Leu Phe Leu Leu
1 5 10 15

Ile Phe Leu Gly Leu Asp Ser Leu Pro Arg Cys Leu Thr Ala Thr Arg
20 25 30

Leu Gln Ser Pro Ile Ile Ile Phe Ser Thr Leu Ser Cys Ile Cys Ser
35 40 45

Thr Ser Trp Leu Glu Leu Cys Ser Val Tyr Phe Leu Thr Leu Asn Tyr
50 55 60

Leu His Val Val Pro Pro Cys Phe Leu Ile Xaa
65 70 75

<210> 137
<211> 75
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (75)
<223> Xaa equals stop translation

<400> 137
Met Gly Val Leu Thr Arg Glu Leu Phe Gly Val Val Gly Met Leu Tyr
1 5 10 15

Ile Leu Ile Val Gly Met Val Thr Trp Leu Asp Ala Phe Val Lys Thr
20 25 30

His Leu Met Val Met Gln Asn Glu Tyr Ile Leu Phe Tyr Val Asn Tyr
35 40 45

Thr Ser Lys Leu Asn Phe Phe Lys Lys Phe Leu Leu Lys Ser Lys Asp
50 55 60

Ile Cys Gly Ala Ser Cys Lys Phe Tyr Cys Xaa
65 70 75

<210> 138
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 138
Met Lys Val Leu Leu Ser Leu Ser Leu Val Gly Leu Phe Ile Gly Phe
1 5 10 15

Ser Asp Ala Val Leu Asn Glu Thr Cys Arg Phe Trp Ile Asn Thr Ser
20 25 30

Ser Lys Gly Asn Leu Gln Ile Leu Lys Asn Gln Ile Gln Ile Ile Asp
35 40 45

Arg Leu Arg Lys Met Pro Ala Ser Ala Xaa
50 55

<210> 139
<211> 173
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 139
Met Leu Gly Ser Pro Cys Leu Leu Trp Leu Leu Ala Val Thr Phe Leu
1 5 10 15

Val Pro Arg Ala Gln Pro Leu Ala Pro Gln Asp Phe Glu Glu Glu Glu
20 25 30

Ala Asp Glu Thr Glu Thr Ala Trp Pro Pro Leu Pro Ala Val Pro Cys
35 40 45

Asp Tyr Asp His Cys Arg His Leu Gln Val Pro Cys Lys Glu Leu Gln
50 55 60

Arg Val Gly Pro Ala Ala Cys Leu Cys Pro Gly Xaa Ser Ser Pro Ala
65 70 75 80

Gln Pro Pro Asp Pro Pro Arg Met Gly Glu Val Arg Ile Ala Ala Glu
85 90 95

Glu Gly Arg Ala Val Val His Trp Cys Ala Pro Phe Ser Pro Val Leu
100 105 110

His Tyr Trp Leu Leu Leu Trp Asp Gly Ser Glu Xaa Arg Arg Arg Gly
115 120 125

Pro Pro Leu Asn Ala Thr Val Arg Arg Ala Glu Leu Lys Gly Leu Lys
130 135 140

Pro Gly Gly Ile Tyr Val Val Cys Val Val Ala Ala Asn Glu Ala Gly
145 150 155 160

Ala Ser Arg Val Pro Gln Ala Gly Gly Glu Gly Leu Glu
165 170

<210> 140
<211> 46
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (46)
<223> Xaa equals stop translation

<400> 140
Met Thr Ile His Ala Leu Leu Val Tyr Ala Cys Asn Ser Lys Cys Leu

85

1 5 10 15

Trp Phe Ser Ile Ser His Leu His Phe Cys Leu Val Thr Leu Leu Ile
20 25 30

Leu Thr Asn Met Thr Glu Ser Ser Phe Ser Leu Lys Gly Xaa
35 40 45

<210> 141
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 141
Met Val Tyr Arg Ala Phe Leu Ile Ile Ile Leu Arg Phe Ile Leu Ile
1 5 10 15

Phe Leu Phe Lys Leu Asn Tyr Ser Lys Leu Cys Pro Glu Ile Pro Phe
20 25 30

Gly Leu Lys Phe Phe Ser Phe Val Cys Ile Lys Val Gln Ile Lys Lys
35 40 45

Thr Ser Arg Lys Arg Arg Pro Tyr Leu Xaa
50 55

<210> 142
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 142
Met Phe Val Glu Arg Trp Leu Pro Cys Phe Leu Val Val Ala Val Val
1 5 10 15

Val Trp Val Phe Ala Cys Gly Pro Val Glu Asp Lys Glu Asp Ser Phe
20 25 30

Gly Trp Ser Ser Tyr Phe Leu Ala Ser Gly Leu Pro Pro Leu Leu Phe
35 40 45

Glu Ala Ser Gln Thr Arg Thr Val Arg Ala Gly Arg Leu Gly Val Phe
50 55 60

Val Cys Xaa

86

65

<210> 143
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (53)
<223> Xaa equals stop translation

<400> 143
Met Ile Phe Lys Leu Leu Ile Phe Arg Ile Phe Phe His Glu Leu Ala
1 5 10 15

Leu Ala Leu Cys Ile Ser Asn Leu Val Ser Leu Pro Trp Leu Ser Tyr
20 25 30

Phe Trp Cys Pro Glu Met Gln Asn Leu Phe Leu Leu Asp Thr His Ile
35 40 45

Trp Val Leu Met Xaa
50

<210> 144
<211> 66
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (66)
<223> Xaa equals stop translation

<400> 144
Met Val Leu Ser Val Ala Leu Leu His Ala Leu Ser His Leu Met Pro
1 5 10 15

Cys Lys Thr Cys Leu Ala Ser Thr Ser Pro Ser Ala Met Ile Val Ser
20 25 30

Phe Leu Arg Pro Pro Gln Pro Ala Met Trp Asn Cys Glu Ser Ile Lys
35 40 45

Pro Phe Leu Phe Ile His Tyr Pro Val Ser Gly Ser Ile Phe Ile Ala
50 55 60

Val Xaa
65

<210> 145
<211> 57
<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (57)
<223> Xaa equals stop translation

<400> 145
Met Val Ala Ile Leu Leu Arg Glu Leu Pro Leu Ala Phe Leu Leu Val
1 5 10 15

Gly Ser Ser Gly Asp Lys Phe Cys Phe Thr Ser Ser Glu Asn Val Leu
20 25 30

Leu Ser Phe Ser Phe Leu Lys Asp Ile Phe Ala Gly Tyr Lys Asn Ser
35 40 45

Gly Leu Met Val Leu Phe Ile Val Xaa
50 55

<210> 146
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 146
Met Ser Asn Phe Ile Ser Ile Thr Cys Leu Val Phe Thr Ile Leu Gly
1 5 10 15

His Leu Val Ser Leu Gln Val Ala His Ser Ser Val Phe Glu Phe Lys
20 25 30

Thr Leu Tyr Val Leu Lys Thr Asn Arg Tyr Ser Gln Ser Leu Phe Arg
35 40 45

His Phe Cys His Leu Ser Phe Ile Arg Thr Arg Lys Ile Phe Leu Lys
50 55 60

Asn Asn Xaa
65

<210> 147
<211> 49
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (49)
<223> Xaa equals stop translation

<400> 147
Met Met Lys Tyr Phe Phe Asp Val Val Val Phe Leu Thr Phe Phe Leu
1 5 10 15

Val Phe Ser Leu Ser Ile Phe Leu Ser Asp Glu Glu Phe Pro Val Ser
20 25 30

Arg Thr Gln Asn Ile Gly Leu Cys His Phe Asn Pro Ser Phe Ser Glu
35 40 45

Xaa

<210> 148
<211> 89
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (89)
<223> Xaa equals stop translation

<400> 148
Met Leu Leu Leu Cys Leu Tyr Cys Thr Phe Phe Leu Met Pro Phe Ile
1 5 10 15

Ile Lys Tyr Thr Cys Phe His Leu Val Phe Gly Gln Ile Pro Val Thr
20 25 30

Val His Val Asn Ile Trp Gln His Lys Asn Val Thr Phe Phe Ile Leu
35 40 45

His Cys Gly Ile Pro Ala Leu Thr Arg Asp Ser Ala Ala Leu Thr Tyr
50 55 60

Ser Asn Asp Gly Thr Val Ile Glu Thr Leu Leu Phe Leu Ile Leu Tyr
65 70 75 80

Leu Asp Leu Asn Ile Ile Cys Cys Xaa
85

<210> 149
<211> 77
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (77)
<223> Xaa equals stop translation

<400> 149
Met Thr Leu Tyr Ser Lys Leu Leu Trp Leu Phe Lys Gly Glu Leu Leu

1 5 10 15

Phe Pro Leu Val Leu Ala Tyr Val Leu Leu Leu Tyr Ile Val Thr Lys
20 25 30

Phe Asn Tyr Leu Ile Leu Lys Leu Phe Pro Asn Lys Ile Gln Ile Lys
35 40 45

Arg Gly Ser Ile Ala Ser Asn Arg Ser Leu Glu Ser Ser Ala Ser Leu
50 55 60

Pro Ala Arg Lys Glu Glu Lys Leu Leu Lys Lys Phe Xaa
65 70 75

<210> 150
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 150
Met Asn Leu Ser Phe Leu Ser Phe Phe Leu Phe Phe Tyr Leu Leu Trp
1 5 10 15

Ser Pro Ala Glu Ser Val Tyr Lys Lys Gly Met Val Lys Lys Asn Leu
20 25 30

Ser His Ser Ile Val Glu Lys Ile Lys Xaa
35 40

<210> 151
<211> 46
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (46)
<223> Xaa equals stop translation

<400> 151
Met Asn Ala Leu Pro Asn Leu Ala Trp Leu Pro Phe Val Pro Ala Leu
1 5 10 15

Ala Ala Ala Ser Pro Ala Gly Leu Ala Ala Pro Glu Ser Arg Asp Val
20 25 30

Pro Phe Pro Val Ser Pro Ala Thr Gln Leu Asn Ile Gly Xaa
35 40 45

<210> 152
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 152
Met Leu His Leu Leu Cys Leu Gly Leu His Leu Val Pro Pro Gly Leu
1 5 10 15

Leu Ser Val Asn Ser Leu Gln Ser Thr Gln Cys Ser Leu Phe Ser Ala
20 25 30

Ala Lys Phe Phe Ser Ile Val Gln Val Xaa
35 40

<210> 153
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (44)
<223> Xaa equals stop translation

<400> 153
Met Pro Tyr Met Phe Arg Pro Ala Phe Leu Asn Cys Gly Thr Phe Ala
1 5 10 15

Ile Phe Gly Gln Leu Asn Ser Val Val Gly Ala Val Leu Cys Ile Ala
20 25 30

Gly Cys Leu Ala Ala Ser Leu Ala Ser Thr Tyr Xaa
35 40

<210> 154
<211> 123
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (123)
<223> Xaa equals stop translation

<400> 154
Met Pro Pro Leu Ala Pro Gln Leu Cys Arg Ala Val Phe Leu Val Pro
1 5 10 15

Ile Leu Leu Leu Leu Gln Val Lys Pro Leu Asn Gly Ser Pro Gly Pro

20 25 30

Lys Asp Gly Ser Gln Thr Glu Lys Thr Pro Ser Ala Asp Gln Asn Gln
35 40 45

Glu Gln Phe Glu Glu His Phe Val Ala Ser Ser Val Gly Glu Met Trp
50 55 60

Gln Val Val Asp Met Ala Gln Gln Glu Glu Asp Gln Ser Ser Lys Thr
65 70 75 80

Ala Ala Val His Lys His Ser Phe His Leu Ser Phe Cys Phe Ser Leu
85 90 95

Ala Ser Val Met Val Phe Ser Gly Gly Pro Leu Arg Arg Thr Phe Pro
100 105 110

Asn Ile Gln Leu Cys Phe Met Leu Thr His Xaa
115 120

<210> 155
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 155
Met Lys Gln Phe Gly Phe Gly His Pro Ile Lys Leu Leu Lys Thr Lys
1 5 10 15

Leu Cys Arg Ile Val Phe Tyr Leu Val Phe Phe Val Trp Pro Gln Ser
20 25 30

Ser Val Ile Arg Glu Ala Thr Gln Thr Xaa
35 40

<210> 156
<211> 56
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (56)
<223> Xaa equals stop translation

<400> 156
Met Val Leu Ala Ala Pro Leu Val Ala Phe Pro Cys Ile Leu Leu Phe
1 5 10 15

Ala Phe Ser Pro Ser Ala Val Arg Asp His Val Gly Asp Ser Arg Ser

20 25 30

Asp Val Pro Ile Phe Ala Cys Leu Ala Leu Ala Ser Leu Ala Leu Gly
35 40 45

Ser Val Leu Leu Val Ala Phe Xaa
50 55

<210> 157
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 157
Met Met Lys Met Val Leu Gly Leu Phe Phe Leu Met Asn Leu Leu Ser
1 5 10 15

Gly Lys Lys Ser Val Arg His His Ser Lys Asn Tyr Val Lys Lys Met
20 25 30

Gln Thr Phe Gln Phe Pro Arg Val Tyr Lys Leu Met Xaa
35 40 45

<210> 158
<211> 86
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (86)
<223> Xaa equals stop translation

<400> 158
Met Lys Lys Val Leu Leu Leu Ile Thr Ala Ile Leu Ala Val Ala Val
1 5 10 15

Gly Phe Pro Val Ser Gln Asp Gln Glu Arg Glu Lys Arg Ser Ile Ser
20 25 30

Asp Ser Asp Glu Leu Ala Ser Gly Phe Phe Val Phe Pro Tyr Pro Tyr
35 40 45

Pro Phe Arg Pro Leu Pro Pro Ile Pro Phe Pro Arg Phe Pro Trp Phe
50 55 60

Arg Arg Asn Phe Pro Ile Pro Ile Pro Glu Ser Ala Pro Thr Thr Pro
65 70 75 80

Leu Pro Ser Glu Lys Xaa

<210> 159
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 159
Met Ile Cys Leu Cys Ser Ile Lys Met Leu Leu Leu Phe Cys Gln Leu
1 5 10 15

Thr Phe Ala Leu Ile Thr Cys Ile Asn Leu Gln Ser Leu Tyr Leu Phe
20 25 30

Ser Tyr Gln Gln Ile Ile Gly Ile His Ser His Val Xaa
35 40 45

<210> 160
<211> 69
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals stop translation

<400> 160
Met Trp Leu Arg Gly Ile His Pro Phe Leu Trp Leu Ser Gly Ile His
1 5 10 15

Ser Phe Pro Trp Leu Ser Gly Gly Pro Ser Leu Gly Thr Ser Ser Glu
20 25 30

Gln Pro Thr Ser Leu Glu Asp Gly Lys Leu Ile Cys Leu Phe Thr Asp
35 40 45

Phe Ser Gly Ser Ser Phe Gly Leu Phe Met Arg Glu Ala Ala Lys Asn
50 55 60

Ile Ser Gln Met Xaa
65

<210> 161
<211> 53
<212> PRT
<213> Homo sapiens

<220>

<221> SITE
<222> (53)
<223> Xaa equals stop translation

<400> 161
Met Leu Tyr Asp Ser Asn Leu Cys Ser Val Trp His Leu Tyr Leu Ile
1 5 10 15

Leu His Leu Cys Lys Thr Phe Val Tyr Cys Gly Cys Val His Ser Ser
20 25 30

Tyr Leu Ile Ser Gly Thr Val Asn Thr Gln Tyr Phe Ile Val Gln Thr
35 40 45

Val Leu Leu Phe Xaa
50

<210> 162
<211> 57
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (57)
<223> Xaa equals stop translation

<400> 162
Met Arg Val Lys Ile Ser Tyr Leu Met Ile Ala Leu Thr Val Val Gly
1 5 10 15

Cys Ile Phe Met Val Ile Glu Gly Lys Lys Ala Ala Gln Arg His Glu
20 25 30

Thr Leu Thr Ser Leu Asn Leu Glu Lys Lys Ala Arg Leu Lys Glu Glu
35 40 45

Ala Ala Met Lys Ala Lys Thr Glu Xaa
50 55

<210> 163
<211> 56
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (56)
<223> Xaa equals stop translation

<400> 163
Met Arg Glu Lys Thr Gly Ala Leu Pro Arg Cys Leu Gly Leu Leu Gly
1 5 10 15

Val Gly Leu Leu Trp Arg Trp Cys Gly Arg Arg Ala Arg Ala Gly Val

95

20 25 30

Gly Lys Ala Trp Ser Ala Thr Arg Ser Pro Ser Asp Ser Cys Phe Pro
35 40 45

Gly Val Ala Arg Val Gly Ile Xaa
50 55

<210> 164
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 164
Met His Gly His Thr Ser Ser Leu Pro Pro Ser Leu Leu Ser Ser Leu
1 5 10 15

Pro Ser Gly Leu Leu Ala Leu Phe Val Phe Pro Phe Leu Ile Leu Leu
20 25 30

Leu His Ala Glu Asp Leu Pro Tyr Tyr Tyr Phe Gly Asn Ile Glu Xaa
35 40 45

<210> 165
<211> 130
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (130)
<223> Xaa equals stop translation

<400> 165
Met Ser Ala Ser Ser Leu His Arg Leu Pro Val Leu Met Ala Leu Phe
1 5 10 15

Pro Phe Gln Ala Ala Ala Ala Gly Ser Leu Gly Leu Gln Pro Pro Pro
20 25 30

Thr Pro Met Lys Gly Lys Pro Ser Ile Met Leu Pro Pro Gln Tyr Lys
35 40 45

Arg Arg Glu Gly Leu Lys Lys Lys Lys Lys Lys Ile Gln Lys Val Ala
50 55 60

Leu Val Ser Phe Gly Arg Ala Asp Ser Ile Val Gly Asp Gly Leu Pro

96

65 70 75 80

Thr Asn Gln Gly Asp Lys Cys Gln Arg Glu Arg Thr Met Pro Gly Ser
85 90 95

Lys His Ile Ser Pro Gln Thr Pro Gln Val Gly Lys Gln Ala Arg Gly
100 105 110

Ser Thr Asn Pro Ser Gly Arg Pro Gly Val Gln Met Leu Tyr Ser Ser
115 120 125

Ile Xaa
130

<210> 166
<211> 105
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (105)
<223> Xaa equals stop translation

<400> 166
Met Leu Trp Leu Leu Phe Phe Leu Val Thr Ala Ile His Ala Glu Leu
1 5 10 15

Cys Gln Pro Gly Ala Glu Asn Ala Phe Lys Val Arg Leu Ser Ile Arg
20 25 30

Thr Ala Leu Gly Asp Lys Ala Tyr Ala Trp Asp Thr Asn Glu Glu Tyr
35 40 45

Leu Phe Lys Ala Met Val Ala Phe Ser Met Arg Lys Val Pro Asn Arg
50 55 60

Glu Ala Thr Glu Ile Ser His Val Leu Leu Cys Asn Val Thr Gln Arg
65 70 75 80

Tyr His Ser Gly Leu Trp Leu Gln Thr Leu Gln Lys Ile Thr Pro Phe
85 90 95

Leu Leu Leu Arg Cys Asn Gln Pro Xaa
100 105

<210> 167
<211> 77
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (77)
<223> Xaa equals stop translation

<400> 167
Met Thr Lys Ala Arg Leu Phe Arg Leu Trp Leu Val Leu Gly Ser Val
1 5 10 15

Phe Met Ile Leu Leu Ile Ile Val Tyr Trp Asp Ser Ala Ala Pro Arg
20 25 30

Thr Ser Thr Cys Thr Arg Pro Ser Leu Gly Arg Thr Arg Gly Arg Arg
35 40 45

Cys Pro Arg Pro Gly Arg Thr Gly Gln Gly Ala His Gly Arg Leu Arg
50 55 60

Cys Arg Arg Val Ser Gly Gln Phe Leu Met Leu Ala Xaa
65 70 75

<210> 168
<211> 355
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (355)
<223> Xaa equals stop translation

<400> 168
Met Trp Arg Leu Trp Pro Gly Ser Pro Leu Val Pro Leu Ser Trp Leu
1 5 10 15

Trp Pro Ala Arg Ala Ala Phe Leu Ser Gly Pro Trp Thr Leu Pro Pro
20 25 30

Cys Leu Pro Asp Pro Leu Leu Ala Val Pro Lys Cys Cys Leu Thr Leu
35 40 45

Gly Ile His Leu Leu Pro Ala Trp Pro Gly Pro Pro Val Gly Gly Gly
50 55 60

Cys Ser Gln Leu His Arg Gly Cys Cys Tyr Pro Gly Met Gly Cys Leu
65 70 75 80

Asn Arg Asp Leu Cys Pro Pro Ser Leu Val Ser Arg Arg Trp Gly Asp
85 90 95

Gln Leu Leu Trp Ser Pro Asp Gly Ser Lys Ile Leu Ala Thr Thr Pro
100 105 110

Ser Ala Val Phe Arg Val Trp Glu Ala Gln Met Trp Thr Cys Glu Arg
115 120 125

Trp Pro Thr Leu Ser Gly Arg Cys Gln Thr Gly Cys Trp Ser Pro Asp
130 135 140

Gly Ser Arg Leu Leu Phe Thr Val Leu Gly Glu Pro Leu Ile Tyr Ser

145 150 155 160

Leu Ser Phe Pro Glu Arg Cys Gly Glu Gly Lys Gly Cys Val Gly Gly
165 170 175

Ala Lys Ser Ala Thr Ile Val Ala Asp Leu Ser Glu Thr Thr Ile Gln
180 185 190

Thr Pro Asp Gly Glu Glu Arg Leu Gly Gly Glu Ala His Ser Met Val
195 200 205

Trp Asp Pro Ser Gly Glu Arg Leu Ala Val Leu Met Lys Gly Lys Pro
210 215 220

Arg Val Gln Asp Gly Lys Pro Val Ile Leu Leu Phe Arg Thr Arg Asn
225 230 235 240

Ser Pro Val Phe Glu Leu Leu Pro Cys Gly Ile Ile Gln Gly Glu Pro
245 250 255

Gly Ala Gln Pro Gln Leu Ile Thr Phe His Leu Pro Ser Thr Lys Gly
260 265 270

Pro Cys Ser Val Trp Ala Gly Pro Gln Ala Glu Leu Pro Thr Ser Arg
275 280 285

Cys Thr Leu Ser Met Pro Ser Phe His Val Leu Ala Gln Cys Leu Gly
290 295 300

Gly Pro Arg Asn Pro Leu Leu Gly Val Glu Ala Leu Phe Met Thr Cys
305 310 315 320

Pro Ser Leu Leu Arg His Pro Gln Pro Leu Pro Leu Gly Thr Leu Ser
325 330 335

Gln Gly His His Leu Phe Cys Pro Thr Pro His Ile Pro Thr Ser Lys
340 345 350

Asn Lys Xaa
355

<210> 169
<211> 90
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (90)
<223> Xaa equals stop translation

<400> 169
Met Cys Val Cys Tyr Phe Leu Val Phe Leu Gln Ile Trp Ala Arg Leu
1 5 10 15

Ser His Leu Leu Val Trp Ile Tyr Pro Gly Ala Gly Leu Gln Pro Gly

20 25 30

Lys Gly His Pro Ala Gln Ser Leu Phe Pro His Glu His Cys His Leu
35 40 45

Met Pro Gln His Ser Leu Thr Leu Lys Ile Leu Glu Glu Lys Leu Gly
50 55 60

Gly Lys Gly Glu Ser Gly Ser Asn Phe Thr Phe Leu His Cys Lys Ile
65 70 75 80

Leu Ala Thr Ser Ala Leu Asn Phe Ser Xaa
85 90

<210> 170
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals stop translation

<400> 170
Met Val Leu Pro Phe Val Leu Leu Phe Arg Pro Asn Phe Ile Ser Val
1 5 10 15

Leu His Pro Leu Phe Tyr Ser His Cys Leu Phe Leu Tyr Leu Ile Ser
20 25 30

Pro Val His Ser Ser Ser Ile Ile Tyr Tyr Lys Pro Asp His Cys His
35 40 45

Tyr Thr Pro Phe Ile Pro Gly Leu Leu Gln Xaa
50 55

<210> 171
<211> 70
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (70)
<223> Xaa equals stop translation

<400> 171
Met Leu Leu Ser Lys Glu His Thr Ser Leu Gly Trp Leu Val Ile Phe
1 5 10 15

Leu Thr Leu Ala Ser Gln Leu Ile Ser Tyr Gly Ser Arg Thr Gly Asn
20 25 30

Ser Arg Cys Pro Pro Cys Leu Tyr Arg Thr Leu His Thr Val Ser Thr

35 40 45

Ser His Val Leu Ser Ser Leu Phe Val Ser Thr Phe Ser Gly Asp Glu
50 55 60

Leu Val Trp Thr Thr Xaa
65 70

<210> 172
<211> 79
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (79)
<223> Xaa equals stop translation

<400> 172
Met Val Leu Asp Phe Lys Arg Ala Gly Ser Phe Phe Leu Ser Phe Leu
1 5 10 15

Trp Thr Arg Glu Ala Phe Ala Phe Ile Phe Thr Leu Pro Leu Leu Leu
20 25 30

Ser Leu Cys Arg Gly Lys Met Lys Asn Ser Pro Arg Ser Asp Leu Ser
35 40 45

Arg Leu Lys Lys Asn Val Phe Asn Ala Phe Leu Pro Cys Leu Val Pro
50 55 60

Arg Phe Ile Ser Asn Arg Gly Cys Pro Val Tyr Arg Ser Cys Xaa
65 70 75

<210> 173
<211> 174
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (150)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (152)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (174)
<223> Xaa equals stop translation

<400> 173

```
Met Gly Val Pro Thr Ala Pro Glu Ala Gly Ser Trp Arg Trp Gly Ser
 1               5                  10                  15

Leu Leu Phe Ala Leu Phe Leu Ala Ala Ser Leu Asp Ile Thr Ala Ala
            20                  25                  30

Ala Leu Ala Thr Gly Ala Cys Ile Val Glu Ser Ser Ala Ser Pro Ser
        35                  40                  45

Ser Cys Ser Trp Ser Thr Ser Lys Gly Arg Gln Pro Pro Thr Ala Val
    50                  55                  60

Pro Arg Ser Trp Cys Gly Trp Thr Ala Thr Phe Lys Gly Leu Lys Thr
65                  70                  75                  80

Pro Ala Leu Lys Pro His His Leu Pro Arg Gly Tyr Pro Arg Pro Lys
                85                  90                  95

Ser Gly Thr Pro Cys Pro Met Trp Pro Ser Gly Ser Leu Leu Ser Leu
            100                 105                 110

Gly Gly Ile Cys Phe Arg Ser Pro Ala Pro Pro Cys Leu Leu Gln Ala
        115                 120                 125

Pro Glu Thr Ser Ser Ser His Pro Trp Thr Leu Ser Leu Thr Leu Gln
    130                 135                 140

Thr Leu Arg Ser Ser Xaa Pro Xaa Gly Gly Gln Trp Ala Val Val Ala
145                 150                 155                 160

Gly Ser Gly Ala Gly Ala Phe Glu Pro Gly Leu Ala Leu Xaa
                165                 170
```

<210> 174
<211> 64
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (64)
<223> Xaa equals stop translation

<400> 174

```
Met Phe Val Leu Trp Val Phe Lys Ile Thr Tyr Ile Tyr Ile Leu Phe
 1               5                  10                  15

Ala Lys Asn Lys Ser Leu Ala Ser Cys Gln Met Ile Ala Lys Val Asp
            20                  25                  30

Leu Thr Phe Phe Val Ile Met Tyr Ile Phe Ile His Thr Pro Asn Thr
        35                  40                  45

Leu Ser Asp Phe Cys Tyr Phe Leu Gly Ser Thr Ala Leu Arg Leu Xaa
    50                  55                  60
```


<210> 175
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 175

```
Met Ile Ser Ala Gln Ser Ser Ile Ser Trp Ala Leu Ile Phe Ile Met
 1               5                  10                  15

Ala Pro Ala Leu His Leu Val Leu Arg Phe Pro Ser Lys Phe Lys Pro
            20                  25                  30

Glu Arg Lys Gly Glu Ala Arg Ser Pro Lys Xaa
        35                  40
```

<210> 176
<211> 114
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (114)
<223> Xaa equals stop translation

<400> 176

```
Met Trp Ile Ala Gly Pro Ser Trp Val Pro Leu Arg Tyr Val Val Trp
 1               5                  10                  15

Leu Met His Leu Glu Arg Ile Cys Ala Leu His Asn Cys Arg Gly Asn
            20                  25                  30

Met Leu Ser Trp Pro Leu Gln Ile Arg Val Ala Val Leu Gly Cys Cys
        35                  40                  45

Thr Lys Thr Pro Ala Val Gly Phe Leu Gln Val Ala Gly Ser Pro His
    50                  55                  60

Ser Cys Gln Asp Pro Gly Pro Cys Ser His Ser Ala Ala Ile Phe Pro
65                  70                  75                  80

Pro Cys Glu Arg Gly Leu Cys Gly Asp Gly Pro Arg Cys Val Arg Gly
                85                  90                  95

Cys Val His Cys His Arg Ser Leu Leu His Glu Pro Ala Trp Thr Gln
            100                 105                 110
```

Gly Xaa

<210> 177
<211> 156
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (156)
<223> Xaa equals stop translation

<400> 177
Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val Ser Leu
1 5 10 15

Leu Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser Val Leu
20 25 30

Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala Asp Leu
35 40 45

Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu Leu Lys
50 55 60

Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala Asp Gly
65 70 75 80

Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg Thr Ser
85 90 95

Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg Ile His
100 105 110

Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe Gln Asp
115 120 125

Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala Ala Leu
130 135 140

Gly Ser Asn Leu His Val Gly Ser Glu Gly Leu Xaa
145 150 155

<210> 178
<211> 89
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (89)
<223> Xaa equals stop translation

<400> 178

Met Trp Pro Ser Gln Val Pro Leu Leu Ala Phe Cys Phe Leu Leu Val
1 5 10 15

Lys Ser Thr Ser Asn Ile Asn Leu Pro Thr Pro Pro Pro Ser Ser Leu
20 25 30

Glu Asn Ser Ser Phe Val Val Ser Gln Arg Gly Asn Leu Ile Val Phe
35 40 45

Gly Gly Gln Lys Lys Ala Thr Phe Arg Tyr His Phe Tyr Leu Asp Arg
50 55 60

Met Pro Phe Tyr Ser Gln Ile Ser Val Tyr Phe Val Asn Gly Phe Arg
65 70 75 80

Val Asn Gly Tyr Leu Cys Asn Asn Xaa
85

<210> 179
<211> 197
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (197)
<223> Xaa equals stop translation

<400> 179
Met Ala Phe Arg Tyr Leu Ser Trp Ile Leu Phe Pro Leu Leu Gly Cys
1 5 10 15

Tyr Ala Val Tyr Ser Leu Leu Tyr Leu Glu His Lys Gly Trp Tyr Ser
20 25 30

Trp Val Leu Ser Met Leu Tyr Gly Phe Leu Leu Thr Phe Gly Phe Ile
35 40 45

Thr Met Thr Pro Gln Leu Phe Ile Asn Tyr Lys Leu Lys Ser Val Ala
50 55 60

His Leu Pro Trp Arg Met Leu Thr Tyr Lys Ala Leu Asn Thr Phe Ile
65 70 75 80

Asp Asp Leu Phe Ala Phe Val Ile Lys Met Pro Val Met Tyr Arg Ile
85 90 95

Gly Cys Leu Arg Asp Asp Val Val Phe Phe Ile Tyr Leu Tyr Gln Arg
100 105 110

Trp Ile Tyr Arg Val Asp Pro Thr Arg Val Asn Glu Phe Gly Met Ser
115 120 125

Gly Glu Asp Pro Thr Ala Ala Ala Pro Val Ala Glu Val Pro Thr Ala
130 135 140

Ala Gly Ala Leu Thr Pro Thr Pro Ala Pro Thr Thr Thr Thr Ala Thr
145 150 155 160

Arg Glu Glu Ala Ser Thr Ser Leu Pro Thr Lys Pro Thr Gln Gly Ala
165 170 175

Ser Ser Ala Ser Glu Pro Gln Glu Ala Pro Pro Lys Pro Ala Glu Asp
180 185 190

Lys Lys Lys Asp Xaa
195

<210> 180
<211> 129
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (129)
<223> Xaa equals stop translation

<400> 180
Met Tyr Glu Cys Phe Leu Ser Leu Ser Leu Leu Lys Ser Cys Lys Ala
1 5 10 15

Val Ser Gly Leu Met Cys Leu Leu Leu Pro Arg Leu Gly Leu Leu Leu
20 25 30

Leu Leu Pro Ser Glu Arg Cys Phe Cys Trp Ile Pro Val Tyr Ser Leu
35 40 45

Ile Thr Cys Leu Ala Glu Cys Ser Val Val Leu Arg Asp Pro Gly Phe
50 55 60

Ala Gly Ala Phe Gln Val His Arg Arg Gln Ala Cys Phe Ser Thr Leu
65 70 75 80

Arg Trp Ser Cys Leu Leu Leu Trp Trp Val Ser Arg Val Ser Ala Gly
85 90 95

Arg Pro Leu Ile Gly Ser Pro His Met Met Ala Pro Ser Thr Phe Cys
100 105 110

Pro Thr Val Arg Gly Pro Gly Thr Cys Ala Ser Ser Asp Pro Asp Gly
115 120 125

Xaa

<210> 181
<211> 155
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (155)
<223> Xaa equals stop translation

<400> 181
Met Pro Ala Glu Lys Arg Ile Phe Gly Ala Val Leu Leu Phe Ser Trp
1 5 10 15

Thr Val Tyr Leu Trp Glu Thr Phe Leu Ala Gln Arg Gln Arg Arg Ile
20 25 30

Tyr Lys Thr Thr Thr His Val Pro Pro Glu Leu Gly Gln Ile Met Asp
35 40 45

Ser Glu Thr Phe Glu Lys Ser Arg Leu Tyr Gln Leu Asp Lys Ser Thr
50 55 60

Phe Ser Phe Trp Ser Gly Leu Tyr Ser Glu Thr Glu Gly Thr Leu Asn
65 70 75 80

Leu Leu Phe Gly Gly Ile Pro Tyr Leu Trp Arg Leu Ser Gly Arg Phe
85 90 95

Cys Gly Tyr Ala Gly Phe Gly Pro Glu Tyr Glu Ile Thr Gln Ser Leu
100 105 110

Val Phe Leu Leu Leu Ala Thr Leu Phe Ser Ala Leu Thr Gly Val Pro
115 120 125

Trp Ser Leu Tyr Asn Thr Phe Val Ile Lys Lys Thr Trp Leu Gln Ser
130 135 140

Thr Asp Phe Gly Val Leu His Met Glu Ile Xaa
145 150 155

<210> 182
<211> 107
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (107)
<223> Xaa equals stop translation

<400> 182
Met Ser Leu Ser Trp Met Val His Leu Leu Gly Leu Pro Asn Gly Thr
1 5 10 15

Val Trp Tyr Leu Pro Phe Val Cys Phe Thr Arg Gly Ser Pro Met Gly
20 25 30

Gly Gly Ser Gly Gln Trp Arg Trp Asp Arg Lys Phe Ser Lys Thr Leu
35 40 45

Leu Gly Asn Leu Phe Val Ala Phe Lys Glu Met Cys Gly Glu Asp Ile
50 55 60

Trp Met Leu Ala Ala Ile Leu Glu Leu Arg Thr Gln Glu Trp Trp Lys
65 70 75 80

Gly Arg Arg Asn Arg Val Phe Val Ala Val Val Lys Leu Leu Lys Phe
85 90 95

Pro Ser Cys Gln Ala Ser Cys Tyr Met Arg Xaa
100 105

<210> 183
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 183
Met Ile Asn Glu Trp Cys Phe Lys Leu Leu Ser Leu Trp Ser Phe Ala
1 5 10 15

Tyr Ser Asn Cys Lys Leu Ile His Lys Cys Lys Phe Val Phe Leu Lys
20 25 30

Lys Lys Lys Thr Gly Lys Glu Val Ser Val Lys Gly Ser Lys Leu Xaa
35 40 45

<210> 184
<211> 127
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (127)
<223> Xaa equals stop translation

<400> 184
Met Trp Leu Gly Ser Trp Leu Thr Ser Leu Leu Leu Ser Pro Tyr Gly
1 5 10 15

Ser Gly Trp Glu Lys Val Pro Cys Cys Val Thr Gly His Leu Arg Ser
20 25 30

Cys Ser Cys Cys Leu Leu Gly Leu Ala Gly Val Gln Ser Asp His Phe
35 40 45

Ser Glu Gly Phe Phe Ser Glu Tyr Ser Ser Asp Val Leu Pro Trp Gly
50 55 60

Arg Arg Ser Phe Leu Pro Gln Gly Asp Ala Ser Leu Leu Ala Cys Glu
65 70 75 80

Cys Phe Leu His Leu Gln Val Val Trp Gly Gln Phe Cys Leu Leu Glu
85 90 95

Ala Trp Ala Gly Phe Thr Glu Gly Ser Met Pro Ala Pro Ser Cys Arg
100 105 110

Val His Phe Trp Cys Arg Val Asn Thr Cys Pro Phe Met Ser Xaa
115 120 125

<210> 185
<211> 87
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (87)
<223> Xaa equals stop translation

<400> 185
Met Leu Cys Gly Tyr Val Ile Asn Asn Ile Trp Leu Ile Phe Thr Tyr
1 5 10 15

Phe Ile Cys Ile Tyr Ile Ser Arg Ser Tyr Ile Tyr Ile Thr Gln Glu
20 25 30

Thr Gln Val Ile Tyr Ile Cys Gln Glu Met Tyr Asp Tyr Phe Gly Glu
35 40 45

Asn Gly Pro Lys Cys Glu Lys Asp Ile Lys Lys Thr Lys Lys Thr Lys
50 55 60

Lys Lys His Tyr Phe Pro Leu Arg Asn Ile Leu Tyr Ile Ser Lys Glu
65 70 75 80

Glu Lys Leu Lys Asp Ile Xaa
85

<210> 186
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 186

Met Ile Val Ser Tyr Arg Ile Val Ser Leu Pro Ser Ser Val Leu Cys
1 5 10 15

Leu Phe Ile Pro Pro Phe Leu Leu Ile Phe Tyr Cys Leu His Ser Phe
20 25 30

Val Phe Ser Gln Met Leu Tyr Ser Trp Asn Tyr His Val Thr Phe Gln
35 40 45

Met Ala Phe Ser Leu Ile Ile Cys Val Xaa
50 55

<210> 187
<211> 69
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals stop translation

<400> 187
Met Val Ala Ser Gln Ala Trp Trp Leu Ser Asn Leu Trp His Leu Trp
1 5 10 15

Glu Val Gly Ser Ala Gln Gly Leu Pro Leu Asp Pro Pro Ala Leu Ala
20 25 30

Pro Tyr Leu Pro Trp Ala Leu Arg Trp Pro Cys Phe Ser Gly Phe Ala
35 40 45

Ser Leu Ala Gly Ala Leu Val Leu Ala His Ser Leu Pro Thr Ala Trp
50 55 60

Pro Gly Ser Ser Xaa
65

<210> 188
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 188
Met Tyr Leu Phe Leu Leu Cys Cys Phe Ile Ser Glu His Cys Ala Gln
1 5 10 15

His Ser Phe Pro His Thr Cys Pro Asn Trp Lys Thr Arg Val Leu Ser
20 25 30

Phe Pro Leu His Pro Cys Pro His Leu Ile His Pro Asn Asn Thr Xaa
35 40 45

<210> 189
<211> 51
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (51)
<223> Xaa equals stop translation

<400> 189
Met Leu Ser Ser Xaa Tyr Val Pro Met Cys Gln His Phe Ile Tyr Pro
1 5 10 15

Val Leu Trp Val Leu Val His Phe Phe Ser Phe Ile Gln Ile Gln Lys
20 25 30

Asn Thr Asp Gly Ser Asn Val Lys Leu Thr Arg Asn Pro Gly Thr Phe
35 40 45

Ile Ser Xaa
50

<210> 190
<211> 56
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (56)
<223> Xaa equals stop translation

<400> 190
Met Ala Val Arg Val Leu Trp Gly Gly Leu Ser Leu Leu Arg Val Leu
1 5 10 15

Trp Cys Leu Leu Pro Gln Thr Gly Tyr Val His Pro Asp Glu Phe Phe
20 25 30

Gln Ser Pro Glu Val Met Ala Gly Lys Thr Pro His Val Trp Leu Arg
35 40 45

Gln Ala Ala Ala Glu Ser Ala Xaa

50 55

<210> 191
<211> 127
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (127)
<223> Xaa equals stop translation

<400> 191
Met Cys Ser Ser Phe Pro Arg Met Ala Leu Cys Ala Leu Trp Met Trp
1 5 10 15

Pro Ser Val Lys Ser Ser Val Pro Leu Pro Leu Arg Glu Pro Phe Leu
20 25 30

Trp Arg Ser Pro Gly Ser Gln Cys Leu Leu Cys Leu Gln Thr Ile His
35 40 45

Val Ser Cys Ser Glu Ala Cys Pro Leu Leu Glu Asn Ile Ser Lys Asn
50 55 60

Cys Thr Ile Pro Gln Arg Asp Leu Asp Asn Met Ala Phe Pro Gln Ala
65 70 75 80

Leu Pro Leu Glu Lys Arg Cys Glu Arg Phe Leu Gln Lys Ser Tyr Arg
85 90 95

Lys Leu Glu Lys Asn Pro Glu Lys Glu Glu Glu His Trp Ala Arg Leu
100 105 110

Gln Arg Tyr Ser Leu Ser Leu Gln Arg Glu Asn Phe Lys Lys Xaa
115 120 125

<210> 192
<211> 70
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (70)
<223> Xaa equals stop translation

<400> 192
Met Pro Phe Gln Leu Pro Leu Gln Leu Leu Leu Leu Arg Leu Ile Cys
1 5 10 15

Glu Phe Phe Leu Ala Pro Ala Leu Asn Cys Asn Leu Thr Gly Thr Val
20 25 30

Ile Phe Phe Thr Leu Met Ile Ser Leu Gln Leu Met Ile Phe Phe Thr

35 40 45

Leu Gln Phe Ala Asp Gly Phe Gln Ile Gly Val Asp Leu Gln Leu Ser
50 55 60

Glu Leu Asn Ile Leu Xaa
65 70

<210> 193
<211> 71
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (71)
<223> Xaa equals stop translation

<400> 193
Met Ile Ser Gly Val Leu Ile Phe Asn Leu Ile Ala Ser Ser Trp Val
1 5 10 15

Leu Cys Phe Pro Leu Cys Asp Leu Ser Cys Gln Lys Thr Leu Arg Ile
20 25 30

Phe Phe Ala Ser Phe Phe His Ala Val Cys Val His Val Ser Cys Thr
35 40 45

Ser Trp Gln Pro Leu Val Leu Phe Ile Lys Trp Trp Val Val Gly Cys
50 55 60

Ser Pro Ala Val Ser Leu Xaa
65 70

<210> 194
<211> 130
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (130)
<223> Xaa equals stop translation

<400> 194
Met His Val Leu Pro Leu Leu Leu Ser Leu Leu Leu Leu Leu Leu Leu
1 5 10 15

Leu Ser Ala Ser Phe Val Thr Phe Ser Thr Pro Thr Ser Ser Arg Asn
20 25 30

Ser Ser Cys Pro Asp Cys Glu Ser Leu Asn Thr Gly Leu Pro Ser Leu
35 40 45

Met Met Phe Gly Gly Ser Leu Leu Lys Trp Val Gln Asn Thr His Gly

```
     50                  55                  60

Val Glu Ser Leu Leu Ser Ser Ala Lys Val Arg Leu Leu Pro Pro Ala
 65                  70                  75                  80

Leu Gly Val Leu Phe Pro Arg Leu His Pro Gly Thr Leu Thr Leu Val
                85                  90                  95

Phe Leu Leu Ile Pro Phe Leu Thr Val Ser Ser Ser Thr Ser Asp Val
            100                 105                 110

Leu Ser Ser Leu Glu Ser Pro Lys Leu Ser Val Thr Ile Phe His Tyr
        115                 120                 125

Cys Xaa
    130
```

<210> 195
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (55)
<223> Xaa equals stop translation

<400> 195

```
Met Pro Trp Ile Leu Met Leu Leu Phe Thr Met Gly Gln Gly Val Val
  1               5                  10                  15

Ile Leu Ala Phe Arg Ser Cys Leu Glu Ala Glu Val Arg Gly Val Pro
             20                  25                  30

Gly Arg Gly Asn Arg Ser Gly Val Lys Thr Val Val Glu Ala Pro Ala
         35                  40                  45

Val Phe Ala Lys Arg Pro Xaa
     50                  55
```

<210> 196
<211> 80
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (80)
<223> Xaa equals stop translation

<400> 196

```
Met Ala Ala Phe Phe Ala Leu Ala Ala Leu Val Gln Val Val Tyr Thr
  1               5                  10                  15

Ile Pro Ala Val Leu Thr Leu Leu Val Gly Leu Asn Pro Glu Val Thr
```



```
             20                  25                  30

Gly Asn Val Ile Trp Lys Ser Ile Ser Ala Ile His Ile Leu Phe Cys
         35                  40                  45

Thr Val Trp Ala Val Gly Leu Ala Ser Tyr Leu Leu His Arg Thr Gln
     50                  55                  60

Gln Asn Ile Leu His Glu Glu Glu Gly Arg Ser Cys Leu Val Trp Xaa
 65                  70                  75                  80
```

<210> 197
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 197

```
Met Lys His Met Asn Thr Leu Pro Ile Phe Ser Ser Leu Ile Ser Phe
  1               5                  10                  15

Leu Pro Ala Val Ser Ala Gly Arg Ser Ala Ile Thr Thr Leu Cys Asn
             20                  25                  30

Ile Thr Glu Gln Leu Glu Val Leu Gly Xaa
         35                  40
```

<210> 198
<211> 197
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (197)
<223> Xaa equals stop translation

<400> 198

```
Met Lys Tyr Leu Arg His Arg Arg Pro Asn Ala Thr Leu Ile Leu Ala
  1               5                  10                  15

Ile Gly Ala Phe Thr Leu Leu Leu Phe Ser Leu Leu Val Ser Pro Pro
             20                  25                  30

Thr Cys Lys Val Gln Glu Gln Pro Pro Ala Ile Pro Glu Ala Leu Ala
         35                  40                  45

Trp Pro Thr Pro Pro Thr Arg Pro Ala Pro Ala Pro Cys His Ala Asn
```

115

50 55 60

Thr Ser Met Val Thr His Pro Asp Phe Ala Thr Gln Pro Gln His Val
65 70 75 80

Gln Asn Phe Leu Leu Tyr Arg His Cys Arg His Phe Pro Leu Leu Gln
85 90 95

Asp Val Pro Pro Ser Lys Cys Ala Gln Pro Val Phe Leu Leu Leu Val
100 105 110

Ile Lys Ser Ser Pro Ser Asn Tyr Val Arg Arg Glu Leu Leu Arg Arg
115 120 125

Thr Trp Gly Arg Glu Arg Lys Val Arg Gly Leu Gln Leu Arg Leu Leu
130 135 140

Phe Leu Val Gly Thr Ala Ser Asn Pro His Glu Ala Arg Lys Val Asn
145 150 155 160

Arg Leu Leu Glu Leu Glu Ala Gln Thr His Gly Asp Ile Leu Gln Trp
165 170 175

Asp Phe His Asp Ser Phe Phe Asn Leu Thr Leu Lys Gln Val Arg Trp
180 185 190

Thr Gly Val Thr Xaa
195

<210> 199
<211> 124
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (124)
<223> Xaa equals stop translation

<400> 199
Met Lys Leu Leu Leu Leu Ala Leu Pro Met Leu Val Leu Leu Pro Gln
1 5 10 15

Val Ile Pro Ala Tyr Ser Gly Glu Lys Lys Cys Trp Asn Arg Ser Gly
20 25 30

His Cys Arg Lys Gln Cys Lys Asp Gly Glu Ala Val Lys Asp Thr Cys
35 40 45

Lys Asn Leu Arg Ala Cys Cys Ile Pro Ser Asn Glu Asp His Arg Arg
50 55 60

Val Pro Ala Thr Ser Pro Thr Pro Leu Ser Asp Ser Thr Pro Gly Ile
65 70 75 80

Ile Asp Asp Ile Leu Thr Val Arg Phe Thr Thr Asp Tyr Phe Glu Val

116

85 90 95

Ser Ser Lys Lys Asp Met Val Glu Glu Ser Glu Ala Gly Arg Gly Thr
100 105 110

Glu Thr Ser Leu Pro Asn Val His His Ser Ser Xaa
115 120

<210> 200
<211> 549
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (398)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 200
Met Gly Asn Ala Cys Ile Pro Leu Lys Arg Ile Ala Tyr Phe Leu Cys
1 5 10 15

Leu Leu Ser Ala Leu Leu Leu Thr Glu Gly Lys Lys Pro Ala Lys Pro
20 25 30

Lys Cys Pro Ala Val Cys Thr Cys Thr Lys Asp Asn Ala Leu Cys Glu
35 40 45

Asn Ala Arg Ser Ile Pro Arg Thr Val Pro Pro Asp Val Ile Ser Leu
50 55 60

Ser Phe Val Arg Ser Gly Phe Thr Glu Ile Ser Glu Gly Ser Phe Leu
65 70 75 80

Phe Thr Pro Ser Leu Gln Leu Leu Leu Phe Thr Ser Asn Ser Phe Asp
85 90 95

Val Ile Ser Asp Asp Ala Phe Ile Gly Leu Pro His Leu Glu Tyr Leu
100 105 110

Phe Ile Glu Asn Asn Asn Ile Lys Ser Ile Ser Arg His Thr Phe Arg
115 120 125

Gly Leu Lys Xaa Leu Ile His Leu Ser Leu Ala Asn Asn Asn Leu Gln
130 135 140

Thr Leu Pro Lys Asp Ile Phe Lys Gly Leu Asp Ser Leu Thr Asn Val
145 150 155 160

Asp Leu Arg Gly Asn Ser Phe Asn Cys Asp Cys Lys Leu Lys Trp Leu
165 170 175

```
Val Glu Trp Leu Gly His Thr Asn Ala Thr Val Glu Asp Ile Tyr Cys
            180                 185                 190

Glu Gly Pro Pro Glu Tyr Lys Lys Arg Lys Ile Asn Ser Leu Ser Ser
        195                 200                 205

Lys Asp Phe Asp Cys Ile Ile Thr Glu Phe Ala Lys Ser Gln Asp Leu
    210                 215                 220

Pro Tyr Gln Ser Leu Ser Ile Asp Thr Phe Ser Tyr Leu Asn Asp Glu
225                 230                 235                 240

Tyr Val Val Ile Ala Gln Pro Phe Thr Gly Lys Cys Ile Phe Leu Glu
                245                 250                 255

Trp Asp His Val Glu Lys Thr Phe Arg Asn Tyr Asp Asn Ile Thr Gly
            260                 265                 270

Thr Ser Thr Val Val Cys Lys Pro Ile Val Ile Glu Thr Gln Leu Tyr
        275                 280                 285

Val Ile Val Ala Gln Leu Phe Gly Gly Ser His Ile Tyr Lys Arg Asp
    290                 295                 300

Ser Phe Ala Asn Lys Phe Ile Lys Ile Gln Asp Ile Glu Ile Leu Lys
305                 310                 315                 320

Ile Arg Lys Pro Asn Asp Ile Glu Thr Phe Lys Ile Glu Asn Asn Trp
                325                 330                 335

Tyr Phe Val Val Ala Asp Ser Ser Lys Ala Gly Phe Thr Thr Ile Tyr
            340                 345                 350

Lys Trp Asn Gly Asn Gly Phe Tyr Ser His Gln Ser Leu His Ala Trp
        355                 360                 365

Tyr Arg Asp Thr Asp Val Glu Tyr Leu Glu Ile Val Arg Thr Pro Gln
    370                 375                 380

Thr Leu Arg Thr Pro His Leu Ile Leu Ser Ser Ser Ser Xaa Arg Pro
385                 390                 395                 400

Val Ile Tyr Gln Trp Asn Lys Ala Thr Gln Leu Phe Thr Asn Gln Thr
                405                 410                 415

Asp Ile Pro Asn Met Glu Asp Val Tyr Ala Val Lys His Phe Ser Val
            420                 425                 430

Lys Gly Asp Val Tyr Ile Cys Leu Thr Arg Phe Ile Gly Asp Ser Lys
        435                 440                 445

Val Met Lys Trp Gly Gly Ser Ser Phe Gln Asp Ile Gln Arg Met Pro
    450                 455                 460

Ser Arg Gly Ser Met Val Phe Gln Pro Leu Gln Ile Asn Asn Tyr Gln
465                 470                 475                 480
```



```
Tyr Ala Ile Leu Gly Ser Asp Tyr Ser Phe Thr Gln Val Tyr Asn Trp
                485                 490                 495

Asp Ala Glu Lys Ala Lys Phe Val Lys Phe Gln Glu Leu Asn Val Gln
            500                 505                 510

Ala Pro Arg Ser Phe Thr His Val Ser Ile Asn Lys Arg Asn Phe Leu
        515                 520                 525

Phe Ala Ser Ser Phe Lys Gly Asn Thr Gln Ile Tyr Lys His Val Ile
    530                 535                 540

Val Asp Leu Ser Ala
545


<210> 201
<211> 488
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (344)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (416)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (429)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (430)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 201
Met Ile Leu Ser Leu Leu Phe Ser Leu Gly Gly Pro Leu Gly Trp Gly
  1                 5                  10                  15

Leu Leu Gly Ala Trp Ala Gln Ala Ser Ser Thr Ser Leu Ser Asp Leu
            20                  25                  30

Gln Ser Ser Arg Thr Pro Gly Val Trp Lys Ala Glu Ala Glu Asp Thr
        35                  40                  45

Ser Lys Asp Pro Val Gly Arg Asn Trp Cys Pro Tyr Pro Met Ser Lys
    50                  55                  60

Leu Val Thr Leu Leu Ala Leu Cys Lys Thr Glu Lys Phe Leu Ile His
65                  70                  75                  80
```

```
Ser Gln Gln Pro Cys Pro Gln Gly Ala Pro Asp Cys Gln Lys Val Lys
                85                  90                  95

Val Met Tyr Arg Met Ala His Lys Pro Val Tyr Gln Val Lys Gln Lys
            100                 105                 110

Val Leu Thr Ser Leu Ala Trp Arg Cys Cys Pro Gly Tyr Thr Gly Pro
        115                 120                 125

Asn Cys Glu His His Asp Ser Met Ala Ile Pro Glu Pro Ala Asp Pro
    130                 135                 140

Gly Asp Ser His Gln Glu Pro Gln Asp Gly Pro Val Ser Phe Lys Pro
145                 150                 155                 160

Gly His Leu Ala Ala Val Ile Asn Glu Val Glu Val Gln Gln Glu Gln
                165                 170                 175

Gln Glu His Leu Leu Gly Asp Leu Gln Asn Asp Val His Arg Val Ala
            180                 185                 190

Asp Ser Leu Pro Gly Leu Trp Lys Ala Leu Pro Gly Asn Leu Thr Ala
        195                 200                 205

Ala Val Met Glu Ala Asn Gln Thr Gly His Glu Phe Pro Asp Arg Ser
    210                 215                 220

Leu Glu Gln Val Leu Leu Pro His Val Asp Thr Phe Leu Gln Val His
225                 230                 235                 240

Phe Ser Pro Ile Trp Arg Ser Phe Asn Gln Ser Leu His Ser Leu Thr
                245                 250                 255

Gln Ala Ile Arg Asn Leu Ser Leu Asp Val Glu Ala Asn Arg Gln Ala
            260                 265                 270

Ile Ser Arg Val Gln Asp Ser Ala Val Ala Arg Ala Asp Phe Gln Glu
        275                 280                 285

Leu Gly Ala Lys Phe Glu Ala Lys Val Gln Glu Asn Thr Gln Arg Val
    290                 295                 300

Gly Gln Leu Arg Gln Asp Val Glu Glu Arg Leu His Ala Gln His Phe
305                 310                 315                 320

Thr Leu His Arg Ser Ile Ser Glu Leu Gln Ala Asp Val Asp Thr Lys
                325                 330                 335

Leu Lys Arg Leu His Lys Ala Xaa Glu Ala Pro Gly Thr Asn Gly Ser
            340                 345                 350

Leu Val Leu Ala Thr Pro Gly Ala Gly Ala Arg Pro Glu Pro Asp Ser
        355                 360                 365

Leu Gln Ala Arg Leu Gly Gln Leu Gln Arg Asn Leu Ser Glu Leu His
    370                 375                 380
```



```
Met Thr Thr Ala Arg Arg Glu Glu Glu Leu Gln Tyr Thr Leu Glu Asp
385                 390                 395                 400

Met Arg Ala Thr Leu Thr Arg His Val Asp Glu Ile Lys Glu Leu Xaa
                405                 410                 415

Ser Glu Ser Asp Glu Thr Phe Asp Gln Ile Ser Lys Xaa Xaa Arg Gln
            420                 425                 430

Val Glu Glu Leu Gln Val Asn His Thr Ala Leu Arg Glu Leu Arg Val
        435                 440                 445

Ile Leu Met Glu Lys Ser Leu Ile Met Glu Glu Asn Lys Glu Glu Val
    450                 455                 460

Glu Arg Gln Leu Leu Glu Leu Asn Leu Thr Leu Gln His Leu Gln Gly
465                 470                 475                 480

Gly Met Pro Thr Ser Ser Ser Thr
                485
```

<210> 202
<211> 86
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (86)
<223> Xaa equals stop translation

<400> 202

```
Met Ala His Gly Pro Gln Ser Leu Trp Ser Leu Gly Phe Thr Val Thr
  1               5                  10                  15

Leu Thr Phe Glu Leu Pro Val Gly Cys Val Leu Gly Arg Ile Cys His
            20                  25                  30

Pro Ile Gln Ala Cys Asn Thr Gly Leu Met Thr Pro Thr Pro Gln Gly
        35                  40                  45

Pro Cys Arg Thr Glu Met Met Ser Asn Asp Lys Pro Trp Leu Pro Ala
    50                  55                  60

Asn Ala Pro Ala His Ile Ser Leu Pro Gly Ala Arg Leu Thr Ser Thr
 65                  70                  75                  80

Cys Ala Pro Gly Leu Xaa
                85
```

<210> 203
<211> 400
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (400)
<223> Xaa equals stop translation

<400> 203
Met Ala Ile His Lys Ala Leu Val Met Cys Leu Gly Leu Pro Leu Phe
1 5 10 15

Leu Phe Pro Gly Ala Trp Ala Gln Gly His Val Pro Pro Gly Cys Ser
20 25 30

Gln Gly Leu Asn Pro Leu Tyr Tyr Asn Leu Cys Asp Arg Ser Gly Ala
35 40 45

Trp Gly Ile Val Leu Glu Ala Val Ala Gly Ala Gly Ile Val Thr Thr
50 55 60

Phe Val Leu Thr Ile Ile Leu Val Ala Ser Leu Pro Phe Val Gln Asp
65 70 75 80

Thr Lys Lys Arg Ser Leu Leu Gly Thr Gln Val Phe Phe Leu Leu Gly
85 90 95

Thr Leu Gly Leu Phe Cys Leu Val Phe Ala Cys Val Val Lys Pro Asp
100 105 110

Phe Ser Thr Cys Ala Ser Arg Arg Phe Leu Phe Gly Val Leu Phe Ala
115 120 125

Ile Cys Phe Ser Cys Leu Ala Ala His Val Phe Ala Leu Asn Phe Leu
130 135 140

Ala Arg Lys Asn His Gly Pro Arg Gly Trp Val Ile Phe Thr Val Ala
145 150 155 160

Leu Leu Leu Thr Leu Val Glu Val Ile Ile Asn Thr Glu Trp Leu Ile
165 170 175

Ile Thr Leu Val Arg Gly Ser Gly Glu Gly Gly Pro Gln Gly Asn Ser
180 185 190

Ser Ala Gly Trp Ala Val Ala Ser Pro Cys Ala Ile Ala Asn Met Asp
195 200 205

Phe Val Met Ala Leu Ile Tyr Val Met Leu Leu Leu Leu Gly Ala Phe
210 215 220

Leu Gly Ala Trp Pro Ala Leu Cys Gly Arg Tyr Lys Arg Trp Arg Lys
225 230 235 240

His Gly Val Phe Val Leu Leu Thr Thr Ala Thr Ser Val Ala Ile Trp
245 250 255

Val Val Trp Ile Val Met Tyr Thr Tyr Gly Asn Lys Gln His Asn Ser
260 265 270

Pro Thr Trp Asp Asp Pro Thr Leu Ala Ile Ala Leu Ala Ala Asn Ala
275 280 285

Trp Ala Phe Val Leu Phe Tyr Val Ile Pro Glu Val Ser Gln Val Thr
290 295 300

Lys Ser Ser Pro Glu Gln Ser Tyr Gln Gly Asp Met Tyr Pro Thr Arg
305 310 315 320

Gly Val Gly Tyr Glu Thr Ile Leu Lys Glu Gln Lys Gly Gln Ser Met
325 330 335

Phe Val Glu Asn Lys Ala Phe Ser Met Asp Glu Pro Val Ala Ala Lys
340 345 350

Arg Pro Val Ser Pro Tyr Ser Gly Tyr Asn Gly Gln Leu Leu Thr Ser
355 360 365

Val Tyr Gln Pro Thr Glu Met Ala Leu Met His Lys Val Pro Ser Glu
370 375 380

Glu Leu Thr Thr Ser Ser Ser His Gly Pro Pro Pro Thr Ala Arg Xaa
385 390 395 400

<210> 204
<211> 195
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (195)
<223> Xaa equals stop translation

<400> 204
Met Ser Thr Ala Phe Cys Pro Ile His Ser Ser Leu Gly Ser Met Val
1 5 10 15

Met Cys Leu Cys Ile Leu Ser Pro Leu Cys Ile Ala Ser Lys Ser Leu
20 25 30

Arg Val Cys Thr Lys Ser Tyr Met Glu Gly His Gly Lys Thr Arg Val
35 40 45

Pro Val Val Leu Val Gly Asn Lys Ala Asp Leu Ser Pro Glu Arg Glu
50 55 60

Val Gln Ala Val Glu Gly Lys Lys Leu Ala Glu Ser Trp Gly Ala Thr
65 70 75 80

Phe Met Glu Ser Ser Ala Arg Glu Asn Gln Leu Thr Gln Gly Ile Phe
85 90 95

Thr Lys Val Ile Gln Glu Ile Ala Arg Val Gly Glu Phe Leu Trp Ala
100 105 110

Arg Ala Ser Leu Pro Ser His Val Ser Pro Trp Val Trp Gly Asn Cys
115 120 125

Leu Ala Ser Ala Pro Gly Thr Cys His Val Pro Val Gly Gly Arg Ser
130 135 140

Ser Gly Leu His Gly Tyr Gly Cys Gln Leu Cys Ser Trp Pro Leu Asp
145 150 155 160

Thr Gln Cys Gly Ile Leu Met Phe Ala His Phe Pro Gln Ala Pro Val
165 170 175

Ala Trp Met Ser Met Phe Thr Lys Gly Gln Gly Pro Leu Met Asp Thr
180 185 190

Gly Leu Xaa
195

<210> 205
<211> 57
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (57)
<223> Xaa equals stop translation

<400> 205
Met Pro Leu Glu Glu Ser Phe Glu Ile Val Leu Lys Leu Val Pro Leu
1 5 10 15

Leu Gly Leu Glu Leu Phe Phe Phe Leu Phe Ile Ile Asn Gly Tyr Ile
20 25 30

Asn Val Tyr Cys Pro Ser Gln Tyr Phe Ile Tyr Ala Lys Asp Ser Leu
35 40 45

Ala Gly Leu Ala Leu Ile Pro Gln Xaa
50 55

<210> 206
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (73)
<223> Xaa equals stop translation

<400> 206
Met Ile Val Ile Tyr Leu Thr Leu Thr Trp Thr Phe Leu Ile Asn Leu
1 5 10 15

Leu Ala Cys Pro Leu Tyr His Leu Pro Gln Met Gln Lys Lys Ala Lys
20 25 30

Pro Glu Thr Lys Lys Ala Lys Pro Glu Thr Lys Glu Thr Ile Gln Arg
35 40 45

Gln Arg Asn Leu Phe Leu Val Leu Leu Lys Gln Leu Ala Gly Lys Lys
50 55 60

Cys Ser Ala Leu Phe Leu Ile Val Xaa
65 70

<210> 207
<211> 85
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (85)
<223> Xaa equals stop translation

<400> 207
Met Val Trp Cys Gln Cys Leu Cys Pro Leu Cys Ala Cys Trp Glu Glu
1 5 10 15

Ala Gln Ala Leu Trp Trp Pro Pro Leu Cys Thr Trp Pro Gly Glu Ala
20 25 30

Arg Gly Ser Gly Ala Ser Leu Arg Leu Arg Pro Pro Leu Gln Asn Lys
35 40 45

Leu Ser Pro Gly Val Cys Leu Ser Leu Phe Leu Ser Pro Glu Arg Asn
50 55 60

Ala Gly Val Pro Glu Ala Ser Leu Gln Thr Lys His Pro Cys Thr Ser
65 70 75 80

Tyr Gly Ser Gly Xaa
85

<210> 208
<211> 195
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (195)
<223> Xaa equals stop translation

<400> 208
Met Trp Val Ser Leu Tyr Phe Gly Ile Leu Gly Leu Cys Ser Val Ile
1 5 10 15

Thr Gly Gly Cys Ile Ile Phe Leu His Trp Arg Lys Asn Leu Arg Arg
20 25 30

Glu Glu His Ala Gln Gln Trp Val Glu Val Met Arg Ala Ala Thr Phe
35 40 45

Thr Tyr Ser Pro Leu Leu Tyr Trp Ile Asn Lys Arg Arg Arg Tyr Gly
50 55 60

Met Asn Ala Ala Ile Asn Thr Gly Pro Ala Pro Ala Val Thr Lys Thr
65 70 75 80

Glu Thr Glu Val Gln Asn Pro Asp Val Leu Trp Asp Leu Asp Ile Pro
85 90 95

Glu Gly Arg Ser His Ala Asp Gln Asp Ser Asn Pro Lys Ala Glu Ala
100 105 110

Pro Ala Pro Leu Gln Pro Ala Leu Gln Leu Ala Pro Gln Gln Pro Gln
115 120 125

Ala Arg Ser Pro Phe Pro Leu Pro Ile Phe Gln Glu Val Pro Phe Ala
130 135 140

Pro Pro Leu Cys Asn Leu Pro Pro Leu Leu Asn His Ser Val Ser Tyr
145 150 155 160

Pro Leu Ala Thr Cys Pro Glu Arg Asn Val Leu Phe His Ser Leu Leu
165 170 175

Asn Leu Ala Gln Glu Asp His Ser Phe Asn Ala Lys Pro Phe Pro Ser
180 185 190

Glu Leu Xaa
195

<210> 209
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 209
Met Leu Gln Arg Gly Gln His Leu Tyr Leu Val Val Phe Leu Met Val
1 5 10 15

Ser Phe Ile Pro Leu Leu Asn Pro Lys Gln Asp Leu Lys Lys Leu Lys
20 25 30

Lys Asn Arg Thr Val Arg Asn His Phe Xaa
35 40

<210> 210
<211> 282
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (282)
<223> Xaa equals stop translation

<400> 210
Met Ser Ile Leu Thr Met Ile Ser Ser Trp Pro Phe Ser Arg Val Val
1 5 10 15

Arg Phe Trp Phe Leu His Gln Met Val Leu Asp Leu Cys Leu Gly Gln
20 25 30

Gly Val Pro Gln Gln Asn Leu Gly Lys Pro Lys Gly Lys Lys Lys Leu
35 40 45

Ser Ser Val Arg Gln Lys Phe Asp His Arg Phe Gln Pro Gln Asn Pro
50 55 60

Leu Ser Gly Ala Gln Gln Phe Val Ala Lys Asp Pro Gln Asp Asp Asp
65 70 75 80

Asp Leu Lys Leu Cys Ser His Thr Met Met Leu Pro Thr Arg Gly Gln
85 90 95

Leu Glu Gly Arg Met Ile Val Thr Ala Tyr Glu His Gly Leu Asp Asn
100 105 110

Val Thr Glu Glu Ala Val Ser Ala Val Val Tyr Ala Val Glu Asn His
115 120 125

Leu Lys Asp Ile Leu Thr Ser Val Val Ser Arg Arg Lys Ala Tyr Arg
130 135 140

Leu Arg Asp Gly His Phe Lys Tyr Ala Phe Gly Ser Asn Val Thr Pro
145 150 155 160

Gln Pro Tyr Leu Lys Asn Ser Val Val Ala Tyr Asn Asn Leu Ile Glu
165 170 175

Ser Pro Pro Ala Phe Thr Ala Pro Cys Ala Gly Gln Asn Pro Ala Ser
180 185 190

His Pro Pro Pro Asp Asp Ala Glu Gln Gln Ala Ala Leu Leu Leu Ala
195 200 205

Cys Ser Gly Asp Thr Leu Pro Ala Ser Leu Pro Pro Val Asn Met Tyr
210 215 220

Asp Leu Phe Glu Ala Leu Gln Val His Arg Glu Val Ile Pro Thr His
225 230 235 240

Thr Val Tyr Ala Leu Asn Ile Glu Arg Ile Ile Thr Lys Leu Trp His
245 250 255

Pro Asn His Glu Glu Leu Gln Gln Asp Lys Val His Arg Gln Arg Leu
260 265 270

Ala Ala Lys Glu Gly Leu Leu Leu Cys Xaa
275 280

<210> 211
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 211
Met Pro Lys Thr Cys Leu Pro Ile Leu Cys Leu Pro Leu Thr Gln Ala
1 5 10 15

Val Val Leu Ala Gln Leu Asn Asn Phe Ser Ser Leu Asn Ile Phe Ile
20 25 30

Phe Lys Ile Lys Asn Lys Met Tyr Tyr Ile Trp Ile Tyr Asp Lys Xaa
35 40 45

<210> 212
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals stop translation

<400> 212
Met Trp Pro Cys Cys Leu Asp Ser Leu Leu Phe Gly Phe Trp Leu Trp
1 5 10 15

Ala Gln Gly Ile Thr Leu Leu Ser Glu Asp Ser Ile Arg Ile Val Cys
20 25 30

Ser Ser Cys Glu Pro Glu Val Leu His Val Pro Thr Pro Val Tyr Arg
35 40 45

Pro Cys Pro Ser His Ser Pro Leu Thr Phe Xaa
50 55

<210> 213
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 213
Met Ala Leu Gln Ser Ile Pro Ser Phe Thr Leu Leu Ile Ser Phe Phe
1 5 10 15

Leu Ser Thr Gln Cys Leu Arg Cys Val Tyr Asn Tyr Glu Cys Ile Leu
20 25 30

Phe Met Ala Phe Asn Cys Arg Met Val Phe Xaa
35 40

<210> 214
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (53)
<223> Xaa equals stop translation

<400> 214
Met Pro Ala Val Ser Ala Phe Phe Ser Leu Ala Ala Leu Ala Glu Val
1 5 10 15

Ala Ala Met Glu Asn Val His Arg Gly Gln Arg Ser Thr Pro Leu Thr
20 25 30

His Asp Gly Gln Pro Lys Glu Met Pro Gln Ala Pro Val Leu Ile Ser
35 40 45

Cys Ala Asp Gln Xaa
50

<210> 215
<211> 68
<212> PRT
<213> Homo sapiens

<220>
<221> SITE

<222> (68)
<223> Xaa equals stop translation

<400> 215
Met Cys Thr Gln Ile Leu Val Phe Met Leu Leu Ile Lys Cys Ile Phe
1 5 10 15

Ser Ile Asn Thr His Pro Ile Met Pro Tyr Leu Tyr Met Lys Asn Lys
20 25 30

Val Thr Met Leu Tyr Cys Tyr Val Leu Lys Phe Lys Ser Leu Phe Glu
35 40 45

Lys Pro Ser Asn Trp Cys Phe His Tyr Ile Met Ile His Leu Asp Lys
50 55 60

Thr Pro Asn Xaa
65

<210> 216
<211> 57
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (57)
<223> Xaa equals stop translation

<400> 216
Met Leu Phe Val Ser Leu Leu Val Met Trp Asn Leu Phe Leu Ser Ser
1 5 10 15

Asp Phe Leu Phe Leu Trp Ser Val Leu Gly Tyr Tyr Met Lys Val Arg
20 25 30

Leu Pro Gln Ser Pro Arg Glu Ala His Cys Val Leu Leu Ile Asp Leu
35 40 45

Lys Met Ile Glu Ser Leu Gly Gly Xaa
50 55

<210> 217
<211> 56
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (56)
<223> Xaa equals stop translation

<400> 217
Met Glu Gln Leu Leu Ala Ala Val Val Phe Phe Ser Ile Phe Phe Leu
1 5 10 15

Asn Leu Leu Ala Leu Lys Met Asn Lys Val Tyr Arg Cys Ile Cys Leu
20 25 30

Leu Phe Ser Lys Asn Met His Thr Asn Val Cys Phe Tyr Lys Ser Asn
35 40 45

Thr His Val Ile Ile Cys Met Xaa
50 55

<210> 218
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 218
Met Cys Trp Lys Pro Lys Cys Ile Leu Leu Leu Ser Phe Val Phe Gln
1 5 10 15

Cys Val Ala Ser Ser Thr Phe Asp Pro Leu Gly Ser Glu Arg Pro Trp
20 25 30

Ser Gln Pro Gln Cys Pro Ile Ser Phe Pro Leu Leu Ile Thr Gly Cys
35 40 45

Cys Trp Phe Ser Met Ser Arg Val Ser Xaa
50 55

<210> 219
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals stop translation

<400> 219
Met Arg Thr Phe Leu Thr Phe Val Ile Leu Lys Val Ile Leu Ile Phe
1 5 10 15

Leu Ser Ser Cys Ala Ser Phe Thr Arg Asn Leu Leu Thr Trp Pro Asn
20 25 30

Asp Val Ser Thr Glu Gln Phe Glu Thr Arg Pro Phe Gly Ser Glu Leu
35 40 45

Leu Gln Thr Val Ile Asn Val Ser Arg Thr Xaa
50 55

<210> 220
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 220
Met Arg Phe Phe Phe Gln Ala Tyr Ser Gln Ile Cys Val Gln Asn Phe
1 5 10 15

Leu Thr Phe Leu Leu Cys Ile Ile Ile Glu Phe Ile Ala Ala Asp Phe
20 25 30

Tyr Asn Asp Ser Cys Cys His Val Ser Leu Asn Asn Xaa
35 40 45

<210> 221
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 221
Met Ile Leu Phe Asp Leu Thr Phe Phe Leu Phe Ala Pro Arg Ile Leu
1 5 10 15

Ala Ser Gly Ala Cys Ser Cys Ser Ile Tyr Pro Lys Ile Thr Leu Pro
20 25 30

Thr Lys Tyr Phe Ala Phe Ile Ile Xaa Thr Ser Phe Xaa
35 40 45

<210> 222
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)

<223> Xaa equals stop translation

<400> 222
Met Asp Gly Leu Ile Met Cys Leu Ile Ile Phe Gln Ile Val Asn Phe
1 5 10 15

Trp Leu Pro Cys Ile Ile Leu Leu Gly Ile Leu Asn Pro Thr Tyr Lys
20 25 30

Asn Tyr Val Met Val Ser Thr Lys Cys Trp Met Lys Arg Thr Tyr Glu
35 40 45

His Met Ser Xaa
50

<210> 223
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (73)
<223> Xaa equals stop translation

<400> 223
Met Thr Phe Leu Phe Phe Phe Leu Phe Ser Arg Ile Leu Cys Ile Lys
1 5 10 15

Asn Leu Asp Leu Leu Thr Trp Lys Arg Ser Asn Pro Val Ile Ala Lys
20 25 30

His Leu Tyr Cys Arg Gly His Ile Thr Lys Lys Ser Lys Gly Pro Ala
35 40 45

Gln Trp Thr Ile Tyr Phe Ser Asp Val Gln Tyr Lys Ile Ser Leu Pro
50 55 60

Leu Lys Thr Leu Glu Ser Pro Phe Xaa
65 70

<210> 224
<211> 71
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (71)
<223> Xaa equals stop translation

<400> 224
Met Leu Phe Trp Lys Phe Gly Ser Phe Leu Phe Phe Cys Leu Pro Leu
1 5 10 15

Thr Leu Phe Cys Ile Leu Asn Glu Arg Gly Ile Met His Leu Glu Gly
20 25 30

Gly Thr Leu Leu Asn Ser Leu Ser His Val Arg His Tyr Leu Arg Leu
35 40 45

Arg Leu Ser Cys Phe Glu Lys Ile Pro Leu His Arg Ser Ile Phe Ile
50 55 60

Phe Leu Leu Leu Leu Leu Xaa
65 70

<210> 225
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 225
Met Ala Gly Cys Cys Leu Lys Leu Phe Gly Val Leu Ser Leu Cys Phe
1 5 10 15

Leu Cys Gly Leu Ile Ser Ile Glu Arg Val Ile Cys Asn Pro Val Ser
20 25 30

Ala Asp Phe Gln Val Ser Thr Phe Cys Gln Arg His Cys Leu Leu Arg
35 40 45

Ser Lys Val Met Phe Pro Ile Arg Gly Xaa
50 55

<210> 226
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals stop translation

<400> 226
Met Arg Ile Ser Arg Cys Asn Ile Ser Leu Glu Ile Val Ser Pro Ser
1 5 10 15

Ile Leu Leu Thr Phe Leu Asp Leu Ile Ile Leu Leu Trp Ala Leu Ala
20 25 30

Ser Cys Tyr Arg Arg Phe Thr Ser Phe Pro Ala Leu Asn Leu Pro Asp
35 40 45

Val Asn Ser Thr Leu His Tyr Leu Gln Gln Xaa
50 55

<210> 227
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 227
Met Val Ala Pro Leu His Leu Phe Ile Pro Phe Ser Trp Leu Val Arg
1 5 10 15

Thr Ile Gly Gln Leu Leu Ser Pro Val Gly Lys Ala Leu Ser His Arg
20 25 30

Ser Asn Gln Met Met Pro Arg Ser Trp Gly Xaa
35 40

<210> 228
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 228
Met Arg Thr Ser Leu Phe Phe Phe Phe Phe Lys Asn Ile Leu Val Leu
1 5 10 15

Cys Gly Thr Leu Leu Ile Ser Arg Ser Ser His Ser Gln Ser Ala Pro
20 25 30

Arg Gly Cys Trp Trp Pro His Lys Xaa
35 40

<210> 229
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 229

Met Leu Trp Lys Tyr Phe Leu Ser Leu Phe Leu Pro Trp Tyr Leu Tyr
1 5 10 15

Cys Phe Phe Asn Asn Asn Ile Met Phe Tyr Ser Leu His Ser Val Pro
20 25 30

Met Phe Ile Gln Pro Phe Leu Leu Trp Xaa
35 40

<210> 230
<211> 165
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (165)
<223> Xaa equals stop translation

<400> 230
Met Ser Thr Arg Arg Leu Gly Val Ala Val Ala Val Leu Gly Gly Phe
1 5 10 15

Leu Tyr Ala Val Gly Gly Ser Asp Gly Thr Ser Pro Leu Asn Thr Val
20 25 30

Glu Arg Tyr Asn Pro Gln Glu Asn Arg Trp His Thr Ile Ala Pro Met
35 40 45

Gly Thr Arg Arg Lys His Leu Gly Cys Ala Val Tyr Gln Asp Met Ile
50 55 60

Tyr Ala Val Gly Gly Arg Asp Asp Thr Thr Glu Leu Ser Ser Ala Glu
65 70 75 80

Arg Tyr Asn Pro Arg Thr Asn Gln Trp Ser Pro Val Val Ala Met Thr
85 90 95

Ser Arg Arg Ser Gly Val Gly Leu Ala Val Val Asn Gly Gln Leu Met
100 105 110

Ala Val Gly Gly Phe Asp Gly Thr Thr Tyr Leu Lys Thr Ile Glu Val
115 120 125

Phe Asp Pro Asp Ala Asn Thr Trp Arg Leu Tyr Gly Gly Met Asn Tyr
130 135 140

Arg Arg Leu Gly Gly Gly Val Gly Val Ile Lys Met Thr His Cys Glu
145 150 155 160

Ser His Ile Trp Xaa
165

<210> 231
<211> 52

<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 231
Met Ala Cys Leu Ile Arg Phe Pro Ala Ile Gly Ser Leu Pro Tyr Ser
1 5 10 15

Thr Trp Pro Phe Phe Phe Phe Ile Phe Leu Phe Phe Ser Cys Leu Thr
20 25 30

Phe Ile Pro Phe Ser Pro Leu Ser Ser Phe Cys Glu Pro Tyr Pro Arg
35 40 45

Lys Glu Pro Xaa
50

<210> 232
<211> 130
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (130)
<223> Xaa equals stop translation

<400> 232
Met Phe Leu Leu Asn Phe Arg Tyr Ile Met Arg Phe Phe Phe Trp Pro
1 5 10 15

Met Leu Gln Ala Lys Leu Met Ser Phe His Phe Leu Lys Pro Ile Ile
20 25 30

Phe Met Asn Ser Leu Ile Leu Cys Leu Lys Gln Ser Cys Ser Cys Glu
35 40 45

Val Glu Ile Ser Leu Leu Pro Leu Ser Gln Gln Thr His Arg Thr Asp
50 55 60

Leu Gly Phe Ser His Ser Gly Ser Gln Asn Glu Pro Phe Leu Asn Leu
65 70 75 80

Asp Lys Arg Ala Ala Glu Ala His Cys Ala Val Met Val Leu Cys Leu
85 90 95

Leu Gly Arg Asp Leu Lys Ala Arg Arg Ser Arg Glu Gly Pro Ala Leu
100 105 110

Cys Ser Ser Gln Val Val Ile Cys Ile Leu Lys Leu Ala Arg Lys Arg
115 120 125

Phe Xaa
130

<210> 233
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (55)
<223> Xaa equals stop translation

<400> 233
Met Glu Phe Lys Leu Val Arg Lys Ile Gln Ile Ala Ile Leu Ile Phe
1 5 10 15

Tyr Leu Tyr Leu Val Ala Val Ala Phe Lys Asn Lys Phe Ser Tyr Lys
20 25 30

Ser Phe Gln Phe Phe Gly Leu Glu Ser Ile Phe Gln Asn Lys Lys Leu
35 40 45

Lys Lys Glu Tyr Leu Met Xaa
50 55

<210> 234
<211> 363
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (307)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (363)
<223> Xaa equals stop translation

<400> 234
Met Arg Thr Leu Phe Asn Leu Leu Trp Leu Ala Leu Ala Cys Ser Pro
1 5 10 15

Val His Thr Thr Leu Ser Lys Ser Asp Ala Lys Lys Ala Ala Ser Lys
20 25 30

Thr Leu Leu Glu Lys Ser Gln Phe Ser Asp Lys Pro Val Gln Asp Arg
35 40 45

Gly Leu Val Val Thr Asp Leu Lys Ala Glu Ser Val Val Leu Glu His
50 55 60

Arg Ser Tyr Cys Ser Ala Lys Ala Arg Asp Arg His Phe Ala Gly Asp

65 70 75 80

Val Leu Gly Tyr Val Thr Pro Trp Asn Ser His Gly Tyr Asp Val Thr
85 90 95

Lys Val Phe Gly Ser Lys Phe Thr Gln Ile Ser Pro Val Trp Leu Gln
100 105 110

Leu Lys Arg Arg Gly Arg Glu Met Phe Glu Val Thr Gly Leu His Asp
115 120 125

Val Asp Gln Gly Trp Met Arg Ala Val Arg Lys His Ala Lys Gly Leu
130 135 140

His Ile Val Pro Arg Leu Leu Phe Glu Asp Trp Thr Tyr Asp Asp Phe
145 150 155 160

Arg Asn Val Leu Asp Ser Glu Asp Glu Ile Glu Glu Leu Ser Lys Thr
165 170 175

Val Val Gln Val Ala Lys Asn Gln His Phe Asp Gly Phe Val Val Glu
180 185 190

Val Trp Asn Gln Leu Leu Ser Gln Lys Arg Val Thr Asp Gln Leu Gly
195 200 205

Met Phe Thr His Lys Glu Phe Glu Gln Leu Ala Pro Val Leu Asp Gly
210 215 220

Phe Ser Leu Met Thr Tyr Asp Tyr Ser Thr Ala His Gln Pro Gly Pro
225 230 235 240

Asn Ala Pro Leu Ser Trp Val Arg Ala Cys Val Gln Val Leu Asp Pro
245 250 255

Lys Ser Lys Trp Arg Ser Lys Ile Leu Leu Gly Leu Asn Phe Tyr Gly
260 265 270

Met Asp Tyr Ala Thr Ser Lys Asp Ala Arg Glu Pro Val Val Gly Ala
275 280 285

Arg Tyr Ile Gln Thr Leu Lys Asp His Arg Pro Arg Met Val Trp Asp
290 295 300

Ser Gln Xaa Ser Glu His Phe Phe Glu Tyr Lys Lys Ser Arg Ser Gly
305 310 315 320

Arg His Val Val Phe Tyr Pro Thr Leu Lys Ser Leu Gln Val Arg Leu
325 330 335

Glu Leu Ala Arg Glu Leu Gly Val Gly Val Ser Ile Trp Glu Leu Gly
340 345 350

Gln Gly Leu Asp Tyr Phe Tyr Asp Leu Leu Xaa
355 360

<210> 235
<211> 29
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (29)
<223> Xaa equals stop translation

<400> 235
Met Cys Met Cys Val Leu Leu Cys Val Phe Leu Ile Cys Lys Tyr Ser
1 5 10 15

Lys Ser Phe Leu Ile Leu Arg Leu Lys Phe Ser Cys Xaa
20 25

<210> 236
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 236
Met Gly Asn Ala Cys Ile Pro Leu Lys Arg Ile Ala Tyr Phe Leu Cys
1 5 10 15

Leu Leu Ser Ala Leu Leu Leu Thr Glu Gly Lys Lys Pro Ala Asn Gln
20 25 30

Asn Ala Leu Pro Cys Val Leu Val Pro Lys Ile Met Leu Tyr Val Arg
35 40 45

Met Pro Asp Pro Phe His Ala Pro Phe Leu Leu Met Leu Ser His Tyr
50 55 60

Pro Leu Xaa
65

<210> 237
<211> 114
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (114)
<223> Xaa equals stop translation

<400> 237
Met Ile Leu Ser Leu Leu Phe Ser Leu Gly Gly Pro Leu Gly Trp Gly

1 5 10 15

Leu Leu Gly Ala Trp Ala Gln Ala Ser Ser Thr Ser Leu Ser Asp Leu
20 25 30

Gln Ser Ser Arg Thr Pro Gly Val Trp Lys Ala Glu Ala Glu Asp Thr
35 40 45

Ser Lys Asp Pro Val Gly Arg Asn Trp Cys Pro Tyr Pro Met Ser Lys
50 55 60

Leu Val Thr Leu Leu Ala Leu Cys Lys Thr Glu Lys Phe Leu Ile His
65 70 75 80

Ser Gln Gln Pro Cys Pro Gln Glu Leu Gln Thr Ala Arg Lys Ser Lys
85 90 95

Ser Cys Thr Ala Trp Pro Thr Ser Gln Cys Thr Arg Ser Ser Arg Arg
100 105 110

Cys Xaa

<210> 238
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (106)
<223> Xaa equals stop translation

<400> 238
Met Ala Ile His Lys Ala Leu Val Met Cys Leu Gly Leu Pro Leu Phe
1 5 10 15

Leu Phe Pro Gly Ala Trp Ala Gln Gly His Val Pro Pro Gly Cys Ser
20 25 30

Gln Gly Leu Asn Pro Leu Tyr Tyr Asn Leu Cys Asp Arg Ser Gly Ala
35 40 45

Trp Gly Ile Val Leu Glu Ala Val Ala Gly Ala Gly Ile Val Thr Thr
50 55 60

Phe Val Leu Thr Ile Ile Leu Val Ala Ser Leu Pro Phe Val Gln Asp
65 70 75 80

Thr Lys Lys Arg Ser Leu Leu Gly Thr Gln Leu Arg Gly Arg Cys His
85 90 95

His Thr Ala Gly Thr Met Gly Ser Cys Xaa
100 105

<210> 239
<211> 15
<212> PRT
<213> Homo sapiens

<400> 239
Gly Leu Gly Pro Ala Gln Val Ala Leu Ser Leu Gln Gly Pro Ala
1 5 10 15

<210> 240
<211> 82
<212> PRT
<213> Homo sapiens

<400> 240
Ser Ser Trp Met Ala Gly Thr Gln Pro Arg Thr Ser Trp Trp Glu Met
1 5 10 15

Ser Ser Ala Lys Pro Cys Pro Thr Gly Thr Leu Arg Ser Asn Thr Ser
20 25 30

Ser His Pro Gln Cys Thr Gly Pro Pro Thr Thr His Pro Met Leu Val
35 40 45

Gly Glu Asp Met Ser Cys Pro Glu Pro Gln Cys Gly Ala Ser Arg Leu
50 55 60

Ser Trp Lys Met Leu Asn Ser Ser Pro Leu Met Met Ser Leu Trp Val
65 70 75 80

Cys Ala

<210> 241
<211> 23
<212> PRT
<213> Homo sapiens

<400> 241
Gln Pro Arg Thr Ser Trp Trp Glu Met Ser Ser Ala Lys Pro Cys Pro
1 5 10 15

Thr Gly Thr Leu Arg Ser Asn
20

<210> 242
<211> 23
<212> PRT
<213> Homo sapiens

<400> 242
Met Ser Cys Pro Glu Pro Gln Cys Gly Ala Ser Arg Leu Ser Trp Lys
1 5 10 15

Met Leu Asn Ser Ser Pro Leu
20

<210> 243
<211> 98
<212> PRT
<213> Homo sapiens

<400> 243
Trp Val Ala Leu Tyr Ile Glu Gly Gly Met Lys Tyr Leu Thr Leu Val
1 5 10 15

Phe Leu Leu Gly Arg Ala Trp Arg Met Thr Ser Pro Thr Arg Arg Ser
20 25 30

Trp Ala Gly Ser Gln Pro Ser Arg Asn Ser Asn Thr Leu Gly Thr Trp
35 40 45

Thr Lys Thr Ser Ser Ser Pro Phe Ser Met Lys Trp Ala Trp Gly Gln
50 55 60

Ala Ala Thr Thr Gln Arg Cys Arg Cys Ser Ser Leu Ser Val Arg Leu
65 70 75 80

Lys Lys Ser Ser Val Lys Ser His Trp Arg Met Ser Ser Asn Ser Leu
85 90 95

Leu Ser

<210> 244
<211> 20
<212> PRT
<213> Homo sapiens

<400> 244
Gly Gly Met Lys Tyr Leu Thr Leu Val Phe Leu Leu Gly Arg Ala Trp
1 5 10 15

Arg Met Thr Ser
20

<210> 245
<211> 25
<212> PRT
<213> Homo sapiens

<400> 245
Ser Gln Pro Ser Arg Asn Ser Asn Thr Leu Gly Thr Trp Thr Lys Thr
1 5 10 15

Ser Ser Ser Pro Phe Ser Met Lys Trp
20 25

<210> 246
<211> 26
<212> PRT
<213> Homo sapiens

<400> 246
Thr Thr Gln Arg Cys Arg Cys Ser Ser Leu Ser Val Arg Leu Lys Lys
1 5 10 15

Ser Ser Val Lys Ser His Trp Arg Met Ser
20 25

<210> 247
<211> 223
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (117)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (121)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (122)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (125)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (129)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (130)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 247
Ala Ser Thr Leu Ala Gln Thr Thr Gly Thr Cys Lys Xaa Xaa Xaa Ser
1 5 10 15

Ser Arg Arg Ala Arg Ser Arg Thr Gln Arg Xaa Phe Gln Leu Arg Pro
20 25 30

Asp Lys Arg Ser Ala Pro Ser Leu Leu Gln Phe Ile Gln Ala Gln Glu
35 40 45

Glu Leu Ser Lys Glu Asn Thr Gly Arg Gln Leu Ala Ala Arg Glu Ala
50 55 60

Val Leu Ala Leu Glu Gly Ser Thr Gln Leu Thr Gly Pro Val Thr Gln
65 70 75 80

Val Ala Ala Ser Lys Thr His Cys Ser Gly Met Ala Leu Thr Ala Ser
85 90 95

Pro Val Pro Val Leu Gly Ala Ala Pro Ala Lys Xaa Pro Thr Gln Asn
100 105 110

Xaa Pro Gly Gln Xaa Gly Arg Ala Xaa Xaa Lys Val Xaa Thr Ser Trp
115 120 125

Xaa Xaa Val Ala Thr Lys Val Leu His Gly Leu Glu Val Ser Thr His
130 135 140

Leu Gly Lys Arg Lys Leu Ser Gly Arg Ser Trp Leu Pro Gly Pro Ala
145 150 155 160

Leu His Ala Thr Pro Ser Gln Ser His Thr Gln Thr Gly Ser Gln Ile
165 170 175

Val His Pro Pro Gln Gly Glu Val Arg Glu Val Gly Arg Gly Arg Gly

145

180 185 190

Gln Pro Pro Ala Gln Pro Val His Ala His Pro Ser Gln Gln His Pro
195 200 205

Ser Pro Ala His Leu Ala Gly Leu Ser Leu Trp Thr Gly Thr Ala
210 215 220

<210> 248
<211> 140
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 248
Ala Met Leu Glu Thr Trp Arg Pro Gly Pro Ser Xaa Gly Glu Leu Ala
1 5 10 15

Thr Asn Ser Gly Gln Arg Ala Ser Gln Asp Ser Gln His Ser Pro Pro
20 25 30

His Val Arg Ala His Leu Leu Ile Ser Pro Leu Pro Ala Phe Pro Ser
35 40 45

Met Gly Gly Pro Ala Gly Arg Ser Ala Pro Xaa Xaa Leu Thr Glu Thr
50 55 60

Lys Ser Glu Leu Gln Arg Leu Arg Arg Arg Gln Ala Arg Ala Ser Xaa
65 70 75 80

Ser Xaa Pro Ala Gly Glu Pro Gly Ala Gly His Ser Asp Ser Phe Asn
85 90 95

146

Cys Val Pro Thr Asn Gly Gln Pro Leu Arg Ser Cys Ser Leu Ser Lys
100 105 110

Leu Arg Arg Ser Phe Leu Lys Arg Thr Gln Gly Asp Ser Trp Leu Pro
115 120 125

Glu Lys Gln Ser Trp Leu Trp Lys Ala Pro Pro Ser
130 135 140

<210> 249
<211> 122
<212> PRT
<213> Homo sapiens

<400> 249
Ser His Gln Ser His Leu Ile Asn Pro Ala Ser Ser Ala Lys Gly Ser
1 5 10 15

Trp Ala Gln Leu Lys Ala Gln Pro Pro Ala His Val Leu Gly Gly Thr
20 25 30

Gly Gln Glu Gly Pro Pro Pro Thr Ala Asp Gln Pro Glu Ser Pro Gly
35 40 45

Trp Asp Pro Ser Ser Phe Thr Asn Gly Ser Ser Gly Pro Arg Ala Leu
50 55 60

Pro Thr Ser Val His Pro Thr Leu Gln Gln Gly Ala Pro Cys Arg Arg
65 70 75 80

Asn Trp Ala Pro Cys Arg Gly Leu Val Glu Thr Arg Met Leu Arg Arg
85 90 95

Gln Leu Pro His Gly Thr Ser Lys Arg Asp Leu Gly Trp Ala Ser Leu
100 105 110

Gln Arg Gly Ser Pro Gln Glu Thr Pro Gln
115 120

<210> 250
<211> 35
<212> PRT
<213> Homo sapiens

<400> 250
Arg Pro Asp Lys Arg Ser Ala Pro Ser Leu Leu Gln Phe Ile Gln Ala
1 5 10 15

Gln Glu Glu Leu Ser Lys Glu Asn Thr Gly Arg Gln Leu Ala Ala Arg
20 25 30

Glu Ala Val
35

<210> 251
<211> 33
<212> PRT
<213> Homo sapiens

<400> 251
Ala Thr Pro Ser Gln Ser His Thr Gln Thr Gly Ser Gln Ile Val His
1 5 10 15

Pro Pro Gln Gly Glu Val Arg Glu Val Gly Arg Gly Arg Gly Gln Pro
20 25 30

Pro

<210> 252
<211> 29
<212> PRT
<213> Homo sapiens

<400> 252
Gln Asp Ser Gln His Ser Pro Pro His Val Arg Ala His Leu Leu Ile
1 5 10 15

Ser Pro Leu Pro Ala Phe Pro Ser Met Gly Gly Pro Ala
20 25

<210> 253
<211> 28
<212> PRT
<213> Homo sapiens

<400> 253
Asp Ser Phe Asn Cys Val Pro Thr Asn Gly Gln Pro Leu Arg Ser Cys
1 5 10 15

Ser Leu Ser Lys Leu Arg Arg Ser Phe Leu Lys Arg
20 25

<210> 254
<211> 25
<212> PRT
<213> Homo sapiens

<400> 254
Lys Gly Ser Trp Ala Gln Leu Lys Ala Gln Pro Pro Ala His Val Leu
1 5 10 15

Gly Gly Thr Gly Gln Glu Gly Pro Pro
20 25

<210> 255

<211> 26
<212> PRT
<213> Homo sapiens

<400> 255
Ala Pro Ser Leu Leu Gln Phe Ile Gln Ala Gln Glu Glu Leu Ser Lys
1 5 10 15

Glu Asn Thr Gly Arg Gln Leu Ala Ala Arg
20 25

<210> 256
<211> 6
<212> PRT
<213> Homo sapiens

<400> 256
Lys Pro Ser His Gln Pro
1 5

<210> 257
<211> 21
<212> PRT
<213> Homo sapiens

<400> 257
Cys Ser Tyr Arg Pro Gln Phe Pro Val Asp Pro Arg Val Arg Ala Thr
1 5 10 15

Cys Ile Val Phe Asn
20

<210> 258
<211> 128
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 258
Gly Thr Glu Asn Leu Leu Ala Pro Glu Arg Thr Ile Leu Ser Arg Ala

```
 1               5                  10                  15

Gln Met Gly Lys Cys Met Ala Thr Pro Ala Pro Cys Val Arg Ser Ser
            20                  25                  30

Ser Lys Gln Lys Lys Lys Lys Arg Lys Arg Arg Lys Val Xaa Gln Glu
        35                  40                  45

Thr Lys Asp Asn Leu Arg Val Gln Leu Pro Leu Xaa Ser Cys Val Val
    50                  55                  60

Asn Xaa Ala Asn Pro Gly Lys Thr Asp Gly Phe Phe Ala Pro Glu Arg
65                  70                  75                  80

Met Thr Pro Ser Arg Ala Gln Met Glu Lys Cys Met Ala Thr Pro Ala
                85                  90                  95

Pro Cys Val Arg Pro Ser Phe Asn Lys Lys Lys Glu Gln Glu Gln Arg
            100                 105                 110

Leu Lys Glu Lys Leu Gln Arg Lys Ser Ala Val Asn Phe Gly Thr Lys
        115                 120                 125
```

<210> 259
<211> 26
<212> PRT
<213> Homo sapiens

<400> 259
```
Leu Leu Ala Pro Glu Arg Thr Ile Leu Ser Arg Ala Gln Met Gly Lys
 1               5                  10                  15

Cys Met Ala Thr Pro Ala Pro Cys Val Arg
            20                  25
```

<210> 260
<211> 24
<212> PRT
<213> Homo sapiens

<400> 260
```
Pro Gly Lys Thr Asp Gly Phe Phe Ala Pro Glu Arg Met Thr Pro Ser
 1               5                  10                  15

Arg Ala Gln Met Glu Lys Cys Met
            20
```

<210> 261
<211> 17
<212> PRT
<213> Homo sapiens

<400> 261
```
Glu Gln Arg Leu Lys Glu Lys Leu Gln Arg Lys Ser Ala Val Asn Phe
 1               5                  10                  15

Gly
```

<210> 262
<211> 186
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 262
```
Lys Thr Leu Leu Glu Asn Phe Ser Thr Gln Gly Thr Phe Val Ala Met
 1               5                  10                  15

His Pro Ala Val Arg Ala Thr Asp Trp Ile Thr Leu Pro Cys Thr Lys
            20                  25                  30

Lys Pro Ser Ile Ser His Leu Phe Phe Xaa Phe Leu Ala Lys Ile Leu
        35                  40                  45

Phe Ser Ile Ser Ser Asn Ser Ser Phe Thr Leu Ser Leu Gly Ile Phe
    50                  55                  60

Ser Phe Phe Xaa Xaa Gln Leu Ser Thr His Cys Thr Leu Ile Ala Met
65                  70                  75                  80

Arg Leu Pro Ile Arg Thr Lys Asn Arg Ile Ile Phe Pro Cys Ala Ser
                85                  90                  95

Lys Ser Ser Ile Ser Asn Lys Gly Pro Lys Ser Thr Ala Tyr Ile Leu
            100                 105                 110

Leu Trp Ile Thr Ala Leu Thr Phe Pro Phe Thr Phe Tyr Thr Asn Leu
        115                 120                 125

Gly Pro Gly Phe Arg Ile Leu Ser Thr Gln Cys Thr Ser Val Val Ile
    130                 135                 140
```

Cys Phe Pro Ile Cys Ala Thr Asn Ser Phe Ile Ile Ile Arg Thr Asp
145 150 155 160

Lys Ile Pro Ile Ser Phe Ser Phe Phe Lys Ile Ile Thr Ile Gln Leu
165 170 175

Cys Trp Gly Ser Ser Leu Gly Ser Ser Cys
180 185

<210> 263
<211> 22
<212> PRT
<213> Homo sapiens

<400> 263
Met His Pro Ala Val Arg Ala Thr Asp Trp Ile Thr Leu Pro Cys Thr
1 5 10 15

Lys Lys Pro Ser Ile Ser
20

<210> 264
<211> 17
<212> PRT
<213> Homo sapiens

<400> 264
Leu Ile Ala Met Arg Leu Pro Ile Arg Thr Lys Asn Arg Ile Ile Phe
1 5 10 15

Pro

<210> 265
<211> 26
<212> PRT
<213> Homo sapiens

<400> 265
Ser Ser Ile Ser Asn Lys Gly Pro Lys Ser Thr Ala Tyr Ile Leu Leu
1 5 10 15

Trp Ile Thr Ala Leu Thr Phe Pro Phe Thr
20 25

<210> 266
<211> 23
<212> PRT
<213> Homo sapiens

<400> 266
Ile Ile Ile Arg Thr Asp Lys Ile Pro Ile Ser Phe Ser Phe Phe Lys
1 5 10 15

Ile Ile Thr Ile Gln Leu Cys
20

<210> 267
<211> 165
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (153)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 267
Asn Asp Gly Gln Cys Leu Ala Tyr Asn Thr Thr His Tyr Arg Glu Arg
1 5 10 15

Ala Met Thr Ser His Ala Arg Val Ser Leu Gly Pro Ser Arg Asp Pro
20 25 30

Leu Glu Arg Pro Pro Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe
35 40 45

Lys Phe Glu His Thr Gly Thr His Gly Thr Leu Val Ser Met His Phe
50 55 60

Ala Ile Trp Ala Thr Asp Arg Ile Met Leu Pro Gly Ala Tyr Lys Cys
65 70 75 80

Ser Ile Pro His Leu Val Pro Lys Phe Thr Ala Asp Phe Leu Cys Ser
85 90 95

Phe Ser Phe Ser Leu Cys Ser Cys Ser Phe Phe Leu Leu Lys Glu Gly
100 105 110

Leu Thr His Gly Ala Gly Val Ala Met His Phe Ser Ile Trp Ala Leu
115 120 125

Asp Gly Val Ile Leu Ser Gly Ala Lys Lys Pro Ser Val Phe Pro Gly
130 135 140

Phe Ala Xaa Phe Thr Thr Gln Leu Xaa Lys Gly Ser Cys Thr Leu Arg
145 150 155 160

Leu Ser Phe Val Ser
165

<210> 268
<211> 22

<212> PRT
<213> Homo sapiens

<400> 268
Cys Leu Ala Tyr Asn Thr Thr His Tyr Arg Glu Arg Ala Met Thr Ser
1 5 10 15

His Ala Arg Val Ser Leu
20

<210> 269
<211> 31
<212> PRT
<213> Homo sapiens

<400> 269
Gly Thr Leu Val Ser Met His Phe Ala Ile Trp Ala Thr Asp Arg Ile
1 5 10 15

Met Leu Pro Gly Ala Tyr Lys Cys Ser Ile Pro His Leu Val Pro
20 25 30

<210> 270
<211> 24
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 270
Gly Val Ile Leu Ser Gly Ala Lys Lys Pro Ser Val Phe Pro Gly Phe
1 5 10 15

Ala Xaa Phe Thr Thr Gln Leu Xaa
20

<210> 271
<211> 141
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 271
Lys Lys Ala Ser His Met Glu Gln Val Leu Pro Cys Ile Phe Pro Ser
1 5 10 15

Gly Pro Trp Met Gly Ser Phe Ser Leu Xaa Gln Lys Ser Arg Pro Phe
20 25 30

Phe Leu Asp Leu Arg Xaa Ser Leu His Asn Ser Xaa Lys Glu Ala Val
35 40 45

Leu Leu Asp Cys Leu Leu Phe Leu Xaa Xaa Pro Ser Phe Phe Phe Phe
50 55 60

Ser Ser Ser Ser Ala Trp Lys Lys Thr Ser His Met Glu Gln Val Leu
65 70 75 80

Pro Cys Thr Phe Pro Ser Gly Pro Trp Ile Gly Leu Phe Ser Leu Val
85 90 95

Gln Ala Ser Phe Pro Phe Leu Thr Ser Phe Arg Tyr Ser Leu Gln Ser
100 105 110

Ser Ala Tyr Glu Val Ala Phe Pro Asp Ser Leu Leu Phe Leu Ala Arg
115 120 125

Ala Ser Ala Phe Phe Phe Ser Ser Phe Ser Ala Trp Lys
130 135 140

<210> 272
<211> 28
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 272
Cys Ile Phe Pro Ser Gly Pro Trp Met Gly Ser Phe Ser Leu Xaa Gln
1 5 10 15

Lys Ser Arg Pro Phe Phe Leu Asp Leu Arg Xaa Ser
20 25

<210> 273
<211> 28
<212> PRT
<213> Homo sapiens

<400> 273
Trp Ile Gly Leu Phe Ser Leu Val Gln Ala Ser Phe Pro Phe Leu Thr
1 5 10 15

Ser Phe Arg Tyr Ser Leu Gln Ser Ser Ala Tyr Glu
20 25

<210> 274
<211> 79
<212> PRT
<213> Homo sapiens

<400> 274
Asn Ser Ala Val Asn Ile Lys Ile Arg Gln Arg Met Glu Tyr Phe Ser
1 5 10 15

Val Pro Glu Lys Met Thr Leu Phe Val Val Gln Met Gly Lys Cys Met
20 25 30

Ala Thr Cys Val Pro Cys Val Lys Pro Thr Ser Lys Gln Lys Met Lys
35 40 45

Lys Arg Lys Arg Leu Lys His Glu Leu Glu Thr Lys Glu Asn Leu Glu
50 55 60

Lys Gln Pro His Met Gln Ser Phe Ala Val Asn Ile Glu Ser Leu
65 70 75

<210> 275
<211> 23
<212> PRT
<213> Homo sapiens

<400> 275
Ile Lys Ile Arg Gln Arg Met Glu Tyr Phe Ser Val Pro Glu Lys Met

1 5 10 15

Thr Leu Phe Val Val Gln Met
20

<210> 276
<211> 25
<212> PRT
<213> Homo sapiens

<400> 276
Val Lys Pro Thr Ser Lys Gln Lys Met Lys Lys Arg Lys Arg Leu Lys
1 5 10 15

His Glu Leu Glu Thr Lys Glu Asn Leu
20 25

<210> 277
<211> 63
<212> PRT
<213> Homo sapiens

<400> 277
Pro Arg Val Arg Gly Thr Val Val Arg Leu Arg Gln His Arg Pro Ser
1 5 10 15

Ala Tyr Ile Leu Val Ser Thr Val Leu Thr Leu Met Val Pro Trp His
20 25 30

Ser Leu Asp Pro Asp Ser Ala Leu Ala Asp Ala Phe Tyr Gln Arg Gly
35 40 45

Tyr Arg Trp Ala Gly Phe Ile Val Ala Ala Gly Ser Ile Cys Ala
50 55 60

<210> 278
<211> 25
<212> PRT
<213> Homo sapiens

<400> 278
Thr Val Val Arg Leu Arg Gln His Arg Pro Ser Ala Tyr Ile Leu Val
1 5 10 15

Ser Thr Val Leu Thr Leu Met Val Pro
20 25

<210> 279
<211> 26
<212> PRT
<213> Homo sapiens

<400> 279

Trp His Ser Leu Asp Pro Asp Ser Ala Leu Ala Asp Ala Phe Tyr Gln
1 5 10 15

Arg Gly Tyr Arg Trp Ala Gly Phe Ile Val
20 25

<210> 280
<211> 101
<212> PRT
<213> Homo sapiens

<400> 280
Thr Pro Ser Cys Ser Ala Ser Ser Ser Pro Cys His Ala Leu Ser Met
1 5 10 15

Pro Trp Pro Pro Met Gly Ser Ser Ser Arg Cys Leu Pro Met Cys Thr
20 25 30

Pro Gly His Arg Cys Leu Trp Arg Ala Pro Trp Arg Ser Gly Ser Ser
35 40 45

Arg Pro Ser Trp His Cys Cys Trp Thr Trp Ser Arg Trp Phe Ser Ser
50 55 60

Cys Pro Leu Ala His Ser Trp Pro Thr His Ser Trp Pro Pro Val Ser
65 70 75 80

Leu Cys Cys Ala Ser Arg Ser Leu Pro Arg Pro Ala Pro Gln Ala Gln
85 90 95

Pro Ala Leu Ala Pro
100

<210> 281
<211> 24
<212> PRT
<213> Homo sapiens

<400> 281
Leu Ser Met Pro Trp Pro Pro Met Gly Ser Ser Ser Arg Cys Leu Pro
1 5 10 15

Met Cys Thr Pro Gly His Arg Cys
20

<210> 282
<211> 27
<212> PRT
<213> Homo sapiens

<400> 282
Ala Pro Trp Arg Ser Gly Ser Ser Arg Pro Ser Trp His Cys Cys Trp
1 5 10 15

Thr Trp Ser Arg Trp Phe Ser Ser Cys Pro Leu
20 25

<210> 283
<211> 22
<212> PRT
<213> Homo sapiens

<400> 283
Thr His Ser Trp Pro Pro Val Ser Leu Cys Cys Ala Ser Arg Ser Leu
1 5 10 15

Pro Arg Pro Ala Pro Gln
20

<210> 284
<211> 60
<212> PRT
<213> Homo sapiens

<400> 284
Ala Tyr Ile Leu Val Ser Thr Val Leu Thr Leu Met Val Pro Trp His
1 5 10 15

Ser Leu Asp Pro Asp Ser Ala Leu Ala Asp Ala Phe Tyr Gln Arg Gly
20 25 30

Tyr Arg Trp Ala Gly Phe Ile Val Ala Ala Gly Ser Ile Cys Ala Met
35 40 45

Asn Thr Val Leu Leu Ser Leu Leu Phe Ser Leu Pro
50 55 60

<210> 285
<211> 31
<212> PRT
<213> Homo sapiens

<400> 285
Pro Trp His Ser Leu Asp Pro Asp Ser Ala Leu Ala Asp Ala Phe Tyr
1 5 10 15

Gln Arg Gly Tyr Arg Trp Ala Gly Phe Ile Val Ala Ala Gly Ser
20 25 30

<210> 286
<211> 27
<212> PRT
<213> Homo sapiens

<400> 286
Arg Ile Val Tyr Ala Met Ala Ala Asp Gly Leu Phe Phe Gln Val Phe
1 5 10 15

Ala His Val His Pro Arg Thr Gln Val Pro Val
20 25

<210> 287
<211> 16
<212> PRT
<213> Homo sapiens

<400> 287
Asp Leu Glu Ser Leu Val Gln Phe Leu Ser Leu Gly Thr Leu Leu Ala
1 5 10 15

<210> 288
<211> 15
<212> PRT
<213> Homo sapiens

<400> 288
Tyr Thr Phe Val Ala Thr Ser Ile Ile Val Leu Arg Phe Gln Lys
1 5 10 15

<210> 289
<211> 31
<212> PRT
<213> Homo sapiens

<400> 289
Leu Thr Lys Gln Gln Ser Ser Phe Ser Asp His Leu Gln Leu Val Gly
1 5 10 15

Thr Val His Ala Ser Val Pro Glu Pro Gly Glu Leu Lys Pro Ala
20 25 30

<210> 290
<211> 50
<212> PRT
<213> Homo sapiens

<400> 290
Leu Arg Pro Tyr Leu Gly Phe Leu Asp Gly Tyr Ser Pro Gly Ala Val
1 5 10 15

Val Thr Trp Ala Leu Gly Val Met Leu Ala Ser Ala Ile Thr Ile Gly
20 25 30

Cys Val Leu Val Phe Gly Asn Ser Thr Leu His Leu Pro His Trp Gly
35 40 45

Tyr Ile

50

<210> 291
<211> 27
<212> PRT
<213> Homo sapiens

<400> 291
Pro Gly Ala Val Val Thr Trp Ala Leu Gly Val Met Leu Ala Ser Ala
1 5 10 15

Ile Thr Ile Gly Cys Val Leu Val Phe Gly Asn
20 25

<210> 292
<211> 53
<212> PRT
<213> Homo sapiens

<400> 292
Gly Ala His Gln Gln Gln Tyr Arg Glu Asp Leu Phe Gln Ile Pro Met
1 5 10 15

Val Pro Leu Ile Pro Ala Leu Ser Ile Val Leu Asn Ile Cys Leu Met
20 25 30

Leu Lys Leu Ser Tyr Leu Thr Trp Val Arg Phe Ser Ile Trp Leu Leu
35 40 45

Met Gly Leu Ala Val
50

<210> 293
<211> 26
<212> PRT
<213> Homo sapiens

<400> 293
Met Val Pro Leu Ile Pro Ala Leu Ser Ile Val Leu Asn Ile Cys Leu
1 5 10 15

Met Leu Lys Leu Ser Tyr Leu Thr Trp Val
20 25

<210> 294
<211> 29
<212> PRT
<213> Homo sapiens

<400> 294
Tyr Phe Gly Tyr Gly Ile Arg His Ser Lys Glu Asn Gln Arg Glu Leu
1 5 10 15

Pro Gly Leu Asn Ser Thr His Tyr Val Val Phe Pro Arg
20 25

<210> 295
<211> 23
<212> PRT
<213> Homo sapiens

<400> 295
Phe Pro Pro Ser Pro Ala Pro Pro His Ser Leu Pro Leu Arg Ser Trp
1 5 10 15

Leu Trp Ser Arg Gln Met Gly
20

<210> 296
<211> 148
<212> PRT
<213> Homo sapiens

<400> 296
Gly Thr Ser Phe Arg Gly Met Ile Ser Thr Gln Pro Gly Ser Thr Pro
1 5 10 15

Leu Ala Ser Phe Lys Ile Leu Ala Leu Glu Ser Ala Asp Gly His Gly
20 25 30

Gly Cys Ser Ala Gly Asn Asp Ile Gly Pro Tyr Gly Glu Arg Asp Asp
35 40 45

Gln Gln Val Phe Ile Gln Lys Val Val Pro Ser Ala Ser Gln Leu Phe
50 55 60

Val Arg Leu Ser Ser Thr Gly Gln Arg Val Cys Ser Val Arg Ser Val
65 70 75 80

Asp Gly Ser Pro Thr Thr Ala Phe Thr Val Leu Glu Cys Glu Gly Ser
85 90 95

Pro Ala Ala Arg Leu Ser Ala Pro Ala Leu Pro Ala His Trp Pro Gly
100 105 110

Gln Arg Gln Leu Gly His Val Gly Pro Asn His Arg His Gly Arg Pro
115 120 125

Arg Pro Gly Pro Cys Arg Trp Pro Asp Gly Ala Arg Ala Asp Gly Thr
130 135 140

Ala Gly Thr Leu
145

<210> 297
<211> 29
<212> PRT

<213> Homo sapiens

<400> 297
Pro Gly Ser Thr Pro Leu Ala Ser Phe Lys Ile Leu Ala Leu Glu Ser
1 5 10 15

Ala Asp Gly His Gly Gly Cys Ser Ala Gly Asn Asp Ile
20 25

<210> 298
<211> 24
<212> PRT
<213> Homo sapiens

<400> 298
Gly Glu Arg Asp Asp Gln Gln Val Phe Ile Gln Lys Val Val Pro Ser
1 5 10 15

Ala Ser Gln Leu Phe Val Arg Leu
20

<210> 299
<211> 25
<212> PRT
<213> Homo sapiens

<400> 299
Arg Ser Val Asp Gly Ser Pro Thr Thr Ala Phe Thr Val Leu Glu Cys
1 5 10 15

Glu Gly Ser Pro Ala Ala Arg Leu Ser
20 25

<210> 300
<211> 26
<212> PRT
<213> Homo sapiens

<400> 300
Pro Ala Leu Pro Ala His Trp Pro Gly Gln Arg Gln Leu Gly His Val
1 5 10 15

Gly Pro Asn His Arg His Gly Arg Pro Arg
20 25

<210> 301
<211> 168
<212> PRT
<213> Homo sapiens

<400> 301
Pro Phe Ile Pro Arg Arg Pro Trp Pro Glu Pro Gly Val Pro Thr Gly
1 5 10 15

Ile Arg Glu Ala Pro Glu Ser Pro Arg Thr Arg Ala Ser Gln Gly Ile
20 25 30

Met Ala Ala Ala Leu Phe Lys Lys Glu Val Ser Leu Ser Phe Ile Leu
35 40 45

Gly Gly Val Arg Gly Val Pro Arg Pro Leu Glu Gly His Gly Ala Gly
50 55 60

Val Gly Gly Arg Arg Arg Ser Gly Pro Leu Arg Thr Ser Ser Trp Gln
65 70 75 80

Arg Ser Thr Lys Leu Pro Pro Pro Arg Arg Arg Ala Ser Ala Cys Gly
85 90 95

Gly Leu Gly Leu Pro Arg Trp Pro Asp Lys Glu Val Leu Leu Glu Ala
100 105 110

Glu Trp Arg Leu Val Arg Glu Met Arg Gly Glu Gly Leu Gly Arg Gln
115 120 125

Pro His Glu Gly Ala Glu Arg Ser Arg Arg Gly Gln Leu Thr Val Phe
130 135 140

Gln Leu Phe His Gln Leu Leu Leu Arg Gln Ala Thr Cys Arg Gly Leu
145 150 155 160

Ala Glu Ala Val His Gly Gly Gly
165

<210> 302
<211> 32
<212> PRT
<213> Homo sapiens

<400> 302
Pro Gly Val Pro Thr Gly Ile Arg Glu Ala Pro Glu Ser Pro Arg Thr
1 5 10 15

Arg Ala Ser Gln Gly Ile Met Ala Ala Ala Leu Phe Lys Lys Glu Val
20 25 30

<210> 303
<211> 28
<212> PRT
<213> Homo sapiens

<400> 303
Phe Ile Leu Gly Gly Val Arg Gly Val Pro Arg Pro Leu Glu Gly His
1 5 10 15

Gly Ala Gly Val Gly Gly Arg Arg Arg Ser Gly Pro
20 25

<210> 304
<211> 24
<212> PRT
<213> Homo sapiens

<400> 304
Gly Leu Pro Arg Trp Pro Asp Lys Glu Val Leu Leu Glu Ala Glu Trp
1 5 10 15

Arg Leu Val Arg Glu Met Arg Gly
20

<210> 305
<211> 23
<212> PRT
<213> Homo sapiens

<400> 305
Gly Ala Glu Arg Ser Arg Arg Gly Gln Leu Thr Val Phe Gln Leu Phe
1 5 10 15

His Gln Leu Leu Leu Arg Gln
20

<210> 306
<211> 15
<212> PRT
<213> Homo sapiens

<400> 306
His Ala Ser Ala His Ala Ser Ala His Ala Ser Gly Cys Gly Ala
1 5 10 15

<210> 307
<211> 118
<212> PRT
<213> Homo sapiens

<400> 307
Gln Gly Val Gly Val Ala Asp Glu Gly Gly Leu Glu Arg Gln Arg Val
1 5 10 15

Asp Ala Gly Ala Arg Leu Gly His Met Gly Gln Pro Val Ala Phe Ser
20 25 30

Thr Arg Gln Leu His Leu Ala Leu Pro Ala Pro Gly Thr Ala Gly Val
35 40 45

Thr Val Pro His Pro His Ala Arg Glu Gly Val Val Gly Asp Leu Pro
50 55 60

Leu Val Pro Asp Ala Glu Asp Pro Thr Val Gly Val Pro Ala Glu Gly
65 70 75 80

Leu Leu Val Leu Gly His Val Val Glu Arg Ala Glu Leu Ile Leu Val
85 90 95

Arg Gly Leu His Gln Ala Glu Ala Leu Ala Arg Glu Ser Glu Glu Met
100 105 110

His Gly Ser Arg His Gly
115

<210> 308
<211> 25
<212> PRT
<213> Homo sapiens

<400> 308
Glu Gly Gly Leu Glu Arg Gln Arg Val Asp Ala Gly Ala Arg Leu Gly
1 5 10 15

His Met Gly Gln Pro Val Ala Phe Ser
20 25

<210> 309
<211> 29
<212> PRT
<213> Homo sapiens

<400> 309
Leu Ala Leu Pro Ala Pro Gly Thr Ala Gly Val Thr Val Pro His Pro
1 5 10 15

His Ala Arg Glu Gly Val Val Gly Asp Leu Pro Leu Val
20 25

<210> 310
<211> 28
<212> PRT
<213> Homo sapiens

<400> 310
Pro Ala Glu Gly Leu Leu Val Leu Gly His Val Val Glu Arg Ala Glu
1 5 10 15

Leu Ile Leu Val Arg Gly Leu His Gln Ala Glu Ala
20 25

<210> 311
<211> 125
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 311
His Leu Phe Lys Phe Phe Tyr Thr Ile Ala Phe Met Gln Trp Phe Thr
1 5 10 15

Glu Phe Met Glu Leu Phe Leu Ser Val Trp Glu Leu Ile Lys Thr Xaa
20 25 30

Asn Leu Cys Phe Val Cys Phe Ser Glu His Lys Pro Gly Gln Leu Val
35 40 45

Pro Ala Gly Pro Thr Ser Gln Leu Leu Cys Arg Ala Leu Gly Arg Val
50 55 60

His Leu Cys Ser Pro Thr Thr Arg Ser Gln Thr Pro Thr Gln Ser Trp
65 70 75 80

Val Thr Pro Gln Leu Leu Trp Arg Leu Gly Ser Gly Arg Leu Val Ala
85 90 95

Gln Val Leu Gln Val Gly Ser Phe Cys Gly Pro Arg Val Gly Asp Ala
100 105 110

Val Leu Gly Glu Gln Thr Phe Gln Pro Phe Asp Leu Leu
115 120 125

<210> 312
<211> 29
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 312
Ala Phe Met Gln Trp Phe Thr Glu Phe Met Glu Leu Phe Leu Ser Val
1 5 10 15

Trp Glu Leu Ile Lys Thr Xaa Asn Leu Cys Phe Val Cys
20 25

<210> 313
<211> 26
<212> PRT
<213> Homo sapiens

<400> 313
Arg Ser Gln Thr Pro Thr Gln Ser Trp Val Thr Pro Gln Leu Leu Trp

1 5 10 15

Arg Leu Gly Ser Gly Arg Leu Val Ala Gln
20 25

<210> 314
<211> 39
<212> PRT
<213> Homo sapiens

<400> 314
Gly Ala Trp Gly Val Glu Val Val Ala Val Gly Ser Lys Ala Gly Cys
1 5 10 15

Leu Val Tyr Gln Leu Cys Asp Leu Lys Gln Ile Thr Phe Phe Phe Arg
20 25 30

Ala Ser Val Cys Leu Ser Val
35

<210> 315
<211> 194
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (129)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (131)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (163)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (187)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 315
Pro Ala Ser Leu Gly Ser Ser Trp Gly Gln Lys Leu Arg Gly Gly Thr
1 5 10 15

Arg Lys Ser Phe Gln Glu Leu Ser Pro Ser Ser Ala Pro Pro Ala Cys
20 25 30

Leu Pro Gln Pro Pro Ala Ser Thr Trp Leu Ser Ser Trp Pro Arg Pro
35 40 45

Pro Cys Trp Pro Pro Met Cys Ser Trp Ala Leu Gly Xaa Cys Phe Cys
50 55 60

Pro Ala Thr Gly Gln Trp Leu Pro Thr Ser Cys Cys Leu Trp Trp Cys
65 70 75 80

Pro Asp Ala Gly Gly Arg Gln Lys His Phe Arg Ser Arg Trp Xaa Thr
85 90 95

Ser Trp Glu Thr Trp Gln Pro Tyr Leu Thr Gly Leu Ile Ser Ser Val
100 105 110

Leu Arg Ala Xaa Arg Pro Asp Ser Tyr Leu Gln Arg Phe Arg Ser Leu
115 120 125

Xaa Gln Xaa Xaa Leu Cys Cys Ala Phe Val Ile Ala Leu Gly Gly Gly
130 135 140

Cys Phe Leu Leu Thr Ala Leu Tyr Leu Glu Arg Asp Glu Thr Arg Ala
145 150 155 160

Trp Gln Xaa Val Thr Gly Thr Pro Asp Ser Asn Asp Val Asp Ser Asn
165 170 175

Asp Leu Glu Arg Gln Gly Leu Leu Ser Gly Xaa Gly Ala Ser Thr Glu
180 185 190

Glu Pro

<210> 316
<211> 26
<212> PRT
<213> Homo sapiens

<400> 316

Leu Arg Gly Gly Thr Arg Lys Ser Phe Gln Glu Leu Ser Pro Ser Ser
1 5 10 15

Ala Pro Pro Ala Cys Leu Pro Gln Pro Pro
20 25

<210> 317
<211> 28
<212> PRT
<213> Homo sapiens

<400> 317
Ala Thr Gly Gln Trp Leu Pro Thr Ser Cys Cys Leu Trp Trp Cys Pro
1 5 10 15

Asp Ala Gly Gly Arg Gln Lys His Phe Arg Ser Arg
20 25

<210> 318
<211> 22
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 318
Gly Gly Cys Phe Leu Leu Thr Ala Leu Tyr Leu Glu Arg Asp Glu Thr
1 5 10 15

Arg Ala Trp Gln Xaa Val
20

<210> 319
<211> 124
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (107)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 319
Ala Pro His Leu Arg Leu Gln Pro Ala Cys His Ser Pro Leu Pro Leu
1 5 10 15

Pro Gly Ser Arg Pro Gly Pro Asp His Pro Ala Gly Leu Leu Cys Val
20 25 30

Pro Gly Pro Trp Gly Xaa Ala Ser Val Leu Gln Leu Gly Ser Gly Cys
35 40 45

Arg His Pro Ala Val Cys Gly Gly Ala Gln Met Pro Gly Asp Gly Arg
50 55 60

Ser Thr Ser Asp His Gly Gly Xaa His Pro Gly Xaa Pro Gly Ser Pro
65 70 75 80

Ile Ser Gln Asp Leu Ser Leu Val Ser Cys Gly Pro Xaa Ala Leu Thr
85 90 95

Pro Ile Cys Ser Ala Ser Ala Ala Xaa Xaa Xaa Xaa Xaa Cys Ala Ala
100 105 110

Pro Leu Ser Ser Pro Trp Gly Ala Ala Ala Ser Cys
115 120

<210> 320
<211> 25
<212> PRT
<213> Homo sapiens

<400> 320
Pro Ala Cys His Ser Pro Leu Pro Leu Pro Gly Ser Arg Pro Gly Pro
1 5 10 15

Asp His Pro Ala Gly Leu Leu Cys Val
20 25

<210> 321
<211> 26
<212> PRT
<213> Homo sapiens

<400> 321
Ser Gly Cys Arg His Pro Ala Val Cys Gly Gly Ala Gln Met Pro Gly
1 5 10 15

Asp Gly Arg Ser Thr Ser Asp His Gly Gly
20 25

<210> 322
<211> 95
<212> PRT
<213> Homo sapiens

<400> 322
Gly Leu Lys Val Met Glu Ile Cys Ser Leu Thr Phe Leu Glu Ala Thr
1 5 10 15

Asn Leu Gln Ser Arg Cys Gln Gln Ala Met Leu Pro Leu Lys Ala Leu
20 25 30

Arg Lys Asn Pro Phe Leu Leu Leu Pro Ser Phe Asp Gly Cys Cys Gln
35 40 45

Ser Leu Ala Phe Pro Gly Leu Trp Leu Gln His Ser Asn Leu Cys Leu
50 55 60

Asn His His Met Thr Phe Leu Val Tyr Leu Leu Cys Val Ser Val Phe
65 70 75 80

Lys Tyr Phe Phe Pro Phe Ser Cys Thr Tyr Thr Ser His Trp Ile
85 90 95

<210> 323
<211> 22
<212> PRT
<213> Homo sapiens

<400> 323

Ile Cys Ser Leu Thr Phe Leu Glu Ala Thr Asn Leu Gln Ser Arg Cys
1 5 10 15

Gln Gln Ala Met Leu Pro
20

<210> 324
<211> 26
<212> PRT
<213> Homo sapiens

<400> 324
Gly Leu Trp Leu Gln His Ser Asn Leu Cys Leu Asn His His Met Thr
1 5 10 15

Phe Leu Val Tyr Leu Leu Cys Val Ser Val
20 25

<210> 325
<211> 37
<212> PRT
<213> Homo sapiens

<400> 325
Pro Phe Pro Leu Leu Pro Pro Lys Arg Arg Gly Leu Leu Tyr His Leu
1 5 10 15

Ile Gln Lys Ser Thr Leu Gly Leu Val Val Trp Phe Arg Glu His Leu
20 25 30

Asp Ser Arg Ser Gln
35

<210> 326
<211> 78
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 326
Arg Gly Xaa Pro Ser Trp Pro Met His Thr Leu Val Tyr Ala Gln His
1 5 10 15

Ser Thr Thr His Thr Pro Leu Ile Gln Pro Gln Trp Thr Gln Val Ile
20 25 30

Asp Gln Pro Pro Gly Ile Thr His Gln Phe Cys Val Arg Xaa Cys Xaa
35 40 45

Cys Pro Thr Leu Glu Ser Cys Val Gln Glu Cys Val Thr Arg Ser Arg
50 55 60

Xaa Lys Pro Thr Thr Gly Val Pro Gly Pro Gln Arg Leu Ala
65 70 75

<210> 327
<211> 24
<212> PRT
<213> Homo sapiens

<400> 327
Thr Pro Leu Ile Gln Pro Gln Trp Thr Gln Val Ile Asp Gln Pro Pro
1 5 10 15

Gly Ile Thr His Gln Phe Cys Val
20

<210> 328
<211> 104
<212> PRT
<213> Homo sapiens

<400> 328
Ala Leu Gly Pro Ser Gln Thr Cys Asp Leu Asp Val Trp Leu Val Ala
1 5 10 15

Lys Pro Ser Phe Phe Arg Gly Pro Gln Gly Ile His Tyr Phe Ser Leu
20 25 30

Trp Arg Arg Lys Pro Leu Ser His Trp Val Ser Ile Trp Gln Leu Gln
35 40 45

Gly Gln Glu Thr Met Pro Ala Met Leu Arg Ser Arg Pro Ala Gly Gln
50 55 60

Ala Thr Val Ala Thr Gly Pro Pro Arg Gly Ser Pro Ser Pro Gln Asp
65 70 75 80

Leu Pro Ser Tyr His Arg Lys Gln Val Glu Ser Ser His Arg His Ser
85 90 95

Trp Glu Pro Ala Ser Gln Ser Gln
100

<210> 329
<211> 28
<212> PRT
<213> Homo sapiens

<400> 329
Cys Asp Leu Asp Val Trp Leu Val Ala Lys Pro Ser Phe Phe Arg Gly
1 5 10 15

Pro Gln Gly Ile His Tyr Phe Ser Leu Trp Arg Arg
20 25

<210> 330
<211> 28
<212> PRT
<213> Homo sapiens

<400> 330
Ala Gly Gln Ala Thr Val Ala Thr Gly Pro Pro Arg Gly Ser Pro Ser
1 5 10 15

Pro Gln Asp Leu Pro Ser Tyr His Arg Lys Gln Val
20 25

<210> 331
<211> 79
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 331
Xaa Gly Asp Thr Xaa Thr Gln Asn Ser Arg His Asp Thr Pro Xaa Leu
1 5 10 15

Ile Asp Tyr Tyr Arg Glu Ser Cys Thr Leu Gln Tyr Arg Pro Glu Phe
20 25 30

175

Pro Gly Arg Pro Thr Arg Pro Arg Gly Ser Cys Pro Gln Tyr Pro Gly
35 40 45

Pro Ala Ile Pro Arg Thr Ser Trp Ala Leu Gly Glu Gly Asp Ala Ala
50 55 60

Pro Arg Gly Ala His His Pro Arg Arg Ala Asp Val Pro Leu Gly
65 70 75

<210> 332
<211> 30
<212> PRT
<213> Homo sapiens

<400> 332
Tyr Arg Glu Ser Cys Thr Leu Gln Tyr Arg Pro Glu Phe Pro Gly Arg
1 5 10 15

Pro Thr Arg Pro Arg Gly Ser Cys Pro Gln Tyr Pro Gly Pro
20 25 30

<210> 333
<211> 155
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 333
Gly Lys Leu Tyr Ala Ala Val Pro Ser Gly Ile Pro Gly Ser Thr His
1 5 10 15

Ala Ser Ala Arg Leu Met Pro Pro Val Ser Arg Ser Ser Tyr Ser Glu
20 25 30

Asp Ile Val Gly Ser Arg Arg Arg Arg Arg Ser Ser Ser Gly Ser Pro
35 40 45

Pro Ser Pro Gln Ser Arg Cys Ser Ser Trp Asp Gly Cys Ser Arg Ser
50 55 60

His Ser Arg Gly Arg Glu Gly Xaa Arg Pro Pro Trp Ser Glu Leu Asp
65 70 75 80

Val Gly Ala Leu Tyr Pro Phe Ser Arg Ser Gly Ser Arg Gly Arg Leu
85 90 95

Pro Arg Phe Arg Asn Tyr Ala Phe Ala Ser Ser Trp Ser Thr Ser Tyr
100 105 110

Ser Gly Tyr Arg Tyr His Arg Ala Leu Leu Cys Arg Arg Thr Ala Val

176

115 120 125

Ser Gly Arg Leu Arg Glu Gly Arg Glu Pro Ser Ala Glu Glu Ala Glu
130 135 140

Gly Glu Arg Glu Asp Trp Gly Ile Gly Ser Ala
145 150 155

<210> 334
<211> 23
<212> PRT
<213> Homo sapiens

<400> 334
Ser Gly Ile Pro Gly Ser Thr His Ala Ser Ala Arg Leu Met Pro Pro
1 5 10 15

Val Ser Arg Ser Ser Tyr Ser
20

<210> 335
<211> 29
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 335
Gly Cys Ser Arg Ser His Ser Arg Gly Arg Glu Gly Xaa Arg Pro Pro
1 5 10 15

Trp Ser Glu Leu Asp Val Gly Ala Leu Tyr Pro Phe Ser
20 25

<210> 336
<211> 25
<212> PRT
<213> Homo sapiens

<400> 336
Thr Ala Val Ser Gly Arg Leu Arg Glu Gly Arg Glu Pro Ser Ala Glu
1 5 10 15

Glu Ala Glu Gly Glu Arg Glu Asp Trp
20 25

<210> 337
<211> 134
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 337
Arg Ile Arg Lys Ala Ala Val Gln Ile Pro Thr Arg Lys Asn Ile Gly
1 5 10 15

Xaa Arg Arg Pro Val Val Gln Glu Thr Arg Lys Lys Glu Arg Ile Ser
20 25 30

Arg Leu Lys Glu Ser Ile Gly Asn Ile Leu Ile Val Thr Val Thr Gln
35 40 45

Ser Leu Thr Gln Ile Leu Thr Leu Met Met Ile Lys Arg Glu Leu Lys
50 55 60

Pro Arg Arg Lys Arg Arg Lys Arg Asn Thr Lys Gln Xaa Lys Arg Arg
65 70 75 80

Ile Arg Lys Pro Lys Lys Asn Pro Val Thr Gln Ala Val Lys Thr Gln
85 90 95

Lys Arg Thr Cys Gln Lys Leu Pro Gly Met Glu Gln Pro Asn Val Ala
100 105 110

Asp Thr Met Asp Leu Ile Gly Pro Glu Ala Pro Ile Asn Thr Tyr Leu
115 120 125

Phe Lys Met Lys Asn Leu
130

<210> 338
<211> 28
<212> PRT
<213> Homo sapiens

<400> 338
Thr Arg Lys Lys Glu Arg Ile Ser Arg Leu Lys Glu Ser Ile Gly Asn
1 5 10 15

Ile Leu Ile Val Thr Val Thr Gln Ser Leu Thr Gln
20 25

<210> 339
<211> 28
<212> PRT
<213> Homo sapiens

<400> 339
Val Lys Thr Gln Lys Arg Thr Cys Gln Lys Leu Pro Gly Met Glu Gln
1 5 10 15

Pro Asn Val Ala Asp Thr Met Asp Leu Ile Gly Pro
20 25

<210> 340
<211> 80
<212> PRT
<213> Homo sapiens

<400> 340
Leu Pro Phe Thr Leu Lys Pro Lys Met Val Lys Ile Pro Phe Ser Ser
1 5 10 15

Arg Leu Ile Asn Asn Asn Leu Gln Tyr Ile Asp Cys Ile Leu Ser Leu
20 25 30

Lys Arg Cys Glu Glu Ile Leu Leu Met Trp His Gly Leu Leu Leu Cys
35 40 45

Leu Ala Ser Val Phe Leu Glu Leu Arg Gly Asp Arg Pro Pro Leu Leu
50 55 60

Ala Ser Leu Leu Glu Pro His Lys Met Pro Leu His Ser Ser Ser Leu
65 70 75 80

<210> 341
<211> 24
<212> PRT
<213> Homo sapiens

<400> 341
Leu Lys Pro Lys Met Val Lys Ile Pro Phe Ser Ser Arg Leu Ile Asn
1 5 10 15

Asn Asn Leu Gln Tyr Ile Asp Cys
20

<210> 342
<211> 23
<212> PRT
<213> Homo sapiens

<400> 342
Ser Leu Lys Arg Cys Glu Glu Ile Leu Leu Met Trp His Gly Leu Leu
1 5 10 15

Leu Cys Leu Ala Ser Val Phe

20

<210> 343
<211> 21
<212> PRT
<213> Homo sapiens

<400> 343
Leu Arg Gly Asp Arg Pro Pro Leu Leu Ala Ser Leu Leu Glu Pro His
1 5 10 15

Lys Met Pro Leu His
20

<210> 344
<211> 79
<212> PRT
<213> Homo sapiens

<400> 344
Leu Gln Met His Thr Gly Ser Gly Phe Lys Gly Lys Ser Cys Glu Val
1 5 10 15

Ala Phe Tyr Val Ala Gln Ala Glu Lys Pro Gly Glu Gly Ala Tyr Leu
20 25 30

His Gly Ala Gln Glu Thr Gln Lys Gln Gly Ile Glu Ala Asp His Ala
35 40 45

Thr Leu Arg Gly Ser Pro His Ser Val Ser Lys Thr Lys Tyr Asn Leu
50 55 60

Tyr Ile Ala Asn Tyr Tyr Leu Leu Ala Trp Arg Lys Met Glu Ser
65 70 75

<210> 345
<211> 20
<212> PRT
<213> Homo sapiens

<400> 345
Cys Glu Val Ala Phe Tyr Val Ala Gln Ala Glu Lys Pro Gly Glu Gly
1 5 10 15

Ala Tyr Leu His
20

<210> 346
<211> 23
<212> PRT
<213> Homo sapiens

<400> 346

Ala Thr Leu Arg Gly Ser Pro His Ser Val Ser Lys Thr Lys Tyr Asn
1 5 10 15

Leu Tyr Ile Ala Asn Tyr Tyr
20

<210> 347
<211> 65
<212> PRT
<213> Homo sapiens

<400> 347
Leu Ser Ala Ser Leu Leu Asp Arg Tyr Pro Ala Ser Glu Ser Asn Asn
1 5 10 15

Tyr Ile Phe Asn Phe Val Leu Tyr Met Leu His Phe Leu Ala Gly Thr
20 25 30

Leu Phe Ser Leu Phe Pro Asp Phe Glu Leu Ser Pro Arg Ser Ala Thr
35 40 45

Leu Phe Pro Asp Leu Arg Thr Val Gln Leu Leu Ser Ser Arg Pro His
50 55 60

Leu
65

<210> 348
<211> 23
<212> PRT
<213> Homo sapiens

<400> 348
Leu Leu Asp Arg Tyr Pro Ala Ser Glu Ser Asn Asn Tyr Ile Phe Asn
1 5 10 15

Phe Val Leu Tyr Met Leu His
20

<210> 349
<211> 20
<212> PRT
<213> Homo sapiens

<400> 349
Phe Pro Asp Phe Glu Leu Ser Pro Arg Ser Ala Thr Leu Phe Pro Asp
1 5 10 15

Leu Arg Thr Val
20

<210> 350
<211> 85

<212> PRT
<213> Homo sapiens

<400> 350
Asn Gly Gly Phe Tyr Asp Val Ser Phe Lys Gln Ala Gly Leu Ile Glu
1 5 10 15

Phe Leu Cys Ile Ile Tyr Phe Tyr Pro Met Ala His Val Ile Cys Gly
20 25 30

Ser Arg Phe Thr Ile Val Arg Thr Ile Pro Val His Tyr Val Gly Glu
35 40 45

Tyr Phe Ile Lys Ser Ser Ile Trp Ile Leu Tyr Arg Ile Asn Glu Arg
50 55 60

Thr Ala Thr Lys Lys Ala Ala Ser Asp Phe Gln Lys Asn Phe Arg Cys
65 70 75 80

Phe Leu Asp Ala Phe
85

<210> 351
<211> 19
<212> PRT
<213> Homo sapiens

<400> 351
Lys Gln Ala Gly Leu Ile Glu Phe Leu Cys Ile Ile Tyr Phe Tyr Pro
1 5 10 15

Met Ala His

<210> 352
<211> 23
<212> PRT
<213> Homo sapiens

<400> 352
Tyr Phe Ile Lys Ser Ser Ile Trp Ile Leu Tyr Arg Ile Asn Glu Arg
1 5 10 15

Thr Ala Thr Lys Lys Ala Ala
20

<210> 353
<211> 22
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 353
Ser Pro Arg Xaa Gly Arg Xaa Phe Xaa Thr Ser Arg Lys Gln Ile Ser
1 5 10 15

Gly Phe Leu Glu Phe Asp
20

<210> 354
<211> 56
<212> PRT
<213> Homo sapiens

<400> 354
Met Lys His Ala Ala Phe Gly Leu Ile Pro Leu Val Lys Glu Ile Tyr
1 5 10 15

Arg Tyr Leu Lys Ile Lys Ser Lys Leu Leu Ile Gly Ser Gly Lys Cys
20 25 30

Gln Leu Gln Pro Glu Trp Leu Gln Thr Ser Leu Ile Asn Ser Ser Leu
35 40 45

Leu Met Asp Trp Leu Thr Pro Tyr
50 55

<210> 355
<211> 29
<212> PRT
<213> Homo sapiens

<400> 355
Ile Tyr Arg Tyr Leu Lys Ile Lys Ser Lys Leu Leu Ile Gly Ser Gly
1 5 10 15

Lys Cys Gln Leu Gln Pro Glu Trp Leu Gln Thr Ser Leu
20 25

<210> 356
<211> 68
<212> PRT
<213> Homo sapiens

<400> 356
Gln Leu Gly Leu Pro Trp Asp Gln Ser Lys Gly Pro Arg Lys Asn Gly
1 5 10 15

Leu Ser Met Cys Gly Ser Val Tyr Ser Thr Ile Trp Ser Leu Ile Ala
20 25 30

Ser Arg Arg Glu Glu Thr Ile Arg Val Ile Val Leu Tyr Ile Gln Ser
35 40 45

Pro Asn Ile Asn Thr Arg His Ile Ser Lys Arg Gly Leu Asn Lys Ala
50 55 60

Leu Thr Asn Pro
65

<210> 357
<211> 21
<212> PRT
<213> Homo sapiens

<400> 357
Ser Lys Gly Pro Arg Lys Asn Gly Leu Ser Met Cys Gly Ser Val Tyr
1 5 10 15

Ser Thr Ile Trp Ser
20

<210> 358
<211> 17
<212> PRT
<213> Homo sapiens

<400> 358
Gln Ser Pro Asn Ile Asn Thr Arg His Ile Ser Lys Arg Gly Leu Asn
1 5 10 15

Lys

<210> 359
<211> 19
<212> PRT
<213> Homo sapiens

<400> 359
His Pro Gln Thr Ser Ala Gly Gly Phe Pro Leu His Gln Gly Leu Pro
1 5 10 15

Thr Val Ser

<210> 360

<211> 117
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 360
Pro Ser Trp Phe Pro Glu Leu Ser Pro Trp Pro Leu Lys Thr Leu Lys
1 5 10 15

Lys Arg Arg Gln Met Arg Leu Arg Arg Arg Gly Arg Leu Cys Arg Leu
20 25 30

Ser Pro Ala Thr Thr Thr Thr Ala Asp Thr Cys Arg Cys Pro Ala Arg
35 40 45

Ser Tyr Arg Gly Ser Gly Arg Arg Pro Ala Cys Ala Gln Asp Ser Pro
50 55 60

Ala Pro Pro Ser Arg Pro Thr Arg Arg Ala Trp Glu Lys Cys Ala Leu
65 70 75 80

Arg Pro Lys Arg Ala Ala Gln Trp Ser Thr Gly Val Pro Pro Ser Pro
85 90 95

Arg Ser Ser Thr Thr Gly Cys Cys Phe Gly Thr Ala Ala Xaa Cys Ala
100 105 110

Glu Gly Ala Arg Arg
115

<210> 361
<211> 22
<212> PRT
<213> Homo sapiens

<400> 361
Thr Thr Thr Ala Asp Thr Cys Arg Cys Pro Ala Arg Ser Tyr Arg Gly
1 5 10 15

Ser Gly Arg Arg Pro Ala
20

<210> 362
<211> 24
<212> PRT
<213> Homo sapiens

<400> 362
Pro Ser Arg Pro Thr Arg Arg Ala Trp Glu Lys Cys Ala Leu Arg Pro
1 5 10 15

Lys Arg Ala Ala Gln Trp Ser Thr
20

<210> 363
<211> 20
<212> PRT
<213> Homo sapiens

<400> 363
Ala Arg Gly Val Leu Asn Leu Arg Asn Arg Phe Glu Cys Phe Ser Ile
1 5 10 15

Ile Glu Thr Val
20

<210> 364
<211> 69
<212> PRT
<213> Homo sapiens

<400> 364
Ile Gly Gln Leu Val Met Lys Ser Ile Cys His Phe Gln Arg Leu Leu
1 5 10 15

Ser Val Ala Ile Asp Phe Ala Ser Gln Phe Leu Lys Asn Tyr Ile Phe
20 25 30

Ser Ser Thr His Ser Ser Lys Ala Gly Phe Ser Val Val Cys Ser Leu
35 40 45

Pro Lys Trp Leu Tyr Thr Asp Gly Met Glu Met Val Leu Lys Ile Thr
50 55 60

His Lys Leu Ser Phe
65

<210> 365
<211> 24
<212> PRT
<213> Homo sapiens

<400> 365
Gln Arg Leu Leu Ser Val Ala Ile Asp Phe Ala Ser Gln Phe Leu Lys
1 5 10 15

Asn Tyr Ile Phe Ser Ser Thr His
20

<210> 366
<211> 12
<212> PRT
<213> Homo sapiens

<400> 366
Leu Met Lys Thr Ala Ser Arg Met Leu Leu Leu Glu
1 5 10

<210> 367
<211> 25
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 367
Ala Thr Xaa Trp Asp Xaa Pro Gly Cys Arg Asn Ser Ala Arg Gly Glu
1 5 10 15

Arg Leu His Val Gly Asp Ala Pro Trp
20 25

<210> 368
<211> 109
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 368
Ala Arg Asp Glu Arg Arg Glu Val Leu Lys Thr Leu Met Arg Leu Ser
1 5 10 15

Thr Gln Arg Pro Gln Ala Phe Leu Pro Ser Gln Ser Trp Phe Val Arg
20 25 30

Leu Gln Lys Ala Gly Glu Gly Ala Leu Lys Gln Glu Asn Ser Leu Thr
35 40 45

Ile Gln Asn Cys Leu Leu Cys Leu Pro Arg Val His Arg Gln Arg Pro
50 55 60

Thr Pro Pro Gln Pro Gln Arg Gly Asn Thr Glu Ala Ser Val Leu Gln

65 70 75 80

Thr Ser Thr Glu His Leu Pro Arg Ala Ala Val Leu Leu Val Pro Asn
85 90 95

Ser Cys Ser Pro Gly Xaa Pro Thr Xaa Leu Leu Ser Ser
100 105

<210> 369
<211> 22
<212> PRT
<213> Homo sapiens

<400> 369
Glu Arg Arg Glu Val Leu Lys Thr Leu Met Arg Leu Ser Thr Gln Arg
1 5 10 15

Pro Gln Ala Phe Leu Pro
20

<210> 370
<211> 25
<212> PRT
<213> Homo sapiens

<400> 370
Gly Ala Leu Lys Gln Glu Asn Ser Leu Thr Ile Gln Asn Cys Leu Leu
1 5 10 15

Cys Leu Pro Arg Val His Arg Gln Arg
20 25

<210> 371
<211> 21
<212> PRT
<213> Homo sapiens

<400> 371
Ser Val Leu Gln Thr Ser Thr Glu His Leu Pro Arg Ala Ala Val Leu
1 5 10 15

Leu Val Pro Asn Ser
20

<210> 372
<211> 9
<212> PRT
<213> Homo sapiens

<400> 372
Ala Leu Val Ile Ser Asn Pro Leu Leu
1 5

<210> 373
<211> 63
<212> PRT
<213> Homo sapiens

<400> 373
Pro Tyr Ile Asn Thr Gln Met Cys Val Ser Ser Arg Asn Lys Phe Cys
1 5 10 15

Ile Ser Gly His Gln Lys Tyr Asp Ser His Gly Arg Glu Thr Arg Phe
20 25 30

Glu Met His Lys Ala Arg Ala Ser Ser Trp Lys Asn Ile Leu Lys Ile
35 40 45

Arg Ser Leu Lys Ile Ile Ser Arg Gly Phe Glu Ile Thr Asn Ala
50 55 60

<210> 374
<211> 27
<212> PRT
<213> Homo sapiens

<400> 374
Lys Phe Cys Ile Ser Gly His Gln Lys Tyr Asp Ser His Gly Arg Glu
1 5 10 15

Thr Arg Phe Glu Met His Lys Ala Arg Ala Ser
20 25

<210> 375
<211> 84
<212> PRT
<213> Homo sapiens

<400> 375
His Thr Leu Leu Glu Ile Ala Asn Pro Leu Gln Ala Ala Val Leu Gly
1 5 10 15

Ala Ser Ser Ile His Pro Ser Ile His Thr Ser Thr His Leu Met Phe
20 25 30

Met Gly Leu Lys Trp Thr Glu Leu His His Ser Pro Asp Ser Val Gln
35 40 45

Gly Ala Gly Ala Ala Glu Ala Ala Gln Thr Arg His Ser Leu Arg Pro
50 55 60

Gly Arg Gly Arg Glu Arg His Asp Cys Thr Leu Lys Asn Leu Thr Leu
65 70 75 80

Phe Ile Ile Cys

<210> 376
<211> 22
<212> PRT
<213> Homo sapiens

<400> 376
Asn Pro Leu Gln Ala Ala Val Leu Gly Ala Ser Ser Ile His Pro Ser
1 5 10 15

Ile His Thr Ser Thr His
20

<210> 377
<211> 17
<212> PRT
<213> Homo sapiens

<400> 377
Ser Leu Arg Pro Gly Arg Gly Arg Glu Arg His Asp Cys Thr Leu Lys
1 5 10 15

Asn

<210> 378
<211> 52
<212> PRT
<213> Homo sapiens

<400> 378
Ala Glu Asn Val His Cys Thr Pro Ala Trp Glu Thr Gly Arg Asp Ser
1 5 10 15

Glu Asp Gly Lys Gly Arg Glu Gly Met Gly Arg Asp Arg Lys Gly Trp
20 25 30

Asp Gly Thr Gly Leu Asp Gly Thr Gly Trp Glu Gly Lys Arg Glu Arg
35 40 45

Asn Val Pro Ala
50

<210> 379
<211> 26
<212> PRT
<213> Homo sapiens

<400> 379
Gly Arg Asp Ser Glu Asp Gly Lys Gly Arg Glu Gly Met Gly Arg Asp
1 5 10 15

Arg Lys Gly Trp Asp Gly Thr Gly Leu Asp
20 25

<210> 380
<211> 14
<212> PRT
<213> Homo sapiens

<400> 380
Thr Ser Leu Gly Asp Leu Trp Asp Tyr Asn Asn Ser Ser His
1 5 10

<210> 381
<211> 66
<212> PRT
<213> Homo sapiens

<400> 381
Asp Arg Arg Ile Ile Arg Thr Arg Glu Ala Ala Val Ala Val Ser Arg
1 5 10 15

Glu Arg Pro Leu His Ser Ser Leu Gly Asn Arg Glu Arg Leu Arg Arg
20 25 30

Trp Glu Gly Thr Gly Arg Asp Gly Lys Gly Gln Glu Gly Met Gly Arg
35 40 45

Asp Gly Thr Gly Trp Asp Gly Met Gly Arg Glu Glu Arg Lys Lys Cys
50 55 60

Pro Ser
65

<210> 382
<211> 25
<212> PRT
<213> Homo sapiens

<400> 382
Arg Pro Leu His Ser Ser Leu Gly Asn Arg Glu Arg Leu Arg Arg Trp
1 5 10 15

Glu Gly Thr Gly Arg Asp Gly Lys Gly
20 25

<210> 383
<211> 9
<212> PRT
<213> Homo sapiens

<400> 383
Asn Gln Ser Trp Gly Pro Met Gly Leu
1 5

<210> 384
<211> 59
<212> PRT
<213> Homo sapiens

<400> 384
Gly Gly Gly Gly Cys Ser Glu Pro Arg Thr Ser Ile Ala Leu Gln Pro
1 5 10 15

Gly Lys Gln Gly Glu Thr Pro Lys Met Gly Arg Asp Gly Lys Gly Trp
20 25 30

Glu Gly Thr Gly Arg Asp Gly Thr Gly Arg Asp Trp Met Gly Arg Asp
35 40 45

Gly Lys Gly Arg Glu Lys Glu Met Ser Gln Gln
50 55

<210> 385
<211> 24
<212> PRT
<213> Homo sapiens

<400> 385
Lys Gln Gly Glu Thr Pro Lys Met Gly Arg Asp Gly Lys Gly Trp Glu
1 5 10 15

Gly Thr Gly Arg Asp Gly Thr Gly
20

<210> 386
<211> 32
<212> PRT
<213> Homo sapiens

<400> 386
Pro Val Leu Gly Thr Tyr Gly Thr Ile Thr Thr Pro Val Thr Glu Leu
1 5 10 15

Thr Lys Gly Gln Glu Lys Glu Gly Gly Val Glu Thr Val Leu Tyr Glu
20 25 30

<210> 387
<211> 11
<212> PRT
<213> Homo sapiens

<400> 387
Lys Ile Val Phe Ile Asp Gln Lys Trp Ser Lys
1 5 10

<210> 388
<211> 70
<212> PRT
<213> Homo sapiens

<400> 388
Cys Ser Leu Phe Trp Gly Ile Leu Phe Leu Ser Arg Leu Arg Ile His
1 5 10 15

Leu Phe Leu Ser Leu Lys Pro Cys Met Cys Leu Arg Pro Ile Asp Ile
20 25 30

Leu Ser His Phe Leu Asp Ile Phe Val Thr Ser Val Leu Ser Glu Leu
35 40 45

Glu Lys Ser Ser Leu Lys Thr Thr Glu Thr Phe Ser Phe Ala Val Phe
50 55 60

Leu Leu Leu Met Met Asn
65 70

<210> 389
<211> 26
<212> PRT
<213> Homo sapiens

<400> 389
Leu Ser Arg Leu Arg Ile His Leu Phe Leu Ser Leu Lys Pro Cys Met
1 5 10 15

Cys Leu Arg Pro Ile Asp Ile Leu Ser His
20 25

<210> 390
<211> 22
<212> PRT
<213> Homo sapiens

<400> 390
Val Leu Ser Glu Leu Glu Lys Ser Ser Leu Lys Thr Thr Glu Thr Phe
1 5 10 15

Ser Phe Ala Val Phe Leu
20

<210> 391
<211> 8
<212> PRT
<213> Homo sapiens

<400> 391
Thr Leu Phe Arg Tyr Ile Leu His
1 5

<210> 392
<211> 14
<212> PRT
<213> Homo sapiens

<400> 392
Gly Thr Ser Phe Ser Val Leu Ser Leu Ile His Asp Thr Gly
1 5 10

<210> 393
<211> 63
<212> PRT
<213> Homo sapiens

<400> 393
Val Leu Ile Ser Ala Ser Thr Ile Gly Ser Arg Thr Ser Gly Ala Gln
1 5 10 15

Gly Met Glu Lys Met Thr Ile Pro Thr Leu Ala Val Gly Glu Pro Lys
20 25 30

Thr Pro Glu Lys Ser Lys Cys Ser Leu Lys Gln Cys Phe Ser Ser Cys
35 40 45

Asn Val His Ile Asp His Leu Gly Leu Leu Leu Lys Cys Lys Phe
50 55 60

<210> 394
<211> 23
<212> PRT
<213> Homo sapiens

<400> 394
Ala Ser Thr Ile Gly Ser Arg Thr Ser Gly Ala Gln Gly Met Glu Lys
1 5 10 15

Met Thr Ile Pro Thr Leu Ala
20

<210> 395
<211> 27
<212> PRT
<213> Homo sapiens

<400> 395
Gly Glu Pro Lys Thr Pro Glu Lys Ser Lys Cys Ser Leu Lys Gln Cys
1 5 10 15

Phe Ser Ser Cys Asn Val His Ile Asp His Leu
20 25

<210> 396
<211> 101
<212> PRT
<213> Homo sapiens

<400> 396
Arg Ile Arg Ser Gln Asp Leu Ala Ile Met Thr Thr Cys Phe Lys Lys
1 5 10 15

Tyr Glu Phe Ser Phe Phe Val Leu Gly Phe Leu Arg Arg Trp Gly Ala
20 25 30

Thr Leu Cys Leu Gly Phe Thr Ser Phe Ala Ile Lys Phe His Pro Ser
35 40 45

Ser Leu Cys Ser Glu Lys Glu Gly Lys Asp Phe Ser Gly Phe Ala Leu
50 55 60

Ser Ile His Gly Pro Glu Arg Lys Lys Glu Glu Gly Trp Ala Arg Trp
65 70 75 80

Leu Thr Pro Val Val Pro Val Leu Trp Glu Ala Glu Val Gly Gly Ser
85 90 95

Pro Glu Val Ser Ser
100

<210> 397
<211> 22
<212> PRT
<213> Homo sapiens

<400> 397
Thr Thr Cys Phe Lys Lys Tyr Glu Phe Ser Phe Phe Val Leu Gly Phe
1 5 10 15

Leu Arg Arg Trp Gly Ala
20

<210> 398
<211> 26
<212> PRT
<213> Homo sapiens

<400> 398
Ser Glu Lys Glu Gly Lys Asp Phe Ser Gly Phe Ala Leu Ser Ile His
1 5 10 15

Gly Pro Glu Arg Lys Lys Glu Glu Gly Trp
20 25

<210> 399
<211> 86
<212> PRT

<213> Homo sapiens

<400> 399
Met Asn Glu Cys Ile Ala Lys Pro Cys Met Ala Ala Phe Cys Ser Cys
1 5 10 15

Pro Ser Cys Cys Leu Pro Ser Arg Pro Gly Cys Ser Arg Glu Gln Arg
20 25 30

Cys Ala Phe Ser Cys Glu Pro Cys His Thr Val Glu His Trp Val Glu
35 40 45

Pro Met Gly Gln Gly Gln Arg Gln Glu His Thr Gln Gly Ser Val Leu
50 55 60

Pro Ser Ser His Pro Ser Arg Gly Lys Ala Thr Thr Val His Ser Cys
65 70 75 80

Cys Gln Glu Pro Trp Gly
85

<210> 400
<211> 27
<212> PRT
<213> Homo sapiens

<400> 400
Phe Cys Ser Cys Pro Ser Cys Cys Leu Pro Ser Arg Pro Gly Cys Ser
1 5 10 15

Arg Glu Gln Arg Cys Ala Phe Ser Cys Glu Pro
20 25

<210> 401
<211> 23
<212> PRT
<213> Homo sapiens

<400> 401
Gly Gln Arg Gln Glu His Thr Gln Gly Ser Val Leu Pro Ser Ser His
1 5 10 15

Pro Ser Arg Gly Lys Ala Thr
20

<210> 402
<211> 139
<212> PRT
<213> Homo sapiens

<400> 402
Gly Val Val Asn Ser Cys Leu Leu Pro Leu Pro Pro Arg Leu Leu Ala
1 5 10 15

Thr Gly Met Asp Cys Gly Gly Phe Ala Ser Arg Arg Met Gly Gly Arg
20 25 30

Gln His Ala Ala Leu Ser Val Phe Leu Pro Leu Pro Leu Ala His Gly
35 40 45

Leu Tyr Pro Met Phe Asn Cys Val Ala Gly Leu Thr Gly Lys Gly Thr
50 55 60

Ser Leu Leu Ser Gly Ala Ala Arg Pro Ala Gly Glu Ala Ala Ala Arg
65 70 75 80

Ala Gly Thr Lys Gly Ser His Ala Arg Phe Gly Asn Ala Phe Ile His
85 90 95

Ser Phe Ile His Ser Phe Ile Glu Cys Leu Leu Asn Thr Tyr Cys Val
100 105 110

Pro Ser Ser Ala Leu Thr Ala Val Gly Ile Gly Asp Ile Leu Lys Asn
115 120 125

Lys Asn Asp Lys Ser Ser Cys Leu Cys Ser Cys
130 135

<210> 403
<211> 25
<212> PRT
<213> Homo sapiens

<400> 403
Gly Met Asp Cys Gly Gly Phe Ala Ser Arg Arg Met Gly Gly Arg Gln
1 5 10 15

His Ala Ala Leu Ser Val Phe Leu Pro
20 25

<210> 404
<211> 25
<212> PRT
<213> Homo sapiens

<400> 404
Leu Thr Gly Lys Gly Thr Ser Leu Leu Ser Gly Ala Ala Arg Pro Ala
1 5 10 15

Gly Glu Ala Ala Ala Arg Ala Gly Thr
20 25

<210> 405
<211> 22
<212> PRT
<213> Homo sapiens

<400> 405

Leu Asn Thr Tyr Cys Val Pro Ser Ser Ala Leu Thr Ala Val Gly Ile
1 5 10 15

Gly Asp Ile Leu Lys Asn
20

<210> 406
<211> 55
<212> PRT
<213> Homo sapiens

<400> 406
Thr Ser Leu Ser Gln Leu Trp His Phe Cys His Phe Trp Pro Val Lys
1 5 10 15

Phe Cys Cys Gly Gly Cys Pro Val His Cys Arg Met Phe Ser Ser Ile
20 25 30

Ser Gly Leu Tyr Leu Leu Asn Ala Ser Ala Pro Ser Leu Gln Leu Asn
35 40 45

Asp Pro Lys Cys Leu Gln Thr
50 55

<210> 407
<211> 28
<212> PRT
<213> Homo sapiens

<400> 407
Trp Pro Val Lys Phe Cys Cys Gly Gly Cys Pro Val His Cys Arg Met
1 5 10 15

Phe Ser Ser Ile Ser Gly Leu Tyr Leu Leu Asn Ala
20 25

<210> 408
<211> 20
<212> PRT
<213> Homo sapiens

<400> 408
Ser Cys Arg Cys Trp Ala Leu Gly Ala Gly Gly Gly Gln Arg Gln Trp
1 5 10 15

Val Gly Arg Ser
20

<210> 409
<211> 80
<212> PRT
<213> Homo sapiens

<400> 409
Thr Gly Ala Gln Ala Pro Lys Met Gly Ala Arg Gln Arg Lys Arg Pro
1 5 10 15

Leu Gln Thr Arg Ile Lys Asn Ser Ser Lys Ser Thr Leu Trp Pro Pro
20 25 30

Gln Trp Val Arg Cys Gly Arg Trp Trp Thr Trp Pro Ser Arg Lys Lys
35 40 45

Thr Ser Arg Pro Arg Arg Gln Leu Phe Thr Ser Thr Leu Ser Thr Ser
50 55 60

Ala Ser Ala Leu Val Trp Pro Val Ser Trp Phe Ser Gln Glu Gly His
65 70 75 80

<210> 410
<211> 25
<212> PRT
<213> Homo sapiens

<400> 410
Met Gly Ala Arg Gln Arg Lys Arg Pro Leu Gln Thr Arg Ile Lys Asn
1 5 10 15

Ser Ser Lys Ser Thr Leu Trp Pro Pro
20 25

<210> 411
<211> 23
<212> PRT
<213> Homo sapiens

<400> 411
Pro Arg Arg Gln Leu Phe Thr Ser Thr Leu Ser Thr Ser Ala Ser Ala
1 5 10 15

Leu Val Trp Pro Val Ser Trp
20

<210> 412
<211> 25
<212> PRT
<213> Homo sapiens

<400> 412
Asp Gly Gly Gly Lys Glu Glu Gly Val Ser Cys Leu Lys Ile Ser Leu
1 5 10 15

Leu Cys Gly Pro Trp Leu Trp Leu Pro
20 25

<210> 413
<211> 135
<212> PRT
<213> Homo sapiens

<400> 413
His Glu Met Gly Glu Leu Ala Ile Cys His Thr Arg Val Pro Phe Ser
1 5 10 15

Leu Pro Ser Ser Ala Gln Gly Val Pro Gln Asn Leu Gln Gly Pro Ile
20 25 30

Gly His Leu Ala Val Cys Thr Pro Ser Ser Leu Thr Ser Trp His Phe
35 40 45

Pro Gln Lys Arg Glu Lys Trp Ser Thr Val Asn Lys Arg Gln Arg Phe
50 55 60

Leu Gln Phe Pro Ala Pro Leu Arg Asn Trp Ile Pro Gln Thr Pro Leu
65 70 75 80

Ser Leu Ser Val Ser Ser Gly Pro Leu Gly Ser Phe Thr Val Phe Thr
85 90 95

Leu Leu Ser Leu Cys Ala Trp Pro Trp Cys Cys Arg Asp Cys Tyr Lys
100 105 110

Ser Cys Cys Pro Ile Pro Ile Phe Asn Leu Thr Ala Pro Leu Cys Val
115 120 125

His Thr Pro Glu Pro Ser Ser
130 135

<210> 414
<211> 23
<212> PRT
<213> Homo sapiens

<400> 414
Ser Ser Ala Gln Gly Val Pro Gln Asn Leu Gln Gly Pro Ile Gly His
1 5 10 15

Leu Ala Val Cys Thr Pro Ser
20

<210> 415
<211> 28
<212> PRT
<213> Homo sapiens

<400> 415
Val Asn Lys Arg Gln Arg Phe Leu Gln Phe Pro Ala Pro Leu Arg Asn
1 5 10 15

Trp Ile Pro Gln Thr Pro Leu Ser Leu Ser Val Ser
20 25

<210> 416
<211> 23
<212> PRT
<213> Homo sapiens

<400> 416
Cys Cys Arg Asp Cys Tyr Lys Ser Cys Cys Pro Ile Pro Ile Phe Asn
1 5 10 15

Leu Thr Ala Pro Leu Cys Val
20

<210> 417
<211> 150
<212> PRT
<213> Homo sapiens

<400> 417
Asp Leu Asn Val Thr Asn Glu Gly Glu Gly Lys Glu Val Leu Gly Gln
1 5 10 15

Gly Ser Thr Asn Asn Glu Lys Lys Cys Gln Lys Ala Thr Ser Asn Thr
20 25 30

Glu Pro Arg Ala Arg Glu Ala Lys Ala Arg His Ala Asn Met Gly Thr
35 40 45

Ser Asp Arg Glu Ser Pro Thr Trp Ser Leu Thr Ala Glu Gly Leu Lys
50 55 60

Ala Lys Ser Lys Met Gln Gly Lys Ala Thr Lys Gly Ala Ala Ser Thr
65 70 75 80

Met Gly Ser His Asn Gln Gly Pro His Lys Arg Glu Ile Phe Lys His
85 90 95

Glu Thr Pro Ser Ser Phe Pro Pro Pro Ser Gln Cys Gln Pro Glu Leu
100 105 110

Leu Pro Tyr Lys Tyr Trp Ala Thr Leu Ala Ser Gly Tyr Val Pro Ser
115 120 125

Trp Leu Pro Ser Val Asp Ser Tyr Arg Ile Asn Thr Ala Ile Lys Asp
130 135 140

Lys Asn Gly Gln Asp Thr
145 150

<210> 418
<211> 24

<212> PRT
<213> Homo sapiens

<400> 418
Val Leu Gly Gln Gly Ser Thr Asn Asn Glu Lys Lys Cys Gln Lys Ala
1 5 10 15

Thr Ser Asn Thr Glu Pro Arg Ala
20

<210> 419
<211> 29
<212> PRT
<213> Homo sapiens

<400> 419
Arg Glu Ser Pro Thr Trp Ser Leu Thr Ala Glu Gly Leu Lys Ala Lys
1 5 10 15

Ser Lys Met Gln Gly Lys Ala Thr Lys Gly Ala Ala Ser
20 25

<210> 420
<211> 22
<212> PRT
<213> Homo sapiens

<400> 420
Gly Tyr Val Pro Ser Trp Leu Pro Ser Val Asp Ser Tyr Arg Ile Asn
1 5 10 15

Thr Ala Ile Lys Asp Lys
20

<210> 421
<211> 12
<212> PRT
<213> Homo sapiens

<400> 421
Asn Ser Ala Glu Gln Ser Met Leu Ile Leu Val Thr
1 5 10

<210> 422
<211> 122
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 422
Arg Xaa Asp Arg Xaa Pro Val Pro Glu Leu Pro Gly Tyr Glu Pro Thr
1 5 10 15

Arg Thr Asp Ile Ser Ser Phe Lys Asn Ile Tyr Arg Tyr Ala Phe Asp
20 25 30

Phe Ala Arg Asp Lys Asp Gln Arg Ser Leu Asp Ile Asp Thr Ala Lys
35 40 45

Ser Met Leu Ala Leu Leu Leu Gly Arg Thr Trp Pro Leu Phe Ser Val
50 55 60

Phe Tyr Gln Tyr Leu Glu Gln Ser Lys Tyr Arg Val Met Asn Lys Asp
65 70 75 80

Gln Trp Tyr Asn Val Leu Glu Phe Ser Arg Thr Val His Ala Asp Leu
85 90 95

Ser Asn Tyr Asp Glu Asp Gly Ala Trp Pro Val Leu Leu Asp Glu Phe
100 105 110

Val Glu Trp Gln Lys Val Arg Gln Thr Ser
115 120

<210> 423
<211> 28
<212> PRT
<213> Homo sapiens

<400> 423
Pro Thr Arg Thr Asp Ile Ser Ser Phe Lys Asn Ile Tyr Arg Tyr Ala
1 5 10 15

Phe Asp Phe Ala Arg Asp Lys Asp Gln Arg Ser Leu
20 25

<210> 424
<211> 29
<212> PRT
<213> Homo sapiens

<400> 424
Ser Met Leu Ala Leu Leu Leu Gly Arg Thr Trp Pro Leu Phe Ser Val
1 5 10 15

Phe Tyr Gln Tyr Leu Glu Gln Ser Lys Tyr Arg Val Met
20 25

<210> 425
<211> 27
<212> PRT
<213> Homo sapiens

<400> 425
Phe Ser Arg Thr Val His Ala Asp Leu Ser Asn Tyr Asp Glu Asp Gly
1 5 10 15

Ala Trp Pro Val Leu Leu Asp Glu Phe Val Glu
20 25

<210> 426
<211> 10
<212> PRT
<213> Homo sapiens

<400> 426
Ile Tyr Arg Tyr Ala Phe Asp Phe Ala Arg
1 5 10

<210> 427
<211> 8
<212> PRT
<213> Homo sapiens

<400> 427
Lys Asp Gln Arg Ser Leu Asp Ile
1 5

<210> 428
<211> 8
<212> PRT
<213> Homo sapiens

<400> 428
Asn Val Leu Glu Phe Ser Arg Thr
1 5

<210> 429
<211> 21
<212> PRT
<213> Homo sapiens

<400> 429
Asp Leu Ser Asn Tyr Asp Glu Asp Gly Ala Trp Pro Val Leu Leu Asp
1 5 10 15

Glu Phe Val Glu Trp
20

<210> 430

<211> 37
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 430
Leu Phe Arg Cys Pro Ile Gly Lys Ala Gly Thr Pro Ala Gly Xaa Gly
1 5 10 15

Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Val Arg Glu Lys Glu Leu
20 25 30

Thr Glu Thr Phe Glu
35

<210> 431
<211> 21
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 431
Gly Lys Ala Gly Thr Pro Ala Gly Xaa Gly Pro Glu Phe Pro Gly Arg
1 5 10 15

Pro Thr Arg Pro Val
20

<210> 432
<211> 45
<212> PRT
<213> Homo sapiens

<400> 432
Phe Phe Val Phe Pro Tyr Pro Tyr Pro Phe Arg Pro Leu Pro Pro Ile
1 5 10 15

Pro Phe Pro Arg Phe Pro Trp Phe Arg Arg Asn Phe Pro Ile Pro Ile
20 25 30

Pro Glu Ser Ala Pro Thr Thr Pro Leu Pro Ser Glu Lys
35 40 45

<210> 433
<211> 21
<212> PRT

<213> Homo sapiens

<400> 433
Pro Trp Phe Arg Arg Asn Phe Pro Ile Pro Ile Pro Glu Ser Ala Pro
1 5 10 15

Thr Thr Pro Leu Pro
20

<210> 434
<211> 61
<212> PRT
<213> Homo sapiens

<400> 434
Phe Tyr Pro Pro Met Thr Gln Gly Lys Glu Ser Leu Pro Leu Leu Ala
1 5 10 15

Leu Gln Ile Phe Asn Thr Thr Phe Arg Pro Ser Phe Ala Phe Phe Ser
20 25 30

Gly His Arg Thr Leu Phe Phe Gly Val Arg Ser Pro Asn Pro Pro Lys
35 40 45

Pro Arg Ile Phe Leu Ile Trp Leu Ile Ala Val Ala Leu
50 55 60

<210> 435
<211> 31
<212> PRT
<213> Homo sapiens

<400> 435
Leu Leu Ala Leu Gln Ile Phe Asn Thr Thr Phe Arg Pro Ser Phe Ala
1 5 10 15

Phe Phe Ser Gly His Arg Thr Leu Phe Phe Gly Val Arg Ser Pro
20 25 30

<210> 436
<211> 52
<212> PRT
<213> Homo sapiens

<400> 436
His Leu Ala Gln Thr Val Met Met His Pro Gln Lys Ser Phe Tyr Gln
1 5 10 15

Val Lys Asn Thr Asn His Ser Asp Arg Gly Ala Ile Glu Glu Thr Gln
20 25 30

Ile Leu Glu Asp Arg Leu Gly Gln Ile Pro Leu Cys Leu Glu Ser Gln
35 40 45

Ile Trp Glu Ala
50

<210> 437
<211> 28
<212> PRT
<213> Homo sapiens

<400> 437
Lys Asn Thr Asn His Ser Asp Arg Gly Ala Ile Glu Glu Thr Gln Ile
1 5 10 15

Leu Glu Asp Arg Leu Gly Gln Ile Pro Leu Cys Leu
20 25

<210> 438
<211> 73
<212> PRT
<213> Homo sapiens

<400> 438
Gln Gly Cys Tyr Arg Arg Asp Ser Asn Ile Gly Arg Gln Val Arg Pro
1 5 10 15

Asp Ser Ile Met Leu Arg Lys Pro Asp Leu Gly Ser Ile Thr His Tyr
20 25 30

Gly Ser Val Leu Gly Asn Leu Asn Tyr Cys Asp Leu Pro Gln Leu Tyr
35 40 45

Arg Asn Pro Ser Leu Gly Asn Ser Gly Met Arg Glu Met Phe Ser Pro
50 55 60

Phe Tyr Asn Pro Val Glu Cys His Pro
65 70

<210> 439
<211> 23
<212> PRT
<213> Homo sapiens

<400> 439
Pro Asp Ser Ile Met Leu Arg Lys Pro Asp Leu Gly Ser Ile Thr His
1 5 10 15

Tyr Gly Ser Val Leu Gly Asn
20

<210> 440
<211> 22
<212> PRT
<213> Homo sapiens

<400> 440
Tyr Arg Asn Pro Ser Leu Gly Asn Ser Gly Met Arg Glu Met Phe Ser
1 5 10 15

Pro Phe Tyr Asn Pro Val
20

<210> 441
<211> 21
<212> PRT
<213> Homo sapiens

<400> 441
Asn Ser Ala Arg Gly Leu Ser Gly Gly His Pro Phe Pro Trp Leu Ser
1 5 10 15

Glu Gly His Pro Phe
20

<210> 442
<211> 107
<212> PRT
<213> Homo sapiens

<400> 442
Thr Asp Ser Asp Leu Thr Leu Gly Ile Leu Leu Leu Gly Ile Tyr Thr
1 5 10 15

Asn His Ile Trp Glu Met Phe Leu Ala Ala Ser Arg Ile Asn Ser Pro
20 25 30

Lys Leu Glu Pro Glu Lys Ser Val Lys Arg Gln Ile Asn Phe Pro Ser
35 40 45

Ser Lys Asp Val Gly Cys Ser Leu Glu Val Pro Lys Asp Gly Pro Pro
50 55 60

Leu Ser His Gly Lys Glu Trp Ile Pro Leu Ser His Arg Lys Gly Trp
65 70 75 80

Ile Pro Leu Ser His Met Lys Gly Trp Pro Ser Leu Ser His Gly Lys
85 90 95

Gly Trp Pro Pro Leu Ser Pro Arg Ala Glu Phe
100 105

<210> 443
<211> 20
<212> PRT
<213> Homo sapiens

<400> 443
Leu Gly Ile Leu Leu Leu Gly Ile Tyr Thr Asn His Ile Trp Glu Met
1 5 10 15

Phe Leu Ala Ala
20

<210> 444
<211> 27
<212> PRT
<213> Homo sapiens

<400> 444
Lys Ser Val Lys Arg Gln Ile Asn Phe Pro Ser Ser Lys Asp Val Gly
1 5 10 15

Cys Ser Leu Glu Val Pro Lys Asp Gly Pro Pro
20 25

<210> 445
<211> 27
<212> PRT
<213> Homo sapiens

<400> 445
Gly Lys Glu Trp Ile Pro Leu Ser His Arg Lys Gly Trp Ile Pro Leu
1 5 10 15

Ser His Met Lys Gly Trp Pro Ser Leu Ser His
20 25

<210> 446
<211> 47
<212> PRT
<213> Homo sapiens

<400> 446
Gly Trp Ala Ser Thr Gln Pro Arg Glu Arg Met Asp Pro Ala Gln Pro
1 5 10 15

Gln Glu Arg Met Asp Pro Ser Gln Pro His Glu Arg Met Ala Leu Thr
20 25 30

Gln Pro Trp Lys Arg Met Ala Pro Thr Gln Pro Ser Cys Arg Ile
35 40 45

<210> 447
<211> 24
<212> PRT
<213> Homo sapiens

<400> 447
Pro Ala Gln Pro Gln Glu Arg Met Asp Pro Ser Gln Pro His Glu Arg
1 5 10 15

Met Ala Leu Thr Gln Pro Trp Lys

20

<210> 448
<211> 30
<212> PRT
<213> Homo sapiens

<400> 448
Ile Ala Asn Gly Gly Gly Arg Pro Ile Lys Leu Asn Ala Leu Tyr Lys
1 5 10 15

Ile Gln Asn Glu Cys Lys Ile Val Phe Thr Cys Ile Asp Phe
20 25 30

<210> 449
<211> 33
<212> PRT
<213> Homo sapiens

<400> 449
Met Pro Cys Ile Lys Ser Lys Met Asn Ala Lys Leu Phe Ser Leu Val
1 5 10 15

Leu Thr Leu Cys Cys Met Ile Pro Ile Ser Val Leu Phe Gly Thr Cys
20 25 30

Ile

<210> 450
<211> 101
<212> PRT
<213> Homo sapiens

<400> 450
Gln Val Ala Met Gly Ser Leu Ser Gly Leu Arg Leu Ala Ala Gly Ser
1 5 10 15

Cys Phe Arg Leu Cys Glu Arg Asp Val Ser Ser Ser Leu Arg Leu Thr
20 25 30

Arg Ser Ser Asp Leu Lys Arg Ile Asn Gly Phe Cys Thr Lys Pro Gln
35 40 45

Glu Ser Pro Gly Ala Pro Ser Arg Thr Tyr Asn Arg Val Pro Leu His
50 55 60

Lys Pro Thr Asp Trp Gln Lys Lys Ile Leu Ile Trp Ser Gly Arg Phe
65 70 75 80

Lys Lys Glu Asp Glu Ile Pro Glu Thr Val Ser Leu Glu Met Leu Asp
85 90 95

Ala Ala Lys Asn Lys

100

<210> 451
<211> 25
<212> PRT
<213> Homo sapiens

<400> 451
Gly Leu Arg Leu Ala Ala Gly Ser Cys Phe Arg Leu Cys Glu Arg Asp
1 5 10 15

Val Ser Ser Ser Leu Arg Leu Thr Arg
20 25

<210> 452
<211> 20
<212> PRT
<213> Homo sapiens

<400> 452
Ala Pro Ser Arg Thr Tyr Asn Arg Val Pro Leu His Lys Pro Thr Asp
1 5 10 15

Trp Gln Lys Lys
20

<210> 453
<211> 23
<212> PRT
<213> Homo sapiens

<400> 453
Ile Trp Ser Gly Arg Phe Lys Lys Glu Asp Glu Ile Pro Glu Thr Val
1 5 10 15

Ser Leu Glu Met Leu Asp Ala
20

<210> 454
<211> 63
<212> PRT
<213> Homo sapiens

<400> 454
Met Asp Phe Ala Gln Asn His Arg Lys Val Pro Glu Leu His Pro Ala
1 5 10 15

Leu Thr Thr Glu Cys Leu Tyr Thr Asn Leu Arg Ile Gly Arg Lys Arg
20 25 30

Ser Ser Tyr Gly Gln Val Ala Ser Lys Arg Lys Met Lys Ser Gln Arg
35 40 45

Leu Ser Arg Trp Arg Cys Leu Met Leu Gln Arg Thr Arg Cys Glu
50 55 60

<210> 455
<211> 19
<212> PRT
<213> Homo sapiens

<400> 455
Lys Val Pro Glu Leu His Pro Ala Leu Thr Thr Glu Cys Leu Tyr Thr
1 5 10 15

Asn Leu Arg

<210> 456
<211> 26
<212> PRT
<213> Homo sapiens

<400> 456
Lys Arg Ser Ser Tyr Gly Gln Val Ala Ser Lys Arg Lys Met Lys Ser
1 5 10 15

Gln Arg Leu Ser Arg Trp Arg Cys Leu Met
20 25

<210> 457
<211> 12
<212> PRT
<213> Homo sapiens

<400> 457
Ile Asn Gly Phe Cys Thr Lys Pro Gln Glu Ser Pro
1 5 10

<210> 458
<211> 9
<212> PRT
<213> Homo sapiens

<400> 458
Arg Val Pro Leu His Lys Pro Thr Asp
1 5

<210> 459
<211> 8
<212> PRT
<213> Homo sapiens

<400> 459
Trp Ser Gly Arg Phe Lys Lys Glu

1 5

<210> 460
<211> 9
<212> PRT
<213> Homo sapiens

<400> 460
Glu Met Leu Asp Ala Ala Lys Asn Lys
1 5

<210> 461
<211> 9
<212> PRT
<213> Homo sapiens

<400> 461
Ser Tyr Leu Met Ile Ala Leu Thr Val
1 5

<210> 462
<211> 9
<212> PRT
<213> Homo sapiens

<400> 462
Met Val Ile Glu Gly Lys Lys Ala Ala
1 5

<210> 463
<211> 68
<212> PRT
<213> Homo sapiens

<400> 463
Arg Pro Gly Met Arg Ala Leu Gly Ser Cys Leu Ser Leu Leu Ala Leu
1 5 10 15

Cys Ser Pro Gln Ala Arg Pro Gly Pro Arg Thr Leu Asp Ala Ser Thr
20 25 30

Ala Thr Leu Thr Pro His Phe Ser Pro Cys Ala Arg Phe Ser Pro Val
35 40 45

Gly Pro Ser Ala Val Pro Phe Ala Ala Thr Pro Leu Pro Leu Ala Gly
50 55 60

Pro His Gln Pro
65

<210> 464
<211> 20

<212> PRT
<213> Homo sapiens

<400> 464
Gly Ser Cys Leu Ser Leu Leu Ala Leu Cys Ser Pro Gln Ala Arg Pro
1 5 10 15

Gly Pro Arg Thr
20

<210> 465
<211> 23
<212> PRT
<213> Homo sapiens

<400> 465
His Phe Ser Pro Cys Ala Arg Phe Ser Pro Val Gly Pro Ser Ala Val
1 5 10 15

Pro Phe Ala Ala Thr Pro Leu
20

<210> 466
<211> 92
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 466
Ala Ile Glu Glu Arg Asn Lys Ser Arg Leu Thr Gln Gln Ala Ser Glu
1 5 10 15

Pro Thr Gly Ser Pro Arg Tyr Leu His Glu Gln His Pro Gly Ser Arg
20 25 30

Ser Gln Met Asp Cys Gly Ser Leu Thr Met Xaa Cys Pro Pro Pro Arg
35 40 45

Val Arg Asp Asp Arg Thr Ser Ala Arg Gly Val Pro Arg Gln Ala Ala
50 55 60

Pro Asp Ile Val Gly Gly Arg Pro Ser Ser Arg Ala Cys Val Ser Xaa
65 70 75 80

Pro Ala Cys Ala Pro Ser Ala Ala Val Phe Pro Tyr
85 90

<210> 467
<211> 24
<212> PRT
<213> Homo sapiens

<400> 467
Leu Thr Gln Gln Ala Ser Glu Pro Thr Gly Ser Pro Arg Tyr Leu His
1 5 10 15

Glu Gln His Pro Gly Ser Arg Ser
20

<210> 468
<211> 25
<212> PRT
<213> Homo sapiens

<400> 468
Ser Ala Arg Gly Val Pro Arg Gln Ala Ala Pro Asp Ile Val Gly Gly
1 5 10 15

Arg Pro Ser Ser Arg Ala Cys Val Ser
20 25

<210> 469
<211> 14
<212> PRT
<213> Homo sapiens

<400> 469
Pro Arg Val Arg Lys Thr Pro His Leu Ser Ala Ser Gly Lys
1 5 10

<210> 470
<211> 59
<212> PRT
<213> Homo sapiens

<400> 470
Tyr Tyr Tyr Ser Met Leu Lys Ile Cys His Ile Thr Ile Leu Glu Thr
1 5 10 15

Leu Ser Asp Arg Thr Pro Arg Lys Phe Ala Lys Lys Cys Tyr Ile Leu
20 25 30

Tyr Ile Lys Leu Ser Asp Ser Ser Val Glu Lys Val Ala Tyr Thr Leu
35 40 45

Leu Leu Leu Ile Pro Ala Ala Ile Glu Lys Lys
50 55

<210> 471
<211> 32
<212> PRT
<213> Homo sapiens

<400> 471
Thr Ile Leu Glu Thr Leu Ser Asp Arg Thr Pro Arg Lys Phe Ala Lys
1 5 10 15

Lys Cys Tyr Ile Leu Tyr Ile Lys Leu Ser Asp Ser Ser Val Glu Lys
20 25 30

<210> 472
<211> 17
<212> PRT
<213> Homo sapiens

<400> 472
Val His Thr Lys Glu Ile Phe Arg Glu Arg Ser Ala Gly Phe Pro Val
1 5 10 15

Lys

<210> 473
<211> 97
<212> PRT
<213> Homo sapiens

<400> 473
Leu Glu Met Gly Phe Gln Pro Thr Lys Glu Ile Asn Ala Arg Gly Ser
1 5 10 15

Glu Pro Cys Gln Ala Gln Ser Thr Ser Leu Pro Lys Leu Pro Arg Trp
20 25 30

Gly Ser Arg Pro Glu Ala Pro Gln Thr Pro Gln Gly Gly Leu Glu Ser
35 40 45

Arg Cys Cys Thr Pro Val Ser Lys Gln Ser Leu Asn Leu Lys Ala Asp
50 55 60

Arg Phe Lys Ala Leu Thr Leu Gly Arg Ala Gln Trp Leu Thr Pro Val
65 70 75 80

Ile Gln Ala Leu Ser Glu Leu Arg Trp Val Asp His Leu Arg Ser Gly
85 90 95

Val

<210> 474
<211> 24
<212> PRT
<213> Homo sapiens

<400> 474
Phe Gln Pro Thr Lys Glu Ile Asn Ala Arg Gly Ser Glu Pro Cys Gln
1 5 10 15

Ala Gln Ser Thr Ser Leu Pro Lys
20

<210> 475
<211> 27
<212> PRT
<213> Homo sapiens

<400> 475
Pro Lys Leu Pro Arg Trp Gly Ser Arg Pro Glu Ala Pro Gln Thr Pro
1 5 10 15

Gln Gly Gly Leu Glu Ser Arg Cys Cys Thr Pro
20 25

<210> 476
<211> 27
<212> PRT
<213> Homo sapiens

<400> 476
Arg Phe Lys Ala Leu Thr Leu Gly Arg Ala Gln Trp Leu Thr Pro Val
1 5 10 15

Ile Gln Ala Leu Ser Glu Leu Arg Trp Val Asp
20 25

<210> 477
<211> 176
<212> PRT
<213> Homo sapiens

<400> 477
Arg Ile Pro Leu Gln Ser Asp Gly Ser Phe Leu His Glu Lys Ser Ser
1 5 10 15

Gln Gln Arg Ser Asn Arg Asn Phe Pro Cys Pro Thr Leu Gln Cys Asn
20 25 30

Pro Glu Val Ser Phe Trp Phe Val Val Thr Asp Pro Ser Lys Asn His
35 40 45

Thr Leu Pro Ala Val Glu Val Gln Ser Ala Ile Arg Met Asn Lys Asn
50 55 60

```
Arg Ile Asn Asn Ala Phe Phe Leu Asn Asp Gln Thr Leu Glu Phe Leu
 65                  70                  75                  80

Lys Ile Pro Ser Thr Leu Ala Pro Pro Met Asp Pro Ser Val Pro Ile
                85                  90                  95

Trp Ile Ile Ile Phe Gly Val Ile Phe Cys Ile Ile Ile Val Ala Ile
            100                 105                 110

Ala Leu Leu Ile Leu Ser Gly Ile Trp Gln Arg Arg Arg Lys Asn Lys
        115                 120                 125

Glu Pro Ser Glu Val Asp Asp Ala Glu Asp Lys Cys Glu Asn Met Ile
    130                 135                 140

Thr Ile Glu Asn Gly Ile Pro Ser Asp Pro Leu Asp Met Lys Gly Gly
145                 150                 155                 160

His Ile Asn Asp Ala Phe Met Thr Glu Asp Glu Arg Leu Thr Pro Leu
                165                 170                 175
```

<210> 478
<211> 25
<212> PRT
<213> Homo sapiens

<400> 478

```
Pro Cys Pro Thr Leu Gln Cys Asn Pro Glu Val Ser Phe Trp Phe Val
  1               5                  10                  15

Val Thr Asp Pro Ser Lys Asn His Thr
            20                  25
```

<210> 479
<211> 23
<212> PRT
<213> Homo sapiens

<400> 479

```
Ala Ile Arg Met Asn Lys Asn Arg Ile Asn Asn Ala Phe Phe Leu Asn
  1               5                  10                  15

Asp Gln Thr Leu Glu Phe Leu
            20
```

<210> 480
<211> 24
<212> PRT
<213> Homo sapiens

<400> 480


```
Ile Trp Gln Arg Arg Arg Lys Asn Lys Glu Pro Ser Glu Val Asp Asp
  1               5                  10                  15

Ala Glu Asp Lys Cys Glu Asn Met
            20
```

<210> 481
<211> 19
<212> PRT
<213> Homo sapiens

<400> 481

```
Pro Leu Asp Met Lys Gly Gly His Ile Asn Asp Ala Phe Met Thr Glu
  1               5                  10                  15

Asp Glu Arg
```

<210> 482
<211> 136
<212> PRT
<213> Homo sapiens

<400> 482

```
Gly Ser Arg Thr Thr Ala Leu Gln Arg Gly Val Ser Leu Ser Ser Ser
  1               5                  10                  15

Val Met Lys Ala Ser Leu Ile Cys Pro Pro Phe Met Ser Arg Gly Ser
            20                  25                  30

Glu Gly Met Pro Phe Ser Ile Val Ile Met Phe Ser His Leu Ser Ser
        35                  40                  45

Ala Ser Ser Thr Ser Asp Gly Ser Leu Phe Phe Leu Leu Arg Cys Gln
    50                  55                  60

Ile Pro Asp Lys Ile Ser Ser Ala Ile Ala Thr Met Met Met Gln Asn
65                  70                  75                  80

Ile Thr Pro Asn Ile Ile Ile Gln Met Gly Thr Asp Gly Ser Met Gly
                85                  90                  95

Gly Ala Ser Val Glu Gly Ile Phe Lys Asn Ser Arg Val Trp Ser Phe
            100                 105                 110

Arg Lys Lys Ala Leu Leu Ile Arg Phe Leu Phe Ile Leu Met Ala Asp
        115                 120                 125

Cys Thr Ser Thr Ala Gly Arg Val
    130                 135
```

<210> 483
<211> 28
<212> PRT

<213> Homo sapiens

<400> 483
Val Ser Leu Ser Ser Ser Val Met Lys Ala Ser Leu Ile Cys Pro Pro
1 5 10 15

Phe Met Ser Arg Gly Ser Glu Gly Met Pro Phe Ser
20 25

<210> 484
<211> 24
<212> PRT
<213> Homo sapiens

<400> 484
Ser Met Gly Gly Ala Ser Val Glu Gly Ile Phe Lys Asn Ser Arg Val
1 5 10 15

Trp Ser Phe Arg Lys Lys Ala Leu
20

<210> 485
<211> 29
<212> PRT
<213> Homo sapiens

<400> 485
Gly Ala Arg Gly Ser Gln Gln Asp Ala Pro Ala Leu Gln Glu Ala Glu
1 5 10 15

Val Arg Gly Pro Glu Arg Ala Gln Pro Ala Arg Gly Arg
20 25

<210> 486
<211> 439
<212> PRT
<213> Homo sapiens

<400> 486
Ser Glu Arg Pro Gly Glu Gly Pro Ala Arg Pro Gly Gln Asp Asp Gln
1 5 10 15

Gly Pro Ala Val Pro Ala Val Ala Gly Ala Gly Val Gly Val His Asp
20 25 30

Pro Ala Asp His Arg Val Leu Gly Gln Arg Ser Ala Ala His Phe Tyr
35 40 45

Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro Leu Pro Thr
50 55 60

Pro Gly Pro Asp Arg Thr Gly Ser Ser Arg Pro Thr Pro Met Ser Thr
65 70 75 80

Ser Phe Trp Thr Ile Ser His Ala Gly Val Lys Gln Ser Asp Leu Pro
85 90 95

Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Glu His Gly Gly Glu
100 105 110

Arg Glu Arg Leu Arg Leu Val Pro Ala Arg Arg Pro Ala Gln Pro Arg
115 120 125

Pro Gly Pro Ala Ala Gly Gly Ala Glu Glu Arg Ala Ala Gly Leu Leu
130 135 140

Arg Gln Leu Gln Pro Gly Leu Pro His Gln Gly Ala Arg Ile Arg Arg
145 150 155 160

His Pro Gln Leu Gly Ala Glu Pro Pro Asp Arg Gly Arg Pro Ala Arg
165 170 175

Gly His Leu Leu Leu Arg Ala Gln Gly Gly Leu His Gln Leu Glu Ala
180 185 190

Arg Asp Asp Arg Ala Glu Arg Lys Pro Ala Ala Pro Arg Cys Ala Leu
195 200 205

Pro Arg Pro Ala Ala His Pro Ala Arg Ala Arg Ala Gln Arg Gln Arg
210 215 220

Ala Pro Asp Leu Gln Gln Val Leu Ala Pro Leu Arg Glu Ala Leu Pro
225 230 235 240

Pro Pro His Glu Gly Gln Ala Gln Glu Val His Gln Val Pro Leu Arg
245 250 255

Ala Arg Pro Leu Arg Ala Pro Asp Leu Arg Leu Pro Gln Gln Val Arg
260 265 270

Ala Gly Glu Arg Gly Val Leu Pro Gln Val Arg Arg Ala His Ala Ala
275 280 285

Gly Val Arg Gln Pro His Gln Pro Ala Arg Leu Gly Ala Arg Gly Leu
290 295 300

Pro Arg Trp Pro Gln Gly Val Leu Arg Gln Leu His Pro Val Pro Ala
305 310 315 320

Gly Pro Ala His Gly Glu Ala Gly Ala Leu Gln Arg Ala Leu Ala Ala
325 330 335

Gly Val Pro Pro Leu Pro Pro Val Pro Asp Arg Leu Arg Phe Leu Gly
340 345 350

Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu Leu Gln Leu Leu
355 360 365

Gln Val Asp Arg Gln Ser Ala Ser Pro Arg Ala Thr Gly Thr Gly Pro
370 375 380

```
Pro Ala Ala Gly Arg Arg Thr Gly Ser Pro Arg Ser Pro Trp Pro Gly
385                 390                 395                 400

Gly Ser Ser Cys Ile Asn Ser Thr Arg Pro Thr Leu Phe Ser Ser Ala
                405                 410                 415

Thr Pro Ser Pro Lys Thr Ser Ser Glu Thr Glu Ser Phe Arg Val Ala
            420                 425                 430

Phe Ser Arg Val Pro Gly Thr
        435
```

<210> 487
<211> 25
<212> PRT
<213> Homo sapiens

<400> 487
Arg Pro Gly Gln Asp Asp Gln Gly Pro Ala Val Pro Ala Val Ala Gly
1 5 10 15

Ala Gly Val Gly Val His Asp Pro Ala
20 25

<210> 488
<211> 21
<212> PRT
<213> Homo sapiens

<400> 488
Ser Arg Pro His Thr Gly Pro Pro Leu Pro Thr Pro Gly Pro Asp Arg
1 5 10 15

Thr Gly Ser Ser Arg
20

<210> 489
<211> 23
<212> PRT
<213> Homo sapiens

<400> 489
Ser His Ala Gly Val Lys Gln Ser Asp Leu Pro Arg Lys Glu Thr Glu
1 5 10 15

Gln Pro Pro Ala Pro Gly Glu
20

<210> 490
<211> 23
<212> PRT
<213> Homo sapiens

<400> 490
Arg Arg Pro Ala Gln Pro Arg Pro Gly Pro Ala Ala Gly Gly Ala Glu
1 5 10 15

Glu Arg Ala Ala Gly Leu Leu
20

<210> 491
<211> 23
<212> PRT
<213> Homo sapiens

<400> 491
Arg Arg His Pro Gln Leu Gly Ala Glu Pro Pro Asp Arg Gly Arg Pro
1 5 10 15

Ala Arg Gly His Leu Leu Leu
20

<210> 492
<211> 25
<212> PRT
<213> Homo sapiens

<400> 492
Arg Asp Asp Arg Ala Glu Arg Lys Pro Ala Ala Pro Arg Cys Ala Leu
1 5 10 15

Pro Arg Pro Ala Ala His Pro Ala Arg
20 25

<210> 493
<211> 27
<212> PRT
<213> Homo sapiens

<400> 493
Arg Ala Pro Asp Leu Gln Gln Val Leu Ala Pro Leu Arg Glu Ala Leu
1 5 10 15

Pro Pro Pro His Glu Gly Gln Ala Gln Glu Val
20 25

<210> 494
<211> 26
<212> PRT
<213> Homo sapiens

<400> 494
Asp Leu Arg Leu Pro Gln Gln Val Arg Ala Gly Glu Arg Gly Val Leu
1 5 10 15

Pro Gln Val Arg Arg Ala His Ala Ala Gly

223

20 25

<210> 495
<211> 27
<212> PRT
<213> Homo sapiens

<400> 495
Gln Pro Ala Arg Leu Gly Ala Arg Gly Leu Pro Arg Trp Pro Gln Gly
1 5 10 15

Val Leu Arg Gln Leu His Pro Val Pro Ala Gly
20 25

<210> 496
<211> 24
<212> PRT
<213> Homo sapiens

<400> 496
Ala Gly Val Pro Pro Leu Pro Pro Val Pro Asp Arg Leu Arg Phe Leu
1 5 10 15

Gly Lys Leu Glu Thr Leu Asp Glu
20

<210> 497
<211> 25
<212> PRT
<213> Homo sapiens

<400> 497
Gln Leu Leu Gln Leu Leu Gln Val Asp Arg Gln Ser Ala Ser Pro Arg
1 5 10 15

Ala Thr Gly Thr Gly Pro Pro Ala Ala
20 25

<210> 498
<211> 25
<212> PRT
<213> Homo sapiens

<400> 498
Asn Ser Thr Arg Pro Thr Leu Phe Ser Ser Ala Thr Pro Ser Pro Lys
1 5 10 15

Thr Ser Ser Glu Thr Glu Ser Phe Arg
20 25

<210> 499
<211> 324

224

<212> PRT
<213> Homo sapiens

<400> 499
Leu Gly Gly Lys Arg Thr Ala Gly Pro Pro Gly Val Ala Ala Ala Ala
1 5 10 15

Ala Arg Arg Pro Arg Pro Glu Ser Pro Ala Ser Pro Gly Ile Val Val
20 25 30

Asp Leu Ala Arg Val Ala Glu Ala Val His Leu Pro Pro Val Leu Val
35 40 45

Glu Gly Arg Gln Leu Leu Arg Val Arg Val Gln Gln Val Leu Asp Glu
50 55 60

Val Gly Glu Gly His Leu Glu Ala Ser Ala Glu Gly Leu Ala Arg Arg
65 70 75 80

Gly Gly Gln Ala Gly Val Val Gly Val His Pro Gln His Gly His Gly
85 90 95

Glu Leu Ala Val Glu Leu Leu Val Leu Gln Leu Glu Leu Ala Ala Glu
100 105 110

Gly Gly Asp Gln Ala His Glu Gly Val Ala His Glu Glu Glu Leu Gly
115 120 125

Val Leu Leu Glu Leu Asp Leu His Glu Val Ala Gly Glu Leu Pro Val
130 135 140

Ala Ala Pro Glu Leu Val Glu Gly Gln Val Arg Ala Gly Val Val His
145 150 155 160

Val Leu Ala Arg Asp Ala Gln Arg Val Ala Val Gly Arg Thr Ala Val
165 170 175

Gln Gln Ala Ser Ala Gln His Asp His His Ala Leu Pro Val Gly Ala
180 185 190

Gly His Leu Gly His Val Ala Val Asp Gly Pro Val Pro Val Val His
195 200 205

Asp Gln Val Ala Gln Leu Arg Val Gly Asp Val Val Glu Cys Ala Leu
210 215 220

Leu Gly Gly Glu Gly Gln Ala Gly Val Gly Ala Glu Ala Pro Gln His
225 230 235 240

Val Pro Pro Leu Arg Leu Leu Pro Ala Leu Val Trp Ala Ala Pro Gly
245 250 255

Val Ala Arg Gly Pro Val Val Ala Ser His Ala Leu Leu His Ala Pro
260 265 270

Pro Ala Gln Ala Ala Ala Pro Ser Pro Phe Trp Glu Gly His Ser Ala
275 280 285

225

Ser Arg Gln His Glu Lys Leu Ser Arg Asn Ser Ser Thr Ser Glu Ser
290 295 300

Ala Val Ser Ser Leu Ser Cys Pro Ala Arg Ala Trp Ala Ala Ala Ala
305 310 315 320

Pro Cys Ala Ala

<210> 500
<211> 23
<212> PRT
<213> Homo sapiens

<400> 500
Glu Ala Val His Leu Pro Pro Val Leu Val Glu Gly Arg Gln Leu Leu
1 5 10 15

Arg Val Arg Val Gln Gln Val
20

<210> 501
<211> 24
<212> PRT
<213> Homo sapiens

<400> 501
Gly His Leu Glu Ala Ser Ala Glu Gly Leu Ala Arg Arg Gly Gly Gln
1 5 10 15

Ala Gly Val Val Gly Val His Pro
20

<210> 502
<211> 28
<212> PRT
<213> Homo sapiens

<400> 502
Gln Leu Glu Leu Ala Ala Glu Gly Gly Asp Gln Ala His Glu Gly Val
1 5 10 15

Ala His Glu Glu Glu Leu Gly Val Leu Leu Glu Leu
20 25

<210> 503
<211> 27
<212> PRT
<213> Homo sapiens

<400> 503
Gly Glu Leu Pro Val Ala Ala Pro Glu Leu Val Glu Gly Gln Val Arg

226

1 5 10 15

Ala Gly Val Val His Val Leu Ala Arg Asp Ala
20 25

<210> 504
<211> 25
<212> PRT
<213> Homo sapiens

<400> 504
Ala Val Gln Gln Ala Ser Ala Gln His Asp His His Ala Leu Pro Val
1 5 10 15

Gly Ala Gly His Leu Gly His Val Ala
20 25

<210> 505
<211> 25
<212> PRT
<213> Homo sapiens

<400> 505
His Asp Gln Val Ala Gln Leu Arg Val Gly Asp Val Val Glu Cys Ala
1 5 10 15

Leu Leu Gly Gly Glu Gly Gln Ala Gly
20 25

<210> 506
<211> 23
<212> PRT
<213> Homo sapiens

<400> 506
Ala Leu Val Trp Ala Ala Pro Gly Val Ala Arg Gly Pro Val Val Ala
1 5 10 15

Ser His Ala Leu Leu His Ala
20

<210> 507
<211> 28
<212> PRT
<213> Homo sapiens

<400> 507
Pro Pro Ala Gln Ala Ala Ala Pro Ser Pro Phe Trp Glu Gly His Ser
1 5 10 15

Ala Ser Arg Gln His Glu Lys Leu Ser Arg Asn Ser
20 25

<210> 508
<211> 314
<212> PRT
<213> Homo sapiens

<400> 508
Ser Arg Val Thr Phe Pro Glu Arg Arg Arg Ser Ser Arg Leu Arg Arg
1 5 10 15

Gly Ser Met Glu Glu Ser Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp
20 25 30

Ala Arg Arg Ser Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Asn
35 40 45

Val Leu Arg Gly Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys
50 55 60

Glu Arg Ala Phe Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile
65 70 75 80

Val Asp Asp Arg His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala
85 90 95

Cys Thr Asn Trp Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu
100 105 110

His Arg Gly Ala Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His
115 120 125

Val His Asn Ala Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg
130 135 140

Tyr Gly Lys Leu Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr
145 150 155 160

Thr Lys Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala
165 170 175

Phe Arg Ser Lys Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe
180 185 190

Ala Val Pro Met Leu Arg Val Tyr Ala Asn His Thr Ser Leu Pro Ala
195 200 205

Ser Ala Arg Glu Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn
210 215 220

Phe Ile Gln Tyr Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe
225 230 235 240

Asn Glu His Trp Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile
245 250 255

Asp Tyr Asp Ser Trp Gly Ser Trp Arg Leu Trp Thr Arg Thr Pro Arg
260 265 270

Ser Cys Cys Ser Tyr Ser Arg Trp Thr Gly Ser Pro Leu Pro Pro Glu
275 280 285

Leu Pro Glu Gln Asp Arg Gln Gln Leu Gly Gly Gly Leu Val Arg Gln
290 295 300

Asp Pro Pro Gly Leu Glu Ala Ala Ala Val
305 310

<210> 509
<211> 26
<212> PRT
<213> Homo sapiens

<400> 509
Arg Ser Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Asn Val Leu
1 5 10 15

Arg Gly Phe Cys Ala Asn Ser Ser Leu Ala
20 25

<210> 510
<211> 28
<212> PRT
<213> Homo sapiens

<400> 510
Thr Lys Glu Arg Ala Phe Asp Asp Ile Pro Asn Ser Glu Leu Ser His
1 5 10 15

Leu Ile Val Asp Asp Arg His Gly Ala Ile Tyr Cys
20 25

<210> 511
<211> 23
<212> PRT
<213> Homo sapiens

<400> 511
Phe Asn Lys Phe Trp Arg Arg Tyr Gly Lys Leu Ser Arg His Leu Met
1 5 10 15

Lys Val Lys Leu Lys Lys Tyr
20

<210> 512
<211> 24
<212> PRT
<213> Homo sapiens

<400> 512
Phe Val Arg Leu Ile Ser Ala Phe Arg Ser Lys Phe Glu Leu Glu Asn

1 5 10 15

Glu Glu Phe Tyr Arg Lys Phe Ala
20

<210> 513
<211> 26
<212> PRT
<213> Homo sapiens

<400> 513
Thr Ser Leu Pro Ala Ser Ala Arg Glu Ala Phe Arg Ala Gly Leu Lys
1 5 10 15

Val Ser Phe Ala Asn Phe Ile Gln Tyr Leu
20 25

<210> 514
<211> 25
<212> PRT
<213> Homo sapiens

<400> 514
Ser Tyr Ser Arg Trp Thr Gly Ser Pro Leu Pro Pro Glu Leu Pro Glu
1 5 10 15

Gln Asp Arg Gln Gln Leu Gly Gly Gly
20 25

<210> 515
<211> 6
<212> PRT
<213> Homo sapiens

<400> 515
Ser Thr Gly Cys Ser Glu
1 5

<210> 516
<211> 146
<212> PRT
<213> Homo sapiens

<400> 516
Cys Leu Cys Leu Gly Cys Gly Leu Pro Glu Leu His Ser Tyr Leu Asp
1 5 10 15

Pro Gly Pro Tyr Leu Leu Val Tyr Pro Thr Leu Phe Trp Leu Cys Pro
20 25 30

Ser Ala Val Ser Pro Trp Ala Tyr Thr Cys Tyr Gln Leu Gly Leu Gly
35 40 45

Pro Gln Trp Gly Ala Ala Ala Leu Ser Phe Thr Val Asp Ala Ala Ile
50 55 60

Arg Val Trp Asp Val Ser Thr Glu Thr Cys Val Pro Leu Pro Trp Phe
65 70 75 80

Arg Gly Gly Gly Val Thr Asn Cys Ser Gly Pro Gln Thr Ala Ala Lys
85 90 95

Ser Trp Leu Pro Leu Leu Gln Leu Ser Phe Glu Ser Gly Arg Pro Arg
100 105 110

Cys Gly Leu Val Arg Gly Gly Leu Leu Tyr Gln Gly Ala Val Arg Leu
115 120 125

Ala Ala Gly Ala Gln Met Ala Ala Asp Cys Cys Ser Leu Tyr Trp Glu
130 135 140

Ser His
145

<210> 517
<211> 26
<212> PRT
<213> Homo sapiens

<400> 517
Tyr Pro Thr Leu Phe Trp Leu Cys Pro Ser Ala Val Ser Pro Trp Ala
1 5 10 15

Tyr Thr Cys Tyr Gln Leu Gly Leu Gly Pro
20 25

<210> 518
<211> 25
<212> PRT
<213> Homo sapiens

<400> 518
Asp Val Ser Thr Glu Thr Cys Val Pro Leu Pro Trp Phe Arg Gly Gly
1 5 10 15

Gly Val Thr Asn Cys Ser Gly Pro Gln
20 25

<210> 519
<211> 22
<212> PRT
<213> Homo sapiens

<400> 519
Leu Leu Tyr Gln Gly Ala Val Arg Leu Ala Ala Gly Ala Gln Met Ala
1 5 10 15

Ala Asp Cys Cys Ser Leu
20

<210> 520
<211> 155
<212> PRT
<213> Homo sapiens

<400> 520
Asn Lys Arg Lys Thr Tyr Leu Phe Leu Glu Val Gly Met Trp Gly Val
1 5 10 15

Gly Gln Asn Arg Trp Trp Pro Trp Glu Arg Val Pro Arg Gly Arg Gly
20 25 30

Trp Gly Cys Leu Ser Lys Glu Gly Gln Val Met Asn Arg Ala Ser Thr
35 40 45

Pro Ser Arg Gly Phe Leu Gly Pro Pro Lys His Trp Ala Lys Thr Trp
50 55 60

Lys Leu Gly Ile Asp Lys Val Gln Arg Asp Val Gly Asn Ser Ala Cys
65 70 75 80

Gly Pro Ala His Thr Glu Gln Gly Pro Phe Val Glu Gly Arg Trp Lys
85 90 95

Val Met Ser Trp Gly Trp Ala Pro Gly Ser Pro Trp Ile Met Pro Gln
100 105 110

Gly Arg Ser Ser Asn Thr Gly Leu Phe Arg Val Arg Lys Arg Arg Met
115 120 125

Thr Gly Leu Pro Ser Cys Thr Leu Gly Phe Pro Phe Ile Ser Thr Ala
130 135 140

Arg Arg Ser Pro Leu Gly Ser Gln Thr Met Glu
145 150 155

<210> 521
<211> 26
<212> PRT
<213> Homo sapiens

<400> 521
Gly Val Gly Gln Asn Arg Trp Trp Pro Trp Glu Arg Val Pro Arg Gly
1 5 10 15

Arg Gly Trp Gly Cys Leu Ser Lys Glu Gly
20 25

<210> 522
<211> 26
<212> PRT

<213> Homo sapiens

<400> 522
Ala Lys Thr Trp Lys Leu Gly Ile Asp Lys Val Gln Arg Asp Val Gly
1 5 10 15

Asn Ser Ala Cys Gly Pro Ala His Thr Glu
20 25

<210> 523
<211> 42
<212> PRT
<213> Homo sapiens

<400> 523
Trp Ala Pro Gly Ser Pro Trp Ile Met Pro Gln Gly Arg Ser Ser Asn
1 5 10 15

Thr Gly Leu Phe Arg Val Arg Lys Arg Arg Met Thr Gly Leu Pro Ser
20 25 30

Cys Thr Leu Gly Phe Pro Phe Ile Ser Thr
35 40

<210> 524
<211> 17
<212> PRT
<213> Homo sapiens

<400> 524
Ser Ser Tyr Gln Cys Pro Lys Val Thr Phe Phe Lys Ser Ser Val Asp
1 5 10 15

Thr

<210> 525
<211> 14
<212> PRT
<213> Homo sapiens

<400> 525
Tyr Ile Tyr Ser Tyr Leu Gly Phe Phe Asn Gln Ile Asn Lys
1 5 10

<210> 526
<211> 6
<212> PRT
<213> Homo sapiens

<400> 526
Ala Arg Asp Leu Ile Leu
1 5

<210> 527
<211> 43
<212> PRT
<213> Homo sapiens

<400> 527
Leu Thr Phe Tyr Leu Gln Phe Leu Ala Pro Lys Asp Lys Pro Ser Gly
1 5 10 15

Asp Thr Ala Ala Val Phe Glu Glu Gly Gly Asp Val Asp Asp Leu Val
20 25 30

Ser Thr Phe Asn Met His Leu Val Phe Cys Asp
35 40

<210> 528
<211> 25
<212> PRT
<213> Homo sapiens

<400> 528
Phe Leu Ala Pro Lys Asp Lys Pro Ser Gly Asp Thr Ala Ala Val Phe
1 5 10 15

Glu Glu Gly Gly Asp Val Asp Asp Leu
20 25

<210> 529
<211> 13
<212> PRT
<213> Homo sapiens

<400> 529
Ala Arg Ala Gly Ala Lys Ile Leu Phe Glu Gly Glu Phe
1 5 10

<210> 530
<211> 92
<212> PRT
<213> Homo sapiens

<400> 530
Asn Phe Glu Ile His Ser Ala Phe Pro Phe Met Leu Phe Val Ala Cys
1 5 10 15

Leu Leu His Ser Ser Cys Pro Arg Thr Ala Arg Phe Leu Ala Ser Pro
20 25 30

Leu Ser Glu Ser Asn Val Ile Phe Tyr Gln Asn Gln Tyr Gln Phe Pro
35 40 45

Cys Ile Leu Cys Phe Ile Glu Phe Ala Arg Leu Thr Ser Phe Lys His

50 55 60

Leu Ile His Ser Gln Ser His Leu Val Arg Leu Gln Tyr Glu Asp Phe
65 70 75 80

Ser Val Ser Ser Glu Ala Trp Asp Thr Glu Leu Thr
85 90

<210> 531
<211> 26
<212> PRT
<213> Homo sapiens

<400> 531
Phe Pro Phe Met Leu Phe Val Ala Cys Leu Leu His Ser Ser Cys Pro
1 5 10 15

Arg Thr Ala Arg Phe Leu Ala Ser Pro Leu
20 25

<210> 532
<211> 26
<212> PRT
<213> Homo sapiens

<400> 532
Asn Val Ile Phe Tyr Gln Asn Gln Tyr Gln Phe Pro Cys Ile Leu Cys
1 5 10 15

Phe Ile Glu Phe Ala Arg Leu Thr Ser Phe
20 25

<210> 533
<211> 23
<212> PRT
<213> Homo sapiens

<400> 533
Ser Gln Ser His Leu Val Arg Leu Gln Tyr Glu Asp Phe Ser Val Ser
1 5 10 15

Ser Glu Ala Trp Asp Thr Glu
20

<210> 534
<211> 10
<212> PRT
<213> Homo sapiens

<400> 534
Gln Lys Phe Leu Cys Ala Ser Asp Gly Asp
1 5 10

<210> 535
<211> 177
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (160)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (162)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 535
Ala Glu Val Pro Leu Arg Val Arg Arg Arg His Gly Arg Pro His Gly
1 5 10 15

Pro Gly Gly Arg Gln Leu Ala Leu Gly Ile Pro Ala Leu Arg Ser Leu
20 25 30

Pro Gly Cys Val Pro Arg His His Gly Cys Ser Pro Gly Tyr Gly Cys
35 40 45

Leu His Arg Arg Ile Leu Cys Leu Pro Leu Ile Leu Leu Leu Val Tyr
50 55 60

Lys Gln Arg Gln Ala Ala Ser Asn Arg Arg Ala Gln Glu Leu Val Arg
65 70 75 80

Met Asp Ser Asn Ile Gln Gly Ile Glu Asn Pro Gly Phe Glu Ala Ser
85 90 95

Pro Pro Ala Gln Gly Ile Pro Glu Ala Lys Val Arg His Pro Leu Ser
100 105 110

Tyr Val Ala Gln Arg Gln Pro Ser Glu Ser Gly Arg His Leu Leu Ser
115 120 125

Glu Pro Ser Thr Pro Leu Ser Pro Pro Gly Pro Gly Asp Val Phe Phe
130 135 140

Pro Ser Leu Asp Pro Val Pro Asp Ser Pro Asn Phe Glu Val Ile Xaa
145 150 155 160

Pro Xaa Trp Gly Thr Val Gly Cys Cys Gly Trp Val Trp Gly Arg Cys
165 170 175

Ile

<210> 536
<211> 27
<212> PRT

<213> Homo sapiens

<400> 536
Gly Pro Gly Gly Arg Gln Leu Ala Leu Gly Ile Pro Ala Leu Arg Ser
1 5 10 15

Leu Pro Gly Cys Val Pro Arg His His Gly Cys
20 25

<210> 537
<211> 25
<212> PRT
<213> Homo sapiens

<400> 537
Phe Glu Ala Ser Pro Pro Ala Gln Gly Ile Pro Glu Ala Lys Val Arg
1 5 10 15

His Pro Leu Ser Tyr Val Ala Gln Arg
20 25

<210> 538
<211> 88
<212> PRT
<213> Homo sapiens

<400> 538
Asp Met Ser Leu Gly Met Trp Gln His Gln Trp Asp Lys Met Asp Thr
1 5 10 15

Gly Pro Pro Ser Gln Ala Pro Asp Thr Gly His Gly Gly Glu Thr Ser
20 25 30

Pro Pro Trp His Ala Leu Gly Ser Pro Val Leu Pro Glu Ala Ala Leu
35 40 45

Leu Ser Asp Phe Leu Phe Val Pro Gln Trp Leu Trp Gly Gln Ala Cys
50 55 60

Leu Pro Thr Gly His Arg His Leu Pro Gln Leu Pro Pro Thr Ser Ser
65 70 75 80

Phe Ser Glu Asp Leu Ser Thr Gly
85

<210> 539
<211> 78
<212> PRT
<213> Homo sapiens

<400> 539
Pro Val Asp Arg Ser Ser Glu Lys Leu Leu Val Gly Gly Ser Trp Gly
1 5 10 15

Arg Trp Arg Trp Pro Val Gly Arg Gln Ala Trp Pro Gln Ser His Cys
20 25 30

Gly Thr Lys Arg Lys Ser Asp Arg Arg Ala Ala Ser Gly Lys Thr Gly
35 40 45

Glu Pro Ser Ala Cys His Gly Gly Glu Val Ser Pro Pro Cys Pro Val
50 55 60

Ser Gly Ala Trp Glu Gly Gly Pro Val Ser Ile Leu Ser His
65 70 75

<210> 540
<211> 22
<212> PRT
<213> Homo sapiens

<400> 540
Pro Val Asp Arg Ser Ser Glu Lys Leu Leu Val Gly Gly Ser Trp Gly
1 5 10 15

Arg Trp Arg Trp Pro Val
20

<210> 541
<211> 25
<212> PRT
<213> Homo sapiens

<400> 541
Thr Lys Arg Lys Ser Asp Arg Arg Ala Ala Ser Gly Lys Thr Gly Glu
1 5 10 15

Pro Ser Ala Cys His Gly Gly Glu Val
20 25

<210> 542
<211> 46
<212> PRT
<213> Homo sapiens

<400> 542
Met Thr Ser Lys Phe Gly Glu Ser Gly Thr Gly Ser Arg Asp Gly Lys
1 5 10 15

Lys Thr Ser Pro Gly Pro Gly Gly Asp Arg Gly Val Leu Gly Ser Glu
20 25 30

Ser Arg Cys Arg Pro Asp Ser Glu Gly Cys Arg Trp Ala Thr
35 40 45

<210> 543
<211> 20

<212> PRT
<213> Homo sapiens

<400> 543
Ser Pro Gly Pro Gly Gly Asp Arg Gly Val Leu Gly Ser Glu Ser Arg
1 5 10 15

Cys Arg Pro Asp
20

<210> 544
<211> 23
<212> PRT
<213> Homo sapiens

<400> 544
Pro Pro Ser Gln Ala Pro Asp Thr Gly His Gly Gly Glu Thr Ser Pro
1 5 10 15

Pro Trp His Ala Leu Gly Ser
20

<210> 545
<211> 15
<212> PRT
<213> Homo sapiens

<400> 545
His Glu Val Gln Pro Ser Tyr Leu Pro Ser Asn Ser Gly Leu Ile
1 5 10 15

<210> 546
<211> 22
<212> PRT
<213> Homo sapiens

<400> 546
Leu Arg Ile Ser Val Leu Cys Arg Glu Thr Ala Cys Asn Trp Ser His
1 5 10 15

His Pro Leu Asp Ser Asn
20

<210> 547
<211> 32
<212> PRT
<213> Homo sapiens

<400> 547
Leu Thr Val Thr Val Arg Asn Pro Gly Ser Thr His Ala Ser Gly Arg
1 5 10 15

Pro Arg Arg Arg Ser Gly Val Trp Ala Arg Arg Gly Leu Val Trp Gln

20 25 30

<210> 548
<211> 38
<212> PRT
<213> Homo sapiens

<400> 548
Thr Pro Cys Ser Ala Gln Phe Ser Val Leu Gly Pro Ser Gly Pro Ile
1 5 10 15

Leu Ala Met Val Gly Glu Asp Ala Asp Leu Pro Cys His Leu Phe Pro
20 25 30

Thr Met Ser Ala Glu Thr
35

<210> 549
<211> 60
<212> PRT
<213> Homo sapiens

<400> 549
Met Glu Leu Lys Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val
1 5 10 15

Tyr Ala Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg
20 25 30

Gly Arg Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala
35 40 45

Leu Arg Ile His Asn Val Thr Ala Ser Asp Ser Gly
50 55 60

<210> 550
<211> 26
<212> PRT
<213> Homo sapiens

<400> 550
Leu Glu Val Lys Gly Tyr Glu Asp Gly Gly Ile His Leu Glu Cys Arg
1 5 10 15

Ser Thr Gly Trp Tyr Pro Gln Pro Gln Ile
20 25

<210> 551
<211> 80
<212> PRT

<213> Homo sapiens

<400> 551
Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val Ser Leu
1 5 10 15

Leu Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser Val Leu
20 25 30

Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala Asp Leu
35 40 45

Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu Leu Lys
50 55 60

Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala Asp Gly
65 70 75 80

<210> 552
<211> 103
<212> PRT
<213> Homo sapiens

<400> 552
Arg His Glu Leu Ser His Asn Arg Lys Asn Gly Glu Leu Leu Ile Asp
1 5 10 15

Arg Leu Tyr Ser Val Gly Ser Asp Ser Pro Met Gly Ile Pro Arg Asp
20 25 30

Ile Ile Phe Thr Asp Gly Phe Pro Tyr Trp Asn Pro Lys Val Lys Thr
35 40 45

Leu Lys Asp Arg His Phe Trp Gln Ser Ile Asp Glu Asn Gly Lys Phe
50 55 60

Pro Gly Phe Pro Ser Ala Gln Leu Ser Cys Leu Pro Pro Leu Gly Pro
65 70 75 80

Ala Ala His Ser Leu Leu Ser Ser Val Phe Cys Ala Trp Thr Leu Trp
85 90 95

Ala His Pro Gly His Gly Gly
100

<210> 553
<211> 24
<212> PRT
<213> Homo sapiens

<400> 553
Leu Leu Ile Asp Arg Leu Tyr Ser Val Gly Ser Asp Ser Pro Met Gly

1 5 10 15

Ile Pro Arg Asp Ile Ile Phe Thr
20

<210> 554
<211> 25
<212> PRT
<213> Homo sapiens

<400> 554
Asn Pro Lys Val Lys Thr Leu Lys Asp Arg His Phe Trp Gln Ser Ile
1 5 10 15

Asp Glu Asn Gly Lys Phe Pro Gly Phe
20 25

<210> 555
<211> 24
<212> PRT
<213> Homo sapiens

<400> 555
Leu Gly Pro Ala Ala His Ser Leu Leu Ser Ser Val Phe Cys Ala Trp
1 5 10 15

Thr Leu Trp Ala His Pro Gly His
20

<210> 556
<211> 135
<212> PRT
<213> Homo sapiens

<400> 556
Arg Leu Gln His Trp Val Leu Ile Phe Thr Leu Glu Val Lys Gly Tyr
1 5 10 15

Glu Asp Gly Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro
20 25 30

Gln Pro Gln Ile Gln Trp Ser Asn Ala Lys Gly Glu Asn Ile Pro Ala
35 40 45

Val Glu Ala Pro Val Val Ala Asp Gly Val Gly Leu Tyr Glu Val Ala
50 55 60

Ala Ser Val Ile Met Arg Gly Gly Ser Gly Glu Gly Val Ser Cys Ile
65 70 75 80

Ile Arg Asn Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile
85 90 95

Ala Asp Pro Ser Ser Gly Ala Pro Ser Pro Gly Ser Gln Pro Trp Gln

100 105 110

Gly Pro Cys Leu Ser Cys Cys Cys Phe Ser Pro Glu Pro Val Thr Ser
115 120 125

Cys Gly Asp Asn Arg Arg Lys
130 135

<210> 557
<211> 25
<212> PRT
<213> Homo sapiens

<400> 557
Gly Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro
1 5 10 15

Gln Ile Gln Trp Ser Asn Ala Lys Gly
20 25

<210> 558
<211> 27
<212> PRT
<213> Homo sapiens

<400> 558
Pro Gln Ile Gln Trp Ser Asn Ala Lys Gly Glu Asn Ile Pro Ala Val
1 5 10 15

Glu Ala Pro Val Val Ala Asp Gly Val Gly Leu
20 25

<210> 559
<211> 27
<212> PRT
<213> Homo sapiens

<400> 559
Asn Ile Pro Ala Val Glu Ala Pro Val Val Ala Asp Gly Val Gly Leu
1 5 10 15

Tyr Glu Val Ala Ala Ser Val Ile Met Arg Gly
20 25

<210> 560
<211> 27
<212> PRT
<213> Homo sapiens

<400> 560
Ser Gly Ala Pro Ser Pro Gly Ser Gln Pro Trp Gln Gly Pro Cys Leu
1 5 10 15

Ser Cys Cys Cys Phe Ser Pro Glu Pro Val Thr
20 25

<210> 561
<211> 131
<212> PRT
<213> Homo sapiens

<400> 561
Ser Ser Ser Ile Cys Asp His Glu Arg Arg Leu Arg Gly Gly Cys Ile
1 5 10 15

Leu His His Gln Lys Phe Pro Pro Arg Pro Gly Lys Asp Ser Gln His
20 25 30

Phe His Arg Arg Pro Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala
35 40 45

Leu Ala Gly Thr Leu Pro Ile Leu Leu Leu Leu Leu Ala Gly Ala Ser
50 55 60

Tyr Phe Leu Trp Arg Gln Gln Lys Glu Ile Thr Ala Leu Ser Ser Glu
65 70 75 80

Ile Glu Ser Glu Gln Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu
85 90 95

Arg Glu Ile Ser Leu Arg Glu Ser Leu Gln Glu Glu Leu Lys Arg Lys
100 105 110

Lys Ile Gln Tyr Leu Thr Arg Gly Glu Glu Ser Ser Ser Asp Thr Asn
115 120 125

Lys Ser Ala
130

<210> 562
<211> 28
<212> PRT
<213> Homo sapiens

<400> 562
Lys Asp Ser Gln His Phe His Arg Arg Pro Phe Phe Arg Ser Ala Gln
1 5 10 15

Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu Pro Ile
20 25

<210> 563
<211> 28
<212> PRT
<213> Homo sapiens

<400> 563

Glu Ile Glu Ser Glu Gln Glu Met Lys Glu Met Gly Tyr Ala Ala Thr
1 5 10 15

Glu Arg Glu Ile Ser Leu Arg Glu Ser Leu Gln Glu
20 25

<210> 564
<211> 33
<212> PRT
<213> Homo sapiens

<400> 564
Val Asn Asn Met Ile Ala Phe Tyr Ser Ala Arg Asp Ser Tyr Val Tyr
1 5 10 15

Pro His Phe Ser Gly Glu Glu Met Leu Gln Met Arg Leu His Leu Val
20 25 30

Lys

<210> 565
<211> 38
<212> PRT
<213> Homo sapiens

<400> 565
Thr Pro Cys Ser Ala Gln Phe Ser Val Leu Gly Pro Ser Gly Pro Ile
1 5 10 15

Leu Ala Met Val Gly Glu Asp Ala Asp Leu Pro Cys His Leu Phe Pro
20 25 30

Thr Met Ser Ala Glu Thr
35

<210> 566
<211> 23
<212> PRT
<213> Homo sapiens

<400> 566
Lys Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala Asp
1 5 10 15

Gly Lys Glu Val Glu Asp Arg
20

<210> 567
<211> 25
<212> PRT
<213> Homo sapiens

<400> 567
Arg Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu
1 5 10 15

Arg Ile His Asn Val Thr Ala Ser Asp
20 25

<210> 568
<211> 23
<212> PRT
<213> Homo sapiens

<400> 568
Cys Tyr Phe Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu
1 5 10 15

Lys Val Ala Ala Leu Gly Ser
20

<210> 569
<211> 23
<212> PRT
<213> Homo sapiens

<400> 569
Gly Tyr Glu Asp Gly Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp
1 5 10 15

Tyr Pro Gln Pro Gln Ile Gln
20

<210> 570
<211> 23
<212> PRT
<213> Homo sapiens

<400> 570
Asn Ile Pro Ala Val Glu Ala Pro Val Val Ala Asp Gly Val Gly Leu
1 5 10 15

Tyr Glu Val Ala Ala Ser Val
20

<210> 571
<211> 21
<212> PRT
<213> Homo sapiens

<400> 571
Gln Gln Lys Glu Ile Thr Ala Leu Ser Ser Glu Ile Glu Ser Glu Gln
1 5 10 15

Glu Met Lys Glu Met

20

<210> 572
<211> 24
<212> PRT
<213> Homo sapiens

<400> 572
Leu Arg Glu Ser Leu Gln Glu Glu Leu Lys Arg Lys Lys Ile Gln Tyr
1 5 10 15

Leu Thr Arg Gly Glu Glu Ser Ser
20

<210> 573
<211> 13
<212> PRT
<213> Homo sapiens

<400> 573
Gly Glu Glu Met Leu Gln Met Arg Leu His Leu Val Lys
1 5 10

<210> 574
<211> 40
<212> PRT
<213> Homo sapiens

<400> 574
Ser Ala Gln Phe Ser Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met
1 5 10 15

Val Gly Glu Asp Ala Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser
20 25 30

Ala Glu Thr Met Glu Leu Lys Trp
35 40

<210> 575
<211> 12
<212> PRT
<213> Homo sapiens

<400> 575
Pro Gln Gly Gly Leu Thr Leu Pro Ser Val Trp Gly
1 5 10

<210> 576
<211> 106
<212> PRT
<213> Homo sapiens

<400> 576
Gly Gly Pro Cys His Leu Trp Leu Leu Gly Pro Arg Arg Thr Gln Leu
1 5 10 15

Pro Gly Arg Arg Ala Ser Leu Pro Phe Arg Ser Gln Gly Glu Leu Thr
20 25 30

Gln Ala Phe Leu Leu Gly Leu Trp Lys His Gln Met Pro Ala Leu Thr
35 40 45

Gln Glu Gln Gln Val Arg Ala Glu Arg Arg Arg Glu Ala Val Arg Met
50 55 60

Glu Ile Pro Gly Leu Phe Phe Ala Ser Leu Ala Asn Trp Gly Leu Leu
65 70 75 80

Tyr Arg Thr Ser Gln Asp Phe Ile Ser Pro Tyr Leu Cys Ala Ala Pro
85 90 95

Ser Thr Pro His Pro Pro Leu Gly Gly Pro
100 105

<210> 577
<211> 23
<212> PRT
<213> Homo sapiens

<400> 577
Gly Pro Arg Arg Thr Gln Leu Pro Gly Arg Arg Ala Ser Leu Pro Phe
1 5 10 15

Arg Ser Gln Gly Glu Leu Thr
20

<210> 578
<211> 24
<212> PRT
<213> Homo sapiens

<400> 578
Gln Met Pro Ala Leu Thr Gln Glu Gln Gln Val Arg Ala Glu Arg Arg
1 5 10 15

Arg Glu Ala Val Arg Met Glu Ile
20

<210> 579
<211> 25
<212> PRT
<213> Homo sapiens

<400> 579
Ala Asn Trp Gly Leu Leu Tyr Arg Thr Ser Gln Asp Phe Ile Ser Pro
1 5 10 15

Tyr Leu Cys Ala Ala Pro Ser Thr Pro
20 25

<210> 580
<211> 34
<212> PRT
<213> Homo sapiens

<400> 580
Leu Ser Phe Lys Asp Lys Ser Thr Tyr Ile Glu Ser Ser Thr Lys Val
1 5 10 15

Tyr Asp Asp Met Ala Phe Arg Tyr Leu Ser Trp Ile Leu Phe Pro Leu
20 25 30

Leu Gly

<210> 581
<211> 31
<212> PRT
<213> Homo sapiens

<400> 581
Leu Leu Thr Phe Gly Phe Ile Thr Met Thr Pro Gln Leu Phe Ile Asn
1 5 10 15

Tyr Lys Leu Lys Ser Val Ala His Leu Pro Trp Arg Met Leu Thr
20 25 30

<210> 582
<211> 30
<212> PRT
<213> Homo sapiens

<400> 582
Thr Tyr Lys Ala Leu Asn Thr Phe Ile Asp Asp Leu Phe Ala Phe Val
1 5 10 15

Ile Lys Met Pro Val Met Tyr Arg Ile Gly Cys Leu Arg Asp
20 25 30

<210> 583
<211> 30
<212> PRT
<213> Homo sapiens

<400> 583
Asp Val Val Phe Phe Ile Tyr Leu Tyr Gln Arg Trp Ile Tyr Arg Val
1 5 10 15

Asp Pro Thr Arg Val Asn Glu Phe Gly Met Ser Gly Glu Asp

20 25 30

<210> 584
<211> 44
<212> PRT
<213> Homo sapiens

<400> 584
Val Ala Gly Ile Phe Pro Arg Leu Ser Phe Lys Asp Lys Ser Thr Tyr
1 5 10 15

Ile Glu Ser Ser Thr Lys Val Tyr Asp Asp Met Ala Phe Arg Tyr Leu
20 25 30

Ser Trp Ile Leu Phe Pro Leu Leu Gly Cys Tyr Ala
35 40

<210> 585
<211> 19
<212> PRT
<213> Homo sapiens

<400> 585
Trp Ala Ala Met Pro Ser Thr Val Phe Cys Thr Trp Ser Thr Arg Ala
1 5 10 15

Gly Thr Pro

<210> 586
<211> 28
<212> PRT
<213> Homo sapiens

<400> 586
Pro Trp Val Ala Gly Ile Phe Pro Arg Leu Ser Phe Lys Asp Lys Ser
1 5 10 15

Thr Tyr Ile Glu Ser Ser Thr Lys Val Tyr Asp Asp
20 25

<210> 587
<211> 88
<212> PRT
<213> Homo sapiens

<400> 587
Ala Gly Glu Asp Ser Cys His Pro Val Leu Ser Val Gln Pro Asp Val
1 5 10 15

His Asp Leu Gly Trp Gln Glu Ser Ser Pro Ala Tyr Pro Ser Arg Thr
20 25 30

Ser Pro Arg Ile Ser Ser Pro Arg Pro Lys Cys Met Met Ile Trp His
35 40 45

Ser Gly Thr Cys Pro Gly Ser Ser Ser Arg Ser Trp Ala Ala Met Pro
50 55 60

Ser Thr Val Phe Cys Thr Trp Ser Thr Arg Ala Gly Thr Pro Gly Cys
65 70 75 80

Ser Ala Cys Ser Thr Ala Ser Cys
85

<210> 588
<211> 30
<212> PRT
<213> Homo sapiens

<400> 588
Leu Ser Val Gln Pro Asp Val His Asp Leu Gly Trp Gln Glu Ser Ser
1 5 10 15

Pro Ala Tyr Pro Ser Arg Thr Ser Pro Arg Ile Ser Ser Pro
20 25 30

<210> 589
<211> 25
<212> PRT
<213> Homo sapiens

<400> 589
Gly Ser Ser Ser Arg Ser Trp Ala Ala Met Pro Ser Thr Val Phe Cys
1 5 10 15

Thr Trp Ser Thr Arg Ala Gly Thr Pro
20 25

<210> 590
<211> 22
<212> PRT
<213> Homo sapiens

<400> 590
Cys Tyr Ala Val Tyr Ser Leu Leu Tyr Leu Glu His Lys Gly Trp Tyr
1 5 10 15

Ser Trp Val Leu Ser Met
20

<210> 591
<211> 12
<212> PRT
<213> Homo sapiens

<400> 591
Leu Gly Glu Phe Leu Ser Ser Gln Cys Phe Leu Pro
1 5 10

<210> 592
<211> 20
<212> PRT
<213> Homo sapiens

<400> 592
Arg Ser Arg Arg Asn Arg Val Ala Met Gly Met Trp Ala Ser Leu Asp
1 5 10 15

Ala Leu Trp Glu
20

<210> 593
<211> 92
<212> PRT
<213> Homo sapiens

<400> 593
Pro Arg Val Arg Cys Gln Gln Arg Ala Glu Gly Gly Met Gly Ala Gly
1 5 10 15

Ile Gly Val Gly Pro Ser Glu Arg Thr Asp Ile Ala Val Thr Pro Arg
20 25 30

Gly Arg Ser Glu Gly Ala Ser Val Gly Val Ala Pro Val His Ala Glu
35 40 45

Gly Ala Gly Gly Thr Gly Trp Pro Trp Gly Cys Gly His Arg Trp Thr
50 55 60

Leu Cys Gly Arg Cys Arg Pro Arg Ser Val Ser Ser Gly Pro Cys Cys
65 70 75 80

Ser Phe Pro Gly Gln Cys Ile Phe Gly Arg Pro Ser
85 90

<210> 594
<211> 24
<212> PRT
<213> Homo sapiens

<400> 594
Gly Gly Met Gly Ala Gly Ile Gly Val Gly Pro Ser Glu Arg Thr Asp
1 5 10 15

Ile Ala Val Thr Pro Arg Gly Arg
20

<210> 595

<211> 26
<212> PRT
<213> Homo sapiens

<400> 595
Gly Cys Gly His Arg Trp Thr Leu Cys Gly Arg Cys Arg Pro Arg Ser
1 5 10 15

Val Ser Ser Gly Pro Cys Cys Ser Phe Pro
20 25

<210> 596
<211> 24
<212> PRT
<213> Homo sapiens

<400> 596
Lys Lys His Gly Phe Asn Gln Gln Thr Leu Gly Phe Phe Thr Trp Lys
1 5 10 15

Tyr Asn Lys Asn Lys Asn Leu Val
20

<210> 597
<211> 21
<212> PRT
<213> Homo sapiens

<400> 597
Pro Lys Leu Leu Pro Cys Ser Pro Ala Glu Gly His Thr Ser Leu Gly
1 5 10 15

Pro Leu Leu Pro Phe
20

<210> 598
<211> 70
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 598
Ala Ser Leu Glu Leu Xaa Pro Ser Lys Ser Gln Leu Ser Thr Glu Trp
1 5 10 15

Gly Phe Thr Trp Ile Val Gly Leu Gly Met Ser Pro Ser Thr Ala Leu
20 25 30

Trp Thr Glu Cys Thr Cys Thr Pro Phe Leu Val Leu Leu Ser His Ala
35 40 45

Ser Gly His Phe Phe Trp Leu Ser Pro Leu Ala Ser Leu Val Ile Pro
50 55 60

Pro Val Thr Asp Arg Lys
65 70

<210> 599
<211> 32
<212> PRT
<213> Homo sapiens

<400> 599
Trp Gly Phe Thr Trp Ile Val Gly Leu Gly Met Ser Pro Ser Thr Ala
1 5 10 15

Leu Trp Thr Glu Cys Thr Cys Thr Pro Phe Leu Val Leu Leu Ser His
20 25 30

<210> 600
<211> 106
<212> PRT
<213> Homo sapiens

<400> 600
Val Ala Val Gly Val Cys Arg Glu Asp Val Met Gly Ile Thr Asp Arg
1 5 10 15

Ser Lys Met Ser Pro Asp Val Gly Ile Trp Ala Ile Tyr Trp Ser Ala
20 25 30

Ala Gly Tyr Trp Pro Leu Ile Gly Phe Pro Gly Thr Pro Thr Gln Gln
35 40 45

Glu Pro Ala Leu His Arg Val Gly Val Tyr Leu Asp Arg Gly Thr Gly
50 55 60

Asn Val Ser Phe Tyr Ser Ala Val Asp Gly Val His Leu His Thr Phe
65 70 75 80

Ser Cys Ser Ser Val Ser Arg Leu Arg Pro Phe Phe Leu Val Glu Ser
85 90 95

Ile Ser Ile Phe Ser His Ser Thr Ser Asp
100 105

<210> 601
<211> 27
<212> PRT
<213> Homo sapiens

<400> 601
Ile Thr Asp Arg Ser Lys Met Ser Pro Asp Val Gly Ile Trp Ala Ile
1 5 10 15

Tyr Trp Ser Ala Ala Gly Tyr Trp Pro Leu Ile
20 25

<210> 602
<211> 30
<212> PRT
<213> Homo sapiens

<400> 602
Arg Gly Thr Gly Asn Val Ser Phe Tyr Ser Ala Val Asp Gly Val His
1 5 10 15

Leu His Thr Phe Ser Cys Ser Ser Val Ser Arg Leu Arg Pro
20 25 30

<210> 603
<211> 11
<212> PRT
<213> Homo sapiens

<400> 603
Gly Thr Arg Gly Leu Gln Asn His Arg Thr Glu
1 5 10

<210> 604
<211> 6
<212> PRT
<213> Homo sapiens

<400> 604
Glu Leu Ser Gly Leu Gly
1 5

<210> 605
<211> 6
<212> PRT
<213> Homo sapiens

<400> 605
Met Asp Asp Ile Lys Ile
1 5

<210> 606
<211> 57
<212> PRT
<213> Homo sapiens

<400> 606

255

Asn Phe Cys Val Ser Lys Asn Thr Phe Asn Arg Val Lys Arg Pro Ile
1 5 10 15

Lys Trp Val Lys Ile Phe Ala Asn Asp Ile Ser Cys Lys Arg Leu Ile
20 25 30

Ser Arg Ile His Lys Glu Ile Leu Pro Phe Asn Asn Lys Lys Gln Pro
35 40 45

Asp Phe Lys Val Lys Lys Ser Arg Lys
50 55

<210> 607
<211> 30
<212> PRT
<213> Homo sapiens

<400> 607
Phe Asn Arg Val Lys Arg Pro Ile Lys Trp Val Lys Ile Phe Ala Asn
1 5 10 15

Asp Ile Ser Cys Lys Arg Leu Ile Ser Arg Ile His Lys Glu
20 25 30

<210> 608
<211> 15
<212> PRT
<213> Homo sapiens

<400> 608
Glu Thr Gln Met Ala Asn Lys Tyr Met Lys Arg Cys Ser Thr Leu
1 5 10 15

<210> 609
<211> 59
<212> PRT
<213> Homo sapiens

<400> 609
Val Ile Arg Glu Leu Gln Val Lys Ala Thr Arg Arg Cys His Tyr Thr
1 5 10 15

Pro Ile Lys Trp Ser Lys Ser Lys Thr Leu Ile Ser Ser Asn Ala Asp
20 25 30

Glu Tyr Val Glu Pro Thr Arg Thr Leu Ile His Cys Trp Trp Lys Cys
35 40 45

Lys Ile Val Gln Pro Leu Cys Lys Thr Ala Trp
50 55

<210> 610
<211> 22

256

<212> PRT
<213> Homo sapiens

<400> 610
Ala Thr Arg Arg Cys His Tyr Thr Pro Ile Lys Trp Ser Lys Ser Lys
1 5 10 15

Thr Leu Ile Ser Ser Asn
20

<210> 611
<211> 64
<212> PRT
<213> Homo sapiens

<400> 611
Glu Leu Ser Gly Leu Val Ile Ile Thr Ala Trp Ile Ile Leu Cys His
1 5 10 15

Ser Ser Ser Lys Asn Pro Val Gly Gly Arg Ile Gln Leu Ala Ile Ala
20 25 30

Ile Val Ile Thr Leu Phe Pro Phe Ile Ser Trp Val Tyr Ile Tyr Ile
35 40 45

Asn Lys Glu Met Arg Ser Ser Trp Pro Thr His Cys Lys Thr Val Ile
50 55 60

<210> 612
<211> 57
<212> PRT
<213> Homo sapiens

<400> 612
Gln Cys Pro Gln Gly Thr Glu Thr Glu Ala Gly Val Ser Val Pro Pro
1 5 10 15

Arg Lys Glu Gly Gly Gly Pro Tyr Val Ala Gly Leu Thr Ala Pro His
20 25 30

Val Ala Gly Leu Thr Ala Pro Arg Arg Val Leu Arg Ala Met Ala Pro
35 40 45

Ala Leu Trp Arg Ala Cys Asn Gly Leu
50 55

<210> 613
<211> 32
<212> PRT
<213> Homo sapiens

<400> 613
His Ser Ser Ser Lys Asn Pro Val Gly Gly Arg Ile Gln Leu Ala Ile
1 5 10 15

Ala Ile Val Ile Thr Leu Phe Pro Phe Ile Ser Trp Val Tyr Ile Tyr
20 25 30

<210> 614
<211> 32
<212> PRT
<213> Homo sapiens

<400> 614
Arg Lys Glu Gly Gly Gly Pro Tyr Val Ala Gly Leu Thr Ala Pro His
1 5 10 15

Val Ala Gly Leu Thr Ala Pro Arg Arg Val Leu Arg Ala Met Ala Pro
20 25 30

<210> 615
<211> 32
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 615
Pro Gly Arg Pro Thr Arg Pro Ala Xaa Ala Gly Leu Ser Ser Gly Gly
1 5 10 15

Ala Ala Gln Glu Ala Pro Gln Ala Asp Pro Arg Pro Trp Leu Ala Arg
20 25 30

<210> 616
<211> 51
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 616
His Tyr Xaa Ser Thr Pro Gly Arg Val Pro Val Arg Gln Phe Ala Ala
1 5 10 15

Ala Ser Thr Ser Gly Gly Pro Trp Val Pro Gly Gly Xaa Leu Glu Ala
20 25 30

Pro Phe Gln Val Ala Pro Ser Leu Ser His Ser Thr Pro Val Phe Pro
35 40 45

Gly Leu Ile
50

<210> 617
<211> 22
<212> PRT
<213> Homo sapiens

<400> 617
Ala Arg Gly Lys Tyr Glu Ser Ala Gln Pro Gly Gly Thr Gln Pro Glu
1 5 10 15

Pro Gly Leu Gly Ala Arg
20

<210> 618
<211> 24
<212> PRT
<213> Homo sapiens

<400> 618
Ser Cys Gly Ser Ser Arg Arg Ser Ala Lys Arg Ser Leu Thr Leu Lys
1 5 10 15

Leu Ile Asp Phe Ser His Arg Ile
20

<210> 619
<211> 52
<212> PRT
<213> Homo sapiens

<400> 619
His Tyr Phe Leu Arg Thr Val Ser Gly Leu Ser Val Val Pro Val Ser
1 5 10 15

Leu Arg Cys Cys Met Cys Pro Pro Pro Cys Thr Gly Pro Ala Pro Ala
20 25 30

Thr Ala His Ser Pro Phe Asp Pro Pro Ala Leu Pro Ile Gln Phe Glu
35 40 45

Tyr Gln Gln Ala
50

<210> 620
<211> 45
<212> PRT
<213> Homo sapiens

<400> 620
Gln Leu Glu Ala Glu Ile Glu Asn Leu Ser Trp Lys Val Glu Arg Ala
1 5 10 15

Asp Ser Tyr Asp Arg Gly Asp Leu Glu Asn Gln Met His Ile Ala Glu
20 25 30

Gln Arg Arg Arg Thr Leu Leu Lys Asp Phe His Asp Thr
35 40 45

<210> 621
<211> 24
<212> PRT
<213> Homo sapiens

<400> 621
Val Pro Val Ser Leu Arg Cys Cys Met Cys Pro Pro Pro Cys Thr Gly
1 5 10 15

Pro Ala Pro Ala Thr Ala His Ser
20

<210> 622
<211> 25
<212> PRT
<213> Homo sapiens

<400> 622
Ser Trp Lys Val Glu Arg Ala Asp Ser Tyr Asp Arg Gly Asp Leu Glu
1 5 10 15

Asn Gln Met His Ile Ala Glu Gln Arg
20 25

<210> 623
<211> 227
<212> PRT
<213> Homo sapiens

<220>
<221> SITE

<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 623
His Glu Ala Trp Leu Arg Ser Ala Gly Thr Arg Glu Pro Pro Arg Glu
1 5 10 15

Gln Arg Thr Arg Arg Arg Gln Thr Ala Gln Leu Ala Leu Gln Val Pro
20 25 30

Ala Pro Ser Arg Thr Pro Pro Met Ala Thr Asp Val Phe Asn Ser Lys
35 40 45

Asn Leu Ala Val Xaa Ala Gln Lys Lys Ile Leu Gly Lys Met Val Ser
50 55 60

Lys Ser Ile Ala Thr Thr Leu Ile Asp Asp Thr Ser Ser Glu Val Leu
65 70 75 80

Asp Glu Leu Tyr Arg Val Thr Arg Glu Tyr Thr Gln Asn Lys Lys Glu
85 90 95

Ala Glu Lys Ile Ile Lys Asn Leu Ile Lys Thr Val Ile Lys Leu Ala
100 105 110

Ile Leu Tyr Arg Asn Asn Gln Phe Asn Gln Asp Glu Leu Ala Leu Met
115 120 125

Glu Lys Phe Lys Lys Lys Val His Gln Leu Ala Met Thr Val Val Ser
130 135 140

Phe His Gln Val Asp Tyr Thr Phe Asp Arg Asn Val Leu Ser Arg Leu
145 150 155 160

Leu Asn Glu Cys Arg Glu Met Leu His Gln Ile Ile Gln Arg His Leu
165 170 175

Thr Ala Lys Ser His Gly Arg Val Asn Asn Val Phe Asp His Phe Ser
180 185 190

Asp Cys Glu Phe Leu Ala Ala Leu Tyr Asn Pro Phe Gly Asn Phe Lys
195 200 205

Pro His Leu Gln Lys Leu Cys Asp Gly Ile Asn Lys Met Leu Asp Glu
210 215 220

Glu Asn Ile
225

<210> 624
<211> 52
<212> PRT
<213> Homo sapiens

<400> 624
His Glu Ala Trp Leu Arg Ser Ala Gly Thr Arg Glu Pro Pro Arg Glu

1 5 10 15

Gln Arg Thr Arg Arg Arg Gln Thr Ala Gln Leu Ala Leu Gln Val Pro
20 25 30

Ala Pro Ser Arg Thr Pro Pro Met Ala Thr Asp Val Phe Asn Ser Lys
35 40 45

Asn Leu Ala Val
50

<210> 625
<211> 49
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 625
Xaa Ala Gln Lys Lys Ile Leu Gly Lys Met Val Ser Lys Ser Ile Ala
1 5 10 15

Thr Thr Leu Ile Asp Asp Thr Ser Ser Glu Val Leu Asp Glu Leu Tyr
20 25 30

Arg Val Thr Arg Glu Tyr Thr Gln Asn Lys Lys Glu Ala Glu Lys Ile
35 40 45

Ile

<210> 626
<211> 51
<212> PRT
<213> Homo sapiens

<400> 626
Lys Asn Leu Ile Lys Thr Val Ile Lys Leu Ala Ile Leu Tyr Arg Asn
1 5 10 15

Asn Gln Phe Asn Gln Asp Glu Leu Ala Leu Met Glu Lys Phe Lys Lys
20 25 30

Lys Val His Gln Leu Ala Met Thr Val Val Ser Phe His Gln Val Asp
35 40 45

Tyr Thr Phe
50

<210> 627
<211> 52

<212> PRT
<213> Homo sapiens

<400> 627
Asp Arg Asn Val Leu Ser Arg Leu Leu Asn Glu Cys Arg Glu Met Leu
1 5 10 15

His Gln Ile Ile Gln Arg His Leu Thr Ala Lys Ser His Gly Arg Val
20 25 30

Asn Asn Val Phe Asp His Phe Ser Asp Cys Glu Phe Leu Ala Ala Leu
35 40 45

Tyr Asn Pro Phe
50

<210> 628
<211> 23
<212> PRT
<213> Homo sapiens

<400> 628
Gly Asn Phe Lys Pro His Leu Gln Lys Leu Cys Asp Gly Ile Asn Lys
1 5 10 15

Met Leu Asp Glu Glu Asn Ile
20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27059

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) :C07H 21/00; C12N 1/15, 1/21, 5/10, 15/11, 15/63
US CL :435/91.41, 320.1, 325, 252.3, 254.11; 536/23.1, 23.5, 24.31
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/91.41, 320.1, 325, 252.3, 254.11; 536/23.1, 23.5, 24.31

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
GENBANK, EMBL, SWISS-PROT, SPTREMBL, PIR,
searched: SEQ ID NO: 11-20 & 125-134

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA133381, HILLIER et al. 'WashU-Merck EST Project', complete record, 27 November 1996.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. T12400, LIEW et al. 'A catalogue of genes in the cardiovascular system as identified by expressed sequence tags', complete record, 27 November 1996.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA496982, HILLIER et al. 'WashU-Merck EST Project 1997', complete record, 12 August 1997.	1, 7-10

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"B" earlier document published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
02 MARCH 1999	23 MAR 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer SCOTT D. PRIEBE Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27059

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. U14626, D'ALESSIO et al. 'Cloning vector pSVSport1', complete record, 24 May 1995.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AJ000730, SPERANDEO et al. 'The full cDNA for the human cationic amino acid transporter 3 (HCAT3)', complete record, 02 December 1997.	1
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. R31044, HILLIER et al. 'The WashU-Merck EST Project', complete record, 28 April 1995.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA446873, HILLIER et al. 'WashU-Merck EST Project 1997', complete record, 03 June 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA135715, HILLIER et al. 'WashU-Merck EST Project', complete record, 14 May 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA194015, HILLIER et al. 'WashU-Merck EST Project', complete record, 19 May 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. R72850, HILLIER et al. 'The WashU-Merck EST Project', complete record, 02 June 1995.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. T60940, HILLIER et al. 'WashU-Merck EST Project', complete record, 13 February 1995.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. H86863, HILLIER et al. 'The WashU-Merck EST Project', complete record, 21 November 1995.	1, 7-10

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27059

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10, 21

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27059

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups I-XXVII, claim(s) 1-10 and 21, drawn to a polynucleotide, vector comprising same, first claimed method of use, i.e. using polynucleotide to make a cell, and the cell made by the process. Claims 1-10 and 21 recite 114 independent polynucleotides (SEQ ID NO: 11-124 or encoding SEQ ID NO: 125-238). Group I consists of the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 125-134). Each of groups II-XXVII consists of up to four of the remaining 104 polynucleotides, in order.

Groups XXVIII-CXLI, claim(s) 11, 12, 14-16 and 17 (first part), drawn to a polypeptide, a method of making the polypeptide and first claimed method of use, i.e. in treatment. These claims recite 114 independent polypeptides, each of groups XXVIII-CXLI consists of a single polypeptide as set forth in SEQ ID NOs 125-238, respectively.

Groups CXLI-CCLV, claim(s) 13 and 19, drawn to an antibody to a polypeptide and the first claimed method of using same. These claims recite 114 independent antibodies to 114 independent polypeptides, each of groups CXLI-CCLV consists an antibody against a single polypeptide as set forth in SEQ ID NOs 125-238, respectively.

Groups CCLVI-CCLXXXII, claim(s) 17(second part), drawn to an additional method of using a polynucleotide.Group CCLVI consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 125-134). Each of groups CCLVII-CCLXXXII pertains to up to four of the remaining 104 polynucleotides, in order.

Groups CCLXXXIII-CCCIX, claim(s) 18, drawn to a second additional method of using a polynucleotide. Group CCLXXXIII consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 125-134). Each of groups CCLXXXIV-CCCIX pertains to up to four of the remaining 104 polynucleotides, in order.

Groups CCCX-CDXXIII, claim(s) 20, drawn to an additional method of using the polypeptide. These claims recite 114 independent methods of using 114 independent polypeptides, each of groups CCCX-CDXXIII consists an antibody against a single polypeptide as set forth in SEQ ID NOs 125-238, respectively.

Groups CDXXIV-CDL, claim 22, drawn to a third additional method of using a polynucleotide. Group CDXXIV consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 125-134). Each of groups CDXXV-CDL pertains to up to four of the remaining 53 polynucleotides, in order.

Claim 23 is unsearchable and cannot be grouped as it is drawn to unknown and unspecified compounds.

The inventions listed as Groups I-CDL do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Each of the corresponding polynucleotides, polypeptides and antibodies are independent products, with different uses and being structurally, biochemically and biologically different products. Additional or alternate methods of use are claimed for individual polynucleotides and polypeptides. 37 CFR 1.475(b) does not provide for unity of invention of more than 1 product or more than one method of using a product as a combination of invention having unity of invention. However, with respect to groups drawn to independent polynucleotides or alternate methods of using same recited in the alternative, in accordance with 1192 O.G. 68 (19 November 1966) applicant is entitled to an initial search of inventions pertaining to the first ten independent polynucleotides recited, and may elect to pay an additional fee for each search of up to four additional independent polynucleotides. For additional method of using each of the independent polynucleotides, applicant may further elect to pay an additional fee for an additional search involving the first ten polynucleotides and each additional search involving up to four additional polynucleotides. With respect to groups pertaining to independent polypeptides or antibodies to the independent polypeptides, each product or method of use is an additional invention. An additional fee must be paid for search of each additional invention relating to polypeptides or antibodies against same. With respect to the relationship between the claimed polynucleotides and the claimed polypeptides, there is no one-to-one correspondence, i.e. no corresponding scope, between claims drawn to polynucleotides and their use and those drawn to polypeptides, antibodies and their use. Consequently, there is no special technical feature linking the polynucleotides and the polypeptides or antibodies claimed.

THIS PAGE BLANK (USPTO)